

12/16/99  
U.S. PTO  
12-17-99  
A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: MOBT:175-2

Prior Application Examiner:  
E. Slobodyansky

Classification Designation:

Prior Group Art Unit: 1652

CERTIFICATE OF EXPRESS MAILING

NUMBER EL392860338US

DATE OF DEPOSIT December 16, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

  
Signature

BOX PATENT APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

**REQUEST FOR FILING DIVISIONAL APPLICATION  
UNDER 37 C.F.R. § 1.53(b)**

This is a request for filing a divisional application under Rule 53(b) (37 C.F.R. § 1.53(b)) of co-pending prior application Serial No. 09/137,440 filed August 20, 1998, entitled "GLYPHOSATE-TOLERANT 5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASES."

1. Enclosed is a copy of the prior application Serial No. 09/137,440 as originally filed, including specification, claims, drawings, and declaration. The undersigned hereby verifies that the attached papers are a true copy of the prior application as originally filed and identified above, that no amendments (if any) referred to in the declaration filed to complete the prior application introduced new matter therein, and further that this statement was made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or

jc511 U.S. PRO  
09/464099  
12/16/99

both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.

(a)  The inventorship is the same as prior Application Serial No.

09/137,440.

2. Enclosed is a check in the amount of \$838.00 to cover the filing fee as calculated below and the fee for any new claims added in the Preliminary Amendment referred to in Clause No. 7 below.

CLAIMS AS FILED IN THE PRIOR APPLICATION  
LESS CLAIMS CANCELED BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee -----				\$760.00
Total Claims	8 - 20 =	0 X	\$18.00 =	\$ 0.00
Independent Claims	4 - 3 =	1 X	\$78.00 =	\$ 78.00
Multiple Dependent Claim(s)	-----			\$ -0-00
<b>TOTAL FILING FEES:</b>				<b>\$838.00</b>

3. If the check is missing or insufficient, the Assistant Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 to 1.21 which may be required for any reason relating to this application, or credit any overpayment to Arnold White & Durkee Deposit Account No. 01-2508/MOBT:175-2/PAT.

4. Enclosed is a copy of the current Power of Attorney in the prior application.

5. Address all future communications to:

Elizabeth Graf  
ARNOLD WHITE & DURKEE  
750 Bering Drive  
Houston, Texas 77057-2198  
(713) 787-1400

6. The prior application is presently assigned to Monsanto Company.

7. Enclosed is a preliminary amendment. Any additional fees incurred by this amendment are included in the check at No. 2 above and said fee has been calculated after calculation of claims and after amendment of claims by the preliminary amendment.

8. Amend the specification by inserting before the first line the sentence: --This is a divisional of co-pending application Serial No. 09/137,440 filed August 20, 1998--.

9. Enclosed are formal drawings.

10. Transfer the sequence information, including the computer readable form previously submitted in the parent application, Serial No. 09/137,440 filed August 20, 1998, for use in this application. Under 37 C.F.R. § 1.821(e), Applicant states that the paper copy of the sequence listing in this application is identical to the computer readable copy in parent application Serial No. 09/137,440 filed August 20, 1998. Under 37 C.F.R. § 1.821(f), Applicant also states that the information recorded in computer readable form is identical to the written sequence listing.

11. Return Receipt Postcard (should be specifically itemized).

Respectfully submitted,



Christopher J. Buntel, Ph.D.  
Reg. No. 44,573  
AGENT FOR ASSIGNEE,  
MONSANTO COMPANY

ARNOLD, WHITE & DURKEE  
P.O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1400

Date: December 16, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gerard F. Barry et al.

Serial No.: To be Assigned

Filed: December 16, 1999

For: GLYPHOSATE-TOLERANT 5-  
ENOLPYRUVYLSHIKIMATE-3-  
PHOSPHATE SYNTHASES

Group Art Unit: To be Assigned

Examiner: To be Assigned

Atty. Dkt. No.: MOBT:175-2/PAT

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Please amend this application as follows:

**In The Specification**

At page 2, line 1, insert the following:

--This is a divisional of co-pending application Serial No. 09/137,440, filed August 20, 1998.--

**In the Claims**

Cancel claims 1-100, without prejudice.

<p>CERTIFICATE OF EXPRESS MAIL NUMBER EL392860338US DATE OF DEPOSIT December 16, 1999</p> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.</p> <p><u>Marie F. Barry</u> Signature</p>
--

Please add the following new claims:

--101. (Added) An antibody immunoreactive with a 5-enolpyruvylshikimate-3-phosphate synthase enzyme, the enzyme comprising the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;

X<sub>2</sub> is S or T; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is S or T; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and

-N-X<sub>5</sub>-T-R-(SEQ ID NO:40), in which

X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.

102. (Added) The antibody of claim 101, wherein X<sub>1</sub> is D or N; X<sub>2</sub> is S or T; X<sub>3</sub> is S or T; X<sub>4</sub> is V, I or L; and X<sub>5</sub> is P or Q.

103. (Added) The antibody of claim 101, wherein the enzyme comprises SEQ ID NO:3.

104. (Added) The antibody of claim 101, further defined as a polyclonal antibody.

105. (Added) The antibody of claim 101, further defined as a monoclonal antibody.

106. (Added) A method of detecting a 5-enolpyruvylshikimate-3-phosphate synthase enzyme in a sample, the method comprising:

selecting a sample suspected of containing a 5-enolpyruvylshikimate-3-phosphate synthase enzyme;

contacting the sample with an antibody to form an enzyme-antibody complex; and

detecting the presence of the enzyme-antibody complex; wherein the antibody is immunoreactive with SEQ ID NO:3.

107. (Added) A method of detecting a 5-enolpyruvylshikimate-3-phosphate synthase enzyme in plant cells or plant tissue, the method comprising:

selecting plant cells or plant tissue suspected of containing a 5-enolpyruvylshikimate-3-phosphate synthase enzyme;

preparing a sample from the plant cells or plant tissue;

contacting the sample with an antibody to form an enzyme-antibody complex; and

detecting the presence of the enzyme-antibody complex; wherein the antibody is immunoreactive with SEQ ID NO:3.

108. (Added) A kit for the detection of a 5-enolpyruvylshikimate-3-phosphate synthase enzyme in a sample, the kit comprising:

a container comprising an antibody immunoreactive with SEQ ID NO:3; and

a detection agent.--

REMARKS

Claims 1-100 were initially filed in the parent case, application Serial No. 09/137,440 and thus have been canceled from this divisional application. The parent application was allowed on November 23, 1999 but has not yet issued.

The active claims in this case are claims 101-108. Added claims 101-108 correspond to cancelled claims 104-111 in the parent case. No new matter is introduced by the addition of claims 101-108.

The specification has been amended to recite the relationship with the parent case, namely that it is a divisional application.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Assistant Commissioner is authorized to deduct said fees from Arnold White & Durkee Deposit Account No. 01-2508/MOBT:175-2/PAT.

Respectfully submitted,

Christopher D. Doss

Christopher J. Buntel, Ph.D.  
Reg. No. 44,573  
Agent for Assignee,  
Monsanto Company

ARNOLD, WHITE & DURKEE  
P.O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1400

Date: December 16, 1999

**PATENT**  
38-21(10660)A

**GLYPHOSATE-TOLERANT**  
**5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASES**

*Seeb*  
*A1*

This is a continuation-in-part of a copending U.S. patent application serial number 07/749,611, filed August 28, 1991 which is a continuation-in-part of U.S. patent application serial number 07/576,537, filed August 31, 1990, now abandoned.

**BACKGROUND OF THE INVENTION**

This invention relates in general to plant molecular biology and, more particularly, to a new class of glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases.

Recent advances in genetic engineering have provided the requisite tools to transform plants to contain foreign genes. It is now possible to produce plants which have unique characteristics of agronomic importance. Certainly, one such advantageous trait is more cost effective, environmentally compatible weed control via herbicide tolerance. Herbicide-tolerant plants may reduce the need for tillage to control weeds thereby effectively reducing soil erosion.

One herbicide which is the subject of much investigation in this regard is N-phosphonomethylglycine commonly referred to as glyphosate. Glyphosate inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, plant hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter

referred to as EPSP synthase or EPSPS). For purposes of the present invention, the term "glyphosate" should be considered to include any herbicidally effective form of N-phosphonomethylglycine (including any salt thereof) and other forms which result in the production of the glyphosate anion in planta.

It has been shown that glyphosate-tolerant plants can be produced by inserting into the genome of the plant the capacity to produce a higher level of EPSP synthase in the chloroplast of the cell (Shah *et al.*, 1986) which enzyme is preferably glyphosate-tolerant (Kishore *et al.* 1988). Variants of the wild-type EPSPS enzyme have been isolated which are glyphosate-tolerant as a result of alterations in the EPSPS amino acid coding sequence (Kishore and Shah, 1988; Schulz *et al.*, 1984; Sost *et al.*, 1984; Kishore *et al.*, 1986). These variants typically have a higher  $K_i$  for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate-tolerant phenotype, but these variants are also characterized by a high  $K_m$  for PEP which makes the enzyme kinetically less efficient (Kishore and Shah, 1988; Sost *et al.*, 1984; Schulz *et al.*, 1984; Kishore *et al.*, 1986; Sost and Amrhein, 1990). For example, the apparent  $K_m$  for PEP and the apparent  $K_i$  for glyphosate for the native EPSPS from *E. coli* are 10  $\mu\text{M}$  and 0.5  $\mu\text{M}$  while for a glyphosate-tolerant isolate having a single amino acid substitution of an alanine for the glycine at position 96 these values are 220  $\mu\text{M}$  and 4.0 mM, respectively. A number of glyphosate-tolerant plant variant EPSPS genes have been constructed by mutagenesis. Again, the glyphosate-tolerant EPSPS was impaired due to an increase in the  $K_m$  for PEP and a slight reduction of the  $V_{\text{max}}$  of the native plant enzyme (Kishore and Shah, 1988) thereby lowering the catalytic efficiency ( $V_{\text{max}}/K_m$ ) of the enzyme. Since the kinetic constants of the variant enzymes are impaired with respect to PEP, it has been proposed that high levels of overproduction of the variant enzyme, 40-80 fold, would be required to

maintain normal catalytic activity in plants in the presence of glyphosate (Kishore *et al.*, 1988).

While such variant EPSP synthases have proved useful in obtaining transgenic plants tolerant to glyphosate, it would be increasingly beneficial to obtain an EPSP synthase that is highly glyphosate-tolerant while still kinetically efficient such that the amount of the glyphosate-tolerant EPSPS needed to be produced to maintain normal catalytic activity in the plant is reduced or that improved tolerance be obtained with the same expression level.

Previous studies have shown that EPSPS enzymes from different sources vary widely with respect to their degree of sensitivity to inhibition by glyphosate. A study of plant and bacterial EPSPS enzyme activity as a function of glyphosate concentration showed that there was a very wide range in the degree of sensitivity to glyphosate. The degree of sensitivity showed no correlation with any genus or species tested (Schulz *et al.*, 1985). Insensitivity to glyphosate inhibition of the activity of the EPSPS from the *Pseudomonas* sp. PG2982 has also been reported but with no details of the studies (Fitzgibbon, 1988). In general, while such natural tolerance has been reported, there is no report suggesting the kinetic superiority of the naturally occurring bacterial glyphosate-tolerant EPSPS enzymes over those of mutated EPSPS enzymes nor have any of the genes been characterized. Similarly, there are no reports on the expression of naturally glyphosate-tolerant EPSPS enzymes in plants to confer glyphosate tolerance.

For purposes of the present invention the term "mature EPSP synthase" relates to the EPSPS polypeptide without the N-terminal chloroplast transit peptide. It is now known that the precursor form of the EPSP synthase in plants (with the transit peptide) is expressed and upon delivery to the chloroplast, the transit peptide is cleaved yielding the mature EPSP synthase. All numbering of amino acid positions are given with respect to the mature EPSP synthase (without chloroplast transit peptide leader) to facilitate comparison of EPSPS sequences from sources which have

chloroplast transit peptides (i.e., plants and fungi) to sources which do not utilize a chloroplast targeting signal (i.e., bacteria).

In the amino acid sequences which follow, the standard single letter or three letter nomenclature are used. All peptide structures represented in the following description are shown in conventional format in which the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus at the right. Likewise, amino acid nomenclature for the naturally occurring amino acids found in protein is as follows: alanine (Ala;A), asparagine (Asn;N), aspartic acid (Asp;D), arginine (Arg;R), cysteine (Cys;C), glutamic acid (Glu;E), glutamine (Gln;Q), glycine (Gly;G), histidine (His;H), isoleucine (Ile;I), leucine (Leu;L), lysine (Lys;K), methionine (Met;M), phenylalanine (Phe;F), proline (Pro;P), serine (Ser;S), threonine (Thr;T), tryptophan (Trp;W), tyrosine (Tyr;Y), and valine (Val;V). An "X" is used when the amino acid residue is unknown and parentheses designate that an unambiguous assignment is not possible and the amino acid designation within the parentheses is the most probable estimate based on known information.

The term "nonpolar" amino acids include alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine. The term "uncharged polar" amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The term "charged polar" amino acids includes the "acidic" and "basic" amino acids. The term "acidic" amino acids includes aspartic acid and glutamic acid. The term "basic" amino acid includes lysine, arginine and histidine. The term "polar" amino acids includes both "charged polar" and "uncharged polar" amino acids.

Deoxyribonucleic acid (DNA) is a polymer comprising four mononucleotide units, dAMP (2'-Deoxyadenosine-5- monophosphate), dGMP (2'-Deoxyguanosine-5- monophosphate), dCMP (2'-Deoxycytosine-5- monophosphate) and dTMP (2'-Deoxythymosine-5- monophosphate) linked in various sequences by 3',5'-phosphodiester bridges. The structural DNA consists of multiple nucleotide triplets called "codons" which code for the amino

acids. The codons correspond to the various amino acids as follows: Arg (CGA, CGC, CGG, CGT, AGA, AGG); Leu (CTA, CTC, CTG, CTT, TTA, TTG); Ser (TCA, TCC, TCG, TCT, AGC, AGT); Thr (ACA, ACC, ACG, ACT); Pro (CCA, CCC, CCG, CCT); Ala (GCA, GCC, GCG, GCT); Gly (GGA, GGC, GGG, GGT); Ile (ATA, ATC, ATT); Val (GTA, GTC, GTG, GTT); Lys (AAA, AAG); Asn (AAC, AAT); Gln (GAA, CAG); His (CAC, CAT); Glu (GAA, GAG); Asp (GAC, GAT); Tyr (TAC, TAT); Cys (TGC, TGT); Phe (TTC, TTT); Met (ATG); and Trp (UGG). Moreover, due to the redundancy of the genetic code (i.e., more than one codon for all but two amino acids), there are many possible DNA sequences which may code for a particular amino acid sequence.

## **SUMMARY OF THE INVENTION**

DNA molecules comprising DNA encoding kinetically efficient, glyphosate-tolerant EPSP synthases are disclosed. The EPSP synthases of the present invention reduce the amount of overproduction of the EPSPS enzyme in a transgenic plant necessary for the enzyme to maintain catalytic activity while still conferring glyphosate tolerance. The EPSP synthases described herein represent a new class of EPSPS enzymes, referred to hereinafter as Class II EPSPS enzymes. Class II EPSPS enzymes of the present invention usually share only between about 47% and 55% amino acid similarity or between about 22% and 30% amino acid identity to other known bacterial or plant EPSPS enzymes and exhibit tolerance to glyphosate while maintaining suitable  $K_m$  (PEP) ranges. Suitable ranges of  $K_m$  (PEP) for EPSPS for enzymes of the present invention are between 1-150  $\mu$ M, with a more preferred range of between 1-35  $\mu$ M, and a most preferred range between 2-25  $\mu$ M. These kinetic constants are determined under the assay conditions specified hereinafter. An EPSPS of the present invention preferably has a  $K_i$  for glyphosate range of between 15-10000  $\mu$ M. The  $K_i/K_m$  ratio should be

between about 2-500, and more preferably between 25-500. The  $V_{max}$  of the purified enzyme should preferably be in the range of 2-100 units/mg ( $\mu$ moles/minute.mg at 25°C) and the  $K_m$  for shikimate-3-phosphate should preferably be in the range of 0.1 to 50  $\mu$ M.

Genes coding for Class II EPSPS enzymes have been isolated from five (5) different bacteria: *Agrobacterium tumefaciens* sp. strain CP4, *Achromobacter* sp. strain LBAA, *Pseudomonas* sp. strain PG2982, *Bacillus subtilis*, and *Staphylococcus aureus*. The LBAA and PG2982 Class II EPSPS genes have been determined to be identical and the proteins encoded by these two genes are very similar to the CP4 protein and share approximately 84% amino acid identity with it. Class II EPSPS enzymes often may be distinguished from Class I EPSPS's by their inability to react with polyclonal antibodies prepared from Class I EPSPS enzymes under conditions where other Class I EPSPS enzymes would readily react with the Class I antibodies as well as the presence of certain unique regions of amino acid homology which are conserved in Class II EPSP synthases as discussed hereinafter.

Other Class II EPSPS enzymes can be readily isolated and identified by utilizing a nucleic acid probe from one of the Class II EPSPS genes disclosed herein using standard hybridization techniques. Such a probe from the CP4 strain has been prepared and utilized to isolate the Class II EPSPS genes from strains LBAA and PG2982. These genes may also optionally be adapted for enhanced expression in plants by known methodology. Such a probe has also been used to identify homologous genes in bacteria isolated *de novo* from soil.

The Class II EPSPS enzymes are preferably fused to a chloroplast transit peptide (CTP) to target the protein to the chloroplasts of the plant into which it may be introduced. Chimeric genes encoding this CTP-Class II EPSPS fusion protein may be prepared with an appropriate promoter and 3' polyadenylation site for introduction into a desired plant by standard methods.

To obtain the maximal tolerance to glyphosate herbicide it is preferable to transform the desired plant with a plant-expressible Class II EPSPS gene in

conjunction with another plant-expressible gene which expresses a protein capable of degrading glyphosate such as a plant-expressible gene encoding a glyphosate oxidoreductase enzyme as described in PCT Application No. WO 92/00377, the disclosure of which is hereby incorporated by reference.

Therefore, in one aspect, the present invention provides a new class of EPSP synthases that exhibit a low  $K_m$  for phosphoenolpyruvate (PEP), a high  $V_{max}/K_m$  ratio, and a high  $K_i$  for glyphosate such that when introduced into a plant, the plant is made glyphosate-tolerant such that the catalytic activity of the enzyme and plant metabolism are maintained in a substantially normal state. For purposes of this discussion, a highly efficient EPSPS refers to its efficiency in the presence of glyphosate.

More particularly, the present invention provides EPSPS enzymes having a  $K_m$  for phosphoenolpyruvate (PEP) between 1-150  $\mu\text{M}$  and a  $K_i(\text{glyphosate})/K_m(\text{PEP})$  ratio between 3-500, said enzymes having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is an uncharged polar or acidic amino acid,

X<sub>2</sub> is serine or threonine; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is serine or threonine; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is any amino acid; and

-N-X<sub>5</sub>-T-R- (SEQ ID:40), in which

X<sub>5</sub> is any amino acid.

Exemplary Class II EPSPS enzyme sequences are disclosed from seven sources: *Agrobacterium* sp. strain designated CP4, *Achromobacter* sp. strain LBAA, *Pseudomonas* sp. strain PG2982, *Bacillus subtilis* 1A2, *Staphylococcus aureus* (ATCC 35556), *Synechocystis* sp. PCC6803 and *Dichelobacter nodosus*.

In another aspect of the present invention, a double-stranded DNA molecule comprising DNA encoding a Class II EPSPS enzyme is disclosed. Exemplary Class II EPSPS enzyme DNA sequences are disclosed from seven sources: *Agrobacterium* sp. strain designated CP4, *Achromobacter* sp. strain LBAA, *Pseudomonas* sp. strain PG2982, *Bacillus subtilis* 1A2, *Staphylococcus aureus* (ATCC 35556), *Synechocystis* sp. PCC6803 and *Dichelobacter nodosus*.

In a further aspect of the present invention, nucleic acid probes from EPSPS Class II genes are presented that are suitable for use in screening for Class II EPSPS genes in other sources by assaying for the ability of a DNA sequence from the other source to hybridize to the probe.

In yet another aspect of the present invention, a recombinant, double-stranded DNA molecule comprising in sequence:

- a) a promoter which functions in plant cells to cause the production of an RNA sequence;
- b) a structural DNA sequence that causes the production of an RNA sequence which encodes a Class II EPSPS enzyme having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is an uncharged polar or acidic amino acid.

X<sub>2</sub> is serine or threonine; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is serine or threonine; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is any amino acid; and

-N-X<sub>5</sub>-T-R- (SEQ ID:40), in which

X<sub>5</sub> is any amino acid; and

- c) a 3' nontranslated region which functions in plant cells to cause the addition of a stretch of polyadenyl nucleotides to the 3' end of the RNA sequence

where the promoter is heterologous with respect to the structural DNA sequence and adapted to cause sufficient expression of the EPSP synthase polypeptide to enhance the glyphosate tolerance of a plant cell transformed with said DNA molecule.

In still yet another aspect of the present invention, transgenic plants and transformed plant cells are disclosed that are made glyphosate-tolerant by the introduction of the above-described plant-expressible Class II EPSPS DNA molecule into the plant's genome.

In still another aspect of the present invention, a method for selectively controlling weeds in a crop field is presented by planting crop seeds or crop plants transformed with a plant-expressible Class II EPSPS DNA molecule to confer glyphosate tolerance to the plants which allows for glyphosate containing herbicides to be applied to the crop to selectively kill the glyphosate sensitive weeds, but not the crops.

Other and further objects, advantages and aspects of the invention will become apparent from the accompanying drawing figures and the description of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

*Figures 1A + 1B show*  
Figure 1 shows the DNA sequence (SEQ ID NO:1) for the full-length promoter of figwort mosaic virus (FMV35S).

*Figures 2A, 2B, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 3I, 3J, 3K, 3L, 3M, 3N, 3O, 3P, 3Q, 3R, 3S, 3T, 3U, 3V, 3W, 3X, 3Y, 3Z show*  
Figure 2 shows the cosmid cloning vector pMON17020.  
Figure 3 shows the structural DNA sequence (SEQ ID NO:2) for the Class II EPSPS gene from bacterial isolate *Agrobacterium* sp. strain CP4 and the deduced amino acid sequence (SEQ ID NO:3).

*Figures 4A - 4E show*  
Figure 4 shows the structural DNA sequence (SEQ ID NO:4) for the Class II EPSPS gene from the bacterial isolate *Achromobacter* sp. strain LBAA and the deduced amino acid sequence (SEQ ID NO:5).

1 *Figures 5A-5E Show*  
1 *Figure 5* shows the structural DNA sequence (SEQ ID NO:6) for the Class II EPSPS gene from the bacterial isolate *Pseudomonas sp.* strain PG2982 and the deduced amino acid sequence (SEQ ID NO:7).

4 *Figures 6A-6B Show*  
4 *Figure 6* shows the Bestfit comparison of the CP4 EPSPS amino acid sequence (SEQ ID NO:3) with that for the *E. coli* EPSPS (SEQ ID NO:8).

5 *Figures 7A-7B Show*  
5 *Figure 7* shows the Bestfit comparison of the CP4 EPSPS amino acid sequence (SEQ ID NO:3) with that for the LBAA EPSPS (SEQ ID NO:5).

6 *Figures 8A-8B Show*  
6 *Figure 8* shows the structural DNA sequence (SEQ ID NO:9) for the synthetic CP4 Class II EPSPS gene.

7 *Figures 9A-9B Show*  
7 *Figure 9* shows the DNA sequence (SEQ ID NO:10) of the chloroplast transit peptide (CTP) and encoded amino acid sequence (SEQ ID NO:11) derived from the *Arabidopsis thaliana* EPSPS CTP and containing a *SphI* restriction site at the chloroplast processing site, hereinafter referred to as CTP2.

8 *Figures 10A-10B Show*  
8 *Figure 10* shows the DNA sequence (SEQ ID NO:12) of the chloroplast transit peptide and encoded amino acid sequence (SEQ ID NO:13) derived from the *Arabidopsis thaliana* EPSPS gene and containing an *EcoRI* restriction site within the mature region of the EPSPS, hereinafter referred to as CTP3.

9 *Figures 11A-11B Show*  
9 *Figure 11* shows the DNA sequence (SEQ ID NO:14) of the chloroplast transit peptide and encoded amino acid sequence (SEQ ID NO:15) derived from the *Petunia hybrida* EPSPS CTP and containing a *SphI* restriction site at the chloroplast processing site and in which the amino acids at the processing site are changed to -Cys-Met-, hereinafter referred to as CTP4.

10 *Figures 12A-12B Show*  
10 *Figure 12* shows the DNA sequence (SEQ ID NO:16) of the chloroplast transit peptide and encoded amino acid sequence (SEQ ID NO:17) derived from the *Petunia hybrida* EPSPS gene with the naturally occurring *EcoRI* site in the mature region of the EPSPS gene, hereinafter referred to as CTP5.

11 *Figure 13* shows a plasmid map of CP4 plant transformation/ expression vector pMON17110.

Figure 14 shows a plasmid map of CP4 synthetic EPSPS gene plant transformation/expression vector pMON17131.

Figure 15 shows a plasmid map of CP4 EPSPS free DNA plant transformation expression vector pMON13640.

Figure 16 shows a plasmid map of CP4 plant transformation/direct selection vector pMON17227.

Figure 17 shows a plasmid map of CP4 plant transformation/expression vector pMON19653.

<sup>Figures 18A-18D show</sup>  
Figure 18 shows the structural DNA sequence (SEQ ID NO:41) for the Class II EPSPS gene from the bacterial isolate *Bacillus subtilis* and the deduced amino acid sequence (SEQ ID NO:42).

<sup>Figures 19A-19D show</sup>  
Figure 19 shows the structural DNA sequence (SEQ ID NO:43) for the Class II EPSPS gene from the bacterial isolate *Staphylococcus aureus* and the deduced amino acid sequence (SEQ ID NO:44).

<sup>Figures 20A-20C show</sup>  
Figure 20 shows the Bestfit comparison of the representative Class II EPSPS amino acid sequences *Pseudomonas* sp. strain PG2982 (SEQ ID NO:7), *Achromobacter* sp. strain LBAA (SEQ ID NO:5), *Agrobacterium* sp. strain designated CP4 (SEQ ID NO:3), *Bacillus subtilis* (SEQ ID NO:42), and *Staphylococcus aureus* (SEQ ID NO:44) with that for representative Class I EPSPS amino acid sequences [*Saccharomyces cerevisiae* (SEQ ID NO:49), *Aspergillus nidulans* (SEQ ID NO:50), *Brassica napus* (SEQ ID NO:51), *Arabidopsis thaliana* (SEQ ID NO:52), *Nicotina tabacum* (SEQ ID NO:53), *L. esculentum* (SEQ ID NO:54), *Petunia hybrida* (SEQ ID NO:55), *Zea mays* (SEQ ID NO:56), *Solmenella gallinarum* (SEQ ID NO:57), *Solmenella typhimurium* (SEQ ID NO:58), *Solmenella typhi* (SEQ ID NO:65), *E. coli* (SEQ ID NO:8), *K. pneumoniae* (SEQ ID NO:59), *Y. enterocolitica* (SEQ ID NO:60), *H. influenzae* (SEQ ID NO:61), *P. multocida* (SEQ ID NO:62), *Aeromonas salmonicida* (SEQ ID NO:63), *Bacillus pertussis* (SEQ ID NO:64)] and illustrates the conserved regions among Class II EPSPS sequences which are unique to Class II EPSPS sequences. To aid in a comparison of the EPSPS sequences, only mature

EPSPS sequences were compared. That is, the sequence corresponding to the chloroplast transit peptide, if present in a subject EPSPS, was removed prior to making the sequence alignment.

~~Figures 21A, 21B show~~  
- ~~Figure 21~~ shows the structural DNA sequence (SEQ ID NO:66) for the Class II EPSPS gene from the bacterial isolate *Synechocystis* sp. PCC6803 and the deduced amino acid sequence (SEQ ID NO:67).

~~Figures 22A - 22B show~~  
- ~~Figure 22~~ shows the structural DNA sequence (SEQ ID NO:68) for the Class II EPSPS gene from the bacterial isolate *Dichelobacter nodosus* and the deduced amino acid sequence (SEQ ID NO:69).

~~Figures 23A - 23D show~~  
- ~~Figure 23~~ shows the Bestfit comparison of the representative Class II EPSPS amino acid sequences *Pseudomonas* sp. strain PG2982 (SEQ ID NO:7), *Achromobacter* sp. strain LBAA (SEQ ID NO:5), *Agrobacterium* sp. strain designated CP4 (SEQ ID NO:3), *Synechocystis* sp. PCC6803 (SEQ ID NO:67), *Bacillus subtilis* (SEQ ID NO:42), *Dichelobacter nodosus* (SEQ ID NO:69) and *Staphylococcus aureus* (SEQ ID NO:44).

Figure 24 a plasmid map of canola plant transformation/expression vector pMON17209.

Figure 25 a plasmid map of canola plant transformation/expression vector pMON17237.

#### STATEMENT OF THE INVENTION

The expression of a plant gene which exists in double-stranded DNA form involves synthesis of messenger RNA (mRNA) from one strand of the DNA by RNA polymerase enzyme, and the subsequent processing of the mRNA primary transcript inside the nucleus. This processing involves a 3' non-translated region which adds polyadenylate nucleotides to the 3' end of the RNA.

Transcription of DNA into mRNA is regulated by a region of DNA usually referred to as the "promoter." The promoter region contains a sequence

of bases that signals RNA polymerase to associate with the DNA, and to initiate the transcription into mRNA using one of the DNA strands as a template to make a corresponding complementary strand of RNA. A number of promoters which are active in plant cells have been described in the literature. These include the nopaline synthase (NOS) and octopine synthase (OCS) promoters (which are carried on tumor-inducing plasmids of *Agrobacterium tumefaciens*), the cauliflower mosaic virus (CaMV) 19S and 35S promoters, the light-inducible promoter from the small subunit of ribulose bis-phosphate carboxylase (ssRUBISCO, a very abundant plant polypeptide) and the full-length transcript promoter from the figwort mosaic virus (FMV35S), promoters from the maize ubiquitin and rice actin genes. All of these promoters have been used to create various types of DNA constructs which have been expressed in plants; see, e.g., PCT publication WO 84/02913 (Rogers *et al.*, Monsanto).

Promoters which are known or found to cause transcription of DNA in plant cells can be used in the present invention. Such promoters may be obtained from a variety of sources such as plants and plant DNA viruses and include, but are not limited to, the CaMV35S and FMV35S promoters and promoters isolated from plant genes such as ssRUBISCO genes and the maize ubiquitin and rice actin genes. As described below, it is preferred that the particular promoter selected should be capable of causing sufficient expression to result in the production of an effective amount of a Class II EPSPS to render the plant substantially tolerant to glyphosate herbicides. The amount of Class II EPSPS needed to induce the desired tolerance may vary with the plant species. It is preferred that the promoters utilized have relatively high expression in all meristematic tissues in addition to other tissues inasmuch as it is now known that glyphosate is translocated and accumulated in this type of plant tissue. Alternatively, a combination of chimeric genes can be used to cumulatively result in the necessary overall expression level of the selected Class II EPSPS enzyme to result in the glyphosate-tolerant phenotype.

The mRNA produced by a DNA construct of the present invention also contains a 5' non-translated leader sequence. This sequence can be derived from the promoter selected to express the gene, and can be specifically modified so as to increase translation of the mRNA. The 5' non-translated regions can also be obtained from viral RNAs, from suitable eukaryotic genes, or from a synthetic gene sequence. The present invention is not limited to constructs, as presented in the following examples, wherein the non-translated region is derived from both the 5' non-translated sequence that accompanies the promoter sequence and part of the 5' non-translated region of the virus coat protein gene. Rather, the non-translated leader sequence can be derived from an unrelated promoter or coding sequence as discussed above.

Preferred promoters for use in the present invention the the full-length transcript (SEQ ID NO:1) promoter from the figwort mosaic virus (FMV35S) and the full-length transcript (35S) promoter from cauliflower mosaic virus (CaMV), including the enhanced CaMV35S promoter (Kay *et al.* 1987). The FMV35S promoter functions as strong and uniform promoter with particularly good expression in meristematic tissue for chimeric genes inserted into plants, particularly dicotyledons. The resulting transgenic plant in general expresses the protein encoded by the inserted gene at a higher and more uniform level throughout the tissues and cells of the transformed plant than the same gene driven by an enhanced CaMV35S promoter. Referring to Figure 1, the DNA sequence (SEQ ID NO:1) of the FMV35S promoter is located between nucleotides 6368 and 6930 of the FMV genome. A 5' non-translated leader sequence is preferably coupled with the promoter. The leader sequence can be from the FMV35S genome itself or can be from a source other than FMV35S.

For expression of heterologous genes in monocotyledonous plants the use of an intron has been found to enhance expression of the heterologous gene. While one may use any of a number of introns which have been isolated from plant genes, the use of the first intron from the maize heat shock 70 gene is preferred.

The 3' non-translated region of the chimeric plant gene contains a polyadenylation signal which functions in plants to cause the addition of polyadenylate nucleotides to the 3' end of the viral RNA. Examples of suitable 3' regions are (1) the 3' transcribed, non-translated regions containing the polyadenylated signal of Agrobacterium tumor-inducing (Ti) plasmid genes, such as the nopaline synthase (NOS) gene, and (2) plant genes like the soybean storage protein genes and the small subunit of the ribulose-1,5-bisphosphate carboxylase (ssRUBISCO) gene. An example of a preferred 3' region is that from the ssRUBISCO gene from pea (E9), described in greater detail below.

The DNA constructs of the present invention also contain a structural coding sequence in double-stranded DNA form which encodes a glyphosate-tolerant, highly efficient Class II EPSPS enzyme.

**Identification of glyphosate-tolerant, highly efficient EPSPS enzymes**

In an attempt to identify and isolate glyphosate-tolerant, highly efficient EPSPS enzymes, kinetic analysis of the EPSPS enzymes from a number of bacteria exhibiting tolerance to glyphosate or that had been isolated from suitable sources was undertaken. It was discovered that in some cases the EPSPS enzymes showed no tolerance to inhibition by glyphosate and it was concluded that the tolerance phenotype of the bacterium was due to an impermeability to glyphosate or other factors. In a number of cases, however, microorganisms were identified whose EPSPS enzyme showed a greater degree of tolerance to inhibition by glyphosate and that displayed a low  $K_m$  for PEP when compared to that previously reported for other microbial and plant sources. The EPSPS enzymes from these microorganisms were then subjected to further study and analysis.

Table I displays the data obtained for the EPSPS enzymes identified and isolated as a result of the above described analysis. Table I includes data for three identified Class II EPSPS enzymes that were observed to have a high

tolerance to inhibition to glyphosate and a low  $K_m$  for PEP as well as data for the native Petunia EPSPS and a glyphosate-tolerant variant of the Petunia EPSPS referred to as GA101. The GA101 variant is so named because it exhibits the substitution of an alanine residue for a glycine residue at position 101 (with respect to Petunia). When the change introduced into the Petunia EPSPS (GA101) was introduced into a number of other EPSPS enzymes, similar changes in kinetics were observed, an elevation of the  $K_i$  for glyphosate and of the  $K_m$  for PEP.

**Table I Kinetic characterization of EPSPS enzymes**

ENZYME SOURCE	$K_m$ PEP ( $\mu$ M)	$K_i$ Glyphosate ( $\mu$ M)	$K_i/K_m$
Petunia	5	0.4	0.08
Petunia GA101	200	2000	10
PG2982	2.1-3.1 <sup>1</sup>	25-82	~8-40
LBAA	~7.3-8 <sup>2</sup>	60 (est) <sup>7</sup>	~7.9
CP4	12 <sup>3</sup>	2720	227
<i>B. subtilis</i>	1A2	13 <sup>4</sup>	440
<i>S. aureus</i>		55	33.8
		200	40

1 Range of PEP tested = 1-40  $\mu$ M

2 Range of PEP tested = 5-80  $\mu$ M

3 Range of PEP tested = 1.5-40  $\mu$ M

4 Range of PEP tested = 1-60  $\mu$ M

5 Range of PEP tested = 1-50  $\mu$ M

7 (est) = estimated

The *Agrobacterium* sp. strain CP4 was initially identified by its ability to grow on glyphosate as a carbon source (10 mM) in the presence of 1 mM phosphate. The strain CP4 was identified from a collection obtained from a fixed-bed immobilized cell column that employed Mannville R-635 diatomaceous earth beads. The column had been run for three months on a

waste-water feed from a glyphosate production plant. The column contained 50 mg/ml glyphosate and NH<sub>3</sub> as NH<sub>4</sub>Cl. Total organic carbon was 300 mg/ml and BOD's (Biological Oxygen Demand - a measure of "soft" carbon availability) were less than 30 mg/ml. This treatment column has been described (Heitkamp *et al.*, 1990). Dworkin-Foster minimal salts medium containing glyphosate at 10 mM and with phosphate at 1 mM was used to select for microbes from a wash of this column that were capable of growing on glyphosate as sole carbon source. Dworkin-Foster minimal medium was made up by combining in 1 liter (with autoclaved H<sub>2</sub>O), 1 ml each of A, B and C and 10 ml of D (as per below) and thiamine HCl (5 mg).

A. D-F Salts (1000X stock; per 100 ml; autoclaved):

H <sub>3</sub> BO <sub>3</sub>	1 mg
MnSO <sub>4</sub> .7H <sub>2</sub> O	1 mg
ZnSO <sub>4</sub> .7H <sub>2</sub> O	12.5 mg
CuSO <sub>4</sub> .5H <sub>2</sub> O	8 mg
NaMoO <sub>3</sub> .3H <sub>2</sub> O	1.7 mg

B. FeSO <sub>4</sub> .7H <sub>2</sub> O (1000X stock; per 100 ml; autoclaved)	0.1 g
C. MgSO <sub>4</sub> .7H <sub>2</sub> O (1000X stock; per 100 ml; autoclaved)	20 g
D. (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> (100X stock; per 100 ml; autoclaved)	20 g

Yeast Extract (YE; Difco) was added to a final concentration of 0.01 or 0.001%. The strain CP4 was also grown on media composed of D-F salts, amended as described above, containing glucose, gluconate and citrate (each at 0.1 %) as carbon sources and with inorganic phosphate (0.2 - 1.0 mM) as the phosphorous source.

Other Class II EPSPS containing microorganisms were identified as *Achromobacter* sp. strain LBAA (Hallas *et al.*, 1988), *Pseudomonas* sp. strain

PG2982 (Moore *et al.*, 1983; Fitzgibbon 1988), *Bacillus subtilis* 1A2 (Henner *et al.*, 1984) and *Staphylococcus aureus* (O'Connell *et al.*, 1993). It had been reported previously, from measurements in crude lysates, that the EPSPS enzyme from strain PG2982 was less sensitive to inhibition to glyphosate than that of *E. coli*, but there has been no report of the details of this lack of sensitivity and there has been no report on the  $K_m$  for PEP for this enzyme or of the DNA sequence for the gene for this enzyme (Fitzgibbon, 1988; Fitzgibbon and Braymer, 1990).

**Relationship of the Class II EPSPS to those previously studied**

All EPSPS proteins studied to date have shown a remarkable degree of homology. For example, bacterial and plant EPSPS's are about 54% identical and with similarity as high as 80%. Within bacterial EPSPS's and plant EPSPS's themselves the degree of identity and similarity is much greater (see Table II).

**Table II Comparison between exemplary Class I EPSPS**

**protein sequences**

	<u>similarity</u>	<u>identity</u>
<i>E. coli</i> vs. <i>S. typhimurium</i>	93	88
<i>P. hybrida</i> vs. <i>E. coli</i>	72	55
<i>P. hybrida</i> vs. <i>L. esculentum</i>	93	88

1 The EPSPS sequences compared here were obtained from the following references: *E. coli*, Rogers *et al.*, 1983; *S. typhimurium*, Stalker *et al.*, 1985; *Petunia hybrida*, Shah *et al.*, 1986; and tomato (*L. esculentum*), Gasser *et al.*, 1988.

When crude extracts of CP4 and LBAA bacteria (50  $\mu$ g protein) were probed using rabbit anti-EPSPS antibody (Padgette *et al.*, 1987) to the Petunia EPSPS protein in a Western analysis, no positive signal could be detected, even with extended exposure times (Protein A -  $^{125}$ I development system) and

under conditions where the control EPSPS (Petunia EPSPS, 20 ng; a Class I EPSPS) was readily detected. The presence of EPSPS activity in these extracts was confirmed by enzyme assay. This surprising result, indicating a lack of similarity between the EPSPS's from these bacterial isolates and those previously studied, coupled with the combination of a low  $K_m$  for PEP and a high  $K_i$  for glyphosate, illustrates that these new EPSPS enzymes are different from known EPSPS enzymes (now referred to as Class I EPSPS).

#### Glyphosate-tolerant Enzymes in Microbial Isolates

For clarity and brevity of disclosure, the following description of the isolation of genes encoding Class II EPSPS enzymes is directed to the isolation of such a gene from a bacterial isolate. Those skilled in the art will recognize that the same or similar strategy can be utilized to isolate such genes from other microbial isolates, plant or fungal sources.

#### Cloning of the *Agrobacterium* sp. strain CP4 EPSPS Gene(s) in *E. coli*

Having established the existence of a suitable EPSPS in *Agrobacterium* sp. strain CP4, two parallel approaches were undertaken to clone the gene: cloning based on the expected phenotype for a glyphosate-tolerant EPSPS; and purification of the enzyme to provide material to raise antibodies and to obtain amino acid sequences from the protein to facilitate the verification of clones. Cloning and genetic techniques, unless otherwise indicated, are generally those described in Maniatis *et al.*, 1982 or Sambrook *et al.*, 1987. The cloning strategy was as follows: introduction of a cosmid bank of strain *Agrobacterium* sp. strain CP4 into *E. coli* and selection for the EPSPS gene by selection for growth on inhibitory concentrations of glyphosate.

Chromosomal DNA was prepared from strain *Agrobacterium* sp. strain CP4 as follows: The cell pellet from a 200 ml L-Broth (Miller, 1972), late log phase culture of *Agrobacterium* sp. strain CP4 was resuspended in 10 ml of Solution I; 50 mM Glucose, 10 mM EDTA, 25 mM Tris -CL pH 8.0 (Birnboim

and Doly, 1979). SDS was added to a final concentration of 1% and the suspension was subjected to three freeze-thaw cycles, each consisting of immersion in dry ice for 15 minutes and in water at 70°C for 10 minutes. The lysate was then extracted four times with equal volumes of phenol:chloroform (1:1; phenol saturated with TE; TE = 10 mM Tris pH8.0; 1.0 mM EDTA) and the phases separated by centrifugation (15000g; 10 minutes). The ethanol-precipitable material was pelleted from the supernatant by brief centrifugation (8000g; 5 minutes) following addition of two volumes of ethanol. The pellet was resuspended in 5 ml TE and dialyzed for 16 hours at 4°C against 2 liters TE. This preparation yielded a 5 ml DNA solution of 552 µg/ml.

Partially-restricted DNA was prepared as follows. Three 100 µg aliquot samples of CP4 DNA were treated for 1 hour at 37°C with restriction endonuclease *Hind*III at rates of 4, 2 and 1 enzyme unit/µg DNA, respectively. The DNA samples were pooled, made 0.25 mM with EDTA and extracted with an equal volume of phenol:chloroform. Following the addition of sodium acetate and ethanol, the DNA was precipitated with two volumes of ethanol and pelleted by centrifugation (12000 g; 10 minutes). The dried DNA pellet was resuspended in 500 µl TE and layered on a 10-40% Sucrose gradient (in 5% increments of 5.5 ml each) in 0.5 M NaCl, 50 mM Tris pH8.0, 5 mM EDTA. Following centrifugation for 20 hours at 26,000 rpm in a SW28 rotor, the tubes were punctured and ~1.5 ml fractions collected. Samples (20 µl) of each second fraction were run on 0.7% agarose gel and the size of the DNA determined by comparison with linearized lambda DNA and *Hind*III-digested lambda DNA standards. Fractions containing DNA of 25-35 kb fragments were pooled, desalted on AMICON10 columns (7000 rpm; 20°C; 45 minutes) and concentrated by precipitation. This procedure yielded 15 µg of CP4 DNA of the required size. A cosmid bank was constructed using the vector pMON17020. This vector, a map of which is presented in Figure 2, is based on the pBR327 replicon and contains the spectinomycin/streptomycin (Spr;spc) resistance gene from Tn7 (Fling *et al.*, 1985), the chloramphenicol resistance gene

(Cmr;cat) from Tn9 (Alton *et al.*, 1979), the gene10 promoter region from phage T7 (Dunn *et al.*, 1983), and the 1.6 kb *Bgl*II phage lambda *cos* fragment from pHC79 (Hohn and Collins, 1980). A number of cloning sites are located downstream of the *cat* gene. Since the predominant block to the expression of genes from other microbial sources in *E. coli* appears to be at the level of transcription, the use of the T7 promoter and supplying the T7 polymerase *in trans* from the pGP1-2 plasmid (Tabor and Richardson, 1985), enables the expression of large DNA segments of foreign DNA, even those containing RNA polymerase transcription termination sequences. The expression of the *spc* gene is impaired by transcription from the T7 promoter such that only Cmr can be selected in strains containing pGP1-2. The use of antibiotic resistances such as Cm resistance which do not employ a membrane component is preferred due to the observation that high level expression of resistance genes that involve a membrane component, i.e.  $\beta$ -lactamase and Amp resistance, give rise to a glyphosate-tolerant phenotype. Presumably, this is due to the exclusion of glyphosate from the cell by the membrane localized resistance protein. It is also preferred that the selectable marker be oriented in the same direction as the T7 promoter.

The vector was then cut with *Hind*III and treated with calf alkaline phosphatase (CAP) in preparation for cloning. Vector and target sequences were ligated by combining the following:

Vector DNA ( <i>Hind</i> III/CAP)	3 $\mu$ g
Size fractionated CP4 <i>Hind</i> III fragments	1.5 $\mu$ g
10X ligation buffer	2.2 $\mu$ l
T4 DNA ligase (New England Biolabs) (400 U/ $\mu$ l)	1.0 $\mu$ l

and adding H<sub>2</sub>O to 22.0  $\mu$ l. This mixture was incubated for 18 hours at 16°C. 10X ligation buffer is 250 mM Tris-HCl, pH 8.0; 100 mM MgCl<sub>2</sub>; 100 mM Dithiothreitol; 2 mM Spermidine. The ligated DNA (5  $\mu$ l) was packaged into

lambda phage particles (Stratagene; Gigapack Gold) using the manufacturer's procedure.

A sample (200  $\mu$ l) of *E. coli* HB101 (Boyer and Rolland-Dussoix, 1973) containing the T7 polymerase expression plasmid pGP1-2 (Tabor and Richardson, 1985) and grown overnight in L-Broth (with maltose at 0.2% and kanamycin at 50  $\mu$ g/ml) was infected with 50  $\mu$ l of the packaged DNA. Transformants were selected at 30°C on M9 (Miller, 1972) agar containing kanamycin (50  $\mu$ g/ml), chloramphenicol (25  $\mu$ g/ml), L-proline (50  $\mu$ g/ml), L-leucine (50  $\mu$ g/ml) and B1 (5  $\mu$ g/ml), and with glyphosate at 3.0 mM. Aliquot samples were also plated on the same media lacking glyphosate to titer the packaged cosmids. Cosmid transformants were isolated on this latter medium at a rate of  $\sim$ 5 x 10<sup>5</sup> per  $\mu$ g CP4 *Hind*III DNA after 3 days at 30°C. Colonies arose on the glyphosate agar from day 3 until day 15 with a final rate of  $\sim$ 1 per 200 cosmids. DNA was prepared from 14 glyphosate-tolerant clones and, following verification of this phenotype, was transformed into *E. coli* GB100/pGP1-2 (*E. coli* GB100 is an *aroA* derivative of MM294 [Talmadge and Gilbert, 1980]) and tested for complementation for growth in the absence of added aromatic amino acids and aminobenzoic acids. Other *aroA* strains such as SR481 (Bachman *et al.*, 1980; Padgett *et al.*, 1987), could be used and would be suitable for this experiment. The use of GB100 is merely exemplary and should not be viewed in a limiting sense. This *aroA* strain usually requires that growth media be supplemented with L-phenylalanine, L-tyrosine and L-tryptophan each at 100  $\mu$ g/ml and with para-hydroxybenzoic acid, 2,3-dihydroxybenzoic acid and para-aminobenzoic acid each at 5  $\mu$ g/ml for growth in minimal media. Of the fourteen cosmids tested only one showed complementation of the *aroA*- phenotype. Transformants of this cosmid, pMON17076, showed weak but uniform growth on the unsupplemented minimal media after 10 days.

The proteins encoded by the cosmids were determined *in vivo* using a T7 expression system (Tabor and Richardson, 1985). Cultures of *E. coli* containing

pGP1-2 (Tabor and Richardson, 1985) and test and control cosmids were grown at 30°C in L-broth (2 ml) with chloramphenicol and kanamycin (25 and 50 µg/ml, respectively) to a Klett reading of ~ 50. An aliquot was removed and the cells collected by centrifugation, washed with M9 salts (Miller, 1972) and resuspended in 1 ml M9 medium containing glucose at 0.2%, thiamine at 20 µg/ml and containing the 18 amino acids at 0.01% (minus cysteine and methionine). Following incubation at 30°C for 90 minutes, the cultures were transferred to a 42°C water bath and held there for 15 minutes. Rifampicin (Sigma) was added to 200 µg/ml and the cultures held at 42°C for 10 additional minutes and then transferred to 30°C for 20 minutes. Samples were pulsed with 10 µCi of <sup>35</sup>S-methionine for 5 minutes at 30°C. The cells were collected by centrifugation and suspended in 60-120 µl cracking buffer (60 mM Tris-HCl 6.8, 1% SDS, 1% 2-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue). Aliquot samples were electrophoresed on 12.5% SDS-PAGE and following soaking for 60 minutes in 10 volumes of Acetic Acid-Methanol-water (10:30:60), the gel was soaked in ENLIGHTNING™ (DUPONT) following manufacturer's directions, dried, and exposed at -70°C to X-Ray film. Proteins of about 45 kd in size, labeled with <sup>35</sup>S-methionine, were detected in number of the cosmids, including pMON17076.

#### Purification of EPSPS from *Agrobacterium* sp. strain CP4

All protein purification procedures were carried out at 3-5°C. EPSPS enzyme assays were performed using either the phosphate release or radioactive HPLC method, as previously described in Padgett et al., 1987, using 1 mM phosphoenol pyruvate (PEP, Boehringer) and 2 mM shikimate-3-phosphate (S3P) substrate concentrations. For radioactive HPLC assays, <sup>14</sup>C-PEP (Amersham) was utilized. S3P was synthesized as previously described in Wibbenmeyer et al. 1988. N-terminal amino acid sequencing was performed by loading samples onto a Polybrene precycled filter in aliquots while drying. Automated Edman degradation chemistry was used to determine the N-

terminal protein sequence, using an Applied Biosystems Model 470A gas phase sequencer (Hunkapiller *et al.*, 1983) with an Applied Biosystems 120A PTH analyzer.

Five 10-litre fermentations were carried out on a spontaneous "smooth" isolate of strain CP4 that displayed less clumping when grown in liquid culture. This reduced clumping and smooth colony morphology may be due to reduced polysaccharide production by this isolate. In the following section dealing with the purification of the EPSPS enzyme, CP4 refers to the "smooth" isolate - CP4-S1. The cells from the three batches showing the highest specific activities were pooled. Cell paste of *Agrobacterium* sp. CP4 (300 g) was washed twice with 0.5 L of 0.9% saline and collected by centrifugation (30 minutes, 8000 rpm in a GS3 Sorvall rotor). The cell pellet was suspended in 0.9 L extraction buffer (100 mM TrisCl, 1 mM EDTA, 1 mM BAM (Benzamidine), 5 mM DTT, 10% glycerol, pH 7.5) and lysed by 2 passes through a Manton Gaulin cell. The resulting solution was centrifuged (30 minutes, 8000 rpm) and the supernatant was treated with 0.21 L of 1.5% protamine sulfate (in 100 mM TrisCl, pH 7.5, 0.2% w/v final protamine sulfate concentration). After stirring for 1 hour, the mixture was centrifuged (50 minutes, 8000 rpm) and the resulting supernatant treated with solid ammonium sulfate to 40% saturation and stirred for 1 hour. After centrifugation (50 minutes, 8000 rpm), the resulting supernatant was treated with solid ammonium sulfate to 70% saturation, stirred for 50 minutes, and the insoluble protein was collected by centrifugation (1 hour, 8000 rpm). This 40-70% ammonium sulfate fraction was then dissolved in extraction buffer to give a final volume of 0.2 L, and dialyzed twice (Spectrum 10,000 MW cutoff dialysis tubing) against 2 L of extraction buffer for a total of 12 hours.

To the resulting dialyzed 40-70% ammonium sulfate fraction (0.29 L) was added solid ammonium sulfate to give a final concentration of 1 M. This material was loaded (2 ml/min) onto a column (5 cm x 15 cm, 295 ml) packed with phenyl Sepharose CL-4B (Pharmacia) resin equilibrated with extraction

buffer containing 1 M ammonium sulfate, and washed with the same buffer (1.5 L, 2 ml/min). EPSPS was eluted with a linear gradient of extraction buffer going from 1 M to 0.00 M ammonium sulfate (total volume of 1.5 L, 2 ml/min). Fractions were collected (20 ml) and assayed for EPSPS activity by the phosphate release assay. The fractions with the highest EPSPS activity (fractions 36-50) were pooled and dialyzed against 3 x 2 L (18 hours) of 10 mM TrisCl, 25 mM KCl, 1 mM EDTA, 5 mM DTT, 10% glycerol, pH 7.8.

The dialyzed EPSPS extract (350 ml) was loaded (5 ml/min) onto a column (2.4 cm x 30 cm, 136 ml) packed with Q-Sepharose Fast Flow (Pharmacia) resin equilibrated with 10 mM TrisCl, 25 mM KCl, 5 mM DTT, 10% glycerol, pH 7.8 (Q Sepharose buffer), and washed with 1 L of the same buffer. EPSPS was eluted with a linear gradient of Q Sepharose buffer going from 0.025 M to 0.40 M KCl (total volume of 1.4 L, 5 ml/min). Fractions were collected (15 ml) and assayed for EPSPS activity by the phosphate release assay. The fractions with the highest EPSPS activity (fractions 47-60) were pooled and the protein was precipitated by adding solid ammonium sulfate to 80% saturation and stirring for 1 hour. The precipitated protein was collected by centrifugation (20 minutes, 12000 rpm in a GSA Sorvall rotor), dissolved in Q Sepharose buffer (total volume of 14 ml), and dialyzed against the same buffer (2 x 1 L, 18 hours).

The resulting dialyzed partially purified EPSPS extract (19 ml) was loaded (1.7 ml/min) onto a Mono Q 10/10 column (Pharmacia) equilibrated with Q Sepharose buffer, and washed with the same buffer (35 ml). EPSPS was eluted with a linear gradient of 0.025 M to 0.35 M KCl (total volume of 119 ml, 1.7 ml/min). Fractions were collected (1.7 ml) and assayed for EPSPS activity by the phosphate release assay. The fractions with the highest EPSPS activity (fractions 30-37) were pooled (6 ml).

The Mono Q pool was made 1 M in ammonium sulfate by the addition of solid ammonium sulfate and 2 ml aliquots were chromatographed on a Phenyl Superose 5/5 column (Pharmacia) equilibrated with 100 mM TrisCl, 5 mM

DTT, 1 M ammonium sulfate, 10% glycerol, pH 7.5 (Phenyl Superose buffer). Samples were loaded (1 ml/min), washed with Phenyl Superose buffer (10 ml), and eluted with a linear gradient of Phenyl Superose buffer going from 1 M to 0.00 M ammonium sulfate (total volume of 60 ml, 1 ml/min). Fractions were collected (1 ml) and assayed for EPSPS activity by the phosphate release assay. The fractions from each run with the highest EPSPS activity (fractions ~36-40) were pooled together (10 ml, 2.5 mg protein). For N-terminal amino acid sequence determination, a portion of one fraction (#39 from run 1) was dialyzed against 50 mM NaHCO<sub>3</sub> (2 x 1 L). The resulting pure EPSPS sample (0.9 ml, 77 µg protein) was found to exhibit a single N-terminal amino acid sequence of:

XH(G)ASSRPATARKSS(G)LX(G)(T)V(R)IPG(D)(K)(M) (SEQ ID NO:18).

The remaining Phenyl Superose EPSPS pool was dialyzed against 50 mM TrisCl, 2 mM DTT, 10 mM KCl, 10% glycerol, pH 7.5 (2 x 1 L). An aliquot (0.55 ml, 0.61 mg protein) was loaded (1 ml/min) onto a Mono Q 5/5 column (Pharmacia) equilibrated with Q Sepharose buffer, washed with the same buffer (5 ml), and eluted with a linear gradient of Q Sepharose buffer going from 0-0.14 M KCl in 10 minutes, then holding at 0.14 M KCl (1 ml/min). Fractions were collected (1 ml) and assayed for EPSPS activity by the phosphate release assay and were subjected to SDS-PAGE (10-15%, Phast System, Pharmacia, with silver staining) to determine protein purity. Fractions exhibiting a single band of protein by SDS-PAGE (22-25, 222 µg) were pooled and dialyzed against 100 mM ammonium bicarbonate, pH 8.1 (2 x 1 L, 9 hours).

**Trypsinolysis and peptide sequencing of *Agrobacterium* sp strain CP4 EPSPS**

To the resulting pure *Agrobacterium* sp. strain CP4 EPSPS (111 µg) was added 3 µg of trypsin (Calbiochem), and the trypsinolysis reaction was

allowed to proceed for 16 hours at 37°C. The tryptic digest was then chromatographed (1ml/min) on a C18 reverse phase HPLC column (Vydac) as previously described in Padgett *et al.*, 1988 for *E. coli* EPSPS. For all peptide purifications, 0.1% trifluoroacetic acid (TFA, Pierce) was designated buffer "RP-A" and 0.1% TFA in acetonitrile was buffer "RP-B". The gradient used for elution of the trypsinized *Agrobacterium* sp. CP4 EPSPS was: 0-8 minutes, 0% RP-B; 8-28 minutes, 0-15% RP-B; 28-40 minutes, 15-21% RP-B; 40-68 minutes, 21-49% RP-B; 68-72 minutes, 49-75% RP-B; 72-74 minutes, 75-100% RP-B. Fractions were collected (1 ml) and, based on the elution profile at 210 nm, at least 70 distinct peptides were produced from the trypsinized EPSPS. Fractions 40-70 were evaporated to dryness and redissolved in 150 µl each of 10% acetonitrile, 0.1% trifluoroacetic acid.

The fraction 61 peptide was further purified on the C18 column by the gradient: 0-5 minutes, 0% RP-B; 5-10 minutes, 0-38% RP-B; 10-30 minutes, 38-45% B. Fractions were collected based on the UV signal at 210 nm. A large peptide peak in fraction 24 eluted at 42% RP-B and was dried down, resuspended as described above, and rechromatographed on the C18 column with the gradient: 0-5 minutes, 0% RP-B; 5-12 min, 0-38% RP-B; 12-15 min, 38-39% RP-B; 15-18 minutes, 39% RP-B; 18-20 minutes. 39-41% RP-B; 20-24 minutes, 41% RP-B; 24-28 minutes, 42% RP-B. The peptide in fraction 25, eluting at 41% RP-B and designated peptide 61-24-25, was subjected to N-terminal amino acid sequencing, and the following sequence was determined:

APSM(I)(D)EYPILAV (SEQ ID NO:19)

The CP4 EPSPS fraction 53 tryptic peptide was further purified by C18 HPLC by the gradient 0% B (5 minutes), 0-30% B (5-17 minutes), 30-40% B (17-37 minutes). The peptide in fraction 28, eluting at 34% B and designated peptide 53-28, was subjected to N-terminal amino acid sequencing, and the following sequence was determined:

ITGLLEGEDVINTGK (SEQ ID NO:20).

In order to verify the CP4 EPSPS cosmid clone, a number of oligonucleotide probes were designed on the basis of the sequence of two of the tryptic sequences from the CP4 enzyme (Table III). The probe identified as MID was very low degeneracy and was used for initial screening. The probes identified as EDV-C and EDV-T were based on the same amino acid sequences and differ in one position (underlined in Table III below) and were used as confirmatory probes, with a positive to be expected only from one of these two probes. In the oligonucleotides below, alternate acceptable nucleotides at a particular position are designated by a "/" such as A/C/T.

**Table III Selected CP4 EPSPS peptide sequences and DNA probes**

PEPTIDE 61-24-25 APSM(I)(D)EYPILAV (SEQ ID NO:19)

Probe MID; 17-mer; mixed probe; 24-fold degenerate

ATGATA/C/TGAC/TGAG/ATAC/TCC (SEQ ID NO:21)

PEPTIDE 53-28 ITGLLEGEDVINTGK (SEQ ID NO:20)

Probe EDV-C; 17-mer; mixed probe; 48-fold degenerate

GAA/GGAC/TGTA/C/G/TATA/C/TAACAC (SEQ ID NO:22)

Probe EDV-T; 17-mer; mixed probe; 48-fold degenerate

GAA/GGAC/TGTA/C/G/TATA/C/TAATAC (SEQ ID NO:23)

The probes were labeled using gamma-<sup>32</sup>P-ATP and polynucleotide kinase. DNA from fourteen of the cosmids described above was restricted with EcoRI, transferred to membrane and probed with the oligonucleotide probes. The conditions used were as follows: prehybridization was carried out in 6X SSC, 10X Denhardt's for 2-18 hour periods at 60°C, and hybridization was for 48-72 hours in 6X SSC, 10X Denhardt's, 100 µg/ml tRNA at 10°C below the T<sub>d</sub> for the probe. The T<sub>d</sub> of the probe was approximated by the formula 2°C x

(A+T) + 4°C x (G+C). The filters were then washed three times with 6X SSC for ten minutes each at room temperature, dried and autoradiographed. Using the MID probe, an ~9.9 kb fragment in the pMON17076 cosmid gave the only positive signal. This cosmid DNA was then probed with the EDV-C (SEQ ID NO:22) and EDV-T (SEQ ID NO:23) probes separately and again this ~9.9 kb band gave a signal and only with the EDV-T probe.

The combined data on the glyphosate-tolerant phenotype, the complementation of the *E. coli* aroA- phenotype, the expression of a ~45 Kd protein, and the hybridization to two probes derived from the CP4 EPSPS amino acid sequence strongly suggested that the pMON17076 cosmid contained the EPSPS gene.

#### Localization and subcloning of the CP4 EPSPS gene

The CP4 EPSPS gene was further localized as follows: a number of additional Southern analyses were carried out on different restriction digests of pMON17076 using the MID (SEQ ID NO:21) and EDV-T (SEQ ID NO:23) probes separately. Based on these analyses and on subsequent detailed restriction mapping of the pBlueScript (Stratagene) subclones of the ~9.9 kb fragment from pMON17076, a 3.8 kb *Eco*RI-*Sal*I fragment was identified to which both probes hybridized. This analysis also showed that MID (SEQ ID NO:21) and EDV-T (SEQ ID NO:23) probes hybridized to different sides of *Bam*HI, *Cla*I, and *Sac*II sites. This 3.8 kb fragment was cloned in both orientations in pBlueScript to form pMON17081 and pMON17082. The phenotypes imparted to *E. coli* by these clones were then determined. Glyphosate tolerance was determined following transformation into *E. coli* MM294 containing pGP1-2 (pBlueScript also contains a T7 promoter) on M9 agar media containing glyphosate at 3 mM. Both pMON17081 and pMON17082 showed glyphosate-tolerant colonies at three days at 30°C at about half the size of the controls on the same media lacking glyphosate. This result suggested that the 3.8 kb fragment contained an intact EPSPS gene.

The apparent lack of orientation-dependence of this phenotype could be explained by the presence of the T7 promoter at one side of the cloning sites and the *lac* promoter at the other. The *aroA* phenotype was determined in transformants of *E. coli* GB100 on M9 agar media lacking aromatic supplements. In this experiment, carried out with and without the *P<sub>lac</sub>* inducer IPTG, pMON17082 showed much greater growth than pMON17081, suggesting that the EPSPS gene was expressed from the *SalI* site towards the *EcoRI* site.

Nucleotide sequencing was begun from a number of restriction site ends, including the *BamHI* site discussed above. Sequences encoding protein sequences that closely matched the N-terminus protein sequence and that for the tryptic fragment 53-28 (SEQ ID NO:20) (the basis of the EDV-T probe) (SEQ ID NO:23) were localized to the *SalI* side of this *BamHI* site. These data provided conclusive evidence for the cloning of the CP4 EPSPS gene and for the direction of transcription of this gene. These data coupled with the restriction mapping data also indicated that the complete gene was located on an ~2.3 kb *XhoI* fragment and this fragment was subcloned into pBlueScript. The nucleotide sequence of almost 2 kb of this fragment was determined by a combination of sequencing from cloned restriction fragments and by the use of specific primers to extend the sequence. The nucleotide sequence of the CP4 EPSPS gene and flanking regions is shown in Figure 3 (SEQ ID NO:2). The sequence corresponding to peptide 61-24-25 (SEQ ID NO:19) was also located. The sequence was determined using both the SEQUENASE™ kit from IBI (International Biotechnologies Inc.) and the T7 sequencing/Deaza Kit from Pharmacia.

That the cloned gene encoded the EPSPS activity purified from the *Agrobacterium* sp. strain CP4 was verified in the following manner: By a series of site directed mutageneses, *BglII* and *NcoI* sites were placed at the N-terminus with the fMet contained within the *NcoI* recognition sequence, the first internal *NcoI* site was removed (the second internal *NcoI* site was

removed later), and a *SacI* site was placed after the stop codons. At a later stage the internal *NotI* site was also removed by site-directed mutagenesis. The following list includes the primers for the site-directed mutagenesis (addition or removal of restriction sites) of the CP4 EPSPS gene. Mutagenesis was carried out by the procedures of Kunkel et al. (1987), essentially as described in Sambrook et al. (1989).

PRIMER BgNc (addition of *Bgl*II and *Nco*I sites to N-terminus)

CGTGGATAGATCTAGGAAGACAACCATGGCTCACGGTC

(SEQ ID NO:24)

PRIMER Sph2 (addition of *Sph*I site to N-terminus)

GGATAGATTAAGGAAGACGCGCATGCTTCACGGTGCAAGCAGCC

(SEQ ID NO:25)

PRIMER S1 (addition of *Sac*I site immediately after stop codons)

GGCTGCCTGATGAGCTCCACAATGCCATCGATGG

(SEQ ID NO:26)

PRIMER N1 (removal of internal *Not*I recognition site)

CGTCGCTCGTGTGCGTGGCCGCCCTGACGGC

(SEQ ID NO:27)

PRIMER Nco1 (removal of first internal *Nco*I recognition site)

CGGGCAAGGCCATGCAGGCTATGGGCGCC

(SEQ ID NO:28)

PRIMER Nco2 (removal of second internal *Nco*I recognition site)

CGGGCTGCCGCCTGACTATGGGCCTCGCGG

(SEQ ID NO:29)

This CP4 EPSPS gene was then cloned as a *Nco*I-*Bam*HI N-terminal fragment plus a *Bam*HI-*Sac*I C-terminal fragment into a *PrecA-gene10L* expression vector similar to those described (Wong et al., 1988; Olins et al., 1988) to form pMON17101. The  $K_m$  for PEP and the  $K_i$  for glyphosate were determined for the EPSPS activity in crude lysates of pMON17101/GB100 transformants following induction with nalidixic acid (Wong et al., 1988) and found to be the same as that determined for the purified and crude enzyme preparations from *Agrobacterium* sp. strain CP4.

**Characterization of the EPSPS gene from *Achromobacter* sp. strain LBAA and from *Pseudomonas* sp. strain PG2982**

A cosmid bank of partially *Hind*III-restricted LBAA DNA was constructed in *E. coli* MM294 in the vector pHC79 (Hohn and Collins, 1980). This bank was probed with a full length CP4 EPSPS gene probe by colony hybridization and positive clones were identified at a rate of ~1 per 400 cosmids. The LBAA EPSPS gene was further localized in these cosmids by Southern analysis. The gene was located on an ~2.8 kb *Xba*I fragment and by a series of sequencing steps, both from restriction fragment ends and by using the oligonucleotide primers from the sequencing of the CP4 EPSPS gene, the nucleotide sequence of the LBAA EPSPS gene was completed and is presented in Figure 4 (SEQ ID NO:4).

The EPSPS gene from PG2982 was also cloned. The EPSPS protein was purified, essentially as described for the CP4 enzyme, with the following differences: Following the Sepharose CL-4B column, the fractions with the highest EPSPS activity were pooled and the protein precipitated by adding solid ammonium sulfate to 85% saturation and stirring for 1 hour. The precipitated protein was collected by centrifugation, resuspended in Q Sepharose buffer and following dialysis against the same buffer was loaded

onto the column (as for the CP4 enzyme). After purification on the Q Sepharose column, ~40 mg of protein in 100 mM Tris pH 7.8, 10% glycerol, 1 mM EDTA, 1 mM DTT, and 1 M ammonium sulfate, was loaded onto a Phenyl Superose (Pharmacia) column. The column was eluted at 1.0 ml/minutes with a 40 ml gradient from 1.0 M to 0.00 M ammonium sulfate in the above buffer.

Approximately 1.0 mg of protein from the active fractions of the Phenyl Superose 10/10 column was loaded onto a Pharmacia Mono P 5/10 Chromatofocusing column with a flow rate of 0.75 ml/minutes. The starting buffer was 25 mM bis-Tris at pH 6.3, and the column was eluted with 39 ml of Polybuffer 74, pH 4.0. Approximately 50  $\mu$ g of the peak fraction from the Chromatofocusing column was dialyzed into 25 mM ammonium bicarbonate. This sample was then used to determine the N-terminal amino acid sequence.

The N-terminal sequence obtained was:

XHSASPKPATARRSE (where X = an unidentified residue)  
(SEQ ID NO:30)

A number of degenerate oligonucleotide probes were designed based on this sequence and used to probe a library of PG2982 partial-*Hind*III DNA in the cosmid pHc79 (Hohn and Collins, 1980) by colony hybridization under nonstringent conditions. Final washing conditions were 15 minutes with 1X SSC, 0.1% SDS at 55°C. One probe with the sequence GCGGTBGCSGGYTTSGG (where B = C, G, or T; S = C or G, and Y = C or T) (SEQ ID NO:31) identified a set of cosmid clones.

The cosmid set identified in this way was made up of cosmids of diverse *Hind*III fragments. However, when this set was probed with the CP4 EPSPS gene probe, a cosmid containing the PG2982 EPSPS gene was identified (designated as cosmid 9C1 originally and later as pMON20107). By a series of restriction mappings and Southern analysis this gene was localized to a ~2.8

kb *Xba*I fragment and the nucleotide sequence of this gene was determined. This DNA sequence (SEQ ID NO:6) is shown in Figure 5. There are no nucleotide differences between the EPSPS gene sequences from LBAA (SEQ ID NO:4) and PG2982 (SEQ ID NO:6). The kinetic parameters of the two enzymes are within the range of experimental error.

A gene from PG2982 that imparts glyphosate tolerance in *E. coli* has been sequenced (Fitzgibbon, 1988; Fitzgibbon and Braymer, 1990). The sequence of the PG2982 EPSPS Class II gene shows no homology to the previously reported sequence suggesting that the glyphosate-tolerant phenotype of the previous work is not related to EPSPS.

#### Characterization of the EPSPS from *Bacillus subtilis*

*Bacillus subtilis* 1A2 (prototroph) was obtained from the *Bacillus* Genetic Stock Center at Ohio State University. Standard EPSPS assay reactions contained crude bacterial extract with, 1 mM phosphoenolpyruvate (PEP), 2 mM shikimate-3-phosphate (S3P), 0.1 mM ammonium molybdate, 5 mM potassium fluoride, and 50 mM HEPES, pH 7.0 at 25°C. One unit (U) of EPSPS activity is defined as one  $\mu$ mol EPSP formed per minute under these conditions. For kinetic determinations, reactions contained crude bacterial, 2 mM S3P, varying concentrations of PEP, and 50 mM HEPES, pH 7.0 at 25°C. The EPSPS specific activity was found to be 0.003 U/mg. When the assays were performed in the presence of 1 mM glyphosate, 100% of the EPSPS activity was retained. The app $K_m$ (PEP) of the *B. subtilis* EPSPS was determined by measuring the reaction velocity at varying concentrations of PEP. The results were analyzed graphically by the hyperbolic, Lineweaver-Burk and Eadie-Hofstee plots, which yielded app $K_m$ (PEP) values of 15.3  $\mu$ M, 10.8  $\mu$ M and 12.2  $\mu$ M, respectively. These three data treatments are in good agreement, and yield an average value for app $K_m$ (PEP) of 13  $\mu$ M. The app $K_i$ (glyphosate) was estimated by determining the reaction rates of *B. subtilis* 1A2 EPSPS in the presence of several concentrations of glyphosate, at

a PEP concentration of 2  $\mu$ M. These results were compared to the calculated  $V_{max}$  of the EPSPS, and making the assumption that glyphosate is a competitive inhibitor versus PEP for *B. subtilis* EPSPS, as it is for all other characterized EPSPSs, an app $K_i$ (glyphosate) was determined graphically. The app $K_i$ (glyphosate) was found to be 0.44 mM.

The EPSPS expressed from the *B. subtilis aroE* gene described by Henner *et al.* (1986) was also studied. The source of the *B. subtilis aroE* (EPSPS) gene was the *E. coli* plasmid-bearing strain ECE13 (original code = MM294[p trp100]; Henner, *et al.*, 1984; obtained from the *Bacillus* Genetic Stock Center at Ohio State University; the culture genotype is [pBR322 trp100] Ap [in MM294] [pBR322::6 kb insert with trpFBA-hisH]). Two strategies were taken to express the enzyme in *E. coli* GB100 (*aroA* $\cdot$ ): 1) the gene was isolated by PCR and cloned into an overexpression vector, and 2) the gene was subcloned into an overexpression vector. For the PCR cloning of the *B. subtilis aroE* from ECE13, two oligonucleotides were synthesized which incorporated two restriction enzyme recognition sites (*Nde*I and *Eco*RI) to the sequences of the following oligonucleotides:

GGAACATATGAAACGAGATAAGGTGCAG (SEQ ID NO:45)

GGAATTCAAACCTCAGGATCTTGAGATAGAAAATG (SEQ ID NO:46)

The other approach to the isolation of the *B. subtilis aroE* gene, subcloning from ECE13 into pUC118, was performed as follows:

- (i) Cut ECE13 and pUC with *Xma*I and *Sph*I.
- (ii) Isolate 1700bp *aroE* fragment and 2600bp pUC118 vector fragment.
- (iii) Ligate fragments and transform into GB100.

The subclone was designated pMON21133 and the PCR-derived clone was named pMON21132. Clones from both approaches were first confirmed for

complementation of the aroA mutation in *E. coli* GB100. The cultures exhibited EPSPS specific activities of 0.044 U/mg and 0.71 U/mg for the subclone (pMON21133) and PCR-derived clone (pMON21132) enzymes, respectively. These specific activities reflect the expected types of expression levels of the two vectors. The *B. subtilis* EPSPS was found to be 88% and 100% resistant to inhibition by 1 mM glyphosate under these conditions for the subcloned (pMON21133) and PCR-derived (pMON21132) enzymes, respectively. The appK<sub>m</sub>(PEP) and the appK<sub>i</sub>(glyphosate) of the subcloned *B. subtilis* EPSPS (pMON21133) were determined as described above. The data were analyzed graphically by the same methods used for the 1A2 isolate, and the results obtained were comparable to those reported above for *B. subtilis* 1A2 culture.

#### Characterization of the EPSPS gene from *Staphylococcus aureus*

The kinetic properties of the *S. aureus* EPSPS expressed in *E. coli* were determined, including the specific activity, the appK<sub>m</sub>(PEP), and the appK<sub>i</sub>(glyphosate). The *S. aureus* EPSPS gene has been previously described (O' Connell *et al.*, 1993)

The strategy taken for the cloning of the *S. aureus* EPSPS was polymerase chain reaction (PCR), utilizing the known nucleotide sequence of the *S. aureus* aroA gene encoding EPSPS (O' Connell *et al.*, 1993). The *S. aureus* culture (ATCC 35556) was fermented in an M2 facility in three 250 mL shake flasks containing 55 mL of TYE (tryptone 5g/L, yeast extract 3 g/L, pH 6.8). The three flasks were inoculated with 1.5 mL each of a suspension made from freeze dried ATCC 35556 *S. aureus* cells in 90 mL of PBS (phosphate-buffered saline) buffer. Flasks were incubated at 30°C for 5 days while shaking at 250 rpm. The resulting cells were lysed (boiled in TE [tris/EDTA] buffer for 8 minutes) and the DNA utilized for PCR reactions. The EPSPS gene was amplified using PCR and engineered into an *E. coli* expression vector as follows:

(i) two oligonucleotides were synthesized which incorporated two restriction enzyme recognition sites (NcoI and SacI) to the sequences of the oligonucleotides:

GGGGCCATGGTAAATGAACAAATCATTG (SEQ ID NO:47)

:

GGGGGAGCTCATTATCCCTCATTGTAAAAGC (SEQ ID NO:48)

(ii) The purified, PCR-amplified *aroA* gene from *S. aureus* was digested using NcoI and SacI enzymes.

(iii) DNA of pMON 5723, which contains a pRecA bacterial promoter and Gene10 leader sequence (Olins *et al.*, 1988) was digested NcoI and SacI and the 3.5 kb digestion product was purified.

(iv) The *S. aureus* PCR product and the NcoI / SacI pMON 5723 fragment were ligated and transformed into *E. coli* JM101 competent cells.

(v) Two spectinomycin-resistant *E. coli* JM101 clones from above (SA#2 and SA#3) were purified and transformed into a competent *aroA*- *E. coli* strain, GB100

For complementation experiments SAGB#2 and SAGB#3 were utilized, which correspond to SA#2 and SA#3, respectively, transformed into *E. coli* GB100. In addition, *E. coli* GB100 (negative control) and pMON 9563 (*wt* petunia EPSPS, positive control) were tested for *AroA* complementation. The organisms were grown in minimal media plus and minus aromatic amino acids. Later analyses showed that the SA#2 and SA#3 clones were identical, and they were assigned the plasmid identifier pMON21139.

SAGB#2 in *E. coli* GB100 (pMON21139) was also grown in M9 minimal media and induced with nalidixic acid. A negative control, *E. coli* GB100, was grown under identical conditions except the media was supplemented with

aromatic amino acids. The cells were harvested, washed with 0.9% NaCl, and frozen at -80°C, for extraction and EPSPS analysis.

The frozen pMON21139 *E. coli* GB100 cell pellet from above was extracted and assayed for EPSPS activity as previously described. EPSPS assays were performed using 1 mM phosphoenolpyruvate (PEP), 2 mM shikimate-3-phosphate (S3P), 0.1 mM ammonium molybdate, 5 mM potassium fluoride, pH 7.0, 25°C. The total assay volume was 50 µL, which contained 10 µL of the undiluted desalting extract.

The results indicate that the two clones contain a functional *aroA*/EPSPS gene since they were able to grow in minimal media which contained no aromatic amino acids. As expected, the GB100 culture did not grow on minimal medium without aromatic amino acids (since no functional EPSPS is present), and the pMON9563 did confer growth in minimal media. These results demonstrated the successful cloning of a functional EPSPS gene from *S. aureus*. Both clones tested were identical, and the *E. coli* expression vector was designated pMON21139.

The plasmid pMON21139 in *E. coli* GB100 was grown in M9 minimal media and was induced with nalidixic acid to induce EPSPS expression driven from the RecA promoter. A desalting extract of the intracellular protein was analyzed for EPSPS activity, yielding an EPSPS specific activity of 0.005 µmol/min mg. Under these assay conditions, the *S. aureus* EPSPS activity was completely resistant to inhibition by 1 mM glyphosate. Previous analysis had shown that *E. coli* GB100 is devoid of EPSPS activity.

The appK<sub>m</sub>(PEP) of the *S. aureus* EPSPS was determined by measuring the reaction velocity of the enzyme (in crude bacterial extracts) at varying concentrations of PEP. The results were analyzed graphically using several standard kinetic plotting methods. Data analysis using the hyperbolic, Lineweaver-Burke, and Eadie-Hofstee methods yielded appK<sub>m</sub>(PEP) constants of 7.5, 4.8, and 4.0 µM, respectively. These three data treatments are in good agreement, and yield an average value for appK<sub>m</sub>(PEP) of 5 µM.

Further information of the glyphosate tolerance of *S. aureus* EPSPS was obtained by determining the reaction rates of the enzyme in the presence of several concentrations of glyphosate, at a PEP concentration of 2  $\mu$ M. These results were compared to the calculated maximal velocity of the EPSPS, and making the assumption that glyphosate is a competitive inhibitor versus PEP for *S. aureus* EPSPS, as it is for all other characterized EPSPSs, an app $K_i$ (glyphosate) was determined graphically. The app $K_i$ (glyphosate) for *S. aureus* EPSPS estimated using this method was found to be 0.20 mM.

The EPSPS from *S. aureus* was found to be glyphosate-tolerant, with an app $K_i$ (glyphosate) of approximately 0.2 mM. In addition, the app $K_m$ (PEP) for the enzyme is approximately 5  $\mu$ M, yielding a app $K_i$ (glyphosate) / app $K_m$ (PEP) of 40.

#### Alternative Isolation Protocols for Other Class II EPSPS Structural Genes

A number of Class II genes have been isolated and described here. While the cloning of the gene from CP4 was difficult due to the low degree of similarity between the Class I and Class II enzymes and genes, the identification of the other genes was greatly facilitated by the use of this first gene as a probe. In the cloning of the LBAA EPSPS gene, the CP4 gene probe allowed the rapid identification of cosmid clones and the localization of the intact gene to a small restriction fragment and some of the CP4 sequencing primers were also used to sequence the LBAA (and PG2982) EPSPS gene(s). The CP4 gene probe was also used to confirm the PG2982 gene clone. The high degree of similarity of the Class II EPSPS genes may be used to identify and clone additional genes in much the same way that Class I EPSPS gene probes have been used to clone other Class I genes. An example of the latter was in the cloning of the *A. thaliana* EPSPS gene using the *P. hybrida* gene as a probe (Klee *et al.*, 1987).

Glyphosate-tolerant EPSPS activity has been reported previously for EPSP synthases from a number of sources. These enzymes have not been

characterized to any extent in most cases. The use of Class I and Class II EPSPS gene probes or antibody probes provide a rapid means of initially screening for the nature of the EPSPS and provide tools for the rapid cloning and characterization of the genes for such enzymes.

Two of the three genes described were isolated from bacteria that were isolated from a glyphosate treatment facility (Strains CP4 and LBAA). The third (PG2982) was from a bacterium that had been isolated from a culture collection strain. This latter isolation confirms that exposure to glyphosate is not a prerequisite for the isolation of high glyphosate-tolerant EPSPS enzymes and that the screening of collections of bacteria could yield additional isolates. It is possible to enrich for glyphosate degrading or glyphosate resistant microbial populations (Quinn *et al.*, 1988; Talbot *et al.*, 1984) in cases where it was felt that enrichment for such microorganisms would enhance the isolation frequency of Class II EPSPS microorganisms. Additional bacteria containing class II EPSPS gene have also been identified. A bacterium called C12, isolated from the same treatment column beads as CP4 (see above) but in a medium in which glyphosate was supplied as both the carbon and phosphorus source, was shown by Southern analysis to hybridize with a probe consisting of the CP4 EPSPS coding sequence. This result, in conjunction with that for strain LBAA, suggests that this enrichment method facilitates the identification of Class II EPSPS isolates. New bacterial isolates containing Class II EPSPS genes have also been identified from environments other than glyphosate waste treatment facilities. An inoculum was prepared by extracting soil (from a recently harvested soybean field in Jerseyville, Illinois) and a population of bacteria selected by growth at 28°C in Dworkin-Foster medium containing glyphosate at 10 mM as a source of carbon (and with cycloheximide at 100 µg/ml to prevent the growth of fungi). Upon plating on L-agar media, five colony types were identified. Chromosomal DNA was prepared from 2ml L-broth cultures of these isolates and the presence of a Class II EPSPS gene was probed using a the CP4 EPSPS coding sequence probe by Southern analysis under stringent

hybridization and washing conditions. One of the soil isolates, S2, was positive by this screen.

Class II EPSPS enzymes are identifiable by an elevated  $K_i$  for glyphosate and thus the genes for these will impart a glyphosate tolerance phenotype in heterologous hosts. Expression of the gene from recombinant plasmids or phage may be achieved through the use of a variety of expression promoters and include the T7 promoter and polymerase. The T7 promoter and polymerase system has been shown to work in a wide range of bacterial (and mammalian) hosts and offers the advantage of expression of many proteins that may be present on large cloned fragments. Tolerance to growth on glyphosate may be shown on minimal growth media. In some cases, other genes or conditions that may give glyphosate tolerance have been observed, including over expression of beta-lactamase, the *igrA* gene (Fitzgibbon and Braymer, 1990), or the gene for glyphosate oxidoreductase (PCT Pub. No. WO92/00377). These are easily distinguished from Class II EPSPS by the absence of EPSPS enzyme activity.

The EPSPS protein is expressed from the *aroA* gene (also called *aroE* in some genera, for example, in *Bacillus*) and mutants in this gene have been produced in a wide variety of bacteria. Determining the identity of the donor organism (bacterium) aids in the isolation of Class II EPSPS gene - such identification may be accomplished by standard microbiological methods and could include Gram stain reaction, growth, color of culture, and gas or acid production on different substrates, gas chromatography analysis of methylesters of the fatty acids in the membranes of the microorganism, and determination of the GC% of the genome. The identity of the donor provides information that may be used to more easily isolate the EPSPS gene. An *AroA*- host more closely related to the donor organism could be employed to clone the EPSPS gene by complementation but this is not essential since complementation of the *E. coli* *AroA* mutant by the CP4 EPSPS gene was observed. In addition, the information on the GC content the genome may be

used in choosing nucleotide probes - donor sources with high GC% would preferably use the CP4 EPSPS gene or sequences as probes and those donors with low GC would preferably employ those from *Bacillus subtilis*, for example.

### Relationships between different EPSPS genes

The deduced amino acid sequences of a number of Class I and the Class II EPSPS enzymes were compared using the Bestfit computer program provided in the UWGCG package (Devereux *et al.* 1984). The degree of similarity and identity as determined using this program is reported. The degree of similarity/identity determined within Class I and Class II protein sequences is remarkably high, for instance, comparing *E. coli* with *S. typhimurium* (similarity/identity = 93%/88%) and even comparing *E. coli* with a plant EPSPS (*Petunia hybrida*; 72%/55%). These data are shown in Table IV. The comparison of sequences between Class I and Class II, however, shows a much lower degree of relatedness between the Classes (similarity/identity = 50-53%/23-30%). The display of the Bestfit analysis for the *E. coli* (SEQ ID NO:8) and CP4 (SEQ ID NO:3) sequences shows the positions of the conserved residues and is presented in Figure 6. Previous analyses of EPSPS sequences had noted the high degree of conservation of sequences of the enzymes and the almost invariance of sequences in two regions - the "20-35" and "95-107" regions (Gasser *et al.*, 1988; numbered according to the *Petunia* EPSPS sequence) - and these regions are less conserved in the case of CP4 and LBAA when compared to Class I bacterial and plant EPSPS sequences (see Figure 6 for a comparison of the *E. coli* and CP4 EPSPS sequences with the *E. coli* sequence appearing as the top sequence in the Figure). The corresponding sequences in the CP4 Class II EPSPS are:

PGDKSISHRSFMFGGL	(SEQ ID NO:32) and
LDFGNAATGCRLT	(SEQ ID NO:33).

These comparisons show that the overall relatedness of Class I and Class II EPSPS proteins is low and that sequences in putative conserved regions have also diverged considerably.

In the CP4 EPSPS an alanine residue is present at the "glycine101" position. The replacement of the conserved glycine (from the "95-107" region) by an alanine results in an elevated  $K_i$  for glyphosate and in an elevation in the  $K_m$  for PEP in Class I EPSPS. In the case of the CP4 EPSPS, which contains an alanine at this position, the  $K_m$  for PEP is in the low range, indicating that the Class II enzymes differ in many aspects from the EPSPS enzymes heretofore characterized.

Within the Class II isolates, the degree of similarity/identity is as high as that noted for that within Class I (Table IVA). Figure 7 displays the Bestfit computer program alignment of the CP4 (SEQ ID NO:3) and LBAA (SEQ ID NO:5) EPSPS deduced amino acid sequences with the CP4 sequence appearing as the top sequence in the Figure. The symbols used in Figures 6 and 7 are the standard symbols used in the Bestfit computer program to designate degrees of similarity and identity.

EPA Docket # 2002-10660-A

**Table IV A 1,2**

---

<b>Comparison of relatedness of EPSPS protein sequences</b>		
<b>Comparison between Class I and Class II EPSPS protein sequences</b>		
	<b>similarity</b>	<b>identity</b>
<i>S. cerevisiae</i> vs. CP4	54	30
<i>A. nidulans</i> vs. CP4	50	25
<i>B. napus</i> vs. CP4	47	22
<i>A. thaliana</i> vs. CP4	48	22
<i>N. tabacum</i> vs. CP4	50	24
<i>L. esculentum</i> vs. CP4	50	24
<i>P. hybrida</i> vs. CP4	50	23
<i>Z. mays</i> vs. CP4	48	24
<i>S. gallinarum</i> vs. CP4	51	25
<i>S. typhimurium</i> vs. CP4	51	25
<i>S. typhi</i> vs. CP4	51	25
<i>K. pneumoniae</i> vs. CP4	56	28
<i>Y. enterocolitica</i> vs. CP4	53	25
<i>H. influenzae</i> vs. CP4	53	27
<i>P. multocida</i> vs. CP4	55	30
<i>A. salmonicida</i> vs. CP4	53	23
<i>B. pertussis</i> vs. CP4	53	27
<i>E. coli</i> vs. CP4	52	26
<i>E. coli</i> vs. LBAA	52	26
<i>E. coli</i> vs. <i>B. subtilis</i>	55	29
<i>E. coli</i> vs. <i>D. nodosus</i>	55	32
<i>E. coli</i> vs. <i>S. aureus</i>	55	29
<i>E. coli</i> vs. <i>Synechocystis</i> sp. PCC6803	53	30

Comparison between Class I EPSPS protein sequences

	<u>similarity</u>	<u>identity</u>
<i>E. coli</i> vs. <i>S. typhimurium</i>	93	88
<i>P. hybrida</i> vs. <i>E. coli</i>	72	55

:

Comparison between Class II EPSPS protein sequences

	<u>similarity</u>	<u>identity</u>
<i>D. nodosus</i> vs. CP4	62	43
LBAA vs. CP4	90	83
PG2892 vs. CP4	90	83
<i>S. aureus</i> vs. CP4	58	34
<i>B. subtilis</i> vs. CP4	59	41
<i>Synechocystis</i> sp. PCC6803 vs. CP4	62	45

1 The EPSPS sequences compared here were obtained from the following references: *E. coli*, Rogers *et al.*, 1983; *S. typhimurium*, Stalker *et al.*, 1985; *Petunia hybrida*, Shah *et al.*, 1986; *B. pertussis*, Maskell *et al.*, 1988; *S. cerevisiae*, Duncan *et al.*, 1987, *Synechocystis* sp. PCC6803, Dalla Chiesa *et al.*, 1994 and *D. nodosus*, Alm *et al.*, 1994.

2 "GAP" Program, Genetics Computer Group, (1991), Program Manual for the GCG Package, Version 7, April 1991, 575 Science Drive, Madison, Wisconsin, USA 53711

The relative locations of the major conserved sequences among Class II EPSP synthases which distinguishes this group from the Class I EPSP synthases is listed below in Table IVB.

Table IVB Location of Conserved Sequences in  
Class II EPSP Synthases

<u>Source</u>	<u>Seq. 1<sup>1</sup></u>	<u>Seq. 2<sup>2</sup></u>	<u>Seq. 3<sup>3</sup></u>	<u>Seq. 4<sup>4</sup></u>
<b>CP4</b>				
start	200	26	173	
end	204	29	177	271
				274
<b>LBAA</b>	:			
start	200	26	173	
end	204	29	177	271
				274
<b>PG2982</b>				
start	200	26	173	
end	204	29	177	273
				276
<b><i>B. subtilis</i></b>				
start	190	17	164	
end	194	20	168	257
				260
<b><i>S. aureus</i></b>				
start	193	21	166	
end	197	24	170	261
				264
<b><i>Synechocystis</i> sp. PCC6803</b>				
start	210	34	183	
end	214	38	187	278
				281
<b><i>D. nodosus</i></b>				
start	195	22	168	
end	199	25	172	261
				264
<b>min. start</b>	<b>190</b>	<b>17</b>	<b>164</b>	<b>257</b>
<b>max. end</b>	<b>214</b>	<b>38</b>	<b>187</b>	<b>281</b>

<sup>1</sup> -R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37)

<sup>2</sup> -G-D-K-X<sub>3</sub>- (SEQ ID NO:38)

<sup>3</sup> -S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39)

<sup>4</sup> -N-X<sub>5</sub>-T-R- (SEQ ID NO:40)

The domains of EPSP synthase sequence identified in this application were determined to be those important for maintenance of glyphosate resistance and productive binding of PEP. The information used in identifying these domains included sequence alignments of numerous glyphosate-sensitive EPSPS molecules and the three-dimensional x-ray structures of *E. coli* EPSPS (Stallings, *et al.* 1991) and CP4 EPSPS. The structures are representative of a glyphosate-sensitive (i.e., Class I) enzyme, and a naturally-occurring glyphosate-tolerant (i.e., Class II) enzyme of the present invention. These exemplary molecules were superposed three-dimensionally and the results displayed on a computer graphics terminal. Inspection of the display allowed for structure-based fine-tuning of the sequence alignments of glyphosate-sensitive and glyphosate-resistant EPSPS molecules. The new sequence alignments were examined to determine differences between Class I and Class II EPSPS enzymes. Seven regions were identified and these regions were located in the x-ray structure of CP4 EPSPS which also contained a bound analog of the intermediate which forms catalytically between PEP and S3P.

The structure of the CP4 EPSPS with the bound intermediate analog was displayed on a computer graphics terminal and the seven sequence segments were examined. Important residues for glyphosate binding were identified as well as those residues which stabilized the conformations of those important residues: adjoining residues were considered necessary for maintenance of correct three-dimensional structural motifs in the context of glyphosate- sensitive EPSPS molecules. Three of the seven domains were

determined not to be important for glyphosate tolerance and maintainance of productive PEP binding. The following four primary domains were determined to be characteristic of Class II EPSPS enzymes of the present invention:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E (SEQ ID NO:37), in which

X<sub>1</sub> is an uncharged polar or acidic amino acid,

X<sub>2</sub> is serine or threonine,

The Arginine (R) residue at position 1 is important because the positive charge of its guanidium group destabilizes the binding of glyphosate. The Histidine (H) residue at position 3 stabilizes the Arginine (R) residue at position 4 of SEQ ID NO:40. The Glutamic Acid (E) residue at position 5 stabilizes the Lysine (K) residue at position 5 of SEQ ID NO:39.

-G-D-K-X<sub>3</sub> ( SEQ ID NO:38), in which

X<sub>3</sub> is serine or threonine,

The Aspartic acid (D) residue at position 2 stabilizes the Arginine (R) residue at position 4 of SEQ ID NO:40. The Lysine (K) residue at position 3 is important because for productive PEP binding.

-S-A-Q-X<sub>4</sub>-K (SEQ ID NO:39), in which

X<sub>4</sub> is any amino acid,

The Alanine (A) residue at position 2 stabilizes the Arginine (R) residue at position 1 of SEQ ID NO:37. The Serine (S) residue at position 1 and the Glutamine (Q) residue at position 3 are important for productive S3P binding.

-N-X<sub>5</sub>-T-R (SEQ ID NO:40) in which

X<sub>5</sub> is any amino acid,

The Asparagine (N) residue at position 1 and the Threonine (T) residue at position 3 stabilize residue X<sub>1</sub> at position 2 of SEQ ID NO:37. The Arginine (R) residue at position 4 is important because the positive charge of its guanidium group destabilizes the binding of glyphosate.

Since the above sequences are only representative of the Class II EPSPSs which would be included within the generic structure of this group of EPSP synthases, the above sequences may be found within a subject EPSP synthase molecule within slightly more expanded regions. It is believed that the above-described conserved sequences would likely be found in the following regions of the mature EPSP synthases molecule:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37) located between amino acids 175 and 230 of the mature EPSP synthase sequence;

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38) located between amino acids 5 and 55 of the mature EPSP synthase sequence;

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39) located between amino acids 150 and 200 of the mature EPSP synthase sequence; and

-N-X<sub>5</sub>-T-R- (SEQ ID NO:40) located between amino acids 245 and 295 of the mature EPSPS synthase sequence.

One difference that may be noted between the deduced amino acid sequences of the CP4 and LBAA EPSPS proteins is at position 100 where an Alanine is found in the case of the CP4 enzyme and a Glycine is found in the case of the LBAA enzyme. In the Class I EPSPS enzymes a Glycine is usually found in the equivalent position, i.e Glycine96 in *E. coli* and *K. pneumoniae* and Glycine101 in Petunia. In the case of these three enzymes it has been reported that converting that Glycine to an Alanine results in an elevation of the appKi for glyphosate and a concomitant elevation in the appKm for PEP (Kishore *et al.*, 1986; Kishore and Shah, 1988; Sost and Amrhein, 1990), which, as discussed above, makes the enzyme less efficient especially under conditions of lower PEP concentrations. The Glycine100 of the LBAA EPSPS was converted to an Alanine and both the appKm for PEP and the appKi for glyphosate were determined for the variant. The Glycine100Alanine change was introduced by mutagenesis using the following primer:

CGGCAATGCCGCCACCGGCGCGCGCC (SEQ ID NO:34)

and both the wild type and variant genes were expressed in *E. coli* in a *RecA* promoter expression vector (pMON17201 and pMON17264, respectively) and the appKm's and appKi's determined in crude lysates. The data indicate that the appKi(glyphosate) for the G100A variant is elevated about 16-fold (Table

V). This result is in agreement with the observation of the importance of this G-A change in raising the appKi(glyphosate) in the Class I EPSPS enzymes. However, in contrast to the results in the Class I G-A variants, the appKm(PEP) in the Class II (LBAA) G-A variant is unaltered. This provides yet another distinction between the Class II and Class I EPSPS enzymes.

**Table V**

Lysate prepared from:	<u>appKm(PEP)</u>	<u>appKi( glyphosate)</u>
<i>E. coli</i> /pMON17201 (wild type)	5.3 $\mu$ M	28 $\mu$ M*
<i>E. coli</i> /pMON17264 (G100A variant)	5.5 $\mu$ M	459 $\mu$ M#

@ range of PEP: 2-40  $\mu$ M

\* range of glyphosate: 0-310  $\mu$ M; # range of glyphosate: 0-5000  $\mu$ M.

The LBAA G100A variant, by virtue of its superior kinetic properties, should be capable of imparting improved *in planta* glyphosate tolerance.

**Modification and Resynthesis of the *Agrobacterium* sp. strain CP4 EPSPS Gene Sequence**

The EPSPS gene from *Agrobacterium* sp. strain CP4 contains sequences that could be inimical to high expression of the gene in plants. These sequences include potential polyadenylation sites that are often and A+T rich, a higher G+C% than that frequently found in plant genes (63% *versus* ~50%), concentrated stretches of G and C residues, and codons that are not used frequently in plant genes. The high G+C% in the CP4 EPSPS gene has a number of potential consequences including the following: a higher usage of G or C than that found in plant genes in the third position in codons, and the

potential to form strong hair-pin structures that may affect expression or stability of the RNA. The reduction in the G+C content of the CP4 EPSPS gene, the disruption of stretches of G's and C's, the elimination of potential polyadenylation sequences, and improvements in the codon usage to that used more frequently in plant genes, could result in higher expression of the CP4 EPSPS gene in plants.

A synthetic CP4 gene was designed to change as completely as possible those inimical sequences discussed above. In summary, the gene sequence was redesigned to eliminate as much as possible the following sequences or sequence features (while avoiding the introduction of unnecessary restriction sites): stretches of G's and C's of 5 or greater; and A+T rich regions (predominantly) that could function as polyadenylation sites or potential RNA destabilization region. The sequence of this gene is shown in Figure 8 (SEQ ID NO:9). This coding sequence was expressed in *E. coli* from the *RecA* promoter and assayed for EPSPS activity and compared with that from the native CP4 EPSPS gene. The apparent Km for PEP for the native and synthetic genes was 11.8 and 12.7, respectively, indicating that the enzyme expressed from the synthetic gene was unaltered. The N-terminus of the coding sequence was mutagenized to place an SphI site at the ATG to permit the construction of the CTP2-CP4 synthetic fusion for chloroplast import. The following primer was used to accomplish this mutagenesis:

GGACGGCTGCTTGCACCGTGAAGCATGCTTAAGCTTGGCGTAATCATGG  
(SEQ ID NO:35).

#### Expression of Chloroplast Directed CP4 EPSPS

The glyphosate target in plants, the 5-enolpyruvyl-shikimate-3-phosphate synthase (EPSPS) enzyme, is located in the chloroplast. Many chloroplast-localized proteins, including EPSPS, are expressed from nuclear genes as precursors and are targeted to the chloroplast by a chloroplast

transit peptide (CTP) that is removed during the import steps. Examples of other such chloroplast proteins include the small subunit (SSU) of Ribulose-1,5-bisphosphate carboxylase (RUBISCO), Ferredoxin, Ferredoxin oxidoreductase, the Light-harvesting-complex protein I and protein II, and Thioredoxin F. It has been demonstrated *in vivo* and *in vitro* that non-chloroplast proteins may be targeted to the chloroplast by use of protein fusions with a CTP and that a CTP sequence is sufficient to target a protein to the chloroplast.

A CTP-CP4 EPSPS fusion was constructed between the *Arabidopsis thaliana* EPSPS CTP (Klee *et al.*, 1987) and the CP4 EPSPS coding sequences. The *Arabidopsis* CTP was engineered by site-directed mutagenesis to place a *Sph*I restriction site at the CTP processing site. This mutagenesis replaced the Glu-Lys at this location with Cys-Met. The sequence of this CTP, designated as CTP2 (SEQ ID NO:10), is shown in Figure 9. The N-terminus of the CP4 EPSPS gene was modified to place a *Sph*I site that spans the Met codon. The second codon was converted to one for leucine in this step also. This change had no apparent effect on the *in vivo* activity of CP4 EPSPS in *E. coli* as judged by rate of complementation of the *aroA* allele. This modified N-terminus was then combined with the *Sac*I C-terminus and cloned downstream of the CTP2 sequences. The CTP2-CP4 EPSPS fusion was cloned into pBlueScript KS(+). This vector may be transcribed *in vitro* using the T7 polymerase and the RNA translated with <sup>35</sup>S-Methionine to provide material that may be evaluated for import into chloroplasts isolated from *Lactuca sativa* using the methods described hereinafter (della-Cioppa *et al.*, 1986, 1987). This template was transcribed *in vitro* using T7 polymerase and the <sup>35</sup>S-methionine-labeled CTP2-CP4 EPSPS material was shown to import into chloroplasts with an efficiency comparable to that for the control Petunia EPSPS (control = <sup>35</sup>S labeled PreEPSPS [pMON6140; della-Cioppa *et al.*, 1986]).

In another example the *Arabidopsis* EPSPS CTP, designated as CTP3, was fused to the CP4 EPSPS through an *Eco*RI site. The sequence of this

CTP3 (SEQ ID NO:12) is shown in Figure 10. An *Eco*RI site was introduced into the *Arabidopsis* EPSPS mature region around amino acid 27, replacing the sequence -Arg-Ala-Leu-Leu- with -Arg-Ile-Leu-Leu- in the process. The primer of the following sequence was used to modify the N-terminus of the CP4 EPSPS gene to add an *Eco*RI site to effect the fusion to the

CTP3: GGAAGACGCCAGAATTCACGGTGCAAGCAGCCGG  
(SEQ ID NO:36) (the *Eco*RI site is underlined.)

This CTP3-CP4 EPSPS fusion was also cloned into the pBlueScript vector and the T7 expressed fusion was found to also import into chloroplasts with an efficiency comparable to that for the control Petunia EPSPS (pMON6140).

A related series of CTPs, designated as CTP4 (*Sph*I) and CTP5 (*Eco*RI), based on the Petunia EPSPS CTP and gene were also fused to the *Sph*I- and *Eco*RI-modified CP4 EPSPS gene sequences. The *Sph*I site was added by site-directed mutagenesis to place this restriction site (and change the amino acid sequence to -Cys-Met-) at the chloroplast processing site. All of the CTP-CP4 EPSPS fusions were shown to import into chloroplasts with approximately equal efficiency. The CTP4 (SEQ ID NO:14) and CTP5 (SEQ ID NO:16) sequences are shown in Figures 11 and 12.

A CTP2-LBAA EPSPS fusion was also constructed following the modification of the N-terminus of the LBAA EPSPS gene by the addition of a *Sph*I site. This fusion was also found to be imported efficiently into chloroplasts.

By similar approaches, the CTP2-CP4 EPSPS and the CTP4-CP4 EPSPS fusion have also been shown to import efficiently into chloroplasts prepared from the leaf sheaths of corn. These results indicate that these CTP-CP4 fusions could also provide useful genes to impart glyphosate tolerance in monocot species.

The use of CTP2 or CTP4 is preferred because these transit peptide constructions yield mature EPSPS enzymes upon import into the chloroplast which are closer in composition to the native EPSPSs not containing a transit peptide signal. Those skilled in the art will recognize that various chimeric constructs can be made which utilize the functionality of a particular CTP to import a Class II EPSPS enzyme into the plant cell chloroplast. The chloroplast import of the Class II EPSPS can be determined using the following assay.

#### Chloroplast Uptake Assay

Intact chloroplasts are isolated from lettuce (*Latuca sativa*, var. *longifolia*) by centrifugation in Percoll/ficoll gradients as modified from Bartlett *et al.*, (1982). The final pellet of intact chloroplasts is suspended in 0.5 ml of sterile 330 mM sorbitol in 50 mM Hepes-KOH, pH 7.7, assayed for chlorophyll (Arnon, 1949), and adjusted to the final chlorophyll concentration of 4 mg/ml (using sorbitol/Hepes). The yield of intact chloroplasts from a single head of lettuce is 3-6mg chlorophyll.

A typical 300  $\mu$ l uptake experiment contained 5 mM ATP, 8.3 mM unlabeled methionine, 322 mM sorbitol, 58.3 mM Hepes-KOH (pH 8.0), 50  $\mu$ l reticulocyte lysate translation products, and intact chloroplasts from *L. sativa* (200  $\mu$ g chlorophyll). The uptake mixture is gently rocked at room temperature (in 10 x 75 mm glass tubes) directly in front of a fiber optic illuminator set at maximum light intensity (150 Watt bulb). Aliquot samples of the uptake mix (about 50  $\mu$ l) are removed at various times and fractionated over 100  $\mu$ l silicone-oil gradients (in 150  $\mu$ l polyethylene tubes) by centrifugation at 11,000 X g for 30 seconds. Under these conditions, the intact chloroplasts form a pellet under the silicone-oil layer and the incubation medium (containing the reticulocyte lysate) floats on the surface. After centrifugation, the silicone-oil gradients are immediately frozen in dry ice. The chloroplast pellet is then resuspended in 50-100  $\mu$ l of lysis buffer (10 mM Hepes-KOH pH 7.5, 1 mM

PMSF, 1 mM benzamidine, 5 mM *o*-amino-*n*-caproic acid, and 30 µg/ml aprotinin) and centrifuged at 15,000 X g for 20 minutes to pellet the thylakoid membranes. The clear supernatant (stromal proteins) from this spin, and an aliquot of the reticulocyte lysate incubation medium from each uptake experiment, are mixed with an equal volume of 2X SDS-PAGE sample buffer for electrophoresis (Laemmli, 1970).

SDS-PAGE is carried out according to Laemmli (1970) in 3-17% (w/v) acrylamide slab gels (60 mm X 1.5 mm) with 3% (w/v) acrylamide stacking gels (5 mm X 1.5 mm). The gel is fixed for 20-30 min in a solution with 40% methanol and 10% acetic acid. Then, the gel is soaked in EN<sup>3</sup>HANCE™ (DuPont) for 20-30 minutes, followed by drying the gel on a gel dryer. The gel is imaged by autoradiography, using an intensifying screen and an overnight exposure to determine whether the CP4 EPSPS is imported into the isolated chloroplasts.

### Plant Transformation

Plants which can be made glyphosate-tolerant by practice of the present invention include, but are not limited to, soybean, cotton, corn, canola, oil seed rape, flax, sugarbeet, sunflower, potato, tobacco, tomato, wheat, rice, alfalfa and lettuce as well as various tree, nut and vine species.

A double-stranded DNA molecule of the present invention ("chimeric gene") can be inserted into the genome of a plant by any suitable method. Suitable plant transformation vectors include those derived from a Ti plasmid of *Agrobacterium tumefaciens*, as well as those disclosed, e.g., by Herrera-Estrella (1983), Bevan (1984), Klee (1985) and EPO publication 120,516 (Schilperoort *et al.*). In addition to plant transformation vectors derived from the Ti or root-inducing (Ri) plasmids of *Agrobacterium*, alternative methods can be used to insert the DNA constructs of this invention into plant cells. Such methods may involve, for example, the use of liposomes, electroporation.

chemicals that increase free DNA uptake, free DNA delivery via microprojectile bombardment, and transformation using viruses or pollen.

### Class II EPSPS Plant transformation vectors

Class II EPSPS DNA sequences may be engineered into vectors capable of transforming plants by using known techniques. The following description is meant to be illustrative and not to be read in a limiting sense. One of ordinary skill in the art would know that other plasmids, vectors, markers, promoters, etc. would be used with suitable results. The CTP2-CP4 EPSPS fusion was cloned as a *Bgl*II-*Eco*RI fragment into the plant vector pMON979 (described below) to form pMON17110, a map of which is presented in Figure 13. In this vector the CP4 gene is expressed from the enhanced CaMV35S promoter (E35S; Kay *et al.* 1987). A FMV35S promoter construct (pMON17116) was completed in the following way: The *Sal*I-*Not*I and the *Not*I-*Bgl*II fragments from pMON979 containing the Spc/AAC(3)-III/oriV and the pBR322/Right Border/NOS 3'/CP4 EPSPS gene segment from pMON17110 were ligated with the *Xho*I-*Bgl*II FMV35S promoter fragment from pMON981. These vectors were introduced into tobacco, cotton and canola.

A series of vectors was also completed in the vector pMON977 in which the CP4 EPSPS gene, the CTP2-CP4 EPSPS fusion, and the CTP3-CP4 fusion were cloned as *Bgl*II-*Sac*I fragments to form pMON17124, pMON17119, and pMON17120, respectively. These plasmids were introduced into tobacco. A pMON977 derivative containing the CTP2-LBAA EPSPS gene was also completed (pMON17206) and introduced into tobacco.

The pMON979 plant transformation/expression vector was derived from pMON886 (described below) by replacing the neomycin phosphotransferase typeII (KAN) gene in pMON886 with the 0.89 kb fragment containing the bacterial gentamicin-3-N-acetyltransferase type III (AAC(3)-III) gene (Hayford *et al.*, 1988). The chimeric P-35S/AA(3)-III/NOS 3' gene encodes

gentamicin resistance which permits selection of transformed plant cells. pMON979 also contains a 0.95 kb expression cassette consisting of the enhanced CaMV 35S promoter (Kay *et al.*, 1987), several unique restriction sites, and the NOS 3' end (P-En-CaMV35S/NOS 3'). The rest of the pMON979 DNA segments are exactly the same as in pMON886.

Plasmid pMON886 is made up of the following segments of DNA. The first is a 0.93 kb *Ava*I to engineered-*Eco*RV fragment isolated from transposon Tn7 that encodes bacterial spectinomycin/streptomycin resistance (Spc/Str), which is a determinant for selection in *E. coli* and *Agrobacterium tumefaciens*. This is joined to the 1.61 kb segment of DNA encoding a chimeric kanamycin resistance which permits selection of transformed plant cells. The chimeric gene (P-35S/KAN/NOS 3') consists of the cauliflower mosaic virus (CaMV) 35S promoter, the neomycin phosphotransferase typeII (KAN) gene, and the 3'-nontranslated region of the nopaline synthase gene (NOS 3') (Fraley *et al.*, 1983). The next segment is the 0.75 kb *ori*V containing the origin of replication from the RK2 plasmid. It is joined to the 3.1 kb *Sal*I to *Pvu*I segment of pBR322 (*ori*322) which provides the origin of replication for maintenance in *E. coli* and the *bom* site for the conjugational transfer into the *Agrobacterium tumefaciens* cells. The next segment is the 0.36 kb *Pvu*I to *Bcl*I from pTiT37 that carries the nopaline-type T-DNA right border (Fraley *et al.*, 1985).

The pMON977 vector is the same as pMON981 except for the presence of the P-En-CaMV35S promoter in place of the FMV35S promoter (see below).

The pMON981 plasmid contains the following DNA segments: the 0.93 kb fragment isolated from transposon Tn7 encoding bacterial spectinomycin/streptomycin resistance [Spc/Str; a determinant for selection in *E. coli* and *Agrobacterium tumefaciens* (Fling *et al.*, 1985)]; the chimeric kanamycin resistance gene engineered for plant expression to allow selection of the transformed tissue, consisting of the 0.35 kb cauliflower mosaic virus 35S promoter (P-35S) (Odell *et al.*, 1985), the 0.83 kb neomycin phosphotransferase typeII gene (KAN), and the 0.26 kb 3'-nontranslated

region of the nopaline synthase gene (NOS 3') (Fraley *et al.*, 1983); the 0.75 kb origin of replication from the RK2 plasmid (*oriV*) (Stalker *et al.*, 1981); the 3.1 kb *SalI* to *PvuI* segment of pBR322 which provides the origin of replication for maintenance in *E. coli* (*ori-322*) and the *bom* site for the conjugational transfer into the *Agrobacterium tumefaciens* cells, and the 0.36 kb *PvuI* to *BclI* fragment from the pTiT37 plasmid containing the nopaline-type T-DNA right border region (Fraley *et al.*, 1985). The expression cassette consists of the 0.6 kb 35S promoter from the figwort mosaic virus (P-FMV35S) (Gowda *et al.*, 1989) and the 0.7 kb 3' non-translated region of the pea *rbcS-E9* gene (E9 3') (Coruzzi *et al.*, 1984, and Morelli *et al.*, 1985). The 0.6 kb *SspI* fragment containing the FMV35S promoter (Figure 1) was engineered to place suitable cloning sites downstream of the transcriptional start site. The CTP2-CP4syn gene fusion was introduced into plant expression vectors (including pMON981, to form pMON17131; Figure 14) and transformed into tobacco, canola, potato, tomato, sugarbeet, cotton, lettuce, cucumber, oil seed rape, poplar, and *Arabidopsis*.

The plant vector containing the Class II EPSPS gene may be mobilized into any suitable *Agrobacterium* strain for transformation of the desired plant species. The plant vector may be mobilized into an ABI *Agrobacterium* strain. A suitable ABI strain is the A208 *Agrobacterium tumefaciens* carrying the disarmed Ti plasmid pTiC58 (pMP90RK) (Koncz and Schell, 1986). The Ti plasmid does not carry the T-DNA phytohormone genes and the strain is therefore unable to cause the crown gall disease. Mating of the plant vector into ABI was done by the triparental conjugation system using the helper plasmid pRK2013 (Ditta *et al.*, 1980). When the plant tissue is incubated with the ABI:plant vector conjugate, the vector is transferred to the plant cells by the *vir* functions encoded by the disarmed pTiC58 plasmid. The vector opens at the T-DNA right border region, and the entire plant vector sequence may be inserted into the host plant chromosome. The pTiC58 Ti plasmid does not transfer to the plant cells but remains in the *Agrobacterium*.

DO NOT DESTROY

**Class II EPSPS free DNA vectors**

Class II EPSPS genes may also be introduced into plants through direct delivery methods. A number of direct delivery vectors were completed for the CP4 EPSPS gene. The vector pMON13640, a map of which is presented in Figure 15, is described here. The plasmid vector is based on a pUC plasmid (Vieira and Messing, 1987) containing, in this case, the *nptII* gene (kanamycin resistance; KAN) from Tn903 to provide a selectable marker in *E. coli*. The CTP4-EPSPS gene fusion is expressed from the P-FMV35S promoter and contains the NOS 3' polyadenylation sequence fragment and from a second cassette consisting of the E35S promoter, the CTP4-CP4 gene fusion and the NOS 3' sequences. The scoreable GUS marker gene (Jefferson *et al.*, 1987) is expressed from the mannopine synthase promoter (P-MAS; Velten *et al.*, 1984) and the soybean 7S storage protein gene 3' sequences (Schuler *et al.*, 1982). Similar plasmids could also be made in which CTP-CP4 EPSPS fusions are expressed from the enhanced CaMV35S promoter or other plant promoters. Other vectors could be made that are suitable for free DNA delivery into plants and such are within the skill of the art and contemplated to be within the scope of this disclosure.

**Plastid transformation:**

While transformation of the nuclear genome of plants is much more developed at this time, a rapidly advancing alternative is the transformation of plant organelles. The transformation of plastids of land plants and the regeneration of stable transformants has been demonstrated (Svab *et al.*, 1990; Maliga *et al.*, 1993). Transformants are selected, following double cross-over events into the plastid genome, on the basis of resistance to spectinomycin conferred through rRNA changes or through the introduction of an aminoglycoside 3'-adenyltransferase gene (Svab *et al.*, 1990; Svab and Maliga, 1993), or resistance to kanamycin through the neomycin phosphotransferase NptII

(Carrer *et al.*, 1993). DNA is introduced by biolistic means (Svab *et al.*, 1990; Maliga *et al.*, 1993) or by using polyethylene glycol (O'Neill *et al.*, 1993). This transformation route results in the production of 500-10,000 copies of the introduced sequence per cell and high levels of expression of the introduced gene have been reported (Carrer *et al.*, 1993; Maliga *et al.*, 1993). The use of plastid transformation offers the advantages of not requiring the chloroplast transit peptide signal sequence to result in the localization of the heterologous Class II EPSPS in the chloroplast and the potential to have many copies of the heterologous plant-expressible Class II EPSPS gene in each plant cell since at least one copy of the gene would be in each plastid of the cell.

### Plant Regeneration

When expression of the Class II EPSPS gene is achieved in transformed cells (or protoplasts), the cells (or protoplasts) are regenerated into whole plants. Choice of methodology for the regeneration step is not critical, with suitable protocols being available for hosts from Leguminosae (alfalfa, soybean, clover, etc.), Umbelliferae (carrot, celery, parsnip), Cruciferae (cabbage, radish, rapeseed, etc.), Cucurbitaceae (melons and cucumber), Gramineae (wheat, rice, corn, etc.), Solanaceae (potato, tobacco, tomato, peppers), various floral crops as well as various trees such as poplar or apple, nut crops or vine plants such as grapes. See, e.g., Ammirato, 1984; Shimamoto, 1989; Fromm, 1990; Vasil, 1990.

The following examples are provided to better elucidate the practice of the present invention and should not be interpreted in any way to limit the scope of the present invention. Those skilled in the art will recognize that various modifications, truncations, etc. can be made to the methods and genes described herein while not departing from the spirit and scope of the present invention.

In the examples that follow, EPSPS activity in plants is assayed by the following method. Tissue samples were collected and immediately frozen in

liquid nitrogen. One gram of young leaf tissue was frozen in a mortar with liquid nitrogen and ground to a fine powder with a pestle. The powder was then transferred to a second mortar, extraction buffer was added (1 ml /gram), and the sample was ground for an additional 45 seconds. The extraction buffer for canola consists of 100 mM Tris, 1 mM EDTA, 10 % glycerol, 5 mM DTT, 1 mM BAM, 5 mM ascorbate, 1.0 mg/ml BSA, pH 7.5 (4°C). The extraction buffer for tobacco consists of 100 mM Tris, 10 mM EDTA, 35 mM KCl, 20 % glycerol, 5 mM DTT, 1 mM BAM, 5 mM ascorbate, 1.0 mg/ml BSA, pH 7.5 (4°C). The mixture was transferred to a microfuge tube and centrifuged for 5 minutes. The resulting supernatants were desalted on spin G-50 (Pharmacia) columns, previously equilibrated with extraction buffer (without BSA), in 0.25 ml aliquots. The desalted extracts were assayed for EPSP synthase activity by radioactive HPLC assay. Protein concentrations in samples were determined by the BioRad microprotein assay with BSA as the standard.

Protein concentrations were determined using the BioRad Microprotein method. BSA was used to generate a standard curve ranging from 2 - 24  $\mu$ g. Either 800  $\mu$ l of standard or diluted sample was mixed with 200  $\mu$ l of concentrated BioRad Bradford reagent. The samples were vortexed and read at A(595) after ~ 5 minutes and compared to the standard curve.

EPSPS enzyme assays contained HEPES (50 mM), shikimate-3-phosphate (2 mM), NH<sub>4</sub> molybdate (0.1 mM) and KF (5 mM), with or without glyphosate (0.5 or 1.0 mM). The assay mix (30  $\mu$ l) and plant extract (10  $\mu$ l) were preincubated for 1 minute at 25°C and the reactions were initiated by adding <sup>14</sup>C-PEP (1 mM). The reactions were quenched after 3 minutes with 50  $\mu$ l of 90% EtOH/0.1M HOAc, pH 4.5. The samples were spun at 6000 rpm and the resulting supernatants were analyzed for <sup>14</sup>C-EPSP production by HPLC. Percent resistant EPSPS is calculated from the EPSPS activities with and without glyphosate.

The percent conversion of <sup>14</sup>C labeled PEP to <sup>14</sup>C EPSP was determined by HPLC radioassay using a C18 guard column (Brownlee) and an AX100

HPLC column (0.4 X 25 cm, Synchropak) with 0.28 M isocratic potassium phosphate eluant, pH 6.5, at 1 ml/min. Initial velocities were calculated by multiplying fractional turnover per unit time by the initial concentration of the labeled substrate (1 mM). The assay was linear with time up to ~ 3 minutes and 30% turnover to EPSPS. Samples were diluted with 10 mM Tris, 10% glycerol, 10 mM DTT, pH 7.5 (4°C) if necessary to obtain results within the linear range.

In these assays DL-dithiotheitol (DTT), benzamidine (BAM), and bovine serum albumin (BSA, essentially globulin free) were obtained from Sigma. Phosphoenolpyruvate (PEP) was from Boehringer Mannheim and phosphoenol-[1-<sup>14</sup>C]pyruvate (28 mCi/mmol) was from Amersham.

## EXAMPLES

### Example 1

Transformed tobacco plants have been generated with a number of the Class II EPSPS gene vectors containing the CP4 EPSPS DNA sequence as described above with suitable expression of the EPSPS. These transformed plants exhibit glyphosate tolerance imparted by the Class II CP4 EPSPS.

Transformation of tobacco employs the tobacco leaf disc transformation protocol which utilizes healthy leaf tissue about 1 month old. After a 15-20 minutes surface sterilization with 10% Clorox plus a surfactant, the leaves are rinsed 3 times in sterile water. Using a sterile paper punch, leaf discs are punched and placed upside down on MS104 media (MS salts 4.3 g/l, sucrose 30 g/l, B5 vitamins 500X 2 ml/l, NAA 0.1 mg/l, and BA 1.0 mg/l) for a 1 day preculture.

The discs are then inoculated with an overnight culture of a disarmed *Agrobacterium* ABI strain containing the subject vector that had been diluted 1/5 (i.e.: about 0.6 OD). The inoculation is done by placing the discs in centrifuge tubes with the culture. After 30 to 60 seconds, the liquid is drained

off and the discs were blotted between sterile filter paper. The discs are then placed upside down on MS104 feeder plates with a filter disc to co-culture.

After 2-3 days of co-culture, the discs are transferred, still upside down, to selection plates with MS104 media. After 2-3 weeks, callus tissue formed, and individual clumps are separated from the leaf discs. Shoots are cleanly cut from the callus when they are large enough to be distinguished from stems. The shoots are placed on hormone-free rooting media (MSO: MS salts 4.3 g/l, sucrose 30 g/l, and B5 vitamins 500X 2 ml/l) with selection for the appropriate antibiotic resistance. Root formation occurred in 1-2 weeks. Any leaf callus assays are preferably done on rooted shoots while still sterile. Rooted shoots are then placed in soil and kept in a high humidity environment (i.e.: plastic containers or bags). The shoots are hardened off by gradually exposing them to ambient humidity conditions.

#### Expression of CP4 EPSPS protein in transformed plants

Tobacco cells were transformed with a number of plant vectors containing the native CP4 EPSPS gene, and using different promoters and/or CTP's. Preliminary evidence for expression of the gene was given by the ability of the leaf tissue from antibiotic selected transformed shoots to recallus on glyphosate. In some cases, glyphosate-tolerant callus was selected directly following transformation. The level of expression of the CP4 EPSPS was determined by the level of glyphosate-tolerant EPSPS activity (assayed in the presence of 0.5 mM glyphosate) or by Western blot analysis using a goat anti-CP4 EPSPS antibody. The Western blots were quantitated by densitometer tracing and comparison to a standard curve established using purified CP4 EPSPS. These data are presented as % soluble leaf protein. The data from a number of transformed plant lines and transformation vectors are presented in Table VI below.

**Table VI Expression of CP4 EPSPS in transformed tobacco tissue**

Vector	Plant #	CP4 EPSPS ** (% leaf protein)
pMON17110	25313	0.02
pMON17110	25329	0.04
pMON17116	25095	0.02
pMON17119	25106	0.09
pMON17119	25762	0.09
pMON17119	25767	0.03

\*\* Glyphosate-tolerant EPSPS activity was also demonstrated in leaf extracts for these plants.

Glyphosate tolerance has also been demonstrated at the whole plant level in transformed tobacco plants. In tobacco,  $R_0$  transformants of CTP2-CP4 EPSPS were sprayed at 0.4 lb/acre (0.448 kg/hectare), a rate sufficient to kill control non-transformed tobacco plants corresponding to a rating of 3, 1 and 0 at days 7, 14 and 28, respectively, and were analyzed vegetatively and reproductively (Table VII).

**Table VII Glyphosate tolerance in *R. tobacco* CP4 transformants\***

Vector/Plant #	Score**			
	Vegetative			
	day 7	day 14	day 28	
pMON17110/25313	6	4	2	no
pMON17110/25329	9	10	10	yes
pMON17119/25106	9	9	10	yes

\* Spray rate = 0.4 lb/acre (0.448kg/hectare)

\*\*Plants are evaluated on a numerical scoring system of 0-10 where a vegetative score of 10 represents no damage relative to nonsprayed controls and 0 represents a dead plant. Reproductive scores (Fertile) are determined at 28 days after spraying and are evaluated as to whether or not the plant is fertile.

#### **Example 2A**

Canola plants were transformed with the pMON17110, pMON17116, and pMON17131 vectors and a number of plant lines of the transformed canola were obtained which exhibit glyphosate tolerance.

#### **Plant Material**

Seedlings of *Brassica napus* cv *Westar* were established in 2 inch (~ 5 cm) pots containing Metro Mix 350. They were grown in a growth chamber at 24°C, 16/8 hour photoperiod, light intensity of 400  $\mu\text{Em}^{-2}\text{sec}^{-1}$  (HID lamps). They were fertilized with Peters 20-10-20 General Purpose Special. After 2 1/2 weeks they were transplanted to 6 inch (~ 15 cm) pots and grown in a growth chamber at 15/10°C day/night temperature, 16/8 hour photoperiod, light

intensity of  $800 \text{ uEm}^{-2}\text{sec}^{-1}$  (HID lamps). They were fertilized with Peters 15-30-15 Hi-Phos Special.

### Transformation/Selection/Regeneration

Four terminal internodes from plants just prior to bolting or in the process of bolting but before flowering were removed and surfaced sterilized in 70% v/v ethanol for 1 minute, 2% w/v sodium hypochlorite for 20 minutes and rinsed 3 times with sterile deionized water. Stems with leaves attached could be refrigerated in moist plastic bags for up to 72 hours prior to sterilization. Six to seven stem segments were cut into 5mm discs with a Redco Vegetable Slicer 200 maintaining orientation of basal end.

The *Agrobacterium* was grown overnight on a rotator at 24°C in 2mls of Luria Broth containing 50mg/l kanamycin, 24mg/l chloramphenicol and 100 mg/l spectinomycin. A 1:10 dilution was made in MS (Murashige and Skoog) media giving approximately  $9 \times 10^8$  cells per ml. This was confirmed with optical density readings at 660 mu. The stem discs (explants) were inoculated with 1.0 ml of *Agrobacterium* and the excess was aspirated from the explants.

The explants were placed basal side down in petri plates containing 1/10X standard MS salts, B5 vitamins, 3% sucrose, 0.8% agar, pH 5.7, 1.0 mg/l 6-benzyladenine (BA). The plates were layered with 1.5 ml of media containing MS salts, B5 vitamins, 3% sucrose, pH 5.7, 4.0 mg/l p-chlorophenoxyacetic acid, 0.005 mg/l kinetin and covered with sterile filter paper.

Following a 2 to 3 day co-culture, the explants were transferred to deep dish petri plates containing MS salts, B5 vitamins, 3% sucrose, 0.8% agar, pH 5.7, 1 mg/l BA, 500 mg/l carbenicillin, 50mg/l cefotaxime, 200 mg/l kanamycin or 175 mg/l gentamicin for selection. Seven explants were placed on each plate. After 3 weeks they were transferred to fresh media, 5 explants per plate. The explants were cultured in a growth room at 25°C, continuous light (Cool White).

### Expression Assay

After 3 weeks shoots were excised from the explants. Leaf recallusing assays were initiated to confirm modification of  $R_0$  shoots. Three tiny pieces of leaf tissue were placed on recallusing media containing MS salts, B5 vitamins, 3% sucrose, 0.8% agar, pH 5.7, 5.0mg/l BA, 0.5 mg/l naphthalene acetic acid (NAA), 500 mg/l carbenicillin, 50mg/l cefotaxime and 200 mg/l kanamycin or gentamicin or 0.5 mM glyphosate. The leaf assays were incubated in a growth room under the same conditions as explant culture. After 3 weeks the leaf recallusing assays were scored for herbicide tolerance (callus or green leaf tissue) or sensitivity (bleaching).

### Transplantation

At the time of excision, the shoot stems were dipped in Rootone® and placed in 2 inch (~ 5 cm) pots containing Metro-Mix 350 and placed in a closed humid environment. They were placed in a growth chamber at 24°C, 16/8 hour photoperiod, 400  $\mu\text{Em}^{-1}\text{sec}^{-2}$ (HID lamps) for a hardening-off period of approximately 3 weeks.

The seed harvested from  $R_0$  plants is  $R_1$  seed which gives rise to  $R_1$  plants. To evaluate the glyphosate tolerance of an  $R_0$  plant, its progeny are evaluated. Because an  $R_0$  plant is assumed to be hemizygous at each insert location, selfing results in maximum genotypic segregation in the  $R_1$ . Because each insert acts as a dominant allele, in the absence of linkage and assuming only one hemizygous insert is required for tolerance expression, one insert would segregate 3:1, two inserts, 15:1, three inserts 63:1, etc. Therefore, relatively few  $R_1$  plants need be grown to find at least one resistant phenotype.

Seed from an  $R_0$  plant is harvested, threshed, and dried before planting in a glyphosate spray test. Various techniques have been used to grow the plants for  $R_1$  spray evaluations. Tests are conducted in both greenhouses and growth chambers. Two planting systems are used; ~ 10 cm pots or plant trays

containing 32 or 36 cells. Soil used for planting is either Metro 350 plus three types of slow release fertilizer or plant Metro 350. Irrigation is either overhead in greenhouses or sub-irrigation in growth chambers. Fertilizer is applied as required in irrigation water. Temperature regimes appropriate for canola were maintained. A sixteen hour photoperiod was maintained. At the onset of flowering, plants are transplanted to ~15 cm pots for seed production.

A spray "batch" consists of several sets of  $R_1$  progenies all sprayed on the same date. Some batches may also include evaluations of other than  $R_1$  plants. Each batch also includes sprayed and unsprayed non-transgenic genotypes representing the genotypes in the particular batch which were putatively transformed. Also included in a batch is one or more non-segregating transformed genotypes previously identified as having some resistance.

Two-six plants from each individual  $R_0$  progeny are not sprayed and serve as controls to compare and measure the glyphosate tolerance, as well as to assess any variability not induced by the glyphosate. When the other plants reach the 2-4 leaf stage, usually 10 to 20 days after planting, glyphosate is applied at rates varying from 0.28 to 1.12 kg/ha, depending on objectives of the study. Low rate technology using low volumes has been adopted. A laboratory track sprayer has been calibrated to deliver a rate equivalent to field conditions.

A scale of 0 to 10 is used to rate the sprayed plants for vegetative resistance. The scale is relative to the unsprayed plants from the same  $R_0$  plant. A 0 is death, while a 10 represents no visible difference from the unsprayed plant. A higher number between 0 and 10 represents progressively less damage as compared to the unsprayed plant. Plants are scored at 7, 14, and 28 days after treatment (DAT), or until bolting, and a line is given the average score of the sprayed plants within an  $R_0$  plant family.

Six integers are used to qualitatively describe the degree of reproductive damage from glyphosate:

- 0: No floral bud development
- 2: Floral buds present, but aborted prior to opening
- 4: Flowers open, but no anthers, or anthers fail to extrude past petals
- 6: Sterile anthers
- 8: Partially sterile anthers
- 10: Fully fertile flowers

Plants are scored using this scale at or shortly after initiation of flowering, depending on the rate of floral structure development.

#### Expression of EPSPS in Canola

After the 3 week period, the transformed canola plants were assayed for the presence of glyphosate-tolerant EPSPS activity (assayed in the presence of glyphosate at 0.5 mM). The results are shown in Table VIII.

DRAFT - 9/2011

**Table VIII Expression of CP4 EPSPS in transformed Canola plants**

	Plant #	% resistant EPSPS activity of Leaf extract (at 0.5 mM glyphosate)
Vector Control		0
pMON17110	41	47
pMON17110	52	28
pMON17110	71	82
pMON17110	104	75
pMON17110	172	84
pMON17110	177	85
pMON17110	252	29*
pMON17110	350	49
pMON17116	40	25
pMON17116	99	87
pMON17116	175	94
pMON17116	178	43
pMON17116	182	18
pMON17116	252	69
pMON17116	298	44*
pMON17116	332	89
pMON17116	383	97
pMON17116	395	52

\*assayed in the presence of 1.0 mM glyphosate

*R*<sub>1</sub> transformants of canola were then grown in a growth chamber and sprayed with glyphosate at 0.56 kg/ha (kilogram/hectare) and rated vegetatively. These results are shown in Table IXA - IXc. It is to be noted that expression of glyphosate resistant EPSPS in all tissues is preferred to observe optimal glyphosate tolerance phenotype in these transgenic plants. In the Tables below, only expression results obtained with leaf tissue are described.

**Table IXA Glyphosate tolerance in Class II EPSPS  
canola R<sub>1</sub> transformants**

(pMON17110 = P-E35S; pMON17116 = P-FMV35S; R<sub>1</sub> plants;  
Spray rate = 0.56 kg/ha)

Vector/Plant No.	% resistant <u>EPSPS*</u>	Vegetative	
		Score**	day 7 day 14
Control Westar	0	5	3
pMON17110/41	47	6	7
pMON17110/71	82	6	7
pMON17110/177	85	9	10
pMON17116/40	25	9	9
pMON17116/99	87	9	10
pMON17116/175	94	9	10
pMON17116/178	43	6	3
pMON17116/182	18	9	10
pMON17116/383	97	9	10

**Table IXB Glyphosate tolerance in Class II EPSPS**  
**canola R<sub>1</sub> transformants**

(pMON17131 = P-FMV35S; R1 plants; Spray rate = 0.84 kg/ha)

Vector/Plant No.	Vegetative score**		Reproductive score	
	day 14	day 28	day 14	day 28
17131/78	10		10	
17131/102	9		10	
17131/115	9		10	
17131/116	9		10	
17131/157	9		10	
17131/169	10		10	
17131/255	10		10	
control Westar	1		0	

**Table IXC Glyphosate tolerance in Class I EPSPS**  
**canola transformants**

(P-E35S; R2 Plants; Spray rate = 0.28 kg/ha)

Vector/Plant No.	EPSPS*	Vegetative	
		% resistant	Score**
		day 7	day 14
Control Westar	0	4	2
pMON899/715	96	5	6
pMON899/744	95	8	8
pMON899/794	86	6	4
pMON899/818	81	7	8
pMON899/885	57	7	6

\* % resistant EPSPS activity in the presence of 0.5 mM glyphosate

\*\* A vegetative score of 10 indicates no damage, a score of 0 is given to a dead plant.

The data obtained for the Class II EPSPS transformants may be compared to glyphosate-tolerant Class I EPSP transformants in which the

same promoter is used to express the EPSPS genes and in which the level of glyphosate-tolerant EPSPS activity was comparable for the two types of transformants. A comparison of the data of pMON17110 [in Table IXA] and pMON17131 [Table IXB] with that for pMON899 [in Table IXC; the Class I gene in pMON899 is that from *A. thaliana* (Klee *et al.*, 1987) in which the glycine at position 101 was changed to an alanine] illustrates that the Class II EPSPS is at least as good as that of the Class I EPSPS. An improvement in vegetative tolerance of Class II EPSPS is apparent when one takes into account that the Class II plants were sprayed at twice the rate and were tested as R<sub>1</sub> plants.

#### **Example 2B**

The construction of two plant transformation vectors and the transformation procedures used to produce glyphosate-tolerant canola plants are described in this example. The vectors, pMON17209 and pMON17237, were used to generate transgenic glyphosate-tolerant canola lines. The vectors each contain the gene encoding the 5-enol-pyruvyl-shikimate-3-phosphate synthase (EPSPS) from *Agrobacterium* sp. strain CP4. The vectors also contain either the *gox* gene encoding the glyphosate oxidoreductase enzyme (GOX) from *Achromobacter* sp. strain LBAA (Barry *et al.*, 1992) or the gene encoding a variant of GOX (GOX v.247) which displays improved catalytic properties. These enzymes convert glyphosate to aminomethylphosphonic acid and glyoxylate and protect the plant from damage by the metabolic inactivation of glyphosate. The combined result of providing an alternative, resistant EPSPS enzyme and the metabolism of glyphosate produces transgenic plants with enhanced tolerance to glyphosate.

**Molecular biology techniques.** In general, standard molecular biology and microbial genetics approaches were employed (Maniatis *et al.*, 1982).

Site-directed mutageneses were carried out as described by Kunkel *et al.* (1987). Plant-preferred genes were synthesized and the sequence confirmed.

**Plant transformation vectors.** The following describes the general features of the plant transformation vectors that were modified to form vectors pMON17209 and pMON17237. The *Agrobacterium* mediated plant transformation vectors contain the following well-characterized DNA segments which are required for replication and function of the plasmids (Rogers and Klee, 1987; Klee and Rogers, 1989). The first segment is the 0.45 kb *Cla*I-*Dra*I fragment from the pTi15955 octopine Ti plasmid which contains the T-DNA left border region (Barker *et al.*, 1983). It is joined to the 0.75 kb origin of replication (*oriV*) derived from the broad-host range plasmid RK2 (Stalker *et al.*, 1981). The next segment is the 3.1 kb *Sall*-*Pvu*I segment of pBR322 which provides the origin of replication for maintenance in *E. coli* and the *bom* site for the conjugational transfer into the *Agrobacterium tumefaciens* cells (Bolivar *et al.*, 1977). This is fused to the 0.93 kb fragment isolated from transposon Tn7 which encodes bacterial spectinomycin and streptomycin resistance (Fling *et al.*, 1985), a determinant for the selection of the plasmids in *E. coli* and *Agrobacterium*. It is fused to the 0.36 kb *Pvu*I-*Bcl*I fragment from the pTiT37 plasmid which contains the nopaline-type T-DNA right border region (Fraley *et al.*, 1985). Several chimeric genes engineered for plant expression can be introduced between the Ti right and left border regions of the vector. In addition to the elements described above, this vector also includes the 35S promoter/NPTII/NOS 3' cassette to enable selection of transformed plant tissues on kanamycin (Klee and Rogers, 1989; Fraley *et al.*, 1983; and Odell, *et al.*, 1985) within the borders. An "empty" expression cassette is also present between the borders and consists of the enhanced E35S promoter (Kay *et al.*, 1987), the 3' region from the small subunit of RUBPcarboxylase of pea (E9) (Coruzzi *et al.*, 1984; Morelli *et al.*, 1986), and a number of restriction enzyme sites that may be used for the cloning of DNA sequences for

expression in plants. The plant transformation system based on *Agrobacterium tumefaciens* delivery has been reviewed (Klee and Rogers, 1989; Fraley *et al.*, 1986). The *Agrobacterium* mediated transfer and integration of the vector T-DNA into the plant chromosome results in the expression of the chimeric genes conferring the desired phenotype in plants.

**Bacterial Inoculum.** The binary vectors are mobilized into *Agrobacterium tumefaciens* strain ABI by the triparental conjugation system using the helper plasmid pRK2013 (Ditta *et al.*, 1980). The ABI strain contains the disarmed pTiC58 plasmid pMP90RK (Koncz and Schell, 1986) in the chloramphenicol resistant derivative of the *Agrobacterium tumefaciens* strain A208.

**Transformation procedure.** *Agrobacterium* inocula were grown overnight at 28°C in 2 ml of LBSCK (LBSCK is made as follows: LB liquid medium [1 liter volume] = 10 g NaCl; 5 g Yeast Extract; 10 g tryptone; pH 7.0, and autoclave for 22 minutes. After autoclaving, add spectinomycin (50 mg/ml stock) - 2 ml, kanamycin (50 mg/ml stock) - 1 ml, and chloramphenicol (25 mg/ml stock) - 1 ml.). One day prior to inoculation, the *Agrobacterium* was subcultured by inoculating 200 $\mu$ l into 2 ml of fresh LBSCK and grown overnight. For inoculation of plant material, the culture was diluted with MSO liquid medium to an  $A_{660}$  range of 0.2- 0.4.

Seedlings of *Brassica napus* cv. Westar were grown in Metro Mix 350 (Hummert Seed Co., St. Louis, Mo.) in a growth chamber with a day/night temperature of 15/10°C, relative humidity of 50%, 16h/8h photoperiod, and at a light intensity of 500  $\mu$ mol m $^{-2}$  sec $^{-1}$ . The plants were watered daily (via sub-irrigation) and fertilized every other day with Peter's 15:30:15 (Fogelsville, Pa.).

In general, all media recipes and the transformation protocol follow those in Fry *et. al.* (1987). Five to six week-old Westar plants were harvested when the plants had bolted (but prior to flowering), the leaves and buds were removed, and the 4-5 inches of stem below the flower buds were used as the explant tissue source. Following sterilization with 70% ethanol for 1 min and 38% Clorox for 20 min, the stems were rinsed three times with sterile water and cut into 5 mm-long segments (the orientation of the basal end of the stem segments was noted). The plant material was incubated for 5 minutes with the diluted *Agrobacterium* culture at a rate of 5 ml of culture per 5 stems. The suspension of bacteria was removed by aspiration and the explants were placed basal side down - for an optimal shoot regeneration response - onto co-culture plates (1/10 MSO solid medium with a 1.5 ml TXD (tobacco xanthi diploid) liquid medium overlay and covered with a sterile 8.5 cm filter paper). Fifty-to-sixty stem explants were placed onto each co-culture plate.

After a 2 day co-culture period, stem explants were moved onto MS medium containing 750 mg/l carbenicillin, 50 mg/l cefotaxime, and 1 mg/l BAP (benzylaminopurine) for 3 days. The stem explants were then placed for two periods of three weeks each, again basal side down and with 5 explants per plate, onto an MS/0.1 mM glyphosate, selection medium (also containing carbenicillin, cefotaxime, and BAP (The glyphosate stock [0.5M] is prepared as described in the following: 8.45 g glyphosate [analytical grade] is dissolved in 50 ml deionized water, adding KOH pellets to dissolve the glyphosate, and the volume is brought to 100 ml following adjusting the pH to 5.7. The solution is filter-sterilized and stored at 4°C). After 6 weeks on this glyphosate selection medium, green, normally developing shoots were excised from the stem explants and were placed onto fresh MS medium containing 750 mg/l carbenicillin, 50 mg/l cefotaxime, and 1 mg/l BAP, for further shoot development. When the shoots were 2-3 inches tall, a fresh cut at the end of

the stem was made, the cut end was dipped in Root-tone, and the shoot was placed in Metro Mix 350 soil and allowed to harden-off for 2-3 weeks.

**Construction of Canola transformation vector pMON17209.**

The EPSPS gene was isolated originally from *Agrobacterium* sp. strain CP4 and expresses a highly tolerant enzyme. The original gene contains sequences that could be inimical to high expression of the gene in some plants. These sequences include potential polyadenylation sites that are often A+T rich, a higher G+C% than that frequently found in dicotyledonous plant genes (63% versus ~50%), concentrated stretches of G and C residues, and codons that may not be used frequently in dicotyledonous plant genes. The high G+C% in the CP4 EPSPS gene could also result in the formation of strong hairpin structures that may affect expression or stability of the RNA. A plant preferred version of the gene was synthesized and used for these vectors. This coding sequence was expressed in *E. coli* from a *PRecA-gene10L* vector (Olins *et al.*, 1988) and the EPSPS activity was compared with that from the native CP4 EPSPS gene. The appK<sub>m</sub> for PEP for the native and synthetic genes was 11.8  $\mu$ M and 12.7  $\mu$ M, respectively, indicating that the enzyme expressed from the synthetic gene was unaltered. The N-terminus of the coding sequence was then mutagenized to place an *Sph*I site (GCATGC) at the ATG to permit the construction of the CTP2-CP4 synthetic fusion for chloroplast import. This change had no apparent effect on the *in vivo* activity of CP4 EPSPS in *E. coli* as judged by complementation of the *aroA* mutant. A CTP-CP4 EPSPS fusion was constructed between the *Arabidopsis thaliana* EPSPS CTP (Klee *et al.*, 1987) and the CP4 EPSPS coding sequences. The *Arabidopsis* CTP was engineered by site-directed mutagenesis to place a *Sph*I restriction site at the CTP processing site. This mutagenesis replaced the Glu-Lys at this location with Cys-Met. The CTP2-CP4 EPSPS fusion was tested for import into chloroplasts isolated from *Lactuca sativa* using the methods described previously (della-Cioppa *et al.*, 1986; 1987).

The GOX gene that encodes the glyphosate metabolizing enzyme glyphosate oxidoreductase (GOX) was cloned originally from *Achromobacter* sp. strain LBAA (Hallas *et al.*, 1988; Barry *et al.*, 1992). The *gox* gene from strain LBAA was also resynthesized in a plant-preferred sequence version and in which many of the restriction sites were removed (PCT Appln. No. WO 92/00377). The GOX protein is targeted to the plastids by a fusion between the C-terminus of a CTP and the N-terminus of GOX. A CTP, derived from the SSU1A gene from *Arabidopsis thaliana* (Timko *et al.*, 1988) was used. This CTP (CTP1) was constructed by a combination of site-directed mutageneses. The CTP1 is made up of the SSU1A CTP (amino acids 1-55), the first 23 amino acids of the mature SSU1A protein (56-78), a serine residue (amino acid 79), a new segment that repeats amino acids 50 to 56 from the CTP and the first two from the mature protein (amino acids 80-87), and an alanine and methionine residue (amino acid 88 and 89). An *Nco*I restriction site is located at the 3' end (spans the Met89 codon) to facilitate the construction of precise fusions to the 5' of GOX. At a later stage, a *Bgl*II site was introduced upstream of the N-terminus of the SSU1A sequences to facilitate the introduction of the fusions into plant transformation vectors. A fusion was assembled between CTP1 and the synthetic GOX gene.

The CP4 EPSPS and GOX genes were combined to form pMON17209 as described in the following. The CTP2-CP4 EPSPS fusion was assembled and inserted between the constitutive FMV35S promoter (Gowda *et al.*, 1989; Richins *et al.*, 1987) and the E9 3' region (Coruzzi *et al.*, 1984; Morelli *et al.*, 1985) in a pUC vector (Yannisch-Perron *et al.*, 1985; Vieira and Messing, 1987) to form pMON17190; this completed element may then be moved easily as a *Not*I-*Not*I fragment to other vectors. The CTP1-GOX fusion was also assembled in a pUC vector with the FMV35S promoter. This element was then moved as a *Hind*III-*Bam*HI fragment into the plant transformation

vector pMON10098 and joined to the E9 3' region in the process. The resultant vector pMON17193 has a single *NotI* site into which the FMV 35S/CTP2-CP4 EPSPS/E9 3' element from pMON17190 was cloned to form pMON17194. The kanamycin plant transformation selection cassette (Fraley *et al.*, 1985) was then deleted from pMON17194, by cutting with *XbaI* and re-ligating, to form the pMON17209 vector (Figure 24).

**Construction of Canola transformation vector pMON17237.**

The GOX enzyme has an apparent  $K_m$  for glyphosate [ $appK_m$ (glyphosate)] of ~25 mM. In an effort to improve the effectiveness of the glyphosate metabolic rate *in planta*, a variant of GOX has been identified in which the  $appK_m$ (glyphosate) has been reduced approximately 10-fold; this variant is referred to as GOX v.247 and the sequence differences between it and the original plant-preferred GOX are illustrated in PCT Appln. No. WO 92/00377. The GOX v.247 coding sequence was combined with CTP1 and assembled with the FMV35S promoter and the E9 3' by cloning into the pMON17227 plant transformation vector to form pMON17241. In this vector, effectively, the CP4 EPSPS was replaced by GOX v.247. The pMON17227 vector had been constructed by replacing the CTP1-GOX sequences in pMON17193 with those for the CTP2-CP4 EPSPS, to form pMON17199 and followed by deleting the kanamycin cassette (as described above for pMON17209). The pMON17237 vector (Figure 25) was then completed by cloning the FMV35S/CTP2-CP4 EPSPS/E9 3' element as a *NotI*-*NotI* fragment into pMON17241.

### **Example 3**

Soybean plants were transformed with the pMON13640 (Figure 15) vector and a number of plant lines of the transformed soybean were obtained which exhibit glyphosate tolerance.

Soybean plants are transformed with pMON13640 by the method of microprojectile injection using particle gun technology as described in Christou *et al.* (1988). The seed harvested from  $R_0$  plants is  $R_1$  seed which gives rise to  $R_1$  plants. To evaluate the glyphosate tolerance of an  $R_0$  plant, its progeny are evaluated. Because an  $R_0$  plant is assumed to be hemizygous at each insert location, selfing results in maximum genotypic segregation in the  $R_1$ . Because each insert acts as a dominant allele, in the absence of linkage and assuming only one hemizygous insert is required for tolerance expression, one insert would segregate 3:1, two inserts, 15:1, three inserts 63:1, etc. Therefore, relatively few  $R_1$  plants need be grown to find at least one resistant phenotype.

Seed from an  $R_0$  soybean plant is harvested, and dried before planting in a glyphosate spray test. Seeds are planted into 4 inch (~5 cm) square pots containing Metro 350. Twenty seedlings from each  $R_0$  plant is considered adequate for testing. Plants are maintained and grown in a greenhouse environment. A 12.5-14 hour photoperiod and temperatures of 30°C day and 24°C night is regulated. Water soluble Peters Pete Lite fertilizer is applied as needed.

A spray "batch" consists of several sets of  $R_1$  progenies all sprayed on the same date. Some batches may also include evaluations of other than  $R_1$  plants. Each batch also includes sprayed and unsprayed non-transgenic genotypes representing the genotypes in the particular batch which were putatively transformed. Also included in a batch is one or more non-segregating transformed genotypes previously identified as having some resistance.

One to two plants from each individual  $R_0$  progeny are not sprayed and serve as controls to compare and measure the glyphosate tolerance, as well as

to assess any variability not induced by the glyphosate. When the other plants reach the first trifoliate leaf stage, usually 2-3 weeks after planting, glyphosate is applied at a rate equivalent of 128 oz./acre (8.895 kg/ha) of Roundup®. A laboratory track sprayer has been calibrated to deliver a rate equivalent to those conditions.

A vegetative score of 0 to 10 is used. The score is relative to the unsprayed progenies from the same R<sub>0</sub> plant. A 0 is death, while a 10 represents no visible difference from the unsprayed plant. A higher number between 0 and 10 represents progressively less damage as compared to the unsprayed plant. Plants are scored at 7, 14, and 28 days after treatment (DAT). The data from the analysis of one set of transformed and control soybean plants are described on Table X and show that the CP4 EPSPS gene imparts glyphosate tolerance in soybean also.

**Table X**      Glyphosate tolerance in Class II EPSPS soybean transformants  
(P-E35S, P-FMV35S; R<sub>0</sub> plants; Spray rate = 128 oz./acre)

<u>Vector/Plant No.</u>	<u>Vegetative score</u>		
	<u>day 7</u>	<u>day 14</u>	<u>day 28</u>
13640/40-11	5	6	7
13640/40-3	9	10	10
13640/40-7	4	7	7
control A5403 2	1	0	
control A5403 1	1	0	

**Example 4**

The CP4 EPSPS gene may be used to select transformed plant material directly on media containing glyphosate. The ability to select and to identify transformed plant material depends, in most cases, on the use of a dominant selectable marker gene to enable the preferential and continued growth of the

transformed tissues in the presence of a normally inhibitory substance. Antibiotic resistance and herbicide tolerance genes have been used almost exclusively as such dominant selectable marker genes in the presence of the corresponding antibiotic or herbicide. The nptII/kanamycin selection scheme is probably the most frequently used. It has been demonstrated that CP4 EPSPS is also a useful and perhaps superior selectable marker/selection scheme for producing and identifying transformed plants.

A plant transformation vector that may be used in this scheme is pMON17227 (Figure 16). This plasmid resembles many of the other plasmids described infra and is essentially composed of the previously described bacterial replicon system that enables this plasmid to replicate in *E. coli* and to be introduced into and to replicate in *Agrobacterium*, the bacterial selectable marker gene (Spc/Str), and located between the T-DNA right border and left border is the CTP2-CP4 synthetic gene in the FMV35S promoter-E9 3' cassette. This plasmid also has single sites for a number of restriction enzymes, located within the borders and outside of the expression cassette. This makes it possible to easily add other genes and genetic elements to the vector for introduction into plants.

The protocol for direct selection of transformed plants on glyphosate is outlined for tobacco. Explants are prepared for pre-culture as in the standard procedure as described in Example 1: surface sterilization of leaves from 1 month old tobacco plants (15 minutes in 10% clorox + surfactant; 3X dH<sub>2</sub>O washes); explants are cut in 0.5 x 0.5 cm squares, removing leaf edges, mid-rib, tip, and petiole end for uniform tissue type; explants are placed in single layer, upside down, on MS104 plates + 2 ml 4COO5K media to moisten surface; pre-culture 1-2 days. Explants are inoculated using overnight culture of *Agrobacterium* containing the plant transformation plasmid that is adjusted to a titer of 1.2 X 10<sup>9</sup> bacteria/ml with 4COO5K media. Explants are placed into a centrifuge tube. the *Agrobacterium* suspension is added and the mixture of bacteria and explants is "Vortexed" on maximum setting for 25 seconds to

ensure even penetration of bacteria. The bacteria are poured off and the explants are blotted between layers of dry sterile filter paper to remove excess bacteria. The blotted explants are placed upside down on MS104 plates + 2ml 4COO5K media + filter disc. Co-culture is 2-3 days. The explants are transferred to MS104 + Carbenicillin 1000 mg/l + cefotaxime 100 mg/l for 3 days (delayed phase). The explants are then transferred to MS104 + glyphosate 0.05 mM + Carbenicillin 1000 mg/l + cefotaxime 100 mg/l for selection phase. At 4-6 weeks shoots are cut from callus and placed on MSO + Carbenicillin 500 mg/l rooting media. Roots form in 3-5 days, at which time leaf pieces can be taken from rooted plates to confirm glyphosate tolerance and that the material is transformed.

The presence of the CP4 EPSPS protein in these transformed tissues has been confirmed by immunoblot analysis of leaf discs. The data from one experiment with pMON17227 is presented in the following: 139 shoots formed on glyphosate from 400 explants inoculated with *Agrobacterium* ABI/pMON17227; 97 of these were positive on re-callusing on glyphosate. These data indicate a transformation rate of 24 per 100 explants, which makes this a highly efficient and time saving transformation procedure for plants. Similar transformation frequencies have been obtained with pMON17131 and direct selection of transformants on glyphosate with the CP4 EPSPS genes has also been shown in other plant species, including, *Arabidopsis*, soybean, corn, wheat, potato, tomato, cotton, lettuce, and sugarbeet.

The pMON17227 plasmid contains single restriction enzyme recognition cleavage sites (NotI, XhoI, and BstXI) between the CP4 glyphosate selection region and the left border of the vector for the cloning of additional genes and to facilitate the introduction of these genes into plants.

**Example 5A**

The CP4 EPSPS gene has also been introduced into Black Mexican Sweet (BMS) corn cells with expression of the protein and glyphosate resistance detected in callus.

The backbone for this plasmid was a derivative of the high copy plasmid pUC119 (Viera and Messing, 1987). The 1.3 Kb *Fsp*I-*Dra*I pUC119 fragment containing the origin of replication was fused to the 1.3 Kb *Sma*I-*Hind*III filled fragment from pKC7 (Rao and Rogers, 1979) which contains the neomycin phosphotransferase type II gene to confer bacterial kanamycin resistance. This plasmid was used to construct a monocot expression cassette vector containing the 0.6 kb cauliflower mosaic virus (CaMV) 35S RNA promoter with a duplication of the -90 to -300 region (Kay *et al.*, 1987), an 0.8 kb fragment containing an intron from a maize gene in the 5' untranslated leader region, followed by a polylinker and the 3' termination sequences from the nopaline synthase (NOS) gene (Fraley *et al.*, 1983). A 1.7 Kb fragment containing the 300 bp chloroplast transit peptide from the *Arabidopsis* EPSP synthase fused in frame to the 1.4 Kb coding sequence for the bacterial CP4 EPSP synthase was inserted into the monocot expression cassette in the polylinker between the intron and the NOS termination sequence to form the plasmid pMON19653 (Figure 17).

pMON19653 DNA was introduced into *Black Mexican Sweet* (BMS) cells by co-bombardment with EC9, a plasmid containing a sulfonylurea-resistant form of the maize acetolactate synthase gene. 2.5 mg of each plasmid was coated onto tungsten particles and introduced into log-phase BMS cells using a PDS-1000 particle gun essentially as described (Klein *et al.*, 1989). Transformants are selected on MS medium containing 20 ppb chlorsulfuron. After initial selection on chlorsulfuron, the calli can be assayed directly by Western blot. Glyphosate tolerance can be assessed by transferring the calli to

medium containing 5mM glyphosate. As shown in Table XI, CP4 EPSPS confers glyphosate tolerance to corn callus.

**Table XI. Expression of CP4 in BMS Corn Callus - pMON 19653**

<u>Line</u>	<u>CP4 expression</u> <u>(% extracted protein)</u>
284	0.006 %
287	0.036
290	0.061
295	0.073
299	0.113
309	0.042
313	0.003

To measure CP4 EPSPS expression in corn callus, the following procedure was used: BMS callus (3 g wet weight) was dried on filter paper (Whatman#1) under vacuum, reweighed, and extraction buffer (500  $\mu$ l/g dry weight; 100 mM Tris, 1 mM EDTA, 10% glycerol) was added. The tissue was homogenized with a Wheaton overhead stirrer for 30 seconds at 2.8 power setting. After centrifugation (3 minutes, Eppendorf microfuge), the supernatant was removed and the protein was quantitated (BioRad Protein Assay). Samples (50  $\mu$ g/well) were loaded on an SDS PAGE gel (Jule, 3-17%) along with CP4 EPSPS standard (10 ng), electrophoresed, and transferred to nitrocellulose similarly to a previously described method (Padgett, 1987). The nitrocellulose blot was probed with goat anti-CP4 EPSPS IgG, and developed with I-125 Protein G. The radioactive blot was visualized by autoradiography. Results were quantitated by densitometry on an LKB UltraScan XL laser densitometer and are tabulated below in Table X.

**Table XII. Glyphosate resistance in BMS Corn Callus**  
**using pMON 19653**

<u>Vector</u>	<u>Experiment</u>	<u># chlorsulfuron- resistant lines</u>	<u># cross-resistant to Glyphosate</u>
19653	253	120	81/ 120 = 67.5 %
19653	254	80	37/ 80 = 46%
EC9 control	253/254	8	0/8 = 0%

Improvements in the expression of Class II EPSPS could also be achieved by expressing the gene using stronger plant promoters, using better 3' polyadenylation signal sequences, optimizing the sequences around the initiation codon for ribosome loading and translation initiation, or by combination of these or other expression or regulatory sequences or factors.

### **Example 5B**

The plant- expressible genes encoding the CP4 EPSPS and a glyphosate oxidoreductase enzyme (PCT Pub. No. WO92/00377) were introduced into embryogenic corn callus through particle bombardment. Plasmid DNA was prepared using standard procedures (Ausubel *et al.*, 1987), cesium-chloride purified, and re-suspended at 1 mg/ml in TE buffer. DNA was precipitated onto M10 tungsten or 1.0 $\mu$  gold particles (BioRad) using a calcium chloride/spermidine precipitation protocol, essentially as described by Klein *et al.* (1987). The PDS1000® gunpowder gun (BioRad) was used. Callus tissue was obtained by isolating 1-2 mm long immature embryos from the "Hi-II" genotype (Armstrong *et al.*, 1991), or Hi-II X B73 crosses, onto a modified N6 medium (Armstrong and Green, 1985; Songstad *et al.*, 1991). Embryogenic callus ("type-II"; Armstrong and Green, 1985) initiated from these embryos was maintained by subculturing at two week intervals, and was bombarded when less than two months old. Each plate of callus tissue was bombarded from 1 to 3 times with either tungsten or gold particles coated with the plasmid DNA(s) of interest. Callus was transferred to a modified N6 medium

containing an appropriate selective agent (either glyphosate, or one or more of the antibiotics kanamycin, G418, or paromomycin) 1-8 days following bombardment, and then re-transferred to fresh selection media at 2-3 week intervals. Glyphosate-resistant calli first appeared approximately 6-12 weeks post-bombardment. These resistant calli were propagated on selection medium, and samples were taken for assays gene expression. Plant regeneration from resistant calli was accomplished essentially as described by Petersen *et al.* (1992).

In some cases, both gene(s) were covalently linked together on the same plasmid DNA molecule. In other instances, the genes were present on separate plasmids, but were introduced into the same plant through a process termed "co-transformation". The 1 mg/ml plasmid preparations of interest were mixed together in an equal ratio, by volume, and then precipitated onto the tungsten or gold particles. At a high frequency, as described in the literature (e.g., Schocher *et al.*, 1986), the different plasmid molecules integrate into the genome of the same plant cell. Generally the integration is into the same chromosomal location in the plant cell, presumably due to recombination of the plasmids prior to integration. Less frequently, the different plasmids integrate into separate chromosomal locations. In either case, there is integration of both DNA molecules into the same plant cell, and any plants produced from that cell.

Transgenic corn plants were produced as described above which contained a plant-expressible CP4 gene and a plant-expressible gene encoding a glyphosate oxidoreductase enzyme.

The plant-expressible CP4 gene comprised a structural DNA sequence encoding a CTP2/CP4 EPSPS fusion protein. The CTP2/CP4 EPSPS is a gene fusion composed of the N-terminal 0.23 Kb chloroplast transit peptide sequence from the *Arabidopsis thaliana* EPSPS gene (Klee *et al.* 1987, referred to herein as CTP2), and the C-terminal 1.36 Kb 5-enolpyruvylshikimate-3-phosphate synthase gene (CP4) from an *Agrobacterium* species. Plant

expression of the gene fusion produces a pre-protein which is rapidly imported into chloroplasts where the CTP is cleaved and degraded (della-Cioppa *et al.*, 1986) releasing the mature CP4 protein.

The plant-expressible gene expressing a glyphosate oxidoreductase enzyme comprised a structural DNA sequence comprising CTP1/GOXsyn gene fusion composed of the N-terminal 0.26 Kb chloroplast transit peptide sequence derived from the *Arabidopsis thaliana* SSU 1a gene (Timko *et al.*, 1988 referred to herein as CTP1), and the C-terminal 1.3 Kb synthetic gene sequence encoding a glyphosate oxidoreductase enzyme (GOXsyn, as described in PCT Pub. No. WO92/00377 previously incorporated by reference). The GOXsyn gene encodes the enzyme glyphosate oxidoreductase from an *Achromobacter* sp. strain LBAA which catalyzes the conversion of glyphosate to herbicidally inactive products, aminomethylphosphonate and glyoxylate. Plant expression of the gene fusion produces a pre-protein which is rapidly imported into chloroplasts where the CTP is cleaved and degraded (della-Cioppa *et al.*, 1986) releasing the mature GOX protein.

Both of the above described genes also include the following regulatory sequences for plant expression: (i) a promoter region comprising a 0.6 Kb 35S cauliflower mosaic virus (CaMV) promoter (Odell *et al.*, 1985) with the duplicated enhancer region (Kay *et al.*, 1987) which also contains a 0.8 Kb fragment containing the first intron from the maize heat shock protein 70 gene (Shah *et al.*, 1985 and PCT Pub. No. WO93/19189, the disclosure of which is hereby incorporated by reference); and (ii) a 3' non-translated region comprising a 0.3 Kb fragment of the 3' non-translated region of the nopaline synthase gene (Fraley *et al.*, 1983 and Depicker, *et al.*, 1982) which functions to direct polyadenylation of the mRNA.

The above described transgenic corn plants exhibit tolerance to glyphosate herbicide in greenhouse and field trials.

Example 6

The LBAA Class II EPSPS gene has been introduced into plants and also imparts glyphosate tolerance. Data on tobacco transformed with pMON17206 (infra) are presented in Table XIII.

\*  
Table XIII - Tobacco Glyphosate Spray Test  
(pMON17206: E35S - CTP2-LBAA EPSPS: 0.4 lbs/ac)

<u>Line</u>	<u>7 Day Rating</u>
33358	9
34586	9
33328	9
34606	9
33377	9
34611	10
34607	10
34601	9
34589	9
Samsun (Control)	4

From the foregoing, it will be recognized that this invention is one well adapted to attain all the ends and objects hereinabove set forth together with advantages which are obvious and which are inherent to the invention. It will be further understood that certain features and subcombinations are of utility and may be employed without reference to other features and subcombinations. This is contemplated by and is within the scope of the claims. Since many possible embodiments may be made of the invention without departing from the scope thereof, it is to be understood that all matter herein set forth or shown in the accompanying drawings is to be interpreted as illustrative and not in a limiting sense.

## BIBLIOGRAPHY

Alm, R.A., Dalrymple, B.P. and Mattick, J.S. 1994. Sequencing and expression of the *aroA* gene from *Dichelobacter nodosus*, Gene, 145: 97-101.

Alton, N.K. and Vapnek, D. (1979) Nature 282:864-869.

Ammirato, P.V., *et al.* Handbook of Plant Cell Culture - Crop Species. Macmillan Publ. Co. (1984).

Armstrong, C.L., and Green, C.E. 1985. Establishment and maintenance of friable, embryogenic maize callus and the involvement of L-proline. Planta 164:207-214.

Armstrong, C.L., Green, C.E., and Phillips, R.L. 1991. Development and availability of germplasm with high Type II culture formation response. Maize Genetics Cooperation NewsLetter 65:92-93.

Arnon, D.I. Plant Physiol. 24:1-15 (1949).

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K. 1987. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc. New York.

Bachmann, B. J. *et al.*, Microb. Rev., 44:1-56 (1980).

Barker, R., Idler, K., Thompson, D., and Kemp, J. (1983) Nucleotide sequence of the T-DNA region from the *Agrobacterium tumefaciens* Ti plasmid pTi15955. Plant Mol Biol 2: 335-350

Barry, G., Kishore, G., Padgett, S., Taylor, M., Kolacz, K., Weldon, M., Re D., Eichholtz., Fincher, K., and Hallas, L. (1992) Inhibitors of amino acid biosynthesis: Strategies for imparting glyphosate tolerance to crop plants. In: Biosynthesis and Molecular Regulation of Amino Acids in Plants. pp. 139-145. [Edited by Singh, B. K., Flores, H. E., and Shannon, J. C.] American Society of Plant Physiologists, Rockville, Maryland.

Bartlett, S.G., Grossman, A.R., and Chua, N.H. (1982) in Methods in Chloroplast Molecular Biology, pp. 1081-1091. M. Edelman, R.B., Hallick, and Chua, N.H., eds.

Bevan, M. (1984) Nucleic Acids Res. 12 (22): 8711-8721.

Birnboim, H. C. and Doly, J. (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Nucl. Acids. Res. 7:1513-1525.

Bolivar, F., Rodriguez, R. L., Greene, P. J., Betlach, M. B., Heynecker, H. L., Boyer, H. W., Crosa, J. H., and Falkow, S. (1977) Construction and characterization of new cloning vehicles, II. A multi-purpose cloning system. Gene 2: 95-113.

Boyer, H. W. and Rolland-Dussoix, D. (1969) A complementation analysis of the restriction and modification of DNA in *Escherichia coli*. J. Mol. Biol. 41:459.

Carrer, H., Hockenberry, T. N., Svab, Z., and Maliga, P. (1993) Kanamycin resistance as a selectable marker for plastid transformation in tobacco. Mol. Gen. Genet. 241: 49-56.

Christou, P., D. E. McCabe, and W.F. Swain (1988) Stable transformation of Soybean Callus by DNA-Coated Gold Particles. Plant Physiol. 87:671-674.

Coruzzi, G., Broglie, R., Edwards, C., and Chua, N.H. (1984). Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of ribulose-1,5-bisphosphate carboxylase. EMBO J 3:1671.

Dalla Chiesa, M., Mayes, S.R., Maskell, D.J., Nixon, P.J. and Barber, J. 1994 An *AroA* homologue from *Synechocystis* sp. PCC6803, Gene, 144: 145-146.

della-Cioppa, G., Bauer, S. C., Klein, B. K., Shah, D. M., Fraley, R. T. and Kishore G. K. (1986) Translocation of the precursor of 5-enolpyruvylshikimate-3-phosphate synthase into chloroplasts of higher plants *in vitro*. Proc. Natl. Acad. Sci. USA 83: 6873-6877.

della-Cioppa, G., Bauer, S. C., Taylor, M. T., Rochester, D. E., Klein, B. K., Shah, D. M., Fraley, R. T. and Kishore G. M. (1987) Targeting a herbicide-resistant enzyme from *Escherichia coli* to chloroplasts of higher plants. Bio/Technology 5: 579-584.

Depicker, A., Stachel, S., Dhaese, P., Zambryski, P., and Goodman, H.M. 1982. Nopaline Synthase: Transcript Mapping and DNA Sequence. J. MOLEC. APPL. GENETICS 1:561-573.

Devereux, J., Haeberli, P. and Smithies, O. (1984) A comprehensive set of sequence analysis programs for the VAX. Nucl. Acids. Res. 12:387-395.

Ditta, G., Stanfield, S., Corbin, D., and Helinski, D.R. (1980) Broad host range DNA cloning system for Gram-Negative bacteria: construction of a gene bank of *Rhizobium meliloti*. Proc Natl Acad Sci USA 77, 7347-7351.

Duncan, K., Edwards, R.M., Coggins, J.R. (1987) The pentafunctional *aroM* enzyme of *Saccharomyces cerevisiae* is a mosaic of monofunctional domains. Biochem. J. 246: 375-386.

Dunn, J.J. and Studier, F.W., (1983) J. Mol. Biol. 166:477-535.

Fitzgibbon, J. E. (1988) *Pseudomonas* sp. strain PG2982: uptake of glyphosate and cloning of a gene which confers increased resistance to glyphosate. Ph. D. Dissertation, Louisiana State University.

Fitzgibbon, E. F. and Braymer, H. D. (1990) Cloning of a gene from *Pseudomonas* sp. PG2982 conferring increased glyphosate resistance Appl. Environ. Microbiol. 56: 3382-3388.

Fling, M.E., Kopf, J., and Richards, C. (1985). Nucleotide sequence of the transposon Tn7 gene encoding an aminoglycoside-modifying enzyme, 3"(9)-O-nucleotidyltransferase. Nucleic Acids Res. 13 no.19, 7095-7106.

Fraley, R.T., Rogers, S.G., Horsch, R.B., Sanders, P.R. Flick, J.S., Adams, S.P., Bittner, M.L., Brand, L.A., Fink, C.L., Fry, J.S., Galluppi, G.R., Goldberg, S.B., Hoffman, N.L., and Woo, S.C. 1983. Expression of bacterial genes in plant cells. Proc. Natl. Acad. Sci. USA 80:4803-4807.

Fraley, R. T., Rogers, S. G., Horsch, R. B., Eichholtz D. A., Flick, J. S., Fink, C. L., Hoffmann, N. L. and Sanders, P. R. (1985) The SEV system: a new disarmed Ti plasmid vector system for plant transformation.  
Bio/Technology 3: 629-635.

Fromm, M., (1990) UCLA Symposium on Molecular Strategies for Crop Improvement, April 16-22, 1990. Keystone, CO.

Fry J., Barnason A., and Horsch R. (1987) Plant Cell Reports 6: 321-325.

Gasser, C. S., Winter, J. A., Hironaka, C. M. and Shah, D. M. (1988) Structure, expression, and evolution of the 5-enolpyruvylshikimate 3-phosphate synthase genes of petunia and tomato. J. Biol. Chem. 263: 4280-4289.

Gowda, S., Wu, F.C., and Shepard, R.J. (1989). Identification of promoter sequences for the major RNA transcripts of figwort mosaic and peanut chlorotic streak viruses (caulimovirus group).

Journal of Cellular Biochemistry supplement 13D, 301 (Abstract).

Hallas, L. E., Hahn, E. M. and Korndorfer, C. (1988) Characterization of microbial traits associated with glyphosate biodegradation in industrial activated sludge. J. Industrial Microbiol. 3: 377-385.

Hayford, M. B., Medford, J. I., Hoffmann, N. L., Rogers, S. G. and Klee, H. J. (1988) Development of a plant transformation selection system based on expression of genes encoding gentamicin acetyltransferases. Plant Physiol. 86: 1216-1222.

Herrera-Estrella, L., *et al.* (1983) Nature 303:209

Heitkamp, M. A., Hallas, L. and Adams, W. J. (1990) Biotreatment of industrial wastewater with immobilized microorganisms - Presented in Session 11, Paper S40, Society for Industrial Microbiology Annual Meeting, Orlando, Florida, July 29-August 3, 1990.

Henner, J. H., Band, L. and Shimotsu, H. (1984) Nucleotide sequence of the *Bacillus subtilis* tryptophan operon. Gene, 34: 169-177.

Henner, J. H., Band, L., Flaggs, G. and Chen, E. (1986) The organization and nucleotide sequence of the *Bacillus subtilis* *hisH*, *tyrA* and *aroE* genes Gene 49: 147-152.

Hohn, B. and Collins J. (1980) A small cosmid for efficient cloning of large DNA fragments. Gene 11: 291-298.

Horsch, R.B. and H. Klee. (1986) Proc. Natl. Acad. Sci. U.S.A. 83:4428-32.

Hunkapiller, M. W., Hewick, R. M., Dreyer, R. J., and Hood, L. (1983) Methods Enzymol. 91, 399-413.

Jefferson, R.A., Kavanagh, T.A. and Bevan, M.W., 1987,  
EMBO J., 6:3901-3907.

Kay, R., Chan, A., Daly, M. and McPherson, J. 1987. Duplication of the CaMV 35S promoter sequence creates a strong enhancer for plants.  
Science 236, 1299-1302.

Kishore, G., Shah, D., Padgette, S., della-Cioppa, G., Gasser, C., Re, D., Hironaka, C., Taylor, M., Wibbenmeyer, J., Eichholtz, D., Hayford, M., Hoffman, N., Delannay, X., Horsch, R., Klee, H., Rogers, S., Rochester, D., Brundage, L., Sanders, P. and Fraley, R. T. (1988) 5-Enolpyruvylshikimate 3-phosphate synthase: From Biochemistry to genetic engineering of glyphosate tolerance, in Biotechnology for Crop Protection ACS Symposium series No. 379. Eds. Hedlin P. A., Menn, J. J. and Hollingsworth, R. M. pp. 37-48.

Kishore, G. and Shah, D. (1988) Ann. Rev. Biochem. 57:627-663.

Kishore, G. M., Brundage, L., Kolk, K., Padgette, S. R., Rochester, D., Huynh, Q. K. and della-Cioppa, G. (1986) Fed. Proc. 45: 1506.

Klee, H.J., *et al.* (1985) Bio/Technology 3:637-42.

Klee, H. J., Muskopf, Y. M. and Gasser, C. S. (1987) Cloning of an *Arabidopsis thaliana* gene encoding 5-enolpyruvyl-shikimate-3-phosphate synthase: sequence analysis and manipulation to obtain glyphosate-tolerant plants. Mol. Gen. Genet. 210: 437-442.

Klee, H. J. and Rogers, S. G. (1989) Plant gene vectors and genetic transformation: plant transformation systems based on the use of *Agrobacterium tumefaciens* in: Cell Culture and Somatic Cell: Genetics of Plants eds J. Schell and I.K. Vasil . 6: 1-23.

Klein, T.M., Kornstein, L., Sanford, J.C., and Fromm, M.E. 1989. Genetic transformation of maize cells by particle bombardment. Plant Phys. 91:440-444.

Koncz, C. and Schell, J. (1986) The promoter of T1-DNA gene 5 controls the tissue-specific expression of chimeric genes carried by a novel type of *Agrobacterium* binary vector. Mol. Gen. Genet. 204:383-396.

Kunkel, T. A., Roberts, J. D. and Zakour, R. A. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154:367.

Laemmli, U.K. (1970), "Cleavage of structural proteins during the assembly of the head of the bacteriophage T4" Nature, 227:680.

Maliga, P., Carrer, H., Kanevski, I., Staub, J., and Svab, Z. (1993) Plastid engineering in land plants: a conservative genome is open to change. Philos. Trans. R. Soc. London B Biol. Sci. 342: 203-208.

Maniatis, T., Fritsch, E. F. and Sambrook, J. (1982) Molecular Cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Maskell, D.J., Morrissey, P. and Dougan, G. (1988) Cloning and nucleotide sequence of the *aroA* gene of *Bordetella pertussis*. J. Bacteriol. 170:2467-2471.

Miller, J. H. (1972). Experiments in Molecular Genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Moore, J. K., Braymer, H. D. and Larson, A. D. (1983) Isolation of a *Pseudomonas* sp. which utilizes the phosphonate herbicide glyphosate. Appl. Environ. Microbiol. 46: 316-320.

Morelli, G., Nagy, F., Fraley, R.T., Rogers, S.G., and Chua, N. H. (1985). A short conserved sequence is involved in the light-inducibility of a gene encoding ribulose 1,5-bisphosphate carboxylase small subunit of pea.  
Nature 315, 200-204.

O'Connell, C., Pattee, P. A. and Foster, T. J. (1993) Sequence and mapping of the *aroA* gene of *Staphylococcus aureus* 8325-4.  
J. Gen. Micr. 139: 1449-1460.

Odell, J.T., Nagy, F., and Chua, N.H. (1985). Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter.  
Nature 313, 810-812.

Olins, P. O., Devine, C. S., Rangwala, S. H. and Kavka, K. S.  
(1988) Gene 73: 227-235.

O'Neill, C., Horvath, G. V., Horvath, E., Dix, P. J. and Medgyesy, P. (1993) Chloroplast transformation in plants: polyethylene glycol (PEG) treatment of protoplasts is an alternative to biolistic delivery systems. Plant J. 3: 729-738.

Padgett, S. R., Huynh, Q. K., Borgmeyer, J., Shah, D. M., Brand, L. A., Re, D. B., Bishop, B. F., Rogers, S. G., Fraley, R. T., and Kishore, G. (1987) Bacterial expression and isolation of *Petunia hybrida* 5-enol-pyruvylshikimate-3-phosphate synthase. Arch. Biochem. Biophys. 258, 564-573.

Padgett, S. R., Huynh, Q. K., Aykent, S., Sammons, R. D., Sikorski, J. A., and Kishore, G. M. (1988) J. Biol. Chem. 263, 1798-1802.

Petersen, W.L., Sulc, S., and Armstrong, C.L. 1992. Effect of nurse cultures on the production of macro-calli and fertile plants from maize embryogenic suspension protoplasts. Plant Cell Reports 10:591-594.

Quinn, J. P., Peden, J. M. M. and Dick, E. (1988) Glyphosate tolerance and utilization by the microflora of soils treated with the herbicide. Appl. Microbiol. Biotechnol. 29: 511-516.

Rao, R.N. and Rogers, S.G. (1979). Plasmid pKC7: A vector containing ten restriction endonuclease sites suitable for cloning DNA segments. Gene 7:79.

Richins, R. D., Scholthof, H. B., and Shepard, R. J. (1987) Sequence of the figwort mosaic virus DNA (caulimovirus group).

Nucl. Acids Res. 15: 8451-8466.

Rogers, S.G., Brand, L.A. Holder, S.B. Sharps, E.S. and Brackin, M.J. (1983) Amplification of the *aroA* gene from *E. coli* results in tolerance to the herbicide glyphosate. Appl. Environ. Microbiol. 46:37-43.

Rogers, S.G. and Klee, H. J. (1987). "Pathways to genetic manipulation employing *Agrobacterium*." in Plant Gene Research, Plant DNA Infectious Agents, Vol IV, Hohn, T. and Schell, J., eds. Springer-Verlag, Vienna, pp.179-203.

Sambrook, J., Fritsch, E.F. and Maniatis, T., (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Schocher, R.J., Shillito, R.D., Saul, M.W., Paszkowski, J., and Potrykus, I. (1986). Co-transformation of unlinked foreign genes into plants by direct gene transfer. Bio/Technology 4:1093-1097.

Songstad, D.D., Armstrong, C.L., and Petersen, W.L. (1991). AgNO<sub>3</sub> increases type II callus production from immature embryos of maize inbred B73 and its derivatives. Plant Cell Reports 9: 699-702.

Schuler, M. A., Schmitt, E. S. and Beachy, R.N. (1982)  
Nucleic Acids Res. 10:8225-8244.

Schulz, A., Kruper, A. and Amrhein, N. (1985) Differential sensitivity of bacterial 5-enolpyruvylshikimate-3-phosphate synthases to the herbicide glyphosate. FEMS Microbiol. Lett. 28: 297-301.

Schulz, A., Sost, D. and Amrhein, D. (1984) Arch. Microbiol. 137: 121-123.

Shah, D., Horsch, R., Klee, H., Kishore, G., Winter, J., Turner, N., Hironaka, C., Sanders, P., Gasser, C., Aykent, S., Siegal, N., Rogers, S., and Fraley, R. (1986). Engineering herbicide tolerance in transgenic plants.  
Science 233, 478-481.

Shah, D.M., Rochester, D.E., Krivi, G., Hironaka, C., Mozer, T.J., Fraley, R.T., and D.C. Tiemeier. 1985. Structure and expression of the maize hsp70 gene. Cell. and Mol. Biol. of Plant Stress. Alan R. Liss, Inc. pp. 181-200.

Shimamoto, K. *et al.* (1989) Nature 338:274-276.

Sost, D., Schulz, A. and Amrhein, N. (1984) FEBS Lett. 173: 238-241.

Sost, D. and Amrhein, N. (1990) Substitution of Gly-96 to Ala in the 5-enolpyruvylshikimate 3-phosphate synthase of *Klebsiella pneumoniae* results in greatly reduced affinity for the herbicide glyphosate.  
Arch. Biochem. Biophys. 282: 433-436.

Stalker, D.M., Thomas, C.M., and Helinski, D.R. (1981). Nucleotide sequence of the region of the origin of replication of the broad host range plasmid RK2.  
Mol Gen Genet 181: 8-12.

Stalker, D. M., Hiatt, W. R. and Comai, L. (1985) A single amino acid substitution in the enzyme 5-enolpyruvylshikimate 3-phosphate synthase confers resistance to glyphosate. J. Biol. Chem. 260: 4724-4728.

Stallings, W. C. , Abdel-Meguid, S. S., Lim, L. W., Shieh, Huey-Sheng, Dayringer, H. E., Leimgruber, N. K., Stegeman, R. A., Anderson, K. S., Sikorski, J. A., Padgett, S. R., Kishore, G. M. (1991). Structure and Topological Symmetry of the Glyphosate Target 5-enol-pyruvylshikimate-3-phosphate synthase. Proc. Natl. Acad. Sci. USA 88: 5046-5050.

Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) Stable transformation of plastids in higher plants. Proc. Natl. Acad. Sci. USA 87: 8526-8530.

Svab, Z. and Maliga, P. (1993) High frequency plastid transformation in tobacco by selection for a chimeric aadA gene. Proc. Natl. Acad. Sci. USA 90:913-917.

Tabor, S. and Richardson. C. C. (1985) A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. USA 82: 1074-1078.

Talbot, H. W., Johnson, L. M. and Munnecke, D. M. (1984) Glyphosate utilization by *Pseudomonas* sp. and *Alcaligenes* sp. isolated from environmental sources. Current Microbiol. 10: 255-260.

Talmadge, K., and Gilbert, W., (1980) "Construction of plasmid vectors with unique *Pst*I cloning sites in the signal sequence coding region" Gene, 12: 235-241.

Timko, M.P., Herdies, L., de Almeida, E., Cashmore, A.R., Leemans, J., and Krebbers, E. 1988. Genetic Engineering of Nuclear-Encoded Components of the Photosynthetic Apparatus in *Arabidopsis* in "The Impact of Chemistry on Biotechnology," ACS Books, 279-295.

Vasil, V., F. Redway and I. Vasil. (1990), Bio/Technology 8:429-434.

Vieira, J. and Messing J. (1987) Production of single-stranded plasmid DNA. Methods Enzymol. 153: 3-11.

Yanisch-Perron, C., Vieira, J. and Messing, J. (1985). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33, 103-119

## Annex A

38-21(10535)

PCT/US91/6148 (WO 92/04449) filed August 28, 1991 designated countries:

Australia

European Patent Office (Austria, Belgium, Denmark, France, Great Britain, Greece, Germany, Holland, Italy, Luxembourg, Sweden, Spain, Switzerland)

Japan

Russian Federation

CLAIMS:

1. An isolated DNA sequence other than the structural coding sequence listed in SEQ ID NO:41, SEQ ID NO:43 SEQ ID NO:66 and SEQ ID NO:68, encoding an EPSPS enzyme having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;

X<sub>2</sub> is S or T; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is S or T; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and

-N-X<sub>5</sub>-T-R- (SEQ ID NO:40), in which

X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V.

2. A DNA molecule of Claim 1 in which the K<sub>m</sub> for phosphoenolpyruvate is between 2 and 25  $\mu$ M.

3. A DNA molecule of Claim 1 in which the K<sub>i</sub>/K<sub>m</sub> ratio is between 25 and 500.

4. A DNA molecule of Claim 1 in which X<sub>1</sub> is D or N; X<sub>2</sub> is S or T; X<sub>3</sub> is S or T; X<sub>4</sub> is V, I or L; and X<sub>5</sub> is P or Q.

5. A DNA molecule of Claim 4 which encodes an EPSPS enzyme having the sequence of SEQ ID NO:3.

6. A DNA molecule of Claim 5 having the sequence of SEQ ID NO:2.

7. A DNA molecule of Claim 5 having the sequence of SEQ IDNO:9.
8. A recombinant, double-stranded DNA molecule comprising in sequence:
  - a) a promoter which functions in plant cells to cause the production of an RNA sequence;
  - b) a structural DNA sequence that causes the production of an RNA sequence which encodes a EPSPS enzyme having the sequence domains:  
-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which  
X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;  
X<sub>2</sub> is S or T; and  
-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which  
X<sub>3</sub> is S or T; and  
-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which  
X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and  
-N-X<sub>5</sub>-T-R- (SEQ ID NO:40), in which  
X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V;

and

- c) a 3' non-translated region which functions in plant cells to cause the addition of a stretch of polyadenyl nucleotides to the 3' end of the RNA sequence;

where the promoter is heterologous with respect to the structural DNA sequence and adapted to cause sufficient expression of the encoded EPSPS enzyme to enhance the glyphosate tolerance of a plant cell transformed with the DNA molecule.

9. A DNA molecule of Claim 8 in which the structural DNA sequence encodes a fusion polypeptide comprising an amino-terminal chloroplast transit peptide and the EPSPS enzyme.

10. A DNA molecule of Claim 8 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

11. A DNA molecule of Claim 10 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

12. A DNA molecule of Claim 9 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

13. A DNA molecule of Claim 12 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

14. A DNA molecule of Claim 12 in which the EPSPS sequence is SEQ ID NO:3.

15. A DNA molecule of Claim 14 in which the promoter is a plant DNA virus promoter.

16. A DNA molecule of Claim 15 in which the promoter is selected from the group consisting of CaMV35S and FMV35S promoters.

17. A DNA molecule of Claim 14 in which the structural DNA sequence encodes a chloroplast transit peptide selected from the group consisting of SEQ ID NO:11 and SEQ ID NO:15.

18. A DNA molecule of Claim 17 in which the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

19. A method of producing genetically transformed plants which are tolerant toward glyphosate herbicide, comprising the steps of:

a) inserting into the genome of a plant cell a recombinant, double-stranded DNA molecule comprising:

- i) a promoter which functions in plant cells to cause the production of an RNA sequence,
- ii) a structural DNA sequence that causes the production of an RNA sequence which encodes an EPSPS enzyme having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;

X<sub>2</sub> is S or T; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is S or T; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and

-N-X<sub>5</sub>-T-R- (SEQ ID NO:40), in which

X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V;

and

PENDING PCT/US10/49000

iii) a 3' non-translated DNA sequence which functions in plant cells to cause the addition of a stretch of polyadenyl nucleotides to the 3' end of the RNA sequence;

where the promoter is heterologous with respect to the structural DNA sequence and adapted to cause sufficient expression of the polypeptide to enhance the glyphosate tolerance of a plant cell transformed with the DNA molecule;

- b) obtaining a transformed plant cell; and
- c) regenerating from the transformed plant cell a genetically transformed plant which has increased tolerance to glyphosate herbicide.

20. A method of Claim 17 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

21. A method of Claim 20 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

22. A method of Claim 19 in which the structural DNA sequence encodes a fusion polypeptide comprising an amino-terminal chloroplast transit peptide and the EPSPS enzyme.

23. A method of Claim 22 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

24. A method of Claim 23 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:42 and SEQ ID NO:44.

25. A method of Claim 23 in which the EPSPS enzyme is that set forth in SEQ ID NO:3.

26. A method of Claim 25 in which the promoter is from a plant DNA virus.

27. A method of Claim 26 in which the promoter is selected from the group consisting of CaMV35S and FMV35S promoters.

28. A glyphosate-tolerant plant cell comprising a DNA molecule of Claims 9, 12 or 14.

29. A glyphosate-tolerant plant cell of Claim 28 in which the promoter is a plant DNA virus promoter.

30. A glyphosate-tolerant plant cell of Claim 29 in which the promoter is selected from the group consisting of CaMV35S and FMV35S promoters.

31. A glyphosate-tolerant plant cell of Claim 28 selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

32. A glyphosate-tolerant plant comprising plant cells of Claim 31.

33. A glyphosate-tolerant plant of Claim 32 in which the promoter is from a DNA plant virus promoter.

SEARCHED INDEXED  
SERIALIZED FILED  
JULY 19 1991  
U.S. DEPT. OF AGRICULTURE  
AGRICULTURAL RESEARCH SERVICE  
USDA

34. A glyphosate-tolerant plant of Claim 33 in which the promoter is selected from the group consisting of CaMV35S and FMV35S promoters.

35. A glyphosate-tolerant plant of Claim 34 selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

36. A method for selectively controlling weeds in a field containing a crop having planted crop seeds or plants comprising the steps of:

a) planting the crop seeds or plants which are glyphosate-tolerant as a result of a recombinant double-stranded DNA molecule being inserted into the crop seed or plant, the DNA molecule having:

- i) a promoter which functions in plant cells to cause the production of an RNA sequence,
- ii) a structural DNA sequence that causes the production of an RNA sequence which encodes an EPSPS enzyme having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;

X<sub>2</sub> is S or T; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is S or T; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and

-N-X<sub>5</sub>-T-R- (SEQ ID NO:40), in which

X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V;

and

iii) a 3' non-translated DNA sequence which functions in plant cells to cause the addition of a stretch of polyadenyl nucleotides to the 3' end of the RNA sequence

where the promoter is heterologous with respect to the structural DNA sequence and adapted to cause sufficient expression of the EPSPS enzyme to enhance the glyphosate tolerance of the crop plant transformed with the DNA molecule; and

b) applying to the crop and weeds in the field a sufficient amount of glyphosate herbicide to control the weeds without significantly affecting the crop.

37. A method of Claim 36 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

38. A method of Claim 37 in which the structural DNA sequence encodes an EPSPS enzyme selected from the sequences as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:42 and SEQ ID NO:44.

39. A method of Claim 36 in which the structural DNA sequence encodes a fusion polypeptide comprising an amino-terminal chloroplast transit peptide and the EPSPS enzyme.

40. A method of Claim 39 in which  $X_1$  is D or N;  $X_2$  is S or T;  $X_3$  is S or T;  $X_4$  is V, I or L; and  $X_5$  is P or Q.

41. A method of Claim 40 in which the structural DNA sequence encodes an EPSPS enzyme selected from the sequences as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

42. A method of Claim 40 in which the DNA molecule encodes an EPSPS enzyme as set forth in SEQ ID NO:3.

43. A method of Claim 42 in which the DNA molecule further comprises a promoter selected from the group consisting of the CAMV35S and FMV35S promoters.

44. A method of Claim 43 in which the crop plant is selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

45. A DNA molecule of Claim 9 in which the structural DNA sequence encodes a chloroplast transit peptide selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17.

46. A DNA molecule of Claim 45 in which the chloroplast transit peptide is encoded by a DNA sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:16.

47. A DNA molecule of Claim 9 in which the structural DNA sequence encodes a chloroplast transit peptide selected from the group consisting of SEQ ID NO:11 and SEQ ID NO:15.

48. A DNA molecule of Claim 47 in which the chloroplast transit peptide is encoded by a DNA sequence selected from the group consisting of SEQ ID NO:10 and SEQ ID NO:14.

49. A DNA molecule of Claim 45 in which the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters.

50. A DNA molecule of Claim 46 in which the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters.

51. A DNA molecule of Claim 47 in which the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters.

52. A DNA molecule of Claim 48 in which the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters.

53. A DNA molecule of Claim 49 in which the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

54. A DNA molecule of Claim 50 in which the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

55. A DNA molecule of Claim 51 in which the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

56. A DNA molecule of Claim 52 in which the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

57. A DNA molecule of Claim 53 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SSEQ ID NO:44.

58. A DNA molecule of Claim 54 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SEQ ID NO:44.

59. A DNA molecule of Claim 55 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SEQ ID NO:44.

60. A DNA molecule of Claim 56 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SEQ ID NO:44.

61. A DNA molecule of Claim 57 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

62. A DNA molecule of Claim 58 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

60-10660-21

63. A DNA molecule of Claim 59 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

64. A DNA molecule of Claim 60 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

65. A DNA molecule of Claim 53 in which the structural DNA sequence encodes an EPSPS enzyme having the sequence of SEQ ID NO:3.

66. A DNA molecule of Claim 54 in which the structural DNA sequence encodes an EPSPS enzyme having the sequence of SEQ ID NO:3.

67. A DNA molecule of Claim 55 in which the structural DNA sequence encodes an EPSPS enzyme having the sequence of SEQ ID NO:3.

68. A DNA molecule of Claim 56 in which the structural DNA sequence encodes an EPSPS enzyme having the sequence of SEQ ID NO:3.

69. A DNA molecule of Claim 65 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

70. A DNA molecule of Claim 66 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

71. A DNA molecule of Claim 67 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

72. A DNA molecule of Claim 68 in which the structural DNA sequence contains an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

73. A glyphosate-tolerant plant cell of Claim 29 in which:

- (a) the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters;
- (b) the structural DNA sequence encodes:
  - (i) a chloroplast transit peptide selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17; and
  - (ii) an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SEQ ID NO:44; and
- (c) the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

75. A glyphosate-tolerant plant cell of Claim 73 in which the structural DNA sequence comprises:

- (a) a chloroplast transit peptide encoding DNA sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:16; and
- (b) an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

76. A glyphosate-tolerant plant cell of Claim 73 in which the structural DNA sequence comprises:

- (a) a chloroplast transit peptide encoding DNA sequence selected from the group consisting of SEQ ID NO:10 and SEQ ID NO:14; and
- (b) a DNA sequence encoding an EPSPS enzyme having the sequence of SEQ ID NO:3.

77. A glyphosate-tolerant plant cell of Claim 74 in which the structural DNA sequence comprises an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

78. A glyphosate-tolerant plant cell of Claim 75 selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

79. A glyphosate-tolerant plant comprising a DNA molecule of Claims 9, 12 or 14 in which:

- (a) the promoter is selected from the group consisting of CaMV 35S and FMV 35S promoters;
- (b) the structural DNA sequence encodes:
  - (i) a chloroplast transit peptide selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17; and
  - (ii) an EPSPS enzyme selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:42 and SEQ ID NO:44; and
- (c) the 3' non-translated region is selected from the group consisting of the NOS 3' and the E9 3' non-translated regions.

80. A glyphosate-tolerant plant of Claim 79 in which the structural DNA sequence comprises:

- (a) a chloroplast transit peptide encoding DNA sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:16; and
- (b) an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

81. A glyphosate-tolerant plant of Claim 80 in which the structural DNA sequence comprises:

- (a) a chloroplast transit peptide encoding DNA sequence selected from the group consisting of SEQ ID NO:10 and SEQ ID NO:14; and
- (b) a DNA sequence encoding an EPSPS enzyme having the sequence of SEQ ID NO:3.

82. A glyphosate-tolerant plant of Claim 81 in which the structural DNA sequence comprises an EPSPS encoding sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:9.

83. A glyphosate-tolerant plant of Claim 82 selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

84. A seed of a glyphosate-tolerant plant of Claim 32.

85. A seed of a glyphosate-tolerant plant of Claim 35.

86. A seed of a glyphosate- tolerant plant of Claim 79.

87. A seed of a glyphosate- tolerant plant of Claim 80.

88. A seed of a glyphosate- tolerant plant of Claim 81.

89. A seed of a glyphosate- tolerant plant of Claim 82.

90. A seed of a glyphosate- tolerant plant of Claim 83.

91. A transgenic soybean plant which contains a heterologous gene which encodes an EPSPS enzyme having a  $K_m$  for phosphoenolpyruvate (PEP) between 1 and 150  $\mu\text{M}$  and a  $K_i(\text{glyphosate})/K_m(\text{PEP})$  ratio between about 2 and 500, said plant exhibiting tolerance to N-phosphonomethylglycine herbicide at a rate of 1 lb/acre without significant yield reduction due to herbicide application.

92. Seed of a soybean plant of Claim 91.

93. In a method for the transformation and regeneration of transgenic plants, the improvement which comprises the use of a glyphosate-resistance marker gene comprising:

- i) a promoter which functions in plant cells to cause the production of an RNA sequence,
- ii) a structural DNA sequence that causes the production of an RNA sequence which encodes an EPSPS enzyme having the sequence domains:

-R-X<sub>1</sub>-H-X<sub>2</sub>-E- (SEQ ID NO:37), in which

X<sub>1</sub> is G, S, T, C, Y, N, Q, D or E;

X<sub>2</sub> is S or T; and

-G-D-K-X<sub>3</sub>- (SEQ ID NO:38), in which

X<sub>3</sub> is S or T; and

-S-A-Q-X<sub>4</sub>-K- (SEQ ID NO:39), in which

X<sub>4</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V; and

-N-X<sub>5</sub>-T-R- (SEQ ID NO:40), in which

X<sub>5</sub> is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y or V;

and

iii) a 3' non-translated DNA sequence which functions in plant cells to cause the addition of a stretch of polyadenyl nucleotides to the 3' end of the RNA sequence;

where the promoter is heterologous with respect to the structural DNA sequence and adapted to cause sufficient expression of the polypeptide to render a plant cell transformed with the DNA molecule tolerance to a toxic level of glyphosate.

94. A method of Claim 93 in which X<sub>1</sub> is D or N; X<sub>2</sub> is S or T; X<sub>3</sub> is S or T; X<sub>4</sub> is V, I or L; and X<sub>5</sub> is P or Q.

95. A method of Claim 94 in which the structural DNA sequence encodes an EPSPS enzyme selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:41 and SEQ ID NO:43.

96. A method of Claim 93 in which the structural DNA sequence encodes a fusion polypeptide comprising an amino-terminal chloroplast transit peptide and the EPSPS enzyme.

**ABSTRACT OF THE DISCLOSURE**

Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

2025 RELEASE UNDER E.O. 14176

SSPL

6358 GCTATCAAATATTGAGCATTCCAGATGGGTCATCAACAAAGGTACGGACATAC 6417  
ATCTAGTATTAATAAATCTCGTAAGGTCTAACCCAAGTGTAGTTCCATGCTCGGTATAG  
6418 AGCTTATTCAAATGGTATCGCCAAACCAAGAAGGAACCTCCCTCAAAGGTTGTA  
1'GAAATTAAGTPTAACCATAGCGGTTTGTTCTTCCTTGAGGGTAGGAGTTCCAACAT 6477  
6478 AGGAAAGAAATTCAGTCAGTCCAAAGCCTACAAGGTCAAGGTCAAGGTTACAGAGTCTCCAAACAT  
1'CTCTCTTAAGAGTCAAGGTTCTGGAGTTGTTCCAGTCCATGTCAGAGGTTGGTAAT 6537  
6538 GCCAAAGCTACAGGAGATCAATGAAGAATCTCAATCAAAGTAAACTACTGTTCCAGCA  
CGCTCTCTCGATGCTCTAGTGTACTTCCTAGAAGTGTAGTTCAATTGACAAAGGTCGT 6597  
6598 CATTGCAATCATGGTCAGTAAAGTTCTAGAAGAAGACATCCACCGAAGACTAAAGTTAGTGG  
CTTACCGTACCAAGTCAATCTGTAGGTGGCTCTGAATTCAATCACCC 6657


## Figure 1

SHEET 1 OF 2

6658 GCATCTTGAAGTAATCTTGTCAACATCGAGCAGCTGGCTTGTGGGACCAACAAAA  
(CG)AGAAC"TCAT"AGAACAGTTGTAGCTCGACCGAACACCCCTGGTCTGT"TTT  
6717  
6718 AGGAA"TG"PGCAGAAT"TG"TAGGGCGCACCTACCAAAAGCATCTTGCCTTATTGCAAG  
TCTTACCCACCG"TC"TCACAAATCCGCGTGGATGGTTTTCG"TAGAACGGAATAACGTTTC  
6777  
6778 ATAAACAGAT"CC"TC"TAGTACAACAGTGGAAACAAATAACGTGGAAAGAGCTGTCCTG  
TAATTC"TC"TC"TAAGGAAATCA"GTTCACCCCTTGT"TTTA"TG"CACCTTTCTGACAGGAC  
6837  
6838 ACACCCAC"TCAC"TAAT"GC"GTATGACGAACGCAGTGACGACCACAAAGAATTCCCTCTA  
TG"TG"GG"TGAG"GA"TAACGCATACTGCTTGCCTCAC"TG"GTGGTTCTTAAGGAGAT  
6897  
6898 ATATCTTCCGTAAGTAAGGGTAAACTTCCTAGTAGTCTATGATTGGTTAAAGAG  
SSP1

## Figure 1

SHEET 2 OF 2



**Figure 2**

AAGCCCCGGT	TCTCTCCGCG	GCTCCGGCC	GAGAGCCG	GATAGATTAA	GGAAAGACGCC	60											
C	A'UG	'UUG	CAC	GGU	GU'A	AGC	AGC	CGG	CCC	GCA	ACC	GCC	CGC	AAA	TCC	106	
Met	Ser	His	Gly	Ala	Ser	Ser	Arg	Pro	Ala	Thr	Ala	Arg	Lys	Ser	1		
															15		
'UCP	GGC	C'U'U	TCC	GGA	AC'C	GTC	CGC	ATT	CCC	GGC	GAC	AAG	TCG	ATC	TCC	154	
Ser	Gly	I,eu	Ser	Gly	Thr	Val	Arg	Ile	Pro	Gly	Asp	Lys	Ser	Ile	Ser	20	
															25		
UAC	CGG	TCC	TTC	A'UG	'U'U	GC	GGT	CTC	GCG	AGC	GGT	GAA	ACG	CGC	ATC	202	
His	Arg	Ser	Phe	Met	Phe	Gly	Gly	Leu	Ala	Ser	Gly	Glu	Thr	Arg	Ile	35	
															40		
ACG	GUC	C'U'U	TUG	GGC	GAA	UGC	GAG	GAC	GTC	ATC	AAT	ACG	GGC	AAG	GCC	ATG	250
Thr	Gly	I,eu	I,eu	Glu	Gly	Glu	Glu	Asp	Val	Ile	Asn	Thr	Gly	Lys	Ala	Met	50
															55		
CAG	GC'C	A'UG	GGC	GCC	AGG	ATC	CGT	AAG	GAA	GGC	GAC	ACC	TGG	ATC	ATC	298	
Gln	Ala	Met	Gly	Ala	Arg	Ile	Arg	Iys	Glu	Gly	Asp	Thr	Trp	Ile	Ile	65	
															70		
GA'P	GGC	G'U'U	GGC	AA'P	GGC	GGC	CTC	CTG	GCG	CCT	GAG	GCG	CCG	CRC	GAT	346	
Asp	Gly	Val	Gly	Asn	Gly	Gly	Leu	Leu	Ala	Pro	Glu	Ala	Pro	Leu	Asp	80	
															85		
															90		
															95		

**Figure 3**

**SHEET 1 of 5**

'TC'	GGC	AAT	GCC	GCC	ACG	GGC	TGC	CGC	CTG	ACC	ATG	GGC	CTC	GTC	GGG	394
Phe	Gly	Asn	Ala	Ala	Thr	Gly	Cys	Arg	Leu	Thr	Met	Gly	Leu	Val	Gly	110
100									105							
GTC	TAC	GAT	TTC	GAC	AGC	ACC	TTC	ATC	GGC	GAC	GCC	TCG	CTC	ACA	AAG	442
Val	Tyr	Asp	Phe	Asp	Ser	Thr	Phe	Ile	Gly	Asp	Ala	Ser	Leu	Thr	Lys	
115								120								
CGC	CCG	ATG	GGC	CGC	GTC	TTG	AAC	CCG	CTG	CGC	GAA	ATG	GGC	GTC	CAG	490
Arg	Pro	Met	Gly	Arg	Val	Ieu	Asn	Pro	Leu	Arg	Glu	Met	Gly	Val	Gln	
130							135					140				
GTG	AAA	TCG	GAA	GAC	GAC	GGT	GAC	CGT	CTT	CCC	GTT	ACC	TTG	CGC	GGG	538
Val	Lys	Ser	Glu	Asp	Gly	ASP	Arg	Leu	Pro	Val	Thr	Leu	Arg	Gly	Pro	
145						150				155						
AAG	ACG	CCG	ACG	CCG	ATC	ACC	TAC	CGC	GTC	CCG	ATG	GCC	TCC	GCA	CAG	586
Iys	Thr	Pro	Thr	Pro	Ile	Thr	Tyr	Arg	Val	Pro	Met	Ala	Ser	Ala	Gln	
160					165				170							
GTG	AAG	TCC	GCC	GTG	C <sup>r</sup> TG	CTC	GCC	GGC	CTC	AAC	ACG	CCC	GGC	ATC	ACG	634
Val	Iys	Ser	Ala	Val	Ieu	Ieu	Ala	Gly	Leu	Asn	Thr	Pro	Gly	Ile	Thr	
180						185				190						
ACG	GTC	ATC	GAG	CCG	ATC	ATG	ACG	CGC	GAT	CAT	ACG	GAA	AAG	ATG	CTG	682
Thr	Val	Ile	Glu	Pro	Ile	Met	Thr	Arg	Asp	His	Thr	Glu	Lys	Met	Leu	
195						200				205						

**Figure 3**

**SHEET 2 OF 5**

CAG	GCC	TTC	GCC	GCC	AAC	CTT	ACC	GTC	GAG	ACG	GAT	GCG	GAC	GCG	GTC	730
Gln	Gly	Phe	Gly	Ala	Asn	Leu	Thr	Val	Glu	Thr	Asp	Ala	Asp	Gly	Val	
210																210
CGC	ACC	ATC	CGC	CTG	GAA	GGC	CGC	GGC	AAG	CTC	ACC	GGC	CAA	GTC	ATC	778
Arg	Thr	Ile	Arg	Leu	Glu	Gly	Arg	Gly	Lys	Leu	Thr	Gly	Gln	Val	Ile	
225																225
GAC	GIG	CCG	GGC	GAC	CG	TCC	TCG	ACG	GCC	TTC	CCG	CTG	GTT	GCG	GCC	826
Asp	Val	Pro	Gly	Asp	Pro	Ser	Ser	Thr	Ala	Phe	Pro	Leu	Val	Ala	Ala	
240																240
C"TG	C"TP	G"TP	CCG	GGC	T"CC	GAC	GTC	ACC	ATC	CTC	AAC	GTG	CTG	ATG	AAC	874
Leu	Leu	Val	Pro	Gly	Ser	Asp	Val	Thr	Ile	Leu	Asn	Val	Leu	Met	Asn	
260																260
CCC	ACC	CGC	ACC	GGC	C"TC	ATC	CTG	ACG	CTG	CAG	GAA	ATG	GGC	GCC	GAC	922
Pro	Thr	Arg	Thr	Gly	Ile	Ile	Leu	Thr	Leu	Gln	Glu	Met	Gly	Ala	Asp	
275																275
A"TC	GAA	GTC	A"TC	AAC	C"CG	CGC	CTT	GCC	GGC	GGC	GAA	GAC	GTG	GCG	GAC	970
Ile	Glu	Val	Ile	Asn	Pro	Arg	Leu	Ala	Gly	Gly	Glu	Asp	Val	Ala	Asp	
290																290
C"TG	CGC	G"TP	CGC	TCC	T"CC	ACG	CTG	AAG	GGC	GTC	ACG	GTG	CCG	GAA	GAC	1018
Ile	Arg	Val	Arg	Ser	Ser	Thr	Leu	Lys	Gly	Val	Thr	Val	Pro	Glu	Asp	
305																305
310																310

**Figure 3**

**SHEET 3 of 5**

CGC	GCG	CCT	TCG	ATG	AIC	GAC	GAA	TAT	CCG	ATG	CTC	GCT	GTC	GCC	GCC	1066	
Arg	Ala	Pro	Ser	Met		Ile	Asp	Glu	Tyr	Pro	Ile	Leu	Ala	Val	Ala	Ala	
320					325											335	
GGC	TTC	GCG	GAA	GGG	GCG	ACC	GTG	ATG	AAC	GGT	CTG	GAA	GAA	CTC	CGC	1114	
Ala	Phe	Ala	Glu	Gly	Ala	Thr	Val	Met	Asn	Gly	Leu	Glu	Glu	Leu	Arg	350	
340					345											365	
GTC	AAG	GAA	AGC	GAC	CUC	CTC	TCG	GCC	GTC	GCC	AAT	GGC	CTC	AAG	CTC	1162	
Val	Lys	Glu	Ser	Asp	Asp	Arg	Leu	Ser	Ala	Val	Ala	Asn	Gly	Leu	Lys	Leu	
355					360											380	
AAT	GGC	GTG	GAT	TGC	GAT	GAG	GGC	GAG	ACG	TCG	CTC	GTC	GTG	CGC	GGC	1210	
Asn	Gly	Val	Asp	Cys	Asp	Glu	Gly	Glu	Thr	Ser	Leu	Val	Val	Arg	Gly	370	
375					380											390	
CGC	CCT	GAC	GGC	AAG	GGG	CTC	GGC	AAC	GCC	TCG	GGC	GCC	GCC	GTC	GCC	1258	
Arg	Pro	Asp	Gly	Lys	Gly	Leu	Gly	Asn	Ala	Ser	Gly	Ala	Ala	Val	Ala	385	
390					395											400	
ACC	CAT	CTC	GAT	CAC	CAC	CAC	AIC	GCC	ATG	AGC	TTC	CTC	GTC	ATG	GGC	CTC	1306
Thr	His	Ileu	Asp	His	Arg	Ile	Ala	Met	Ser	Phe	Ileu	Val	Met	Gly	Leu	405	
400					405											410	
GTC	TCG	GAA	AAC	CCT	GTC	ACG	GTG	GAC	GAT	GCC	ACG	ATG	ATC	GCC	ACG	1354	
Val	Ser	Glu	Asn	Pro	Val	Thr	Val	Asp	Asp	Ala	Thr	Met	Ile	Ala	Thr	420	
425					425											430	

**Figure 3**

**SHEET 4 OF 5**

### Figure 3

SHEET 5 OF 5

GGC' GAT GTC TGG ATC A'AC AAC GGC GTC GGC AAT GGC TGC CTG TTG CAG	352
Gly Asp Val Trp.Ile Ile Asn Gly Val Gly Asn Gly Cys Leu Leu Gln	85
75	
GGC GAC AAG TCC ATC T'CG CAT CGC TCC TTC ATG T'TT GGC GGT CTC GCA	208
Gly Asp Lys Ser Ile Ser His Arg Ser Phe Met Phe Gly Gly Leu Ala	40
30	
TCC GGC GAA ACC CGC A'AC ACC GGC CTT CTG GAA GGC GAG GAC GTC ATC	256
Ser Gly Glu Thr Arg Ile Thr Gly Leu Leu Glu Gly Glu Asp Val Ile	55
45	
AA'I' ACA GGC CGC GCC A'IG CAG GCC ATG GGC GCG AAA ATC CGT AAA GAG	304
Asn Thr Gly Arg Ala Met Gln Ala Met GLY Ala Lys Ile Arg Lys Glu	70
60	
GGC ACC GCC CGC CGC TCG GAG GCA CTC ACG GGC GAA ATC CGC ATT CCG	160
Ala Thr Ala Arg Arg Ser Glu Ala Leu Thr Gly Glu Ile Arg Ile Pro	25
10	
GCA ACC GCC CGC CGC TCG GAG GCA CTC ACG GGC GAA ATC CGC ATT CCG	112
Met Ser His Ser Ala Ser Pro Lys Pro	5
1	

## Figure 4

SHEET 1 OF 5

C	C	G	A	G	C	T	G	C	A	T	T	C	G	A	A	T	G	C	G	C	G	C	T	C	400	
Pro	Glu	Ala	Ala	Ieu	Asp	Phe	Gly	Asn	Ala	Gly	Thr	Gly	Ala	Arg	Ieu										448	
90	95	95																							105	
ACC	ATG	GGC	CTT	GTC	GTC	ACC	TAT	GAC	ATG	AAG	ACC	TCC	TTT	ATC	GGC											
Thr	Met	Gly	Ieu	Val	Gly	Thr	Tyr	Asp	Met	Lys	Thr	Ser	Phe	Ile	Gly											
110	115	115																							120	
GAC	GCC	TCC	CTG	TCC	AAG	CAG	CGC	CCG	ATG	GCC	CGC	GTG	CTG	AAC	CCG	TTG										
ASP	Ala	Ser	Leu	Ser	Iys	Arg	Pro	Met	Gly	Arg	Val	Leu	Asn	Pro	Ieu											
125	125	125																							496	
GCG	GAA	ATG	GUC	GTG	CAG	GTG	GAA	GCA	GCC	GAT	GGC	GAC	CGC	ATG	CCG											
Arg	Glu	Met	Gly	Val	Gln	Val	Glu	Ala	Ala	Ala	Asp	Gly	Asp	Arg	Met	Pro										
140	145	145																							544	
C	TG	ACG	C	TG	A	TG	G	G	C	CG	AAG	ACG	GCC	AAT	CCG	ATC	ACC	TAT	CGC	GTG						
I	eu	Thi	Ieu	Ieu	Tle	Gly	Pro	Iys	Thr	Ala	Asn	Pro	Ile	Thr	Tyr	Arg	Val									
155	155	155																							592	
CCG	ATG	GCC	TCC	GCG	CAG	GTA	AAA	TCC	GCC	GTG	CTG	CTG	GCC	GGT	CTC											
Pro	Met	Ala	Ser	Ala	Gln	Val	Lys	Ser	Ala	Val	Leu	Leu	Ala	Gly	Ieu											
170	175	175																							640	
ACG	ACG	CCG	GGC	GTC	ACC	ACC	GTC	ATC	GAG	CCG	GTC	ATG	ACC	CGC	GAC											
Asn	Thr	Pro	Gly	Val	Thr	Thr	Val	Ile	Glu	Pro	Val	Met	Thr	Arg	Asp											
190	195	195																							688	
																									200	

**Figure 4**

SHEET 2 OF 5

CAC	ACC	GAA	AAG	ATG	C <sup>T</sup> G	CAG	GGC	TTT	GGC	GCC	GAC	CTC	ACG	GTC	GAG	736
His	Thr	Glu	Lys	Met	Ileu	Gln	Gly	Phe	Gly	Ala	Asp	Leu	Thr	Val	Glu	
				205				210						215		
ACC	GAC	AAG	GAT	GGC	GTC	CGC	CAT	ATC	CGC	ATC	ACC	GCC	CAG	GGC	AAG	784
Thr	Asp	Lys	Asp	Gly	Val	Arg	His	Ile	Arg	Ile	Thr	Gly	Gln	Gly	Lys	
				220				225				230				
C <sup>T</sup> T	G <sup>T</sup> C	G <sup>T</sup> C	CAG	ACC	A <sup>T</sup> C	GAC	GTG	CCG	GGC	GAT	CCG	TCA	TCG	ACC	GCC	832
Ileu	Val	Gly	Gln	Thr	Tle	Asp	Val	Pro	Gly	Asp	Pro	Ser	Ser	Thr	Ala	
	235			240				245								
T <sup>T</sup> C	CCG	CTC	GT <sup>T</sup>	GCC	G <sup>T</sup> C	CTT	CTG	GTG	GAA	GGT	TCC	GAC	GTC	ACC	ATC	880
Phe	Pro	Leu	Val	Ala	Ala	Leu	Leu	Val	Glu	Gly	Ser	Asp	Val	Thr	Tle	
	250			255				260				265				
C <sup>T</sup> C	AAC	G <sup>T</sup> C	C <sup>T</sup> TG	ATG	A <sup>T</sup> C	CCG	ACC	CGT	ACC	GGC	CTC	ATC	CTC	ACC	T <sup>T</sup> G	928
Arg	Asn	Val	Ileu	Met	Asn	Pro	Thr	Arg	Thr	Gly	Leu	Ile	Leu	Thr	Leu	
	270			275				280								
C <sup>A</sup> G	GAA	A <sup>T</sup> C	G <sup>T</sup> C	G <sup>T</sup> C	C <sup>A</sup> T <sup>T</sup>	ATC	GAA	GTG	C <sup>T</sup> C	A <sup>A</sup> T <sup>T</sup>	GCC	CGT	CT <sup>T</sup>	GCA	GGC	976
Gln	Glu	Met	Gly	Ala	Asp	Ile	Glu	Val	Leu	Asn	Ala	Arg	Leu	Ala	Gly	
	285			290				295								
GGC	GAA	GAC	G <sup>T</sup> C	GCC	GAT	CTG	CGC	GTC	AGG	GCT	TCG	AAG	CTC	AAG	GGC	1024
Gly	Glu	Asp	Val	Ala	Asp	Leu	Arg	Val	Arg	Ala	Ser	Lys	Leu	Lys	Gly	
	300			305				310								

**Figure 4**

**SHEET 3 of 5**

GTC	GTC	GTP	TGG	CCC	AA	CGT	GCG	CCG	TCG	AAG	AAC	GAC	GAA	TAT	CCG	1072
Val	Val	Val	Pro	Pro	Pro	Gl	Arg	Ala	Pro	Ser	Met	Thr	Asp	Glu	Tyr	Pro
315																325
GTC	GTC	GCG	ATT	GCC	GCC	TCC	TTC	GCG	GAA	GCG	GAA	ACC	GTC	ATG	GAC	1120
Val	Leu	Ala	Ile	Ala	Ala	Ser	Phe	Ala	Glu	Gly	Glu	Thr	Val	Met	Asp	345
330																340
GCG	GTC	GAC	GAA	CAG	TGG	CCC	GTC	AAG	GAA	TCG	GAT	CGT	CTG	GCA	GCG	1168
Gly	Ieu	Asp	Glu	L	Arg	Val	Lys	Glu	Ser	Asp	Arg	Leu	Ala	Ala	Val	360
335																355
GAA	GCG	GCG	CAG	GAA	GAC	GGC	GTC	GAT	TGC	ACC	GAA	GCG	GAG	ATG		
Ala	Arg	Gly	Ieu	Glu	Ala	Asn	Gly	Val	Asp	Cys	Thr	Glu	Gly	Glu	Met	375
350																370
TGG	CAG	ACG	CCG	GTT	CGC	GGC	CGC	GAC	GCC	AAG	GGA	CTG	GGC	GGC	GGC	1216
Ser	Leu	Thr	Val	Arg	Gly	Arg	Pro	Asp	Gly	Lys	Gly	Leu	Gly	Gly	Gly	390
365																385
ACG	GTP	GCA	ACC	CAI	TTC	GAT	CAT	CGT	ATC	GCG	ATG	AGC	TTC	CTC	GTC	1312
Thr	Val	Ala	Thr	His	Ieu	Asp	His	Arg	Ile	Ala	Met	Ser	Phe	Leu	Val	405
380																400
ATG	GCG	GTP	GCG	GCG	GAA	AAG	CCG	GTG	ACG	GTP	GAC	GAC	AGT	AAC	ATG	
Met	Gly	Ieu	Ala	Ala	Glu	Lys	Pro	Val	Thr	Val	Asp	Asp	Ser	Asn	Met	1360
410																425

**Figure 4**

SHEET 4 OF 5

5'TC' GCG ACG TCC T <sup>m</sup> TC GCG GAA TTC ATG GAC ATG CCG GGA T <sup>T</sup> TG GGC	1408
Ile Ala Thr Ser Phe Pro Glu Phe Met Asp Met Met Pro Gly Leu Gly	
430	435
5'CA AAC A <sup>m</sup> C GAG T <sup>m</sup> T <sup>m</sup> C AGC AT <sup>m</sup> A CTC TAGTCAC <sup>m</sup> TCG ACAGCGAAA TAT <sup>m</sup> TAT <sup>m</sup> TGC	1462
Ala Lys Ile Glu Leu Ser Ile Leu	
445	
5'AGA <sup>m</sup> T <sup>m</sup> GCGC A <sup>m</sup> T <sup>m</sup> ATTAC <sup>m</sup> CG GT <sup>m</sup> TGGTCTCA GCGGGGTT <sup>m</sup> AATGTCCAAT CTTCCATACG	1522
T <sup>m</sup> A <sup>m</sup> C <sup>m</sup> A <sup>m</sup> C <sup>m</sup> A <sup>m</sup> C AGGAATA <sup>m</sup> A <sup>m</sup> C AAAAAGCTT TAGAAGGAAT TGCTAGAGCA GCGACGCCGC	1582
C <sup>m</sup> T <sup>m</sup> A <sup>m</sup> C <sup>m</sup> T <sup>m</sup> TC' TCAAGAC <sup>m</sup> T <sup>m</sup> TC' GT <sup>m</sup> T <sup>m</sup> AAACTG TACTGAATC CCGGGGGTC CGGGATCAA	1642
T <sup>m</sup> A <sup>m</sup> C <sup>m</sup> T <sup>m</sup> TC <sup>m</sup> A <sup>m</sup> T <sup>m</sup> TC' T <sup>m</sup> TC' T <sup>m</sup> GAC <sup>m</sup> A <sup>m</sup> A <sup>m</sup> T <sup>m</sup> TGGCCTCGC A	1673

## Figure 4

SHEET 5 OF 5

G'GAT'CCGGC	CAAATG'GA	CTGTGAAAAA	TCC	ATG	TCC	CAT	TCT	GCA	TCC	CCG	5	
I <sub>Y</sub> S	Pro	Ala	Thr	Ala	Arg	Arg	Ser	Glu	Ala	Leu	Thr	Met
10												1
A'P' CCG	Ggc	GAC	AAG	TCC	ATC	TCG	CAT	CGC	TCC	TTC	ATG	102
I <sub>le</sub>	Pro	Gly	Asp	Ser	I <sub>Y</sub> S	Ser	I <sub>le</sub>	Ser	His	Arg	Ser	15
25												20
C'IC	GCA	TCG	GGC	GAA	ACC	CGC	ATC	ACC	GGC	CTT <sup>1</sup>	CTG	150
I <sub>leu</sub>	Ala	Ala	Ser	Gly	Glu	Thr	Arg	I <sub>le</sub>	Thr	Gly	I <sub>le</sub>	Arg
40												35
G'IC	A'P' C	AAT	ACA	Ggc	GGC	GGC	GCC	ATG	CAG	GCC	GCG	198
Val	I <sub>le</sub>	I <sub>le</sub>	Asn	Thr	Gly	Arg	Ala	Met	Gln	Ala	Gly	55
60												50
AAA	GAG	GGC	GAT	G'IC	TGG	ATC	ATC	AAC	GGC	GTC	GCC	246
I <sub>Y</sub> S	Glu	Gly	Asp	Val	T <sub>rp</sub>	T <sub>le</sub>	I <sub>le</sub>	Asn	Gly	Val	Gly	294
75												80
T <sup>1</sup> IG	CAG	CCC	GAA	GC'P	GCG	CTC	GAT	T <sup>1</sup> TC	GGC	AAT	GCC	342
I <sub>eu</sub>	Gln	Pro	Glu	Ala	Ala	I <sub>eu</sub>	Asp	Phe	Gly	Asn	Ala	90
95												100

**Figure 5**

**SHEET 1 OF 5**

Arg	Ileu	Thr	Met	Gly	Ileu	Val	Gly	Thr	Tyr	Asp	Met	Lys	Thr	Ser	Phe	390	
105																115	
A <sup>r</sup> GC	G <sup>r</sup> GC	GAC	GCC	T <sup>r</sup> CG	C <sup>r</sup> IG	T <sup>r</sup> CG	AAG	CGC	CCG	A <sup>r</sup> TC	G <sup>r</sup> GC	CGC	GTG	CTG	AAC	438	
Ile	Gly	Asp	Ala	Ser	Ileu	Ser	Lys	Arg	Pro	Met	Gly	Arg	Val	Leu	Asn	135	
120																125	
C <sup>r</sup> CG	T <sup>r</sup> TG	CGC	GAA	A <sup>r</sup> TG	G <sup>r</sup> GC	GTT	CAG	GTG	GAA	GCA	GCC	GAT	GGC	GAC	CGC	486	
Pro	Ileu	Arg	Glu	Met	Gly	Val	Gln	Val	Glu	Ala	Ala	Ala	Asp	Gly	Asp	Arg	140
125																145	
A <sup>r</sup> TG	C <sup>r</sup> CG	C <sup>r</sup> TG	ACG	C <sup>r</sup> IG	A <sup>r</sup> TC	GCC	CCG	AAG	ACG	GCC	AAT	CCG	ATC	ACC	TAT	534	
Met	Pro	Ileu	Thr	Ileu	Tle	Gly	Pro	Lys	Thr	Ala	Asn	Pro	Ile	Thr	Tyr	150	
130																155	
C <sup>r</sup> GC	G <sup>r</sup> IG	CCG	A <sup>r</sup> IG	GCC	T <sup>r</sup> CC	GCG	CAG	GTA	AAA	TCC	GCC	GTG	C <sup>r</sup> IG	CTC	GCC	582	
Arg	Val	Pro	Met	Ala	Ser	Ala	Gln	Val	Lys	Ser	Ala	Val	Leu	Leu	Ala	160	
135																165	
C <sup>r</sup> GC	G <sup>r</sup> IG	CCG	A <sup>r</sup> IG	GCC	T <sup>r</sup> CC	GCG	CAG	GTA	AAA	TCC	GCC	GTG	C <sup>r</sup> IG	CTC	GCC	630	
Gly	Ileu	Asn	Thr	Pro	Gly	Val	Thr	Thr	Val	Ile	Glu	Pro	Val	Met	Thr	170	
140																175	
G <sup>r</sup> GT	C <sup>r</sup> IG	AAAC	ACG	CCG	G <sup>r</sup> GC	GTC	ACC	ACC	GTC	ATC	GAG	CCG	GTC	ATG	ACC	210	
Gly	Ileu	Asn	Thr	Pro	Gly	Val	Thr	Thr	Val	Ile	Glu	Pro	Val	Met	Thr	180	
145																185	
C <sup>r</sup> GC	G <sup>r</sup> AC	CAC	ACC	GAA	AAG	A <sup>r</sup> TG	CTG	CAG	GGC	T <sup>r</sup> TP	G <sup>r</sup> GC	GCC	GAC	CTC	ACG	678	
Arg	Asp	His	Thr	Glu	Lys	Met	Leu	Gln	Gly	Phe	Gly	Ala	Asp	Leu	Thr	200	
205																215	

**Figure 5**

*SHEET 2 OF 5*

GTC	GAC	ACC	GAC	AAG	GAT	GGC	GTG	CGC	CAT	ATC	CGC	ATC	ACC	GGC	CAG	726
Val	Glu	Thr	Asp	Lys	Asp	Gly	Val	Arg	His	Ile	Arg	Ile	Thr	Gly	Gln	
220									225						230	
GTC	AAG	CTT	GTC	GGC	CAG	ACC	ATC	GAC	GTG	CCG	GGC	GAT	CCG	TCA	TCG	774
Gly	Lys	Leu	Val	Gly	Gln	Thr	Ile	Asp	Val	Pro	Gly	Asp	Pro	Ser	Ser	
235									240						245	
GGC	GCC	TTC	CCG	CTC	GTT	GCC	GCC	CTT	CTG	GTG	GAA	GGT	TCC	GAC	GTC	822
Thr	Ala	Phe	Pro	Leu	Val	Ala	Ala	Leu	Leu	Val	Glu	Gly	Ser	Asp	Val	
250									255						260	
ATC	ATC	GGC	AAC	GTC	CIG	ATG	AAC	CCG	ACC	CGT	ACC	GGC	CTC	ATC	CTC	870
Thr	Ile	Arg	Asn	Val	Ile	Met	Asn	Pro	Thr	Arg	Thr	Gly	Leu	Ile	Leu	
265									270						275	
ACC	TTC	CAG	GAA	ATG	GGC	GCC	GAT	ATC	GAA	GTG	CTC	AAT	GCC	CGT	CTT	918
Thr	Ileu	Gln	Glu	Met	Gly	Ala	Asp	Ile	Glu	Val	Leu	Asn	Ala	Arg	Ileu	
280									285						290	
GAA	GGC	GGC	GAA	GAC	GTC	GCC	GAT	CTG	CGC	GTC	AGG	GCT	TCG	AAG	CTC	966
Ala	Gly	Gly	Glut	Asp	Val	Ala	Asp	Leu	Arg	Val	Arg	Ala	Ser	Lys	Leu	
300									305						310	
AAG	GGC	GTC	GTC	GTG	CCG	CAG	CGT	GCC	CCG	TCG	ATG	ATC	GAC	GAA	1014	
Lys	Gly	Val	Val	Val	Pro	Pro	Glu	Arg	Ala	Pro	Ser	Met	Ile	Asp	Glu	
315									320						325	

**Figure 5**

**SHEET 3 OF 5**

<sup>1</sup> ATP	CCG	GTC	CTG	GCG	<sup>2</sup> ATP	GCC	GCC	TCC	TTC	GCG	GAA	GGC	GAA	ACC	GTG	1062
Tyr	Pro	Val	Leu	Ala	Ile	Ala	Ala	Ser	Phe	Ala	Glu	Gly	Glu	Thr	Val	
330								335							340	
ATG	GAC	GGG	CTC	GAC	GAA	CTG	CGC	GTC	AAG	GAA	TCG	GAT	CGT	CTG	GCA	1110
Met	Asp	Gly	Ile	Leu	Asp	Glu	Leu	Arg	Val	Lys	Glu	Ser	Asp	Arg	Leu	Ala
345								350							355	
GCG	GTC	GCA	CGC	GGC	<sup>1</sup> ATP	GAA	GCC	AAC	GGC	GTC	GAT	TGC	ACC	GAA	GGC	1158
Ala	Val	Ala	Arg	Gly	Ile	Glu	Ala	Asn	Gly	Val	ASP	Cys	Thr	Glu	Gly	375
360					365				370							
GAG	ATG	TCG	CTG	ACG	<sup>2</sup> ATP	CGC	GGC	CGC	CCC	GAC	GGC	AAG	GGA	CTG	GCC	1206
Glu	Met	Ser	Leu	Thr	val	Arg	Gly	Arg	Pro	Asp	Gly	Lys	Gly	Leu	Gly	390
					380				385							
GCG	GCC	ACG	GTC	GCA	ACC	CAT	CTC	GAT	CAT	CGT	ATC	GCG	ATG	AGC	TTC	1254
Gly	Gly	Thr	Val	Ala	Thr	His	Leu	Asp	His	Arg	Ile	Ala	Met	Ser	Phe	405
					395				400							
GTC	GTC	ATG	GCG	CTP	GCG	GCG	GAA	AAG	CCG	GTG	ACG	GTT	GAC	GAC	AGT	1302
Leu	Val	Met	Gly	Leu	Ala	Ala	Glu	Lys	Pro	Val	Thr	Val	Asp	Asp	Ser	410
					415				420							
AAC	ATG	ATC	GCC	ACG	<sup>1</sup> ATP	TTC	CCC	GAA	TTC	ATG	GAC	ATG	ATG	CCG	GGA	1350
Asn	Met	Ile	Ala	Thr	Ser	Phe	Pro	Glu	Phe	Met	Asp	Met	Met	Pro	Gly	425
					430				435							

**Figure 5**

**SHEET 4 OF 5**

T<sup>9</sup>T<sup>10</sup>G GGC GCA AAG A<sup>11</sup>T<sup>12</sup>C T<sup>13</sup>A G<sup>14</sup>T<sup>15</sup>G AGC A<sup>16</sup>T<sup>17</sup>A C<sup>18</sup>T<sup>19</sup>C T<sup>20</sup>A G<sup>21</sup>C<sup>22</sup>T<sup>23</sup>C G<sup>24</sup>A<sup>25</sup>G<sup>26</sup>C<sup>27</sup>A<sup>28</sup>A<sup>29</sup>G<sup>30</sup>A<sup>31</sup>A<sup>32</sup>A<sup>33</sup>G<sup>34</sup>C<sup>35</sup>A<sup>36</sup>A<sup>37</sup>A<sup>38</sup>G<sup>39</sup>C<sup>40</sup>A<sup>41</sup>A<sup>42</sup>A<sup>43</sup>G<sup>44</sup>C<sup>45</sup>A<sup>46</sup>A<sup>47</sup>A<sup>48</sup>G<sup>49</sup>C<sup>50</sup>A<sup>51</sup>A<sup>52</sup>A<sup>53</sup>G<sup>54</sup>C<sup>55</sup>A<sup>56</sup>A<sup>57</sup>A<sup>58</sup>G<sup>59</sup>C<sup>60</sup>A<sup>61</sup>A<sup>62</sup>A<sup>63</sup>G<sup>64</sup>C<sup>65</sup>A<sup>66</sup>A<sup>67</sup>A<sup>68</sup>G<sup>69</sup>C<sup>70</sup>A<sup>71</sup>A<sup>72</sup>A<sup>73</sup>G<sup>74</sup>C<sup>75</sup>A<sup>76</sup>A<sup>77</sup>A<sup>78</sup>G<sup>79</sup>C<sup>80</sup>A<sup>81</sup>A<sup>82</sup>A<sup>83</sup>G<sup>84</sup>C<sup>85</sup>A<sup>86</sup>A<sup>87</sup>A<sup>88</sup>G<sup>89</sup>C<sup>90</sup>A<sup>91</sup>A<sup>92</sup>A<sup>93</sup>G<sup>94</sup>C<sup>95</sup>A<sup>96</sup>A<sup>97</sup>A<sup>98</sup>G<sup>99</sup>C<sup>100</sup>A<sup>101</sup>A<sup>102</sup>A<sup>103</sup>G<sup>104</sup>C<sup>105</sup>A<sup>106</sup>A<sup>107</sup>A<sup>108</sup>G<sup>109</sup>C<sup>110</sup>A<sup>111</sup>A<sup>112</sup>A<sup>113</sup>G<sup>114</sup>C<sup>115</sup>A<sup>116</sup>A<sup>117</sup>A<sup>118</sup>G<sup>119</sup>C<sup>120</sup>A<sup>121</sup>A<sup>122</sup>A<sup>123</sup>G<sup>124</sup>C<sup>125</sup>A<sup>126</sup>A<sup>127</sup>A<sup>128</sup>G<sup>129</sup>C<sup>130</sup>A<sup>131</sup>A<sup>132</sup>A<sup>133</sup>G<sup>134</sup>C<sup>135</sup>A<sup>136</sup>A<sup>137</sup>A<sup>138</sup>G<sup>139</sup>C<sup>140</sup>A<sup>141</sup>A<sup>142</sup>A<sup>143</sup>G<sup>144</sup>C<sup>145</sup>A<sup>146</sup>A<sup>147</sup>A<sup>148</sup>G<sup>149</sup>C<sup>150</sup>A<sup>151</sup>A<sup>152</sup>A<sup>153</sup>G<sup>154</sup>C<sup>155</sup>A<sup>156</sup>A<sup>157</sup>A<sup>158</sup>G<sup>159</sup>C<sup>160</sup>A<sup>161</sup>A<sup>162</sup>A<sup>163</sup>G<sup>164</sup>C<sup>165</sup>A<sup>166</sup>A<sup>167</sup>A<sup>168</sup>G<sup>169</sup>C<sup>170</sup>A<sup>171</sup>A<sup>172</sup>A<sup>173</sup>G<sup>174</sup>C<sup>175</sup>A<sup>176</sup>A<sup>177</sup>A<sup>178</sup>G<sup>179</sup>C<sup>180</sup>A<sup>181</sup>A<sup>182</sup>A<sup>183</sup>G<sup>184</sup>C<sup>185</sup>A<sup>186</sup>A<sup>187</sup>A<sup>188</sup>G<sup>189</sup>C<sup>190</sup>A<sup>191</sup>A<sup>192</sup>A<sup>193</sup>G<sup>194</sup>C<sup>195</sup>A<sup>196</sup>A<sup>197</sup>A<sup>198</sup>G<sup>199</sup>C<sup>200</sup>A<sup>201</sup>A<sup>202</sup>A<sup>203</sup>G<sup>204</sup>C<sup>205</sup>A<sup>206</sup>A<sup>207</sup>A<sup>208</sup>G<sup>209</sup>C<sup>210</sup>A<sup>211</sup>A<sup>212</sup>A<sup>213</sup>G<sup>214</sup>C<sup>215</sup>A<sup>216</sup>A<sup>217</sup>A<sup>218</sup>G<sup>219</sup>C<sup>220</sup>A<sup>221</sup>A<sup>222</sup>A<sup>223</sup>G<sup>224</sup>C<sup>225</sup>A<sup>226</sup>A<sup>227</sup>A<sup>228</sup>G<sup>229</sup>C<sup>230</sup>A<sup>231</sup>A<sup>232</sup>A<sup>233</sup>G<sup>234</sup>C<sup>235</sup>A<sup>236</sup>A<sup>237</sup>A<sup>238</sup>G<sup>239</sup>C<sup>240</sup>A<sup>241</sup>A<sup>242</sup>A<sup>243</sup>G<sup>244</sup>C<sup>245</sup>A<sup>246</sup>A<sup>247</sup>A<sup>248</sup>G<sup>249</sup>C<sup>250</sup>A<sup>251</sup>A<sup>252</sup>A<sup>253</sup>G<sup>254</sup>C<sup>255</sup>A<sup>256</sup>A<sup>257</sup>A<sup>258</sup>G<sup>259</sup>C<sup>260</sup>A<sup>261</sup>A<sup>262</sup>A<sup>263</sup>G<sup>264</sup>C<sup>265</sup>A<sup>266</sup>A<sup>267</sup>A<sup>268</sup>G<sup>269</sup>C<sup>270</sup>A<sup>271</sup>A<sup>272</sup>A<sup>273</sup>G<sup>274</sup>C<sup>275</sup>A<sup>276</sup>A<sup>277</sup>A<sup>278</sup>G<sup>279</sup>C<sup>280</sup>A<sup>281</sup>A<sup>282</sup>A<sup>283</sup>G<sup>284</sup>C<sup>285</sup>A<sup>286</sup>A<sup>287</sup>A<sup>288</sup>G<sup>289</sup>C<sup>290</sup>A<sup>291</sup>A<sup>292</sup>A<sup>293</sup>G<sup>294</sup>C<sup>295</sup>A<sup>296</sup>A<sup>297</sup>A<sup>298</sup>G<sup>299</sup>C<sup>300</sup>A<sup>301</sup>A<sup>302</sup>A<sup>303</sup>G<sup>304</sup>C<sup>305</sup>A<sup>306</sup>A<sup>307</sup>A<sup>308</sup>G<sup>309</sup>C<sup>310</sup>A<sup>311</sup>A<sup>312</sup>A<sup>313</sup>G<sup>314</sup>C<sup>315</sup>A<sup>316</sup>A<sup>317</sup>A<sup>318</sup>G<sup>319</sup>C<sup>320</sup>A<sup>321</sup>A<sup>322</sup>A<sup>323</sup>G<sup>324</sup>C<sup>325</sup>A<sup>326</sup>A<sup>327</sup>A<sup>328</sup>G<sup>329</sup>C<sup>330</sup>A<sup>331</sup>A<sup>332</sup>A<sup>333</sup>G<sup>334</sup>C<sup>335</sup>A<sup>336</sup>A<sup>337</sup>A<sup>338</sup>G<sup>339</sup>C<sup>340</sup>A<sup>341</sup>A<sup>342</sup>A<sup>343</sup>G<sup>344</sup>C<sup>345</sup>A<sup>346</sup>A<sup>347</sup>A<sup>348</sup>G<sup>349</sup>C<sup>350</sup>A<sup>351</sup>A<sup>352</sup>A<sup>353</sup>G<sup>354</sup>C<sup>355</sup>A<sup>356</sup>A<sup>357</sup>A<sup>358</sup>G<sup>359</sup>C<sup>360</sup>A<sup>361</sup>A<sup>362</sup>A<sup>363</sup>G<sup>364</sup>C<sup>365</sup>A<sup>366</sup>A<sup>367</sup>A<sup>368</sup>G<sup>369</sup>C<sup>370</sup>A<sup>371</sup>A<sup>372</sup>A<sup>373</sup>G<sup>374</sup>C<sup>375</sup>A<sup>376</sup>A<sup>377</sup>A<sup>378</sup>G<sup>379</sup>C<sup>380</sup>A<sup>381</sup>A<sup>382</sup>A<sup>383</sup>G<sup>384</sup>C<sup>385</sup>A<sup>386</sup>A<sup>387</sup>A<sup>388</sup>G<sup>389</sup>C<sup>390</sup>A<sup>391</sup>A<sup>392</sup>A<sup>393</sup>G<sup>394</sup>C<sup>395</sup>A<sup>396</sup>A<sup>397</sup>A<sup>398</sup>G<sup>399</sup>C<sup>400</sup>A<sup>401</sup>A<sup>402</sup>A<sup>403</sup>G<sup>404</sup>C<sup>405</sup>A<sup>406</sup>A<sup>407</sup>A<sup>408</sup>G<sup>409</sup>C<sup>410</sup>A<sup>411</sup>A<sup>412</sup>A<sup>413</sup>G<sup>414</sup>C<sup>415</sup>A<sup>416</sup>A<sup>417</sup>A<sup>418</sup>G<sup>419</sup>C<sup>420</sup>A<sup>421</sup>A<sup>422</sup>A<sup>423</sup>G<sup>424</sup>C<sup>425</sup>A<sup>426</sup>A<sup>427</sup>A<sup>428</sup>G<sup>429</sup>C<sup>430</sup>A<sup>431</sup>A<sup>432</sup>A<sup>433</sup>G<sup>434</sup>C<sup>435</sup>A<sup>436</sup>A<sup>437</sup>A<sup>438</sup>G<sup>439</sup>C<sup>440</sup>A<sup>441</sup>A<sup>442</sup>A<sup>443</sup>G<sup>444</sup>C<sup>445</sup>A<sup>446</sup>A<sup>447</sup>A<sup>448</sup>G<sup>449</sup>C<sup>450</sup>A<sup>451</sup>A<sup>452</sup>A<sup>453</sup>G<sup>454</sup>C<sup>455</sup>A<sup>456</sup>A<sup>457</sup>A<sup>458</sup>G<sup>459</sup>C<sup>460</sup>A<sup>461</sup>A<sup>462</sup>A<sup>463</sup>G<sup>464</sup>C<sup>465</sup>A<sup>466</sup>A<sup>467</sup>A<sup>468</sup>G<sup>469</sup>C<sup>470</sup>A<sup>471</sup>A<sup>472</sup>A<sup>473</sup>G<sup>474</sup>C<sup>475</sup>A<sup>476</sup>A<sup>477</sup>A<sup>478</sup>G<sup>479</sup>C<sup>480</sup>A<sup>481</sup>A<sup>482</sup>A<sup>483</sup>G<sup>484</sup>C<sup>485</sup>A<sup>486</sup>A<sup>487</sup>A<sup>488</sup>G<sup>489</sup>C<sup>490</sup>A<sup>491</sup>A<sup>492</sup>A<sup>493</sup>G<sup>494</sup>C<sup>495</sup>A<sup>496</sup>A<sup>497</sup>A<sup>498</sup>G<sup>499</sup>C<sup>500</sup>A<sup>501</sup>A<sup>502</sup>A<sup>503</sup>G<sup>504</sup>C<sup>505</sup>A<sup>506</sup>A<sup>507</sup>A<sup>508</sup>G<sup>509</sup>C<sup>510</sup>A<sup>511</sup>A<sup>512</sup>A<sup>513</sup>G<sup>514</sup>C<sup>515</sup>A<sup>516</sup>A<sup>517</sup>A<sup>518</sup>G<sup>519</sup>C<sup>520</sup>A<sup>521</sup>A<sup>522</sup>A<sup>523</sup>G<sup>524</sup>C<sup>525</sup>A<sup>526</sup>A<sup>527</sup>A<sup>528</sup>G<sup>529</sup>C<sup>530</sup>A<sup>531</sup>A<sup>532</sup>A<sup>533</sup>G<sup>534</sup>C<sup>535</sup>A<sup>536</sup>A<sup>537</sup>A<sup>538</sup>G<sup>539</sup>C<sup>540</sup>A<sup>541</sup>A<sup>542</sup>A<sup>543</sup>G<sup>544</sup>C<sup>545</sup>A<sup>546</sup>A<sup>547</sup>A<sup>548</sup>G<sup>549</sup>C<sup>550</sup>A<sup>551</sup>A<sup>552</sup>A<sup>553</sup>G<sup>554</sup>C<sup>555</sup>A<sup>556</sup>A<sup>557</sup>A<sup>558</sup>G<sup>559</sup>C<sup>560</sup>A<sup>561</sup>A<sup>562</sup>A<sup>563</sup>G<sup>564</sup>C<sup>565</sup>A<sup>566</sup>A<sup>567</sup>A<sup>568</sup>G<sup>569</sup>C<sup>570</sup>A<sup>571</sup>A<sup>572</sup>A<sup>573</sup>G<sup>574</sup>C<sup>575</sup>A<sup>576</sup>A<sup>577</sup>A<sup>578</sup>G<sup>579</sup>C<sup>580</sup>A<sup>581</sup>A<sup>582</sup>A<sup>583</sup>G<sup>584</sup>C<sup>585</sup>A<sup>586</sup>A<sup>587</sup>A<sup>588</sup>G<sup>589</sup>C<sup>590</sup>A<sup>591</sup>A<sup>592</sup>A<sup>593</sup>G<sup>594</sup>C<sup>595</sup>A<sup>596</sup>A<sup>597</sup>A<sup>598</sup>G<sup>599</sup>C<sup>600</sup>A<sup>601</sup>A<sup>602</sup>A<sup>603</sup>G<sup>604</sup>C<sup>605</sup>A<sup>606</sup>A<sup>607</sup>A<sup>608</sup>G<sup>609</sup>C<sup>610</sup>A<sup>611</sup>A<sup>612</sup>A<sup>613</sup>G<sup>614</sup>C<sup>615</sup>A<sup>616</sup>A<sup>617</sup>A<sup>618</sup>G<sup>619</sup>C<sup>620</sup>A<sup>621</sup>A<sup>622</sup>A<sup>623</sup>G<sup>624</sup>C<sup>625</sup>A<sup>626</sup>A<sup>627</sup>A<sup>628</sup>G<sup>629</sup>C<sup>630</sup>A<sup>631</sup>A<sup>632</sup>A<sup>633</sup>G<sup>634</sup>C<sup>635</sup>A<sup>636</sup>A<sup>637</sup>A<sup>638</sup>G<sup>639</sup>C<sup>640</sup>A<sup>641</sup>A<sup>642</sup>A<sup>643</sup>G<sup>644</sup>C<sup>645</sup>A<sup>646</sup>A<sup>647</sup>A<sup>648</sup>G<sup>649</sup>C<sup>650</sup>A<sup>651</sup>A<sup>652</sup>A<sup>653</sup>G<sup>654</sup>C<sup>655</sup>A<sup>656</sup>A<sup>657</sup>A<sup>658</sup>G<sup>659</sup>C<sup>660</sup>A<sup>661</sup>A<sup>662</sup>A<sup>663</sup>G<sup>664</sup>C<sup>665</sup>A<sup>666</sup>A<sup>667</sup>A<sup>668</sup>G<sup>669</sup>C<sup>670</sup>A<sup>671</sup>A<sup>672</sup>A<sup>673</sup>G<sup>674</sup>C<sup>675</sup>A<sup>676</sup>A<sup>677</sup>A<sup>678</sup>G<sup>679</sup>C<sup>680</sup>A<sup>681</sup>A<sup>682</sup>A<sup>683</sup>G<sup>684</sup>C<sup>685</sup>A<sup>686</sup>A<sup>687</sup>A<sup>688</sup>G<sup>689</sup>C<sup>690</sup>A<sup>691</sup>A<sup>692</sup>A<sup>693</sup>G<sup>694</sup>C<sup>695</sup>A<sup>696</sup>A<sup>697</sup>A<sup>698</sup>G<sup>699</sup>C<sup>700</sup>A<sup>701</sup>A<sup>702</sup>A<sup>703</sup>G<sup>704</sup>C<sup>705</sup>A<sup>706</sup>A<sup>707</sup>A<sup>708</sup>G<sup>709</sup>C<sup>710</sup>A<sup>711</sup>A<sup>712</sup>A<sup>713</sup>G<sup>714</sup>C<sup>715</sup>A<sup>716</sup>A<sup>717</sup>A<sup>718</sup>G<sup>719</sup>C<sup>720</sup>A<sup>721</sup>A<sup>722</sup>A<sup>723</sup>G<sup>724</sup>C<sup>725</sup>A<sup>726</sup>A<sup>727</sup>A<sup>728</sup>G<sup>729</sup>C<sup>730</sup>A<sup>731</sup>A<sup>732</sup>A<sup>733</sup>G<sup>734</sup>C<sup>735</sup>A<sup>736</sup>A<sup>737</sup>A<sup>738</sup>G<sup>739</sup>C<sup>740</sup>A<sup>741</sup>A<sup>742</sup>A<sup>743</sup>G<sup>744</sup>C<sup>745</sup>A<sup>746</sup>A<sup>747</sup>A<sup>748</sup>G<sup>749</sup>C<sup>750</sup>A<sup>751</sup>A<sup>752</sup>A<sup>753</sup>G<sup>754</sup>C<sup>755</sup>A<sup>756</sup>A<sup>757</sup>A<sup>758</sup>G<sup>759</sup>C<sup>760</sup>A<sup>761</sup>A<sup>762</sup>A<sup>763</sup>G<sup>764</sup>C<sup>765</sup>A<sup>766</sup>A<sup>767</sup>A<sup>768</sup>G<sup>769</sup>C<sup>770</sup>A<sup>771</sup>A<sup>772</sup>A<sup>773</sup>G<sup>774</sup>C<sup>775</sup>A<sup>776</sup>A<sup>777</sup>A<sup>778</sup>G<sup>779</sup>C<sup>780</sup>A<sup>781</sup>A<sup>782</sup>A<sup>783</sup>G<sup>784</sup>C<sup>785</sup>A<sup>786</sup>A<sup>787</sup>A<sup>788</sup>G<sup>789</sup>C<sup>790</sup>A<sup>791</sup>A<sup>792</sup>A<sup>793</sup>G<sup>794</sup>C<sup>795</sup>A<sup>796</sup>A<sup>797</sup>A<sup>798</sup>G<sup>799</sup>C<sup>800</sup>A<sup>801</sup>A<sup>802</sup>A<sup>803</sup>G<sup>804</sup>C<sup>805</sup>A<sup>806</sup>A<sup>807</sup>A<sup>808</sup>G<sup>809</sup>C<sup>810</sup>A<sup>811</sup>A<sup>812</sup>A<sup>813</sup>G<sup>814</sup>C<sup>815</sup>A<sup>816</sup>A<sup>817</sup>A<sup>818</sup>G<sup>819</sup>C<sup>820</sup>A<sup>821</sup>A<sup>822</sup>A<sup>823</sup>G<sup>824</sup>C<sup>825</sup>A<sup>826</sup>A<sup>827</sup>A<sup>828</sup>G<sup>829</sup>C<sup>830</sup>A<sup>831</sup>A<sup>832</sup>A<sup>833</sup>G<sup>834</sup>C<sup>835</sup>A<sup>836</sup>A<sup>837</sup>A<sup>838</sup>G<sup>839</sup>C<sup>840</sup>A<sup>841</sup>A<sup>842</sup>A<sup>843</sup>G<sup>844</sup>C<sup>845</sup>A<sup>846</sup>A<sup>847</sup>A<sup>848</sup>G<sup>849</sup>C<sup>850</sup>A<sup>851</sup>A<sup>852</sup>A<sup>853</sup>G<sup>854</sup>C<sup>855</sup>A<sup>856</sup>A<sup>857</sup>A<sup>858</sup>G<sup>859</sup>C<sup>860</sup>A<sup>861</sup>A<sup>862</sup>A<sup>863</sup>G<sup>864</sup>C<sup>865</sup>A<sup>866</sup>A<sup>867</sup>A<sup>868</sup>G<sup>869</sup>C<sup>870</sup>A<sup>871</sup>A<sup>872</sup>A<sup>873</sup>G<sup>874</sup>C<sup>875</sup>A<sup>876</sup>A<sup>877</sup>A<sup>878</sup>G<sup>879</sup>C<sup>880</sup>A<sup>881</sup>A<sup>882</sup>A<sup>883</sup>G<sup>884</sup>C<sup>885</sup>A<sup>886</sup>A<sup>887</sup>A<sup>888</sup>G<sup>889</sup>C<sup>890</sup>A<sup>891</sup>A<sup>892</sup>A<sup>893</sup>G<sup>894</sup>C<sup>895</sup>A<sup>896</sup>A<sup>897</sup>A<sup>898</sup>G<sup>899</sup>C<sup>900</sup>A<sup>901</sup>A<sup>902</sup>A<sup>903</sup>G<sup>904</sup>C<sup>905</sup>A<sup>906</sup>A<sup>907</sup>A<sup>908</sup>G<sup>909</sup>C<sup>910</sup>A<sup>911</sup>A<sup>912</sup>A<sup>913</sup>G<sup>914</sup>C<sup>915</sup>A<sup>916</sup>A<sup>917</sup>A<sup>918</sup>G<sup>919</sup>C<sup>920</sup>A<sup>921</sup>A<sup>922</sup>A<sup>923</sup>G<sup>924</sup>C<sup>925</sup>A<sup>926</sup>A<sup>927</sup>A<sup>928</sup>G<sup>929</sup>C<sup>930</sup>A<sup>931</sup>A<sup>932</sup>A<sup>933</sup>G<sup>934</sup>C<sup>935</sup>A<sup>936</sup>A<sup>937</sup>A<sup>938</sup>G<sup>939</sup>C<sup>940</sup>A<sup>941</sup>A<sup>942</sup>A<sup>943</sup>G<sup>944</sup>C<sup>945</sup>A<sup>946</sup>A<sup>947</sup>A<sup>948</sup>G<sup>949</sup>C<sup>950</sup>A<sup>951</sup>A<sup>952</sup>A<sup>953</sup>G<sup>954</sup>C<sup>955</sup>A<sup>956</sup>A<sup>957</sup>A<sup>958</sup>G<sup>959</sup>C<sup>960</sup>A<sup>961</sup>A<sup>962</sup>A<sup>963</sup>G<sup>964</sup>C<sup>965</sup>A<sup>966</sup>A<sup>967</sup>A<sup>968</sup>G<sup>969</sup>C<sup>970</sup>A<sup>971</sup>A<sup>972</sup>A<sup>973</sup>G<sup>974</sup>C<sup>975</sup>A<sup>976</sup>A<sup>977</sup>A<sup>978</sup>G<sup>979</sup>C<sup>980</sup>A<sup>981</sup>A<sup>982</sup>A<sup>983</sup>G<sup>984</sup>C<sup>985</sup>A<sup>986</sup>A<sup>987</sup>A<sup>988</sup>G<sup>989</sup>C<sup>990</sup>A<sup>991</sup>A<sup>992</sup>A<sup>993</sup>G<sup>994</sup>C<sup>995</sup>A<sup>996</sup>A<sup>997</sup>A<sup>998</sup>G<sup>999</sup>C<sup>1000</sup>A<sup>1001</sup>A<sup>1002</sup>A<sup>1003</sup>G<sup>1004</sup>C<sup>1005</sup>A<sup>1006</sup>A<sup>1007</sup>A<sup>1008</sup>G<sup>1009</sup>C<sup>1010</sup>A<sup>1011</sup>A<sup>1012</sup>A<sup>1013</sup>G<sup>1014</sup>C<sup>1015</sup>A<sup>1016</sup>A<sup>1017</sup>A<sup>1018</sup>G<sup>1019</sup>C<sup>1020</sup>A<sup>1021</sup>A<sup>1022</sup>A<sup>1023</sup>G<sup>1024</sup>C<sup>1025</sup>A<sup>1026</sup>A<sup>1027</sup>A<sup>1028</sup>G<sup>1029</sup>C<sup>1030</sup>A<sup>1031</sup>A<sup>1032</sup>A<sup>1033</sup>G<sup>1034</sup>C<sup>1035</sup>A<sup>1036</sup>A<sup>1037</sup>A<sup>1038</sup>G<sup>1039</sup>C<sup>1040</sup>A<sup>1041</sup>A<sup>1042</sup>A<sup>1043</sup>G<sup>1044</sup>C<sup>1045</sup>A<sup>1046</sup>A<sup>1047</sup>A<sup>1048</sup>G<sup>1049</sup>C<sup>1050</sup>A<sup>1051</sup>A<sup>1052</sup>A<sup>1053</sup>G<sup>1054</sup>C<sup>1055</sup>A<sup>1056</sup>A<sup>1057</sup>A<sup>1058</sup>G<sup>1059</sup>C<sup>1060</sup>A<sup>1061</sup>A<sup>1062</sup>A<sup>1063</sup>G<sup>1064</sup>C<sup>1065</sup>A<sup>1066</sup>A<sup>1067</sup>A<sup>1068</sup>G<sup>1069</sup>C<sup>1070</sup>A<sup>1071</sup>A<sup>1072</sup>A<sup>1073</sup>G<sup>1074</sup>C<sup>1075</sup>A<sup>1076</sup>A<sup>1077</sup>A<sup>1078</sup>G<sup>1079</sup>C<sup>1080</sup>A<sup>1081</sup>A<sup>1082</sup>A<sup>1083</sup>G<sup>1084</sup>C<sup>1085</sup>A<sup>1086</sup>A<sup>1087</sup>A<sup>1088</sup>G<sup>1089</sup>C<sup>1090</sup>A<sup>1091</sup>A<sup>1092</sup>A<sup>1093</sup>G<sup>1094</sup>C<sup>1095</sup>A<sup>1096</sup>A<sup>1097</sup>A<sup>1098</sup>G<sup>1099</sup>C<sup>1100</sup>A<sup>1101</sup>A<sup>1102</sup>A<sup>1103</sup>G<sup>1104</sup>C<sup>1105</sup>A<sup>1106</sup>A<sup>1107</sup>A<sup>1108</sup>G<sup>1109</sup>C<sup>1110</sup>A<sup>1111</sup>A<sup>1112</sup>A<sup>1113</sup>G<sup>1114</sup>C<sup>1115</sup>A<sup>1116</sup>A<sup>1117</sup>A<sup>1118</sup>G<sup>1119</sup>C<sup>1120</sup>A<sup>1121</sup>A<sup>1122</sup>A<sup>1123</sup>G<sup>1124</sup>C<sup>1125</sup>A<sup>1126</sup>A<sup>1127</sup>A<sup>1128</sup>G<sup>1129</sup>C<sup>1130</sup>A<sup>1131</sup>A<sup>1132</sup>A<sup>1133</sup>G<sup>1134</sup>C<sup>1135</sup>A<sup>1136</sup>A<sup>1137</sup>A<sup>1138</sup>G<sup>1139</sup>C<sup>1140</sup>A<sup>1141</sup>A<sup>1142</sup>A<sup>1143</sup>G<sup>1144</sup>C<sup>1145</sup>A<sup>1146</sup>A<sup>1147</sup>A<sup>1148</sup>G<sup>1149</sup>C<sup>1150</sup>A<sup>1151</sup>A<sup>1152</sup>A<sup>1153</sup>G<sup>1154</sup>C<sup>1155</sup>A<sup>1156</sup>A<sup>1157</sup>A<sup>1158</sup>G<sup>1159</sup>C<sup>1160</sup>A<sup>1161</sup>A<sup>1162</sup>A<sup>1163</sup>G<sup>1164</sup>C<sup>1165</sup>A<sup>1166</sup>A<sup>1167</sup>A<sup>1168</sup>G<sup>1169</sup>C<sup>1170</sup>A<sup>1171</sup>A<sup>1172</sup>A<sup>1173</sup>G<sup>1174</sup>C<sup>1175</sup>A<sup>1176</sup>A<sup>1177</sup>A<sup>1178</sup>G<sup>1179</sup>C<sup>1180</sup>A<sup>1181</sup>A<sup>1182</sup>A<sup>1183</sup>G<sup>1184</sup>C<sup>1185</sup>A<sup>1186</sup>A<sup>1187</sup>A<sup>1188</sup>G<sup>1189</sup>C<sup>1190</sup>A<sup>1191</sup>A<sup>1192</sup>A<sup>1193</sup>G<sup>1194</sup>C<sup>1195</sup>A<sup>1196</sup>A<sup>1197</sup>A<sup>1198</sup>G<sup>1199</sup>C<sup>1200</sup>A<sup>1201</sup>A<sup>1202</sup>A<sup>1203</sup>G<sup>1204</sup>C<sup>1205</sup>A<sup>1206</sup>A<sup>1207</sup>A<sup>1208</sup>G<sup>1209</sup>C<sup>1210</sup>A<sup>1211</sup>A<sup>1212</sup>A<sup>1213</sup>G<sup>1214</sup>C<sup>1215</sup>A<sup>1216</sup>A<sup>1217</sup>A<sup>1218</sup>G<sup>1219</sup>C<sup>1220</sup>A<sup>1221</sup>A<sup>1222</sup>A<sup>1223</sup>G<sup>1224</sup>C<sup>1225</sup>A<sup>1226</sup>A<sup>1227</sup>A<sup>1228</sup>G<sup>1229</sup>C<sup>1230</sup>A<sup>1231</sup>A<sup>1232</sup>A<sup>1233</sup>G<sup>1234</sup>C<sup>1235</sup>A<sup>1236</sup>A<sup>1237</sup>A<sup>1238</sup>G<sup>1239</sup>C<sup>1240</sup>A<sup>1241</sup>A<sup>1242</sup>A<sup>1243</sup>G<sup>1244</sup>C<sup>1245</sup>A<sup>1246</sup>A<sup>1247</sup>A<sup>1248</sup>G<sup>1249</sup>C<sup>1250</sup>A<sup>1251</sup>A<

1 MSHGASSRPATARKSSGLSGTVERIPGDKSISHRSFMFGGLASGETRITGL 50  
1 . . . . . MESL,I,I,QLPIARVDGTTINLPGSKTVSNRA,I,LAALAHGKTIVLTNL 44  
51 LEGEDVLIITGKAMQAMGARIRKEGDTWIIDGVGNGLAPEAPLD..FGN 98  
1 :: : | | : . | : | : | . . . . : | : : | | | | : | : | |  
45 I,DSDDVVRHMINA,I,ALGVSYT,LSADRTRCEI,IGNNGGPLHAEGALELFLGN 94  
99 AATIGCRL,TMGL,V,VYDFDFDSTFIGDASLTKRPMGRV,I,NPLREMGVQVK.SE 147  
1 : | : | : : : : . | . : : | : : : . | : | : : : : | . . : . |  
95 AGTAMRPLAA,I,CLGSNDIVLTGEPRMKERPIGHL,VDALRLGGAKITYLE 144  
148 UGDKL,FVTI,R,G,IKTP,PFITYRVPMAQAQVSAVI,LAGLINTPGITTVTEPI 197  
:: : | : | . | . | . . . . : . . . . : . | : . . . . : . . | .  
145 QENYPPRLI,Q,G,G,F,TGGNVDVDGSVSSQFLTALL,MTAPLAPEDTVIRIKGD 194  
198 MTKDII,TEKML,Q,;F,GANLT,TVETDADGVRTIRLEGGRGKLTGQVIDVPGDPSS 247  
; : . . . . : . : . : . | . : . . : . : . | . . . : . . . : . . |  
195 I,VSKPYI,DIT,I,N,IMK,TFGVIEIENQHYQQFVVKGGQSYQSPGTYLVEGDAS 244

**Figure 6**

**SHEET 1 OF 2**

248 TAFPLVAAILVPGSDVTILNVLMNPTRTGLLT .. LQEMGADIEVINPRL 295  
 249 . | : | | : . | : | . : . : . | . . : : | : | | | . |  
 250 SASYFLAAKAIKQGTVKVIGIGRNSMQGDIRFADVL, EKMGATI . . . . . 2877  
 251 .  
 252 AGGEDDWALLKVKSSTLKGVTVPEDRAPS MIDEYPLAVAAFAEGATVMN 345  
 253 . | : | | : . . . | . : : . : : | : | . . : | . | . | . | : .  
 254 CWGIDDY . . LKQTKGELNAIDMDMNHIF . . . DAAMPIATAALFAKGTTRLR 332  
 255 .  
 256 GLEELRVKESDKL SAVANGLKLNGVDCDEGETSLVVRGRGPDGKGLGNASG 395  
 257 . : : | | | . | | | : | : | : | . : . : | . . : . | : . : . : .  
 258 NIYNWRVKEIDKLFAMATEL RKGVAEEGHDYIRI . TPPEKLNF . . . . 376  
 259 .  
 260 AAVATHLDHRIAMSFLV MGLVSENPVTVDDATMLATSFPEFMDLMAGLGA 445  
 261 | . : | | . | | | : | : : | | : . | | : | : . | . . | : : : | : : .  
 262 AEIATYNDH RMA MCFSLVAL . SDTPV TILD P KCTAK'FPDYF EQLARISQ 425  
 263 .  
 264 KIELSDTKAA 456

Figure 6

SHEET 2 of 2

1 MSHIGASSRPA'AKKSSGLSGTVRIPGDKSISHSRSMFGLASGETRITGL 50  
| |||:|| .:|||||:|| .:|| .:|||||:|||||:|||||:|||||:  
1 MSHASASPKA'ARRSEALTGEIRIPIGDKSISHSRSMFGLASGETRITGL 50  
51 LEGEDDVINT'GKAMQAMGARIRKEGDTWIIDGVNGNGLAAPLDFGNAA 100  
| |||:|| .:|||||:|| .:|| .:|||||:|||||:|| .:|||||:  
51 LEGEDDVINT'GKAMQAMGAKIRKEGDVWIINGVNGNGLQPEAALDFGNAG 100  
101 TGCRLTMGLVGIVYUFDSTFIGDASILTKRPMGRVLNPLREMGVQVKSEGD 150  
| .:|||||:|| .:|| .:|||||:|||||:|||||:|||||:  
101 TGA.RLT.MGLVGIVYUFDSTFIGDASILSKRPMGRVLNPLREMGVQVEAADGD 150  
151 RLFVPLRGEK'IT'PITVYRVPMA.SAQVKS.AVLLAGLNTPGITT'VIEPIMTR 200  
| :|||:|| .:|||||:|||||:|||||:|||||:|||||:|||:  
151 RMPLTLIGFPT'ANPITYRVPMA.SAQVKS.AVLLAGLNTPGVTITVIEPVMTR 200  
201 DITEKMLQGF;A.IITVETDADGVRTIRLEG.RGKLTGQVIDVPGDPSSTAF 250  
| |||:|| .:|||||:|||||:|| .:|| .:|| .:|||||:  
201 DITEKMLQGF;A.IITVETDADGVRTIRLEG.RGKLTGQVIDVPGDPSSTAF 250  
251 PLVAALLVPGSDVTLNVLMPTRTGLILTLQEMGADIEEVINPRLAGGED 300  
| |||:|| .:|||||:|||||:|||||:|| .:|||||:  
251 PLVAALLVPGSDVTLNVLMPTRTGLILTLQEMGADIEEVINPRLAGGED 300

## Figure 7

SHEET 1 of 2

451 UTKAA \* 456

448 L. . . . . 449

## Figure 7

SHEET 2 OF 2

CCATTCGCTTCA CGGTGCAACG AGCCGTCAG CAACTGCTCG	60
GAACCGTCCG TATTCAGGTT GACAAGTCTA TCTCCACAG GTCCTTCATG TTTGGAGGTC	120
TCCGCTAGCGG TGAACCTCGT ATCACCGGTC TTTGGAAGG TGAAGATGTT ATCAACACTG	180
GTAACGCTTAA TCAACGCTTAA GGTGCCAGAA TCCGTAAGGA AGGTGATACT TGGATCATG	240
ATGGTGTGTTA TACGGTGTAA CTCCTTGCTC CTGAGGCTCC TCTCGATTTC GGTAAACGCTG	300
AAAC"TCGTTTG CCGT"TCGAC"TA"GGGTCTTG TTGGTGTAA CGATTTCGAT AGCACTTTCA	360
TGGG"TCGACGCTTCTCACTT AAGCGTCCAA TGGTCTCGTGT GTTGAACCA CTTCGCGAAA	420
TGGG"TCGACGCTTCTCACTT AAGCGTCCAA TGGTCTCGTGT GTTGAACCA CTTCGCGAAA	480
AGAC"TCGAAC GCCAATCACC TACAGGGTAC CTATGGCTTC CGCTCAAGTG AAGTCCGCTG	540
TTC"TCGCTTCG TGGTCTCAAC ACCCCAGGTA TCACCACTG"TA"ATCGAGCCA ATCATGACTC	600
TTCGACCAAC TCAAAAGA"TA"TCGAAGGTTTGGTCTAA CCTTACCGT"TA" GAGACTGATG	660
TTCGACCAAC TCAAAAGA"TA"TCGAAGGTTTGGTCTAA CCTTACCGT"TA" GAGACTGATG	720
ATGGTGTGTTA TGAATCCATTC TCTACTGCTT TCCCATGGT"TGCTGCCCTG CTTGT"TCAG	780
GTTCGGAGG TGAATCCATTC TCTACTGCTT TCCCATGGT"TGCTGCCCTG CTTGT"TCAG	840

**Figure 8**

**SHEET 1 OF 2**

CCGCTGGCTGAA	C'TTGCG'P'G'P'P'	CGTCTCTCTA	CTTGAAAGGG	TGTTACTGTT	CCAGAAGACC	960
TGTTACTGTT	TATGAACTGAA	GAGTATCCAA	TTCTCGCTG	TGCGAGCTGCA	TTCGCTGAAG	1020
TGCGAGCTGCA	TATGAACTGAA	TTGGAAGAAC	TCCGTTAA	GGAAAGCGAC	CGTCTTCTG	1080
GGAAAGCGAC	TGAAACAAK	CGGTCTCAAG	TGCAACGGTG	TGATGCGA	TGAAGGTGAG	1140
CGTCTTCTG	TGAAACAAK	TGCAACGGTG	TGATGCGA	TGAAGGTGAG	ACTTCTCTCG	1200
TGATGCGA	TGCAACGGTG	TGATGCGA	TGATGCGA	TGAAGGTGAG	ACTTCTCTCG	1260
TGATGCGA	TGCAACGGTG	TGATGCGA	TGATGCGA	TGAAGGTGAG	ACTTCTCTCG	1320

## Figure 8

SHEET 2 OF 2

AGA<sup>1</sup>T<sup>2</sup>C<sup>3</sup>A<sup>4</sup>T<sup>5</sup>C<sup>6</sup> AT<sup>7</sup>AAGC<sup>8</sup>T<sup>9</sup>C<sup>10</sup>A<sup>11</sup> T<sup>12</sup>GTAATTGGA GGAAGATCAA AATTTCAAT CCCCCATTCT<sup>13</sup> 60  
 C<sup>14</sup>GAT<sup>15</sup>T<sup>16</sup>C<sup>17</sup>T<sup>18</sup>C<sup>19</sup> AT<sup>20</sup>T<sup>21</sup>GAA<sup>22</sup>G<sup>23</sup>T<sup>24</sup> T<sup>25</sup>TCTCCG AT<sup>26</sup>G GCG CAA G<sup>27</sup>T<sup>28</sup> AGC AGA AT<sup>29</sup>C TGC AAT  
 Met<sup>1</sup> Ala<sup>2</sup> Gln<sup>3</sup> Val<sup>4</sup> Ser<sup>5</sup> Arg<sup>6</sup> Ile<sup>7</sup> Cys<sup>8</sup> Asn<sup>9</sup> 113  
 GGT<sup>10</sup> G<sup>11</sup>T<sup>12</sup>G CAG AAC CCA<sup>13</sup> T<sup>14</sup>C<sup>15</sup>T CTT ATC TCC AAT CTC TCG AAA TCC AGT CAA  
 Gly<sup>10</sup> Val<sup>11</sup> Gln<sup>12</sup> Asn<sup>13</sup> Pro<sup>14</sup> Ser<sup>15</sup> Leu<sup>16</sup> Ile<sup>17</sup> Ser<sup>18</sup> Asn<sup>19</sup> Leu<sup>20</sup> Ser<sup>21</sup> Lys<sup>22</sup> Ser<sup>23</sup> Ser<sup>24</sup> Gln<sup>25</sup> 161  
 C<sup>26</sup>C<sup>27</sup> AAA T<sup>28</sup>C<sup>29</sup>T CCC T<sup>30</sup>T A<sup>31</sup>T<sup>32</sup>G GT<sup>33</sup>T TCT CTG AAG ACG C<sup>34</sup>A GAG C<sup>35</sup>A GAG CAT CCA CGA  
 Arg<sup>26</sup> Iys<sup>27</sup> Ser<sup>28</sup> Pro<sup>29</sup> Ile<sup>30</sup> Ser<sup>31</sup> Val<sup>32</sup> Ser<sup>33</sup> Leu<sup>34</sup> Lys<sup>35</sup> Thr<sup>36</sup> Gln<sup>37</sup> Gln<sup>38</sup> His<sup>39</sup> Pro<sup>40</sup> Arg<sup>41</sup> 209  
 G<sup>42</sup>C<sup>43</sup>T T<sup>44</sup>A<sup>45</sup>T CCG ATT TCG TCG TCG TGG GGA T<sup>46</sup>T G AAG AAG AGT GGG ATG ACG  
 Ala<sup>42</sup> Tyr<sup>43</sup> Pro<sup>44</sup> Ile<sup>45</sup> Ser<sup>46</sup> Ser<sup>47</sup> Trp<sup>48</sup> Gly<sup>49</sup> Leu<sup>50</sup> Lys<sup>51</sup> Lys<sup>52</sup> Ser<sup>53</sup> Gly<sup>54</sup> Met<sup>55</sup> Thr<sup>56</sup> 257  
 T<sup>57</sup>T<sup>58</sup>A A<sup>59</sup>T<sup>60</sup>T GGC T<sup>61</sup>C<sup>62</sup>T GAG C<sup>63</sup>T<sup>64</sup>T CGT CCT CTT AAG GTC ATG TCT TCT GTT TCC  
 Ile<sup>57</sup> Ile<sup>58</sup> Gly<sup>59</sup> Ser<sup>60</sup> Glu<sup>61</sup> Ile<sup>62</sup> Arg<sup>63</sup> Pro<sup>64</sup> Leu<sup>65</sup> Lys<sup>66</sup> Val<sup>67</sup> Met<sup>68</sup> Ser<sup>69</sup> Ser<sup>70</sup> Val<sup>71</sup> Ser<sup>72</sup> 305  
 ACG<sup>73</sup> GCG<sup>74</sup> T<sup>75</sup>C<sup>76</sup> A<sup>77</sup>T G<sup>78</sup>C C<sup>79</sup>T<sup>80</sup> C

Figure 9

AGATCTATCG	ATAAGCTTGA	TGTAATTGGA	GGAAGATCAA	ATTTCAT	CCCCATTCCTT	60										
(GATTC) 5' TGCATTC 3'	AAATGAACTT	TCTCCG	ATG	GCG	CAA	GTT	AGC	AGA	ATC	TGC	AAT	113				
Met	Ala	Gln	Val	Ser	Arg	Ile	Cys	Asn				1				
GGT	GTG	CAG	AAC	CCA	TCT	CTT	ATC	TCC	AAT	CTC	TCG	AAA	TCC	AGT	CAA	161
Gly	Val	Gln	Asn	Pro	Ser	Leu	Ile	Ser	Asn	Leu	Ser	Lys	Ser	Ser	Gln	20
GCC	AAA	TCT	CCC	TTA	TGG	GTT	TCT	CTG	AAG	ACG	CAG	CAG	CAT	CCA	CGA	209
Arg	Lys	Ser	Pro	Leu	Ser	Val	Ser	Leu	lys	Thr	Gln	Gln	His	Pro	Arg	30
GCT	TAT	CCG	AAT	TGG	TGG	GGA	TGG	AAG	AAG	AGT	GGG	ATG	ACG			40
Ala	Tyr	Pro	Ile	Ser	Ser	Ser	Trp	Gly	Leu	Lys	Lys	Ser	Gly	Met	Thr	45
															55	
															50	

## Figure 10

SHEET 1 of 2

T<sup>TA</sup> ATT GGC TCT GAG C<sup>AT</sup>T CGT CCT CTT AAG GTC ATG TCT TCT G<sup>AT</sup>T TCC  
 I<sup>eu</sup> Ile Gly Ser Glu I<sup>eu</sup> Arg Pro Leu Lys Val Met Ser Ser Val Ser 305  
 60  
 A<sup>AT</sup>G GCG GAG AAA GCG; T<sup>AT</sup>G GAG ATT G<sup>TA</sup> CTT CAA CCC ATT AGA GAA ATC  
 Thr Ala Glu Lys Ala Ser Glu Ile Val Leu Gln Pro Ile Arg Glu Ile 353  
 75  
 T<sup>CC</sup>C G<sup>AT</sup>T ATT AAG T<sup>AT</sup>G CCT GGC TCC AAG TCT C<sup>TA</sup> TCA AAT AGA ATT  
 Ser Gly Leu Ile Lys I<sup>eu</sup> Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile 401  
 90  
 95  
 100  
 105  
 C  
 402

**Figure 10**

*SHEET 2 of 2*

AGATC'U'U'CA	AGA	ATG	U'A	CAA	ATT	AAC	AAC	ATG	GCT	CAA	GGG	ATA	CAA	49			
Met	Ala	Gln	Ile	Asn	Asn	Met	Ala	Gln	Gly	Ile	Gln						
1				5													
ACC	C'U'P	AAT	CCC	AAU'	'U'CC	AAT	TTC	CAT	AAA	CCC	CAA	GTT	CCT	AAA	TCT	97	
Thr	Ileu	Asn	Pro	Asn	Ser	Asn	Phe	His	Lys	Pro	Gln	Val	Pro	Lys	Ser		
15					20												
'U'CA	A'G'P	'U'P'	C'P'	G'P'	'U'P'	GGA	TCT	AAA	AAA	CTG	AAA	AAT	TCA	GCA	AAT	145	
Ser	Ser	Phe	Leu	Val	Phe	Gly	Ser	Lys	Lys	Lys	Lys	Ileu	I,Lys	Asn	Ser	Ala	Asn
30					35												
'U'P'	A'U'G	TTG	GTP	TTG	AAA	AAA	GAT	TCA	ATT	T'P'	ATG	CAA	AAG	T'P'	TGT	193	
Ser	Met	Leu	Val	Leu	Lys	Lys	Asp	Ser	Ile	Phe	Met	Gln	Lys	Phe	Cys		
45					50												
'U'CC	T'P'	AGG	ATT	TCA	GCA	TCA	GTC	GCT	ACA	GCC	TGC	ATG	C			233	
Ser	Phe	Arg	Ile	Ser	Ala	Ser	Val	Ala	Thr	Ala	Cys	Met					
65					70												

**Figure 11**


AGATCTGCTA GAAATAA<sup>1</sup>I<sup>1</sup>I<sup>1</sup> TGTAACTT TAAGAAGGAG ATATATCC ATG GCA CAA 57  
 A<sup>1</sup>I<sup>1</sup>I<sup>1</sup> AAC AAC A<sup>1</sup>I<sup>1</sup>G G<sup>1</sup>C<sup>1</sup>I<sup>1</sup> CAA GGG ATA CAA ACC C<sup>1</sup>T<sup>1</sup> AAT CCC AAT TCC AAT 105  
 Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro Asn Ser Asn  
 5 10 15  
 TTC CAT<sup>1</sup> AAA CCC CAA G<sup>1</sup>T<sup>1</sup> CCT AAA TCT TCA AGT T<sup>1</sup>T<sup>1</sup> C<sup>1</sup>T<sup>1</sup> G<sup>1</sup>T<sup>1</sup> T<sup>1</sup>T<sup>1</sup> GGA 153  
 Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu Val Phe Gly  
 20 25 30 35  
 T<sup>1</sup>C<sup>1</sup>I<sup>1</sup> AAA AAA C<sup>1</sup>T<sup>1</sup>G AAA AAT TCA GCA AAT TCT ATG T<sup>1</sup>T<sup>1</sup>G GTT T<sup>1</sup>T<sup>1</sup>G AAA AAA 201  
 Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val Leu Lys Lys  
 40 45 50

**Figure 12**

SHEET 1 OF 2

GAT	TCA	ATP	TTP	ATG	CAA	AAG	TTT	TGT	TCC	TTT	AGG	ATT	TCA	GCA	TCA	249
Asp	Ser	Ile	Phe	Met	Gln	Lys	Phe	Cys	Ser	Phe	Arg	Ile	Ser	Ala	Ser	
55								60								65
C <sup>1</sup> P <sub>1</sub>	C <sup>1</sup> P <sub>1</sub>	ACA	GCA	CAC	AG	CCT	TCT	GAG	ATA	GTG	T <sup>1</sup> TG	CAA	CCC	ATT	AAA	297
Val	Ala	Thr	Ala	Gln	Lys	Pro	Ser	Glu	Ile	Val	Leu	Gln	Pro	Ile	Lys	
								75								80
GAG	ATT	TCA	GGC	AC <sup>1</sup> P <sub>1</sub>	C <sup>1</sup> P <sub>1</sub>	AAA	TTG	CCT	GGC	TCT	AAA	TCA	TTA	TCT	AAT	345
Glu	Ile	Ser	Gly	Thr	Val	Lys	Leu	Pro	Gly	Ser	Lys	Ser	Leu	Ser	Asn	
85								90								95
AGA	AT <sup>1</sup> P <sub>1</sub>	C														
Arg	Ile															
100																

## Figure 12



**Figure 13**




Figure 14




Figure 15





Figure 16



**Figure 17**

ATG	AAA	CGA	GAT	AAG	G'TG	CAG	ACC	TTA	CAT	GGA	GAA	ATA	CAT	ATT	CCC	48
Met	Lys	Arg	Asp	Lys	Val	Gln	Thr	Leu	His	Gly	Glu	Ile	His	Ile	Pro	
1				5				10					15			
GGT	GAT	AAA	TCC	ATP	TCT	CAC	CGC	TCT	GTT	ATG	T'TT	GGC	GCG	CTA	GCG	96
Gly	Asp	Lys	Ser	Ile	Ser	His	Arg	Ser	Val	Met	Phe	Gly	Ala	Leu	Ala	
	20				25							30				
GCA	GCG	ACA	ACA	ACA	G'TT	AAA	AAC	T'TT	CTG	CCG	GGA	GCA	GAT	TGG	CTG	144
Ala	Gly	Thr	Thr	Thr	Val	Val	Lys	Asn	Phe	Leu	Pro	Gly	Ala	Asp	Cys	
	35				40							45				
AGC	ACG	ATC	GAT	TGC	TTT	AGA	AAA	ATG	GGT	GTT	CAC	ATT	GAG	CAA	AGC	192
Ser	Thr	Ile	Asp	Cys	Phe	Arg	Lys	Met	Gly	Val	His	Ile	Glu	Gln	Ser	
	50				55						60					
AGC	AGC	GAT	GTC	GTG	ATP	CAC	GGA	AAA	GGA	ATC	GAT	GCC	CTG	AAA	GAG	240
Ser	Ser	Asp	Val	Val	Ile	His	Gly	Lys	Gly	Ile	Asp	Ala	Leu	Lys	Glu	
	65				70						75					
CCA	GAA	AGC	C'TT	TTA	GAT	GTC	GGA	AAT	TCA	GGT	ACA	ACG	ATT	CGC	CTG	288
Pro	Glu	Ser	Leu	Leu	Asp	Val	Gly	Asn	Ser	Gly	Thr	Thr	Ile	Arg	Leu	
					85						90			95		
ATG	CTC	GGA	ATA	TTG	GCG	GGC	CGT	CCT	T'TT	TAC	AGC	GGC	GTA	GCC	GGA	336
Met	Leu	Gly	Ile	Leu	Ala	Gly	Arg	Pro	Phe	Tyr	Ser	Ala	Val	Ala	Gly	
	100									105		110				

**Figure 18**

**SHEET 1 OF 4**

## Figure 18

# குறு குறு குறு குறு குறு குறு குறு

A'TP	T'P	G'TP	CCT	GGAA	GAC	ATT	TCT	TCA	GCC	GCG	T'P	TTC	CTT	GCT	GCT	720
Ile	Phe	Val	Pro	Gly	Asp	Ile	Ser	Ser	Ala	Ala	Phe	Phe	Leu	Ala	Ala	
225									230							240
GGC	GCG	ATG	GTT	CCA	AAC	AGC	AGA	ATT	GTA	TTC	AAA	AAC	GTA	GGT	TTA	768
Gly	Ala	Met	Val	Pro	Asn	Ser	Arg	Ile	Val	Leu	Lys	Asn	Val	Gly	Leu	
									245							255
AAU	CCG	ACG	CGG	ACG	GGT	ATT	ATT	GAT	GTC	CTT	CAA	AAC	ATG	GGG	GCA	816
Asn	Pro	Thr	Arg	Thr	Gly	Ile	Ile	Asp	Val	Leu	Gln	Asn	Met	Gly	Ala	
									260							270
AAA	C'P	GAA	A'IC	AAA	CCA	TCT	GCT	GAT	AGC	GGT	GCA	GAG	CCT	TAT	GGA	864
Lys	Leu	Glu	Ile	Lys	Pro	Ser	Ala	Asp	Ser	Gly	Ala	Glu	Pro	Tyr	Gly	
									275							285
GAT	T'PG	AT'P	AT'P	GAA	ACG	TCA	TCT	CTA	AAG	GCA	GTT	GAA	ATC	GGA	GGA	912
Asp	Leu	Ile	Ile	Glu	Thr	Ser	Ser	Leu	Lys	Ala	Val	Glu	Ile	Gly	Gly	
									290							300
GAT	A'IC	AT'P	CCG	CGI'	T'PA	ATT	GAT	GAG	ATC	CCT	ATC	GCG	CTT	CTT	960	
Asp	Ile	Ile	Pro	Arg	Leu	Ile	Asp	Glu	Ile	Pro	Ile	Ile	Ala	Leu	Leu	
									305							310
GCG	AC'P	CAG	GCG	GAA	GGA	ACC	ACC	GTT	ATT	AAG	GAC	GCG	GCA	GAG	CTA	1008
Ala	Thr	Gln	Ala	Glu	Gly	Thr	Thr	Val	Ile	Lys	Asp	Ala	Ala	Glu	Glu	
									325							330
																335

**Figure 18**

**SHEET 3 of 4**

AAA	GTC	AAA	GAA	ACA	AAC	CGT	A'TT	GAT	ACT	GTT	TCT	GAG	CTT	CGC	1056
Lys	Val	Lys	Glu	Thr	Asn	Arg	Ile	Asp	Thr	Val	Val	Ser	Glu	Leu	Arg
340															350
AAG	CTG	GGT	GCT	GAA	A'TT	GAA	CCG	ACA	GCA	GAT	GGA	ATG	AAG	GTT	1104
Lys	Leu	Gly	Ala	Glu	Ile	Glu	Pro	Thr	Ala	Asp	Gly	Met	Lys	Val	Tyr
355															365
GTC	AAA	CAA	ACG	TTC	AAA	GGA	GGC	GCT	GCA	GTC	TCC	AGC	CAC	GGA	1152
Gly	Lys	Gln	Thr	Leu	Lys	Gly	Gly	Ala	Ala	Val	Ser	Ser	His	Gly	Asp
370															380
CAT	CGA	A'TC	GGG	ATG	ATG	CTT	GGT	ATT	GCT	TCC	TGT	ATA	ACG	GAG	1200
His	Arg	Ile	Gly	Met	Met	Leu	Gly	Ile	Ala	Ser	Cys	Ile	Thr	Glu	Glu
385															400
CGG	A'TT	GAA	ATC	GAG	CAC	ACG	GAT	GCC	ATT	CAC	GTT	TCT	TAT	CCA	ACC
Pro	Ile	Glu	Ile	Glu	His	Thr	Asp	Ala	Ile	His	Val	Ser	Tyr	Pro	Thr
405															415
TTC	TTC	GAG	CAT	T'TA	AAT	AAG	CTT	TCG	AAA	AAA	TCC	TGA			1248
Phe	Phe	Glu	His	Leu	Asn	Lys	Leu	Ser	Lys	Lys	Ser				1287
420															425

**Figure 18**

*SHEET 4 of 4*

A <sup>1</sup> C <sup>1</sup>	G <sup>1</sup> A <sup>1</sup>	A <sup>1</sup> P <sup>1</sup>	G <sup>1</sup> A <sup>1</sup>	C <sup>1</sup> A <sup>1</sup>	A <sup>1</sup> P <sup>1</sup>	A <sup>1</sup> T <sup>1</sup>	G <sup>1</sup> A <sup>1</sup>	A <sup>1</sup> T <sup>1</sup>	T <sup>1</sup> C <sup>1</sup>	G <sup>1</sup> G <sup>1</sup>	C <sup>1</sup> C <sup>1</sup>	T <sup>1</sup> T <sup>1</sup>	A <sup>1</sup> A <sup>1</sup>	G <sup>1</sup> G <sup>1</sup>	G <sup>1</sup> G <sup>1</sup>	G <sup>1</sup> A <sup>1</sup>
Met <sup>1</sup>	Val <sup>1</sup>	Asn <sup>1</sup>	Glu <sup>1</sup>	Gln <sup>1</sup>	Ile <sup>1</sup>	Ile <sup>1</sup>	Asp <sup>1</sup>	Ile <sup>1</sup>	Ser <sup>1</sup>	Gly <sup>1</sup>	Pro <sup>1</sup>	Leu <sup>1</sup>	Lys <sup>1</sup>	Gly <sup>1</sup>	Glu <sup>1</sup>	48
5																15
ATA <sup>1</sup>	GAA <sup>1</sup>	GTG <sup>1</sup>	CCG <sup>1</sup>	GGC <sup>1</sup>	GAT <sup>1</sup>	AAG <sup>1</sup>	TCA <sup>1</sup>	ATG <sup>1</sup>	ACA <sup>1</sup>	CAC <sup>1</sup>	CGT <sup>1</sup>	GCA <sup>1</sup>	ATC <sup>1</sup>	ATG <sup>1</sup>	TTG <sup>1</sup>	96
Ile <sup>20</sup>	Glu <sup>20</sup>	Val <sup>20</sup>	Pro <sup>20</sup>	Gly <sup>20</sup>	Asp <sup>20</sup>	Lys <sup>20</sup>	Ser <sup>20</sup>	Met <sup>20</sup>	Thr <sup>20</sup>	His <sup>20</sup>	Arg <sup>20</sup>	Ala <sup>20</sup>	Ile <sup>20</sup>	Met <sup>20</sup>	Leu <sup>20</sup>	30
35																45
GAA <sup>35</sup>	GAT <sup>35</sup>	TG <sup>35</sup>	CGT <sup>35</sup>	CGT <sup>35</sup>	GAA <sup>35</sup>	GAT <sup>35</sup>	TCT <sup>35</sup>	ACT <sup>35</sup>	ATA <sup>35</sup>	TAT <sup>35</sup>	AAG <sup>35</sup>	CCA <sup>35</sup>	CTA <sup>35</sup>	CTR <sup>35</sup>	GCC <sup>35</sup>	144
Glu <sup>50</sup>	Asp <sup>50</sup>	Cys <sup>50</sup>	Arg <sup>50</sup>	Arg <sup>50</sup>	Arg <sup>50</sup>	Arg <sup>50</sup>	Thr <sup>50</sup>	Met <sup>50</sup>	Asp <sup>50</sup>	Ile <sup>50</sup>	Phe <sup>50</sup>	Arg <sup>50</sup>	His <sup>50</sup>	Leu <sup>50</sup>	Gly <sup>50</sup>	192
65																60
A <sup>70</sup>	P <sup>70</sup>	C <sup>70</sup>	A <sup>70</sup>	A <sup>70</sup>	G <sup>70</sup>	G <sup>70</sup>	A <sup>70</sup>	A <sup>70</sup>	G <sup>70</sup>	T <sup>70</sup>	C <sup>70</sup>	C <sup>70</sup>	G <sup>70</sup>	G <sup>70</sup>	GAA <sup>70</sup>	240
Ile <sup>75</sup>	Lys <sup>75</sup>	Glu <sup>75</sup>	Asp <sup>75</sup>	Asp <sup>75</sup>	Glu <sup>75</sup>	Iys <sup>75</sup>	Leu <sup>75</sup>	Val <sup>75</sup>	Val <sup>75</sup>	Thr <sup>75</sup>	Ser <sup>75</sup>	Pro <sup>75</sup>	Gly <sup>75</sup>	Tyr <sup>75</sup>	Gln <sup>75</sup>	80
G <sup>80</sup>	AAC <sup>80</sup>	ACG <sup>80</sup>	CCA <sup>80</sup>	CAT <sup>80</sup>	CAA <sup>80</sup>	G <sup>80</sup> A <sup>80</sup>	T <sup>80</sup> G <sup>80</sup>	T <sup>80</sup> A <sup>80</sup>	A <sup>80</sup> C <sup>80</sup>	G <sup>80</sup> G <sup>80</sup>	A <sup>80</sup> T <sup>80</sup>	T <sup>80</sup> C <sup>80</sup>	G <sup>80</sup> A <sup>80</sup>	G <sup>80</sup> A <sup>80</sup>	G <sup>80</sup> A <sup>80</sup>	288
Val <sup>85</sup>	Asn <sup>85</sup>	Thr <sup>85</sup>	Pro <sup>85</sup>	His <sup>85</sup>	Gln <sup>85</sup>	Val <sup>85</sup>	Leu <sup>85</sup>	Tyr <sup>85</sup>	Thr <sup>85</sup>	Gly <sup>85</sup>	Asn <sup>85</sup>	Ser <sup>85</sup>	Gly <sup>85</sup>	Thr <sup>85</sup>	Thr <sup>85</sup>	95
100																110
AC <sup>100</sup>	CA <sup>100</sup>	CG <sup>100</sup>	TA <sup>100</sup>	TG <sup>100</sup>	GC <sup>100</sup>	GG <sup>100</sup>	TT <sup>100</sup>	TA <sup>100</sup>	AG <sup>100</sup>	G <sup>100</sup> T <sup>100</sup>	TT <sup>100</sup>	GG <sup>100</sup>	A <sup>100</sup> T <sup>100</sup>	G <sup>100</sup> A <sup>100</sup>	G <sup>100</sup> A <sup>100</sup>	336
105																110

**Figure 19**

**SHEET 1 OF 4**

T <sup>91</sup> G	T <sup>92</sup> T	GCG	GAT	G <sup>93</sup> T	T <sup>94</sup> A	AT <sup>95</sup> T	GGT	AAA	AGG	CCA	ATG	GAT	CGT	GTC	TTG	384	
I <sup>96</sup>	I <sup>97</sup>	Ser	Gly	Asp	Val	Ser	Ile	Gly	Lys	Arg	Pro	Met	Asp	Arg	Val	Leu	
Leu	Ser	Gly	Asp	Val	Ser	Ile	Gly	Lys	Arg	Pro	Met	Asp	Arg	Val	Leu	125	
115																	
AGA	CCA	T <sup>98</sup> G	AAA	C <sup>99</sup> T	ATG	GAT	GCG	AAT	ATT	GAA	GGT	ATT	GAA	GAT	AAT	432	
Arg	Pro	Ileu	Lys	Leu	Met	Asp	Ala	Asn	Ile	Glu	Gly	Ile	Glu	Asp	Asn		
130						135						140					
T <sup>100</sup> T	A <sup>101</sup> A	CCA	T <sup>102</sup> A	A <sup>103</sup> T	AAG	CCA	TCT	GTC	ATA	AAA	GGT	ATA	AAT	TAT		480	
Tyr	Thr	Pro	Ileu	Ile	Ile	Lys	Pro	Ser	Val	Ile	Lys	Gly	Ile	Asn	Tyr		
145						150						155					
C <sup>104</sup> A	A <sup>105</sup> G	GAA	G <sup>106</sup> T	GCA	A <sup>107</sup> G <sup>108</sup> T	GCA	CAA	GTA	AAA	AG <sup>109</sup> T	GCC	ATT	TTA	TTT	GCA	528	
Gln	Met	Glu	Val	Ala	Ser	Ala	Gln	Val	Lys	Ser	Ala	Ile	Leu	Phe	Ala		
165						170						175					
AGT	T <sup>110</sup> G	T <sup>111</sup> T	TCT	A <sup>112</sup> A	GAA	CCG	ACC	ATC	ATT	AAA	GAA	TTA	GAT	GTA	AGT		
Ser	Ileu	Phe	Ser	Ilys	Glu	Pro	Thr	Ile	Ile	Lys	Glu	Leu	Asp	Val	Ser	576	
180						185						190					
CGA	AAT	CAT	A <sup>116</sup> C	T	GAG	ACG	ATG	TTC	AAA	CAT	TTT	AAT	ATT	CCA	ATT	GAA	624
Arg	Asn	His	Thr	Glu	Thr	Met	Phe	Lys	His	Phe	Asn	Ile	Pro	Ile	Glu		
195						200						205					
GCA	GAA	GGG	T <sup>117</sup> A	TCA	A <sup>118</sup> T	AAT	ACA	ACC	CCT	GAA	GCA	ATT	CGA	TAC	ATT	672	
Ala	Glu	Gly	Ileu	Ser	Ile	Asn	Thr	Thr	Pro	Glu	Ala	Ile	Arg	Tyr	Ile		
210						215						220					

**Figure 19**

**SHEET 2 OF 4**

Figure 19

SHEET 3 OF 4

Figure 19

SHEET 4 OF 4

FG2982	LBAAs	MSHSASPCKPA	TARRSEALTG
<i>Agrobacterium</i> CP4	...	MSHSASPCKPA	TARRSEALTG
<i>B. subtilis</i>	...	MSHGASSRPA	TARKSSGLSG
<i>S. aureus</i>	...	M	KRDKVQTLHG
<i>S. cerevisiae</i>	...	MVNEQ	IIDISGPLKG
<i>A. nidulans</i>	...	LVYP	FKDIPADQKQ
<i>B. napus</i>	...	VHP	..GVAHSSNV
<i>A. thaliana</i>	...	K	ASEI VLQPIREISG
<i>N. tabacum</i>	...	K	ASEI VLQPIREISG
<i>L. esculentum</i>	...	K	PNEI VLQPIKDISG
<i>P. hybrida</i>	...	K	PHEI VLXPIKDISG
<i>Z. mays</i>	...	K	PSEI VLQPIKEISG
<i>S. gallinarum</i>	...	AGAEEL	VLOPIKEISG
<i>S. typhimurium</i>	...	MESL	TLQPIARVDG
<i>S. typhi</i>	...	MESL	TLQPIARVDG
<i>E. coli</i>	...	MESL	TLQPIARVDG
<i>K. pneumoniae</i>	...	MESL	TLQPIARVDG
<i>Y. enterocolitica</i>	...	MESL	TLQPIARVDG
<i>H. influenzae</i>	...	MLESL	TLHPIALING
<i>P. multocida</i>	...	MEKI	TLAPISAVEG
<i>A. salmonicida</i>	...	MIKDATAI	TLNPISYIEG
<i>B. pertussis</i>	...	MSGLAYL	DLPAARLARG
Consensus	-----	-----	-----

Figure 20

PG2982	EIRIPGDKSI	SHRSFMFGGL	ASGETRITGL	LEGEDWINTG	RAMQAM.GAK
LBA	EIRIPGDKSI	SHRSFMFGGL	ASGETRITGL	LEGEDWINTG	RAMQAM.GAK
<i>Agrobacterium</i> CP4	TVRIPGDKSI	SHRSFMFGGL	ASGETRITGL	LEGEDWINTG	KAMQAM.GAR
<i>B. subtilis</i>	ETHIPGDKSI	SHRSFMFGAL	AAGTTVKNF	LPGADCLSTI	DCFRKM.GVH
<i>S. aureus</i>	EIEV <u>PGDKSM</u>	THRAIMLASL	AEGVSTIYKP	LLGEDCRRTM	DIFRHL.GVE
<i>S. cerevisiae</i>	WVIPPGSKSI	SNRALTLAAL	GEGQCKIKNL	LHSDDTKHML	TAVHELGAT
<i>A. nidulans</i>	TCAPPGSKSI	SNRALVLAAL	GSGTCRIKNL	LHSDDTEVML	NALERLGAAT
<i>B. napus</i>	FLKLPGSKSL	SNRILLIAAL	SEGTIVVDNL	LNSDDINYML	DALKKL.GLN
<i>A. thaliana</i>	LIKLPGSKSL	SNRILLIAAL	SEGTIVVDNL	LNSDDINYML	DALKKL.GLN
<i>N. tabacum</i>	TVKLPGSKSL	SNRILLIAAL	SKGRTIVVDNL	LSSDDIHML	GALKTL.GLN
<i>L. esculentum</i>	TVKLPGSKSL	SNRILLIAAL	SEGRTIVVDNL	LSSDDIHML	GALKTL.GLN
<i>P. hybrida</i>	TVKLPGSKSL	SNRILLIAAL	SEGTIVVDNL	LSSDDIHML	GALKTL.GLN
<i>Z. mays</i>	TVKLPGSKSL	SNRILLIAAL	SEGTIVVDNL	LNSEDVHML	GALRTL.GLS
<i>S. gallinarum</i>	AINLPGSKSV	SNRALLIAAL	ACGKTVLTL	LDSDDVRRHML	NALSAL.GIN
<i>S. typhimurium</i>	AINLPGSKSV	SNRALLIAAL	PCGKTALTNL	LDSDDVRRHML	NALSAL.GIN
<i>S. typhi</i>	AINLPGSKSV	SNRALLIAAL	ACGKTVLTL	LDSDDVRRHML	NALSAL.GIN
<i>E. coli</i>	TINLPGSKTV	SNRALLIAAL	AHGKTVLTL	LDSDDVRRHML	NALTAL.GVS
<i>K. pneumoniae</i>	TINLPGSKSV	SNRALLIAAL	ARGTTVLTNL	LDSDDVRRHML	NALSAL.GVH
<i>Y. entero colitica</i>	TINLPGSKSV	SNRALLIAAL	ARGTTVLTNL	LDSDDVRRHML	NALSAL.GVH
<i>H. influenzae</i>	TINLPGSKSL	SNRALLIAAL	AEQTQQLNNL	LDSDDIRHML	NALQAL.GVK
<i>E. multocida</i>	EVRIPGSKSL	SNRALLIAAL	AKGTTKVTNL	LDSDDIRHML	NALKAL.GVR
<i>A. salmonicida</i>	EVNIPGSKSV	SNRALLIAAL	AKGTTLJNL	LDSDDVRRHML	NALKEL.GVT
<i>B. pertussis</i>	EVALPGSKSI	SNRALLIAAL	ARGTTRLJNL	LDSDDIRHML	AALTQL.GVK
Consensus	-----PG-K-----	-----R-----L	-----G-----L	-----D-----	

Figure 20

Figure 20

	151	200
PG2982	DM.....KT	SFIGDASLSK
I.BAA	DM.....KT	RPMGRVLNPL
<i>A. chalcacterium</i>	DF.....DS	REMGVQVEAA
<i>CPA</i>	PF.....YS	DGDRMPLT..
<i>B. subtilis</i>	GN.....ES	REMGVQVKSE
<i>S. aureus</i>	NST.SSQKYI	DGDRLPVT..
<i>S. cerevisiae</i>	NST.SSQKYI	REMGVQVKSE
<i>A. nidulans</i>	NS..STVDSS	DGDRLPVT..
<i>B. napus</i>	G....GNASY	REMGVQVKSE
<i>A. thaliana</i>	G....GNASY	DGDRLPVT..
<i>N. tabacum</i>	G....GHSRY	REMGVQVKSE
<i>L. esculentum</i>	G....GHSRY	DGDRLPVT..
<i>P. hybrida</i>	G....GNSRY	REMGVQVKSE
<i>Z. mays</i>	G....GNATY	DGDRLPVT..
<i>S. gallinarinum</i>	.....GQNEI	REMGVQVKSE
<i>S. typhimurium</i>	.....GQNEI	DGDRLPVT..
<i>S. typhi</i>	.....GQNEI	REMGVQVKSE
<i>E. coli</i>	.....GSNDI	DGDRLPVT..
<i>K. pneumoniae</i>	.....GSNDI	REMGVQVKSE
<i>Y. enteroercolitica</i>	.....GKNDI	DGDRLPVT..
<i>H. influenzae</i>	G.NHEV..EI	REMGVQVKSE
<i>F. multocida</i>	TENREGKNEI	DGDRLPVT..
<i>A. salmonicida</i>	.....GSGEY	REMGVQVKSE
<i>B. pertussis</i>	G.....GDY	DGDRLPVT..
Consensus	-----G-----	DGDRLPVT..

**Figure 20**

107

67

PG2982	.....	LIGPK	TANPITYRVP	MASAQVSAV	LLAGLN	.....	.....	TPGVTT
LBAA	.....	LIGPK	TANPITYRVP	MASAQVSAV	LLAGLN	.....	.....	TPGVTT
<i>Agrobacterium</i> CP4	.....	LRGPK	TPTPITYRVP	MASAQVSAV	LLAGLN	.....	.....	TPGITT
<i>B.</i> <i>subtilis</i>	.....	SVSGA	SLKGIDYVSP	VASAQIKSAV	LLAGLQ	.....	.....	AEGTTT
<i>S. aureus</i>	.....	IIKPS	VIKGINYQME	<u>VASAQVSAI</u>	LFASLF	.....	.....	SKEPTI
<i>S. cerevisiae</i>	YTDHSVFKG	.....	GRIELAA	TVSSQYVSSI	LMCAPYAE	.....	EPVTLALVG	
<i>A. nidulans</i>	AASGGFAG	.....	GNINLAA	KVSSQYVSSL	LMCAPYAK	.....	EPVTLRLVG	
<i>A. thaliana</i>	NANGGLPG	.....	GKVLSG	SISSQYLTAL	LMSAP.LA..	.....	LGDVEIEITI	
<i>N. tabacum</i>	VSKGGLPG	.....	GKVLSG	SISSQYLTAL	LMAAP.LA..	.....	LGDVEIEII	
<i>L. esculentum</i>	VSKGGLPG	.....	GKVLSG	SISSQYLTAL	LMAAP.LA..	.....	LGDVEIEII	
<i>P. hybrida</i>	VSKGGLPG	.....	GKVLSG	SISSQYLTAL	LMAAP.LA..	.....	LGDVEIEII	
<i>Z. mays</i>	NGIGGLPG	.....	GKVLSG	SISSQYLSAL	LMAAP.LP..	.....	LGDVEIEII	
<i>S. gallinarum</i>	RG..GFIG	.....	GDIEVDG	SVSSQFLTAL	LMTAP.LA..	.....	PKDTIIRVK	
<i>S. typhimurium</i>	RG..GFIG	.....	GDIEVDG	SVSSQFLTAL	LMTAP.LA..	.....	PKDTIIRVK	
<i>S. typhi</i>	RG..GFIG	.....	GDIEVDG	SVSSQFLTAL	LMTAP.LA..	.....	PKDTIIRVK	
<i>E. coli</i>	QG..GFTG	.....	GNVDVDG	SVSSQFLTAL	LMTAP.LA..	.....	PEDTVIRIK	
<i>K. pneumoniae</i>	RG..GFTG	.....	GDVEVDG	SVSSQFLTAL	LMASP.LA..	.....	PQDTIVIAIK	
<i>V. enterocolitica</i>	AG..GFRG	.....	GKLTVDG	SVSSQFLTAL	LMTAP.LA..	.....	EQDTEIQIQ	
<i>H. influenzae</i>	RNK.GIKG	.....	GKVKGID	SISSQFLTAL	LMSAP.LA..	.....	ENDTEIEII	
<i>P. multocida</i>	RNT.GLKG	.....	GRIQIDG	SVSSQFLTAL	LMAAP.MA..	.....	EADTEIEII	
<i>A. salmonicida</i>	DAK.GLWG	.....	GDVHVDG	SVSSQFLTAF	LMAAPAMA..	.....	PVIRIHIK	
<i>B. pertussis</i>	GGGSIRVD	.....	GPVRVEG	SVSSQFLTAL	LMAAPVLR	.....	SGQDITIEVW	
Consensus	.....	.....	.....	.....	.....	.....	.....	.....
	-----S-----	-----Q-----	-----L-----	-----	-----	-----	-----	-----

Figure 20

PG2982	251	300
LBAA	VIEPVMTRDH	TEKMLQGFGA
<i>A. yiribacterium</i> CP4	VIEPIMTRDH	TEKMLQGFGA
<i>B. subtilis</i>	VI <del>E</del> PHKSRDH	TEKMLQGFGA
<i>S. aureus</i>	TKELDV <u>SRNH</u>	<u>TE</u> TMFKHFNI
<i>S. cerevisiae</i>	GKPISKIYVD	<u>MT</u> IKMMEKFG
<i>A. nidulans</i>	GKPISQPYID	MTTAMMRSFG
<i>B. napus</i>	DKLISVPPVE	MTLKLMERFG
<i>I. esculentum</i>	DKLISVPPVE	MTLKLMERFG
<i>P. hybrida</i>	DKLISVPPVE	MTLKLMERFG
<i>Z. mays</i>	DKLISI <del>P</del> VE	MTLRLMERFG
<i>S. gallinarum</i>	GELVSKPYID	ITLNLMKTFG
<i>S. typhimurium</i>	GELVSKPYID	ITLNLMKTFG
<i>S. typhi</i>	GELVSKPYID	ITLNLMKTFG
<i>E. coli</i>	GDLVSKPYID	ITLNLMKTFG
<i>K. pneumoniae</i>	GEI <del>N</del> SRPYID	ITLNLMKTFG
<i>Y. enterocolitica</i>	GEI <del>V</del> SKPYID	ITLHLMKTFG
<i>H. influenzae</i>	GEI <del>V</del> SKPYID	ITLHLMKAFG
<i>P. multocida</i>	GEI <del>V</del> SKPYID	ITLMMQTFG
<i>A. salmonicida</i>	GEI <del>V</del> SKPYID	ITLHMNSSG
<i>B. pertussis</i>	GEI <del>L</del> SKPYIE	ITLNLMARFG
Consensus	-----	VS . V.RRDG

Figure 20

۸۷

۲۷۰

PG2982	PGDPSSSTA FP	LVAALLVEGS	DVTIRNLVMN	PTTRTGL...I	LTLQEMGADI
LBAA	PGDPSSSTA FP	LVAALLVEGS	DVTIRNLVMN	PTTRTGL...I	LTLQEMGADI
Agrobacteri um CP4	PGDPSSSTA FP	LVAALLVPGS	DVTILNLVMN	PTTRTGL...I	LTLQEMGADI
B. subtilis	PGDISSAFA F	LAAGAMVPNS	RIVLKNVGLN	PTTRTGI...I	DVLQNMGAKL
S. aureus	PGDISSAFA F	IVAA LITPGS	DVTIHN VGIN	PTTRTGI...I	DIVEKMGNI
S. cerevisiae	ESDASSATYP	LAFAA.MTGT	TVTVPNIGFE	SLQGDARFAR	DVLKPMGCKI
A. nidulans	ESDASCATYP	LA VAA.VTGT	TCTV PNLGSA	SLQGDARFAV	EVLRPMGCTV
B. napus	EGDASSA SYF	LAGAA.TTGE	TVTVEGCC TT	SLQGDVVKFA.	EVLEKMGCKV
A. thaliana	EGDASSA SYF	LAGAA.ITGE	TVTVEGCC TT	SLQGDVVKFA.	EVLEKMGCKV
N. tabacum	EGDASSA SYF	LAGAA.VTGG	TVTVEGCC TS	SLQGDVVKFA.	EVLEKMGAEV
L. esculentum	EGDASSA SYF	LAGAA.VTGG	TVTVEGCC TS	SLQGDVVKFA.	EVLEKMGAEV
P. hybrida	EGDASSA SYF	LAGAA.VTGG	TVTVEGCC TN	SLQGDVVKFA.	EVLEKMGAEV
Z. mays	EGDASSA SYF	LAGAA.ITGG	TVTVEGCC TT	SLQGDVVKFA.	EVLEMMGAKV
S. gallinarum	EGDASSA SYF	LAAGA.IKGG	TVKVTGIGRK	SMQGDIRFA.	DVLEKMGATI
S. typhimurium	EGDASSA SYF	LAAGA.IKGG	TVKVTGIGRK	SMQGDIRFA.	DVLEKMGATI
S. typhi	EGDASSA SYF	LAAGG.IKGG	TVKVTGIGGK	SMQGDIRFA.	DVLHKMGATI
E. coli	EGDASSA SYF	LAAA.IKGG	TVKVTGIGRN	SMQGDIRFA.	DVLEKMGATI
K. pneumoniae	EGDASSA SYF	LAAGA.IKGG	TVKVTGIGRN	SMQGDIRFA.	DVLEKMGATV
V. entero colitica	EGDASSA SYF	LAAA.IKGG	TVKVTGIGKQ	SVQGDTKFA.	DVLEKMGAKI
H. influenzae	EGDASSA SYF	LAAGA.IK.G	KVKVTGIGKN	SIQGDR LFA.	DVLEKMGAKI
P. multoqida	EGDASSA SYF	LAAA.IK.G	KVKVTGVGKN	SIQGDR LFA.	DVLEKMGahi
A. salmonicida	EGDASSA SYF	LAAGA.IK.G	KVRVTGIGKH	SI.GDIHFA.	DVLERMGARI
B. pertussis	EGDASTASYF	LALGA.IGGG	PVRVTGVGED	SIQGDVAFA.	ATLAAMGADV
Consensus	D-S-----	-----	-----	-----	-----MG-----

Figure 20

PG2982	EVLNARLAGG	EDVADLRR.	ASKLKGVVVP	PERAPSMIDE	YPVLAIAASF
LBAA	EVINARLAGG	EDVADLRR.	ASKLKGVVVP	PERAPSMIDE	YPVLAIAASF
Agrobacterium CP4	EVINPRLAGG	EDVADLRR.	SSTLKGVTVP	EDRAPS MIDE	YPLAVA AAF
B. subtilis	EIKPSADSGA	EPYGD LIE.	TSSLKAVEIG	GDII PRLIDE	IPITALLATO
S. aureus	QL. FNQQTG A	EPTASIRIQY	TPMLQPTTE	GELVPA KADE	LPVIALLCTQ
S. cerevisiae	... TQ TATS	TTVSGPPV..	... GTLKPLK	HVDMEPMTDA	FLTACVVAAT
A. nidulans	... EQ TETS	TTVVTG PSD..	... GILRATS	KRG YGGT. NDR	CVPRCFRTGS
B. napus	... SWTENS	VTVTG P S RDA	FGM RHL RAV.	DVN MNKMP DV	AMTLA VVAL F
A. thaliana	... SWTENS	VTVTG P P RDA	FGM RHL RAI.	DVN MNKMP DV	AMTLA VVAL F
I. esculentum	... TWTENS	VTVKG P P RNS	SGMKHL RAV.	DVN MNKMP DV	AMTLA VVAL F
P. hybrida	... TWTENS	VTVKG P P RSS	SGRKHL RAI.	DVN MNKMP DV	AMTLA VVAL Y
Z. mays	... TW TETS	VTVTG P P R E P	FGRKHL KAI.	DVN MNKMP DV	AMTLA VVAL F
S. gallinarum	... TWGDDF	I. .... A	CTR GEL HAI.	DMD MNH I P D A	AMTI A T T A L F
S. typhimurium	... TWGDDF	I. .... A	CTR GEL HAI.	DMD MNH I P D A	AMTI A T T A L F
S. typhi	... TWGDDF	I. .... A	CTR GEL HAI.	DMD MNH I P D A	AMTI A T T A L F
E. coli	... CWGDDY	I. .... S	CTR GEL NAI.	DMD MNH I P D A	AMTI A T A A L F
K. pneumoniae	... TWG D E Y	I. .... A	CTR GEL NAI.	DMD MNH I P D A	AMTI A T A A L F
Y. enterocolitica	... SWGDDY	I. .... E	CSR GEL QGI.	DMD MNH I P D A	AMTI A T T A L F
H. influenzae	... TWG D E F	I. .... Q	A E H A E L N G I.	DMD MNH I P D A	AMTI A T T A L F
F. multocida	... TWG D F F	I. .... Q	VEKG N L K G I.	DMD MNH I P D A	AMTI A T T A L F
A. salmonicida	... TWG D F F	I. .... E	A EQ G P L H G V.	DMD MNH I P D V	GHD HSG Q S H C
B. pertussis	... RY GPGW	I. ETR G V R V A E	GGR. . L K A F.	DAD FN L I P D A	AMTA A T T A L L A Y
Consensus	-----	-----	-----	-----	-----

Figure 20

PG2982	AEG . . . . .	ETVMDGLDEL RVKESDRLLA VARGLEANGV DCTEGEMSLT
LBAA	AEG . . . . .	ETVMDGLDEL RVKESDRLLA VARGLEANGV DCTEGEMSLT
<i>A. hydrocarbonic</i> CP4	AEG . . . . .	ATVMNGLEEL RVKESDRLLA VANGLKNGV DCDEGETSLV
<i>B. subtilis</i>	AEG . . . . .	TTVIKDAEL KVKEKNRIDT VVSELRLKG EIEPTADGM
<i>S. aureus</i>	AVG . . . . .	TSTIKDAEL KVKEKNRIDT TADMNLGF ELQOPTNDGLI
<i>S. cerevisiae</i>	SHDSDPNSAN	TTTIEGIANQ RVKECNRLA MATELAKFGV KTELPLPDGQ
<i>A. nidulans</i>	HIRPMEKSOTT	PPVSSGIANQ RVKECNRIKA MKDELAKEFGV ICREHDDGLE
<i>B. napus</i>	ADG . . . . .	PTTIRDVASW RVKETERMIA ICTELRKLGA TV . EGSDYC
<i>A. thaliana</i>	ADG . . . . .	PTTIRDVASW RVKETERMIA ICTELRKLGA TV . EGSDYC
<i>N. tabacum</i>	ADG . . . . .	PTAIRDVASW RVKETERMIA ICTELRKLGA TV . EGSDYC
<i>L. esculentum</i>	ADG . . . . .	PTTIRDVASW RVKETERMIA ICTELRKLGA TV . EGSDYC
<i>P. hybrida</i>	ADG . . . . .	PTAIRDVASW RVKETERMIA ICTELRKLGA TV . EGSDYC
<i>Z. mays</i>	ADG . . . . .	PTAIRDVASW RVKETERMVA IRTELTKLG SV . EGPDYC
<i>S. gallinarum</i>	AKG . . . . .	PTTIRNITYNW RVKETDRLFA MATELRKVGA EV . EGHDI
<i>S. typhimurium</i>	AKG . . . . .	PTTIRNITYNW RVKETDRLFA MATELRKVGA EV . EGHDI
<i>S. typhi</i>	AKG . . . . .	PTTIRNITYNW RVKETDRLFA MATELRKVGA EV . EGHDI
<i>E. coli</i>	AKG . . . . .	PTTIRNITYNW RVKETDRLFA MATELRKVGA EV . EGHDI
<i>K. pneumoniae</i>	ARG . . . . .	PTTIRNITYNW RVKETDRLFA MATELRKVGA EV . EGEDYI
<i>V. enterocolitica</i>	ADG . . . . .	PTVIRNINYW RVKETDRLSA MATELRKVGA EV . EGHDI
<i>H. influenzae</i>	SNG . . . . .	PTVIRNINYW RVKETDRLTA MATELRKVGA EV . EGEDFI
<i>P. multocida</i>	AEG . . . . .	PTVIRNINYW RVKETDRLTA MATELRKVGA EV . EGEDFI
<i>A. salmonicida</i>	IPR . . . . .	VPPHSQHLQL AVR.DRCTP CTHGRRÄQA GVSEEGTFI
<i>B. pertussis</i>	ADG . . . . .	PCRLRNIGSW RVKETDRIHA MTELEKLGA GV . QSGADWL
Consensus	-----	-----

Figure 20

P-G2982	VRGRRPDGKGL	G...GG...	T'VATHLDHRI	AMSFLVMGLA	.....A
LBAA	VRGRRPDGKGL	G...GG...	TVATHLDHRI	AMSFLVMGLA	.....A
<i>Agrobacterium</i> CP4	VRGRRPDGKGL	GNASGA...	AVATHLDHRI	AMSFLVMGLV	.....S
<i>B. subtilis</i>	VYGKQTLKG.	....GA	AVSSHGDHRI	GMLGIASCI	.....T
<i>S. aureus</i>	IHPSEFKTN.	....AT...	DI..LTDHRI	GMMLAVACVL	.....S
<i>S. cerevisiae</i>	VHGLNSIKDL	KVPSDSSGPV	GVCTYDDHRV	AMFSFSLLAGM	VNSQNERDEV
<i>A. nidulans</i>	IDGIDR..SNL	RQPVG...	GVFCYDDHRV	AFSFSLV..SL	VTPO...
<i>B. napus</i>	VIITP..PAKV	KPA.....	EIDTYDDHRM	AMAFSLAAC.	.....A
<i>A. thaliana</i>	VIITP..PKKV	KTA.....	EIDTYDDHRM	AMAFSLAAC.	.....A
<i>N. tabacum</i>	IITP..PEKL	NVT.....	EIDTYDDHRM	AMAFSLAAC.	.....A
<i>L. esculentum</i>	IITP..PEKL	NVT.....	EIDTYDDHRM	AMAFSLAAC.	.....A
<i>P. hybrida</i>	IITP..PEKL	NVT.....	DIDTYDDHRM	AMAFSLAAC.	.....A
<i>Z. mays</i>	IITP..PEKL	NVT.....	AIDTYDDHRM	AMAFSLAAC.	.....A
<i>S. gallininarum</i>	RIITP..PAKL	QHA.....	DIGTYNDHMRM	AMCFSLVAL.	.....S
<i>S. typhimurium</i>	RIITP..PAKL	QHA.....	DIGTYNDHMRM	AMCFSLVAL.	.....S
<i>S. typhi</i>	RIITP..PAKL	QHA.....	DIGTYNDHMRM	AMCFSLVAL.	.....S
<i>E. coli</i>	RIITP..PEKL	NFA.....	EIATYNDHMRM	AMCFSLVAL.	.....S
<i>K. pneumoniae</i>	RIITP..PLTL	QFA.....	EIGTYNDHMRM	AMCFSLVAL.	.....S
<i>Y. enterocolitica</i>	RVVP..PAQL	IAA.....	EIGTYNDHMRM	AMCFSLVAL.	.....S
<i>H. influenzae</i>	RIQPLALNQF	KHA.....	NIETYNDHMRM	AMCFSLIAL.	.....S
<i>P. multocida</i>	RIQPLALNQF	QHA.....	EINI..HDHRM	AMCFALIAL.	.....S
<i>A. salmonicida</i>	TRDAADPAQA	RRD.....	R..HLQRSRI	AMCFSLVAL.	.....S
<i>B. pertussis</i>	EVAPPPEPGGW	RDA.....	HIGTWDDHRM	AMCFLLAAF.	.....G
Consensus	.....	.....	.....	.....	.....

Figure 20

E'G2982	EVKPVTVDDSN	MIATSFPEFM	DMMPGLGAKI	ELSL...
LBA	EKPVTVDDSN	MIATSFPEFM	DMMPGLGAKI	ELSL...
<i>Agrobacterium</i> CP4	ENPVTVDDAT	MIATSFPEFM	DI.MAGLIGAKI	ELSDTKAA
<i>B. subtilis</i>	EEPIEIEHTD	AIHVSYPTFF	EHLNKLSKKS	.....
<i>S. aureus</i>	SEPVKIKQFD	AVNVSFPFGFL	PKIKLQQNEG	.....
<i>S. cerevisiae</i>	ANPVRILERH	CTGKTTWPGWW	DVLH.....	.....
<i>A. nidulans</i>	. PTLILEKE	CVGKTTWPGWW	DTLRQLFKV.	.....
<i>B. napus</i>	DVVPVTKDPG	CTRKTFFPDYF	QVLESITKH.	.....
<i>A. thaliana</i>	DVVPVITINDSG	CTRKTFFPDYF	QVLERITKH.	.....
<i>N. tabacum</i>	DVVPVTIKDPG	CTRKTFFPDYF	DVLQQYSKH.	.....
<i>I. esculentum</i>	DVVPVTIKNPG	CTRKTFFPDYF	EVI.QKYSKH.	.....
<i>P. hybrida</i>	DVVPVTINGPG	CTRKTFFPDYF	DVLQQYSKH.	.....
<i>Z. mays</i>	EVPVТИRDPG	CTRKTFFPDYF	DVLSTFVKN.	.....
<i>S. gallinarum</i>	DTPVPTILDPK	CTAKTFPDYF	EQLARMSTPA	.....
<i>S. typhimurium</i>	DTPVPTILDPK	CTAKTFPDYF	EQLARMSTPA	.....
<i>S. typhi</i>	DTPVPTILDPK	CTAKTFPDYF	EQLARMSTPA	.....
<i>E. coli</i>	DTPVPTILDPK	CTAKTFPDYF	EQLARISQAA	.....
<i>K. pneumoniae</i>	DTPVPTILDPK	CTAKTFPDYF	GOLARISTLA	.....
<i>V. enteroercolitica</i>	DTPVPTILDPK	CTAKTFPDYF	EQLARLSQIA	.....
<i>H. influenzae</i>	NTPVPTILDPK	CTAKTFPTFF	NEFE...KI	CLKN...
<i>P. multocida</i>	KTSVTILDPS	CTAKTFPTFL	TIFTLNTRREV	AYR...
<i>A. salmonicida</i>	DIAVITNDPG	CTSKTFPDYF	DKIASVSQAV	.....
<i>B. pertussis</i>	DAAVRLDPG	CVSKTFPDYF	DVYAGLLAAR	D.....
Consensus	.....	.....	.....	.....

Figure 20

AAC' AAT' CAT CAA TCC CAT CAA CGC TTA ACT GTP' AAT CCC CCT GCC CAA	340
Asn Asn. His Gln Ser His Gln Arg Leu Thr Val Asn Pro Pro Ala Gln	20
10	
Gly Val Ala Leu Thr Gly Arg Leu Arg Val Pro Gly Asp Lys Ser Ile	388
25	
TCC CAT CGG GCC TTG ATG TTG GGG GCG ATC GCC ACC GGG GAA ACC ATT	436
Ser His Arg Ala Leu Met Ile Gly Ala Ile Ala Thr Gly Glu Thr Ile	50
40	
A'IC GAA GGG C'IA C'IG 'I'IG GGG GAA GAT CCC C'GI AGI' ACG GCC CAT TGC	484
Tle Glu Gly Leu Ile Ile Gly Glu Asp Pro Arg Ser Thr Ala His Cys	70
55	
60	
65	
70	

**Figure 21**

**SHEET 1 OF 5**

I <sup>m</sup> I <sup>m</sup> I <sup>m</sup>	GGG	GCC	ATG	GGA	UCA	GAA	ATC	AGC	GAA	AAT	TCA	GAA	AAA	ATC	532
Phe	Arg	Ala	Met	Gly	Ala	Glu	Ile	Ser	Glu	Leu	Asn	Ser	Glu	Lys	Ile
75															85
ATC	GTT	CAG	GGT	CGG	GGT	CTG	GGA	CAG	TTG	CAG	GAA	CCC	AGT	ACC	GTT
Ile	Val	Gln	Gly	Arg	Gly	Leu	Gly	Gln	Leu	Gln	Glu	Pro	Ser	Thr	Val
90															100
I <sup>m</sup> I <sup>m</sup> G	GAT	GCG	GUG	AAC	I <sup>m</sup> CT	GGC	ACC	ACC	ATG	CGC	I <sup>m</sup> TA	ATG	T <sup>m</sup> TG	GGC	T <sup>m</sup> TG
I <sup>m</sup> eu	Asp	Ala	Gly	Asn	Ser	Gly	Thr	Thr	Met	Arg	Leu	Met	Leu	Gly	Leu
105															628
C <sup>m</sup> TA	GCC	GGG	CAA	AAA	GAT	TGT	TTA	TTC	ACC	GTC	ACC	GGC	GAT	GAT	TCC
I <sup>m</sup> eu	Ala	Gly	Gln	I <sup>m</sup> ys	Asp	Cys	Leu	Phe	Thr	Val	Thr	Gly	Asp	Asp	Ser
120															676
C <sup>m</sup> TC	C <sup>m</sup> TC	CAC	CGC	CCC	ATG	TCC	CGG	GTA	ATT	CAA	CCC	TTG	CAA	CAA	ATG
I <sup>m</sup> eu	Arg	His	Arg	Pro	Met	Ser	Arg	Val	Ile	Gln	Pro	Leu	Gln	Gln	Met
135															724
G <sup>m</sup> GG	GCA	AAA	AT <sup>m</sup> T	TGG	G <sup>m</sup> CC	CGG	AGT	AAC	G <sup>m</sup> CC	AAG	T <sup>m</sup> TT	GCG	CCG	CTG	GCA
Gly	Ala	Iys	Ile	Trp	Ala	Arg	Ser	Asn	Gly	Iys	Phe	Ala	Pro	Ieu	Ala
155															772
G <sup>m</sup> TC	CAG	GCT	AGC	CAA	I <sup>m</sup> IA	AAA	CCG	ATC	CAT	TAC	CAT	TCC	CCC	ATT	GCT
Val	Gln	Gly	Ser	Gln	Ieu	Lys	Pro	Ile	His	Tyr	His	Ser	Pro	Ile	Ala
170															820
175															180

**Figure 21**

**SHEET 2 OF 5**

TCA	GCC	CAG	GTA	AAG	TCC	TGC	CTG	TTG	CTA	GCG	GGG	TTA	ACC	ACC	GAG	868
Ser	Ala	Gln	Val	Iys	Ser	Cys	Leu	Leu	Leu	Ala	Gly	Leu	Thr	Thr	Gl	
185																195
GGG	GAC	ACC	ACG	GTG	ACA	GAA	CCA	GCT	CTA	TCC	CGG	GAT	CAT	AGC	GAA	916
Gly	Asp	Thr	Thr	Val	Thr	Glu	Pro	Ala	Leu	Ser	Arg	Asp	His	Ser	Gl	
200																210
CCG	AAC	TTG	CAG	GCC	TAT	GGA	GCC	AAA	TAA	ACC	ATT	GAT	CCA	GTA	ACC	964
Arg	Met	Leu	Gln	Ala	Phe	Gly	Ala	Lys	Leu	Thr	Ile	Asp	Pro	Val	Thr	
215																230
CAT	AGC	GTC	ACT	GTC	CAT	GGC	CCG	GCC	CAT	TTA	ACG	GGG	CAA	CGG	GTG	1012
His	Ser	Val	Thr	Val	His	Gly	Pro	Ala	His	Leu	Thr	Gly	Gln	Arg	Val	
235																245
GTC	GTG	CCA	GGG	GAC	ATC	AGC	TCG	GCG	GCC	TAT	TGG	TTA	GTG	GCG	GCA	1060
Val	Val	Pro	Gly	Asp	Ile	Ser	Ser	Ala	Ala	Phe	Trp	Leu	Val	Ala	Ala	
250																260
TCC	ATG	TIG	CCT	GGA	TCA	GAA	TTG	TTG	GAA	AAT	GTA	GCG	ATT	AAC		1108
Ser	Ile	Ileu	Pro	Gly	Ser	Glu	Leu	Leu	Val	Glu	Asn	Val	Gly	Ile	Asn	
265																275
CCC	ACC	AGG	ACA	GGG	GTG	TTG	GAA	GTG	TTG	GCC	CAG	ATG	GGG	GCG	GAC	1156
Pro	Thr	Arg	Thr	Gly	Val	Leu	Glu	Val	Leu	Ala	Gln	Met	Gly	Ala	Asp	
280																290

**Figure 21**

**SHEET 3 of 5**

A'P'	ACC	CCG	GAG	AA'P'	GAA	CGA	T'TG	GTA	ACG	GGG	GAA	CCG	GTA	GCA	GAT	1204
T'le	Thr	Pro	Glu	Asn	Glu	Arg	Leu	Val	Thr	Gly	Glu	Pro	Val	Ala	Asp	310
295																
C'P'	CGG	GTT	AGG	GCA	AGC	CAT	CTC	CAG	GGT	T'GC	ACC	TTC	GGC	GGC	GAA	1252
I'eu	Arg	Val	Arg	Ala	Ser	His	Leu	Gln	Gly	Cys	Thr	Phe	Gly	Gly	Glu	
300																
A'P'	A'P'	CCC	CGA	C'P'	A'P'	GAT	GAA	ATT	CCC	ATT	T'TG	GCA	GTC	GCG	GCG	
I'le	I'le	Pro	Arg	Leu	I'le	Asp	Glu	I'le	Pro	I'le	Leu	Ala	Val	Ala	Ala	
305																
G'CC	T'P'	GCA	GAG	GCC	AC'P'	ACC	CGC	ATT	GAA	GAT'	GCC	GCA	GAA	CTG	AGG	
Ala	Phe	Ala	Glu	Gly	Thr	Thr	Arg	I'le	Glu	Asp	Ala	Ala	Glu	Leu	Arg	1300
310																
315																
G'P'	AAA	GAA	AGC	GAT'	C'GC	CTG	GCG	GCC	ATT	GCT	T'CG	GAG	T'TG	GCG	AAA	
Val	Lys	Glu	Ser	Asp	Arg	Leu	Ala	Ala	I'le	Ala	Ser	Glu	Leu	Gly	Lys	1348
320																
325																
A'P'	G'G	GCC	AAA	G'P'	ACC	GAA	T'P'	GAT	GAT	G'GC	C'P'	GAA	ATT	CAA	GGG	
Met	Gly	Ala	Lys	Val	Thr	Glu	Phe	Asp	Asp	Gly	I'eu	Glu	I'le	Gln	Gly	1444
330																
335																
G'P'	AGC	CCC	T'P'	C'AA	C'P'	GCC	GAG	GTG	GAT	AGC	T'TG	ACG	GAT	CAT	CGC	1492
Gly	Ser	Pro	I'eu	Gln	Gly	Ala	Glu	Val	Asp	Ser	Leu	Thr	Asp	His	Arg	
340																
345																
G'P'	AAA	GAA	AGC	GAT'	C'GC	CTG	GCG	GCC	ATT	GCT	T'CG	GAG	T'TG	GCG	AAA	
Val	Lys	Glu	Ser	Asp	Arg	Leu	Ala	Ala	I'le	Ala	Ser	Glu	Leu	Gly	Lys	1396
350																
355																
A'P'	G'G	GCC	AAA	G'P'	ACC	GAA	T'P'	GAT	GAT	G'GC	C'P'	GAA	ATT	CAA	GGG	
Met	Gly	Ala	Lys	Val	Thr	Glu	Phe	Asp	Asp	Gly	I'eu	Glu	I'le	Gln	Gly	390
360																
365																
A'P'	G'G	GCC	AAA	G'P'	ACC	GAA	T'P'	GAT	GAT	G'GC	C'P'	GAA	ATT	CAA	GGG	
Met	Gly	Ala	Lys	Val	Thr	Glu	Phe	Asp	Asp	Gly	I'eu	Glu	I'le	Gln	Gly	395
370																
375																
A'P'	G'G	GCC	AAA	G'P'	ACC	GAA	T'P'	GAT	GAT	G'GC	C'P'	GAA	ATT	CAA	GGG	
Met	Gly	Ala	Lys	Val	Thr	Glu	Phe	Asp	Asp	Gly	I'eu	Glu	I'le	Gln	Gly	400
380																
385																
G'P'	AGC	CCC	T'P'	C'AA	C'P'	GCC	GAG	GTG	GAT	AGC	T'TG	ACG	GAT	CAT	CGC	
Gly	Ser	Pro	I'eu	Gln	Gly	Ala	Glu	Val	Asp	Ser	Leu	Thr	Asp	His	Arg	405
390																
395																

**Figure 21**

**SHEET 4 OF 5**

A'P'P' G'C' A'G GCG T'G G'G ATC GCG GCT TTA GGT AGT GGG GGG CAA ACA	1540	
Ile Ala Met Ala Leu Ala Ile Ala Ala Leu Gly Ser Gly Gly Gln Thr		
410	415	420
A'P'P' ATT AAC CGG GCG GAA GCG GCC GCC ATT TCC TAT CCA GAA TTT TTT	1588	
Ile Ile Asn Arg Ala Glu Ala Ala Ala Ile Ser Tyr Pro Glu Phe Phe		
425	430	435
G'G'C ACG C'P'A GGG CAA G'P'T GCC CAA GGA TAAAGTTAGA AAAACTCCCTG	1635	
Gly Thr Leu Gly Gln Val Ala Gln Gly		
440	445	
G'G'G'G'P'P'TG'T AAATGTT'P'P'A CCAAGGTTAGT TTGGGGTAA GGCCGCCAGCA AGTGCTGCCA	1695	
G'G'P'AA'P'P'A 'P'CCGCAA'P'G ACCAATCGGC ATGGACCGTA TCGTTCAAAC TGGGTTAAATTC	1755	
'P'CC'P'P'AA'P' TCCTTAAAG CTCGCTTAAA ACTGCCAAC GTATCTCCGT AATGGCGAGT	1815	
G'AG'P'AG;AAG'P' AT'GGGGC'CA AACGGCGATC GCCACGGGAA ATTAAAGCCT GCATCACTGA	1875	
C'P'AC'P'P'AT'AA C'P'P'ICGGGGA	1894	
•		

**Figure 21**    *sheet 5 of 5*

'T'P'AAAAC' A'TGAGT'P'AA'A	AAATTAT'P' TCTGGCACAC	GCCTT'TT'TT	TGCAT'TT'TT	60
'T'P'CCCA'P'P'P' 'T'CCGGCACAA	'T'AACGTTGGT TTTATAAAG	GAAATG ATG ATG ACG	Met Met Thr	115
ATP' ATP' TGG CAC ACC GCG CCC GTC TCT GCG CTP' TCC GGC GAA ATA ACG	163			
Asn Ile Trp His Thr Ala Pro Val Ser Ala Leu Ser Gly Glu Ile Thr				
5	10	15		
ATP' TGC GGC GAT AAA 'T'P'ATG TCG CAT CGC GCC TPA TPA TPA GCA GCG	211			
Ile Cys Gly Asp Lys Ser Met Ser His Arg Ala Ile Leu Leu Ala Ala				
20	25	30	35	
'T'P'ATG GCA GAA GGA CAA ACC GAA ATC CGC GGC TTP' TPA GCG TGC GCG GAT	259			
Ileu Ala Ala Glu Gly Gln Thr Glu Ile Arg Gly Phe Leu Ala Cys Ala Asp				
40	45	50		
TGT TTG GCG ACG CGG CAA GCA TTG CGC GCA TTA GGC GTT GAT ATT CAA	307			
CYS Ileu Ala Ala Thr Arg Gln Ala Leu Arg Ala Leu Gly Val Asp Ile Gln				
55	60	65		
AGA GAA AAA GAA ATA GTG ACG ATT CGC GGT GTG GGA TTT CTG GGT TTG	355			
Arg Glu Lys Glu Ile Val Thr Ile Arg Gly Val Gly Phe Leu Gly Leu				
70	75	80		

## Figure 22

sheet 1 of 5

CAG	CCG	CCG	AAA	GCA	CUG	TTA	AAT	ATG	CAA	AAC	AGT	GGC	ACT	AGC	ATG	403
Gln	Pro	Pro	Lys	Ala	Pro	Leu	Asn	Met	Gln	Asn	Ser	Gly	Thr	Ser	Met	
85									90			95				
CGT	T <sup>TA</sup> A	TTG	GCA	GGA	A <sup>TT</sup> T	TTG	GCA	GCG	CAG	CGC	TTT	GAG	AGC	GTG	T <sup>TA</sup>	451
Arg	Leu	Leu	Ala	Gly	Ile	Leu	Ala	Ala	Gln	Arg	Phe	Glu	Ser	Val	Leu	
100					105						110				115	
I <sup>TC</sup> C	G <sup>GC</sup> C	GAT	GAA	TCA	T <sup>TA</sup> A	GAA	AAA	CGT	CCG	ATG	CAG	CGC	ATT	ATT	ACG	
Cys	Gly	Asp	Glu	Ser	Leu	Glu	Lys	Arg	Pro	Met	Gln	Arg	Ile	Ile	Thr	
					120				125				130			499
CCG	C <sup>TT</sup> T	GTG	CAA	A <sup>TT</sup> G	GGG	GCA	AAA	ATT	GTC	AGT	CAC	AGC	AAT	TTT	ACG	
Pro	Leu	Val	Gln	Met	Gly	Ala	Lys	Ile	Val	Ser	His	Ser	Asn	Phe	Thr	547
					135				140				145			
G <sup>CG</sup> G	CCG	T <sup>TA</sup> A	CAT	AT <sup>TT</sup> T	I <sup>TC</sup> A	GGA	CGC	CCG	CTG	ACC	GGC	ATT	GAT	TAC	GCG	
Ala	Pro	Leu	His	Ile	Ser	Gly	Arg	Pro	Leu	Thr	Gly	Ile	Asp	Tyr	Ala	
					150				155				160			595
T <sup>TA</sup> A	CCG	C <sup>TT</sup> T	CCC	AGC	GCG	CAA	T <sup>TA</sup> A	AAA	AGT	TGC	CTT	ATT	TTG	GCA	GGA	
I <sup>eu</sup>	Pro	Leu	Pro	Ser	Ala	Gln	Leu	Lys	Ser	Cys	Leu	Ile	Leu	Ala	Gly	
					165				170				175			643
T <sup>TA</sup> A	T <sup>TT</sup> G	GCT	GAC	GGT	ACG	ACC	CGG	CTG	CAT	ACT	TGC	GGC	ATC	AGT	CGC	
I <sup>eu</sup>	Leu	Leu	Ala	Asp	Gly	Thr	Thr	Arg	Leu	His	Thr	Cys	Gly	Ile	Ser	
					180				185				190			691
															195	

**Figure 22**

**SHEET 2 OF 5**

GAC	CAC	ACG	GAA	CGC	A <sup>r</sup> G	T <sup>r</sup> TG	CCG	C <sup>r</sup> T	T <sup>r</sup> T	GGT	GGC	GCA	C <sup>r</sup> T	GAG	ATC	739
Asp	His	Thr	Glu	Arg	Met	Leu	Pro	Leu	Phe	Gly	Gly	Ala	Leu	Glu	Ile	
																200
AAG	AAA	GAG	CAA	ATA	ATC	GTC	ACC	GGT	GGA	CAA	AAA	TTG	CAC	GGT	TGC	787
Lys	Lys	Glu	Gln	Ile	Ile	Val	Thr	Gly	Gly	Gln	Lys	Leu	His	Gly	Cys	
																215
G <sup>r</sup> G	C <sup>r</sup> T <sup>r</sup>	GAT <sup>r</sup>	A <sup>r</sup> T <sup>r</sup>	GTC	GGC	GAT	T <sup>r</sup> TG	TCG	GCG	GCG	GCG	T <sup>r</sup> T	T <sup>r</sup> T	ATG	G <sup>r</sup> T <sup>r</sup>	835
Val	Leu	ASP	Ile	Val	Gly	Asp	Leu	Ser	Ala	Ala	Ala	Phe	Phe	Met	Val	
																230
GCG	GCT <sup>r</sup>	T <sup>r</sup> TG	ATT	GCG	CCG	CGC	GCG	GAA	GTC	GTT	ATT	CGT	AAT	GTC	GCG	883
Ala	Ala	Leu	Ile	Ala	Pro	Arg	Ala	Glu	Val	Val	Ile	Arg	Asn	Val	Gly	
																245
A <sup>r</sup> T <sup>r</sup>	A <sup>r</sup> T <sup>r</sup>	CCG	ACG	CGG	GCG	GCA	ATC	ATT	ACT	T <sup>r</sup> TG	T <sup>r</sup> TG	CAA	AAA	ATG	GCG	931
Ile	Asn	Pro	Thr	Arg	Ala	Ala	Ile	Ile	Thr	Leu	Ile	Gln	Lys	Met	Gly	
																260
G <sup>r</sup> A	CGG	ATT	GAA	T <sup>r</sup> TG	CAT <sup>r</sup>	CAT	CAG	CGC	TTT	TGG	GGC	GCC	GAA	CCG	GTG	979
Gly	Arg	Ile	Glu	Ile	His	His	Gln	Arg	Phe	Trp	Gly	Ala	Glu	Pro	Val	
																280
GCA	GAT	AT <sup>r</sup> T	G <sup>r</sup> T <sup>r</sup>	G <sup>r</sup> T <sup>r</sup>	TAT	CAT	TCA	AAA	T <sup>r</sup> TG	GCG	GCG	ATT	ACG	GTG	GCG	1027
Ala	Asp	Ile	Val	Val	Tyr	His	Ser	Lys	Leu	Arg	Gly	Ile	Thr	Val	Ala	
																295
																300
																305

**Figure 22**

**SHEET 3 OF 5**

CCG	GAA	TGG	ATT	GCC	AAC	GCG	ATT	GAT	GAA	TTC	CCG	ATT	TTT	TTT	ATT		1075
Pro	Glu	Trp	Ile	Ala	Asn	Ala	Ile	Asp	Glu	Leu	Pro	Ile	Phe	Phe	Ile		
310											315						320
GCG	GCA	GCT	TGC	GCG	GAA	GGG	ACG	ACT	TTT	GTG	GGC	AAT	TTC	TCA	GAA		1123
Ala	Ala	Ala	Cys	Ala	Glu	Gly	Thr	Thr	Phe	Val	Gly	Asn	Leu	Ser	Glu		
325											330						335
TTC	CCT	GTC	AAA	GAA	TTC	GAT	CGT	TTA	GCG	GCG	ATG	GCG	CAA	AAT	TTC		1171
Leu	Arg	Val	Lys	Glu	Ser	Asp	Arg	Leu	Ala	Ala	Met	Ala	Gln	Asn	Ile		
340											345						350
																	355
CAA	ACT	TTC	GGC	GTG	GCG	TGC	GAC	GTT	GCC	GCC	GAT	TTT	ATT	CAT	ATA		1219
Gln	Thr	Leu	Gly	Val	Ala	Cys	Asp	Val	Gly	Ala	Asp	Phe	Ile	His	Ile		
360									365								370
TAT	GGA	AGA	AGC	GAT	CGG	CAA	TTC	TTC	CCG	CCG	CGG	GTG	AAC	AGT	TTC		1267
Tyr	Gly	Arg	Ser	Asp	Arg	Gln	Phe	Leu	Pro	Ala	Arg	Val	Asn	Ser	Phe		
375									380								385
GCG	GAT	CAT	CGG	ATT	GCG	ATG	AGT	TTC	GCG	GCA	GGT	GTG	CGC	GCG			1315
Gly	Asp	His	Arg	Ile	Ala	Met	Ser	Leu	Ala	Val	Ala	Gly	Val	Arg	Ala		
390									395								400
GCA	GGT	GAA	TTA	TTC	ATT	GAT	GAC	GGC	GGC	GTG	GCG	GGT	GTG	TCT	ATG		1363
Ala	Gly	Glu	Leu	Leu	Ile	Asp	Asp	Gly	Ala	Val	Ala	Ala	Val	Ser	Met		
405									410								415

**Figure 22**

**SHEET 4 OF 5**

CCG CAA TTT CGC GAT TTT GCC GCC GCA ATT GGT ATG AAT GTA GGA GAA 1411  
Pro Gln Phe Arg Asp Phe Ala Ala Ala Ile Gly Met Asn Val Gly Glu  
420 425 430 435  
Asp GAT GCG AAA AAT TGT CAC GAT TGATGGTCCT AGCGGTGTTG GAAAAGGCAC 1465  
Lys Asp Ala Lys Asn Cys His Asp  
440  
GCGGGCAA GCTT 1479

## Figure 22

SHEET 5 OF 5

Figure 23 SHEET 1 OF 4

PG2982	TY . DMKTSFI	GDASLSKRPM	GRVLNPLREM	GVQVEADGD
LBAA	TY . DMKTSFI	GDASLSKRPM	GRVLNPLREM	GVQVEADGD
Agrobacterium CP4	VY . DFDSTFI	GDASLTKRPM	GRVLNPLREM	GVQVKSEDDG
Synechocystis sp. PCC6803	GQKDCLFTVT	GDDSLRHRPM	SRVIQPLQQM	GAKIWARSNG
B. subtilis	G.RPFYSAVA	GDESIAKRPM	KRVTEPLKKM	GAKIDGRAGG
D. nodosus	AQR.FESVLC	GDESLEKRP	QRIITPLVQM	GAKIVSHSNF
S. aureus	GLGN.ESVLS	GDVSIGKRP	DRVLRPLKLM	DANIEGIEDN
Consensus	-----	GD-S---RPM	-RV--PL--M	---I-----
161				200
PG2982	RMPLTLIGPK	TANPITYRVP	MASAQVSAV	LLAGLNTPGV
LBAA	RMPLTLIGPK	TANPITYRVP	MASAQVSAV	LLAGLNTPGI
Agrobacterium CP4	RLPVTLRGPK	TPTPITYRVP	MASAQVSAV	LLAGLNTPGI
Synechocystis sp. PCC6803	KFAPIAVQGS	QLKPIHYHSP	IASAQVKSC	LLAGLTTEGD
B. subtilis	EFTPILSVSGA	SLKGIDYVSP	VASAQIKSAV	LLAGLQAEGT
D. nodosus	T.APLHISGR	PLTGIDYALP	LPSAQLKSC	LLAGLLADGT
S. aureus	.YTPPLIKPS	VIKGINVQME	VASAQVKS	LFASLFSKEP
Consensus	-----	I-Y---	--SAQ-KS--	-LA-L-----
201				240
PG2982	TTVIEPVMT	DHTEKMLQGF	....GADLT	VETDKDGVRH
LBAA	TTVIEPVMT	DHTEKMLQGF	....GADLT	VETDKDGVRH
Agrobacterium CP4	TTVIEPIMTR	DHTEKMLQGF	....GANLT	VETDADGVRT
Synechocystis sp. PCC6803	TTVTEPALSR	DHSERMLQAF	....GAKLT	IDPVTHSV..
B. subtilis	TTVTEPHKSR	DHTERMLSAF	....GVKLS	EDQT..SV..
D. nodosus	TRLHTCGISR	DHTERMLPF	....GGALE	IKK..EQI..
S. aureus	TIKELDVSR	NHTETMFKH	NIPIEAEGLS	INTTPEAIRY
Consensus	T-----R	-H-E-ML--F	-----L-	-----V--

Figure 23

SHEET 2 OF 4

PG2982	241	IRITGQGKLV GQTIDVPGDP SSTAFLVAA LLVEGSDVTI	280
LBAA		IRITGQGKLV GQTIDVPGDP SSTAFLVAA LLVEGSDVTI	
Agrobacterium CP4		IRLEGRGKLT GQVIDVPGDP SSTAFLVAA LLVEGSDVTI	
Synechocystis sp. PCC6803		.TVHGP AHLT GQRVWPGDI SSAFLVAA SILPGSELLV	
B. subtilis		.SIAGGQKLT AADIFVPGDI SSAFFLAA AMVPSRIVL	
D. nodosus		.IVTGGQKLH GCVLDIVGDL SAAFFMVAA LIAPRAEVVI	
S. aureus		IKPAD. .... .FHVPGDI SSAFFTIVAA LITPGSDVTI	
Consensus		-----V-GD- S--AF--A- -----	
PG2982	281	RNVLMNPTRT GLILTLQEMG ADIEVNARL AGGEDVADLR	320
LBAA		RNVLMNPTRT GLILTLQEMG ADIEVNARL AGGEDVADLR	
Agrobacterium CP4		LNVLNMNPTRT GLILTLQEMG ADIEVNARL AGGEDVADLR	
Synechocystis sp. PCC6803		ENVGINPRTT GVLEVLAQMG ADITPENERL VTGEPVADLR	
B. subtilis		KNVGLNPTRT GLIDVLQNMG AKLEIKPSAD SGAEPYGDLL	
D. nodosus		RNVGINPTRA AITLLQKMG GRIELHHQRF WGAEPVADIV	
S. aureus		HNVGINQTRS GIIDIVEKMG GNIQLFNQT. TGAEPTASIR	
Consensus		-NV--N-TR- -----MG -----E-----	
PG2982	321	VR.ASKLKGV VVPPERAPSM IDEYPVLAIA ASFAEGETVM	360
LBAA		VR.ASKLKGV VVPPERAPSM IDEYPVLAIA ASFAEGETVM	
Agrobacterium CP4		VR.SSTLKGV TVPEDRAPSM IDEYPLAVA AAFAGEATVM	
Synechocystis sp. PCC6803		VR.ASHLQGC TFGGEIIPRL IDEIPLAVA AAFAGEGTRI	
B. subtilis		IE.TSSLKAV EIGGDIIPRL IDEIPIALL ATQAEGTIVI	
D. nodosus		VY.HSKLRGI TVAPEWIANA IDELPIFFIA AACAEGTTFV	
S. aureus		IQYTPMLQPI TIEGELVPKA IDELPVIALL CTQAVGTTSTI	
Consensus		V-----L-----E----- IDE-PI----- A-G-----	

**Figure 23** SHEET 3 OF 4

		361	
PG2982	DGLDELRLVKE	SDRLAAVARG	LEANGVDCTE
LBAA	DGLDELRLVKE	SDRLAAVARG	GEMSLTVRGR
Agrobacterium CP4	NGLEELRVKE	SDRLSAVANG	LEANGVDCTE
Synechocystis sp. PCC6803	EDAAELRVKE	SDRLAAIASE	GEMSLTVRGR
B. subtilis	KDAELKVKE	TNRIDTVVSE	LKLNGVDCDE
D. nodosus			GETSLWVRGR
S. aureus			FDDGLEIQQG
Consensus			TADGMKVYGR
	-----EL-VKE	--R-----	G-----
			-----V---
		401	
PG2982	PDGKGLG...	GGIIVATHLDH	RIAMSLVVMG
LBAA	PDGKGLG...	GGTVATHLDH	RIAMSLVVMG
Agrobacterium CP4	PDGKGLGNAS	GAAVATHLDH	RIAMSLVVMG
Synechocystis sp. PCC6803	SPLQ.....	GAEVDSLTDH	RIAMALIAAA
B. subtilis	QTLK.G....	GAAVSSHGDH	RIGMLIGTAS
D. nodosus	SDRQFL....	PARVNSFGDH	CITEEPIEIE
S. aureus	E.....FK	TNATDILTDH	RIAMSLAVAG
Consensus	-----	-----DH	VRAAGELLID
			VLSSSEPVKIK
		441	
PG2982	DSNMIATSFP	EFMDMMPGLG	AKIELSIL...
LBAA	DSNMIATSFP	EFMDMMPGLG	AKIELSIL...
Agrobacterium CP4	DATMIATSFP	EFMDIMAGLG	AKIELSDTKA
Synechocystis sp. PCC6803	RAEAAATSYF	EFFGTLGQVA	QC*
B. subtilis	HTDAIHVSYP	TFFEHLNKL	S KKS.....
D. nodosus	DGAVAAVSMP	QFRDFAAAIG	MNVGEKDAKN
S. aureus	QFDAVNVSFP	GFLPKLKLQ	CHD NEG.....
Consensus	-----S-P	-F-----	-----
		473	

**Figure 23**

SHEET 4 OF 4




Figure 24




Figure 25

**APPLICATION FOR UNITED STATES PATENT**  
**DECLARATION \* POWER OF ATTORNEY \* PETITION**

AS A BELOW-NAMED INVENTOR, I hereby declare that:  
MY RESIDENCE, citizenship, and post office address are as stated below,  
next to my name.

I BELIEVE I am:

1.  the original, first and sole inventor,
2.  an original, first and joint inventor,

of the subject matter which is claimed and for which  
a patent is sought on the invention entitled

3. **GLYPHOSATE TOLERANT 5-ENOLPYRUVYLSHIKIMATE-3-PHOSPHATE SYNTHASES,**

the specification of which, with any Preliminary Amendment,

4.  is attached hereto

5.  was filed on

- 5(a). as application Serial No.

6.  including Amendment(s) filed on \_\_\_\_\_ (date)  
and \_\_\_\_\_ (date)

7.  together with any Amendment(s) filed herewith.

I HEREBY STATE that I have reviewed and understand the contents of the  
above-identified Specification, including the Claims, as amended by any Amendment(s)  
referred to above.

I ACKNOWLEDGE my Duty to Disclose information of which I am aware  
which is material to the Examination of this Application in accordance with Title 37, Code  
of Federal Regulations, §1.56(a) including any such information which occurred between  
the filing date of any prior application listed below for which the benefit of Title 35, United  
States Code §120 is claimed and the filing date of this Application.

I HEREBY STATE that the subject matter which is claimed in any  
Amendment(s) referred to above was part of my or our invention and was invented before  
the filing of this Application.

**BENEFIT OF EARLIER FILING DATE**

THIS APPLICATION in whole or in part discloses and claims subject  
matter disclosed in and I hereby claim the benefit under Title 35, United States Code,  
§120 of any of my or our prior United States application(s) listed below:

	<u>SERIAL NO.</u>	<u>FILING DATE</u>	<u>STATUS</u>
8.	<u>07/749.611</u>	<u>08-28-91</u>	<u>Pending</u>
	<u>07/576.537</u>	<u>08-31-90</u>	<u>Abandoned</u>

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or Inventor's Certificate(s) listed below:

	<u>NUMBER</u>	<u>COUNTRY</u>	<u>FILING DATE</u>
9.	_____	_____	_____

Any foreign application(s) for patent or Inventor's Certificate(s) filed by me or us which claims or discloses all or any part of the subject matter claimed in this Application and which has a filing date before that of the above-listed application(s) on which foreign priority is claimed is identified below:

	<u>NUMBER</u>	<u>COUNTRY</u>	<u>FILING DATE</u>
10.	_____	_____	_____

AS TO ANY subject matter which is claimed in this Application which is not common to any above-identified prior application(s) for which the benefit of 35 USC §119 or §120 is claimed, I do not know and do not believe that the same was ever known or used in the United States before my or our invention or discovery thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the date of this Application, or in public use or on sale in the United States more than one year prior to the date of this Application, that said subject matter has not been patented or made the subject of an Inventor's Certificate issued before the date of this Application in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to this Application.

AS TO ANY subject matter which is claimed in this Application which is common to any above-identified prior application(s) for which the benefit of 35 USC §120 is claimed, I do not know and believe that the same was ever known or used in the United States before my or our invention or discovery thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the earliest of said prior application(s) to which said subject matter is common, or in public use or on sale in the United States more than one year prior to the earliest of said prior application(s) to which said subject matter is common, that said subject matter has not been patented or made the subject of an Inventor's Certificate issued before the date of the earliest of said prior application(s) to which said subject matter is common in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the earliest of said prior application(s) to which said subject matter is common.

11.  ALL APPLICATION(S), if any, for patent or Inventor's Certificate on any part of said subject claimed in this Application filed by me or my representatives or assigns in any country foreign to the United States of America in addition to any listed above on which priority is claimed are listed in Annex A, attached hereto.

I HEREBY appoint the following as my attorney(s) and/or agent(s) of record with full power of substitution and revocation to prosecute this Application and to transact all business in the Patent and Trademark Office connected therewith.

12. Dennis R. Hoerner, Jr. Reg. No. 30,914  
Richard H. Shear Reg. No. 26,583  
James C. Bolding Reg. No. 26,843  
Grace L. Bonner Reg. No. 32,963  
Lawrence M. Lavin, Jr. Reg. No. 30,768

ALL correspondence/telephone calls in connection with this Application should be directed to:

13. Dennis R. Hoerner, Jr. - BB4F  
MONSANTO COMPANY  
700 Chesterfield Parkway North  
St. Louis, Missouri 63198  
13(a). Telephone Number: (314) 537-6099

I FURTHER declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

WHEREFORE, I PRAY that Letters Patent be granted to me solely or jointly with the additional inventor(s) (if any) named below for the invention described and claimed in the above-identified specification and claims, and I hereby subscribe my name to the above-identified specification and claims, Declaration, Power of Attorney and this Petition.

14(a). SOLE or FIRST JOINT INVENTOR,  
full name: Gerard Francis Barry

RESIDENCE (State/Country): Missouri/United States

CITIZENSHIP: Republic of Ireland

POST OFFICE ADDRESS: 6350 Waterman Avenue  
St. Louis, Missouri 63130

INVENTOR'S SIGNATURE: Gerard Francis Barry

DATE: September 13, 1994

14(b). SECOND JOINT INVENTOR (if any), full name: Ganesh Murthy Kishore  
RESIDENCE (State/Country): Missouri/United States  
CITIZENSHIP: United States  
POST OFFICE ADDRESS: 15354 Grantley Drive  
Chesterfield, Missouri 63017  
INVENTOR'S SIGNATURE: Ganesh murthy Kishore  
DATE: September 13, 94

14(c). THIRD JOINT INVENTOR (if any), full name: Stephen Rogers Padgett  
RESIDENCE (State/Country): Missouri/United States  
CITIZENSHIP: United States  
POST OFFICE ADDRESS: 553 Nantucket Pointe Drive  
Grover, Missouri 63040  
INVENTOR'S SIGNATURE: Stephen Rogers Padgett  
DATE: September 13, 1994

14(c). FOURTH JOINT INVENTOR (if any), full name: William Carlton Stallings  
RESIDENCE (State/Country): Missouri/United States  
CITIZENSHIP: United States  
POST OFFICE ADDRESS: 19165 Old Logging Road  
Glencoe, Missouri 63038  
INVENTOR'S SIGNATURE: William Carlton Stallings  
DATE: Sept. 13, 1994

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Barry, Gerard F.  
Kishore, Ganesh M.  
Padgett, Stephen R.  
Stallings, William C.

(ii) TITLE OF INVENTION: Glyphosate Tolerant  
5-Enolpyruvylshikimate-3-Phosphate Synthases

(iii) NUMBER OF SEQUENCES: 69

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Dennis R. Hoerner, Jr., Monsanto Co. BB4F  
(B) STREET: 700 Chesterfield Village Parkway  
(C) CITY: St. Louis  
(D) STATE: Missouri  
(E) COUNTRY: USA  
(F) ZIP: 63198

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/749,611  
(B) FILING DATE: 28-AUG-1991  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/576,537  
(B) FILING DATE: 31-AUG-1990  
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hoerner Jr., Dennis R.  
(B) REGISTRATION NUMBER: 30,914  
(C) REFERENCE/DOCKET NUMBER: 38-21(10660)A

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (314)537-6099  
(B) TELEFAX: (314)537-6047

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 597 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCATCAAAAT ATTTAGCAGC ATTCCAGATT GGGTTCAATC AACAAAGGTAC GAGCCATATC	60
ACTTTATTCA AATTGGTATC GCCAAAACCA AGAAGGAACT CCCATCCTCA AAGGTTTGTA	120
AGGAAGAATT CTCAGTCCAA AGCCTCAACA AGGTCAGGGT ACAGAGTCTC CAAACCATTA	180
GCCAAAAGCT ACAGGGAGATC AATGAAGAAT CTTCAATCAA AGTAAACTAC TGTTCAGCA	240
CATGCATCAT GGTCAGTAAG TTTCAGAAA AGACATCCAC CGAAGACTTA AAGTTAGTGG	300
GCATCTTGAG AAGTAATCTT GTCAACATCG AGCAGCTGGC TTGTGGGAC CAGACAAAAA	360
AGGAATGGTG CAGAATTGTT AGGCGCACCT ACCAAAAGCA TCTTTGCCTT TATTGCAAAG	420
ATAAAGCAGA TTCCCTAGT ACAAGTGGGG AACAAAATAA CGTGGAAAAG AGCTGTCCCTG	480
ACAGCCCAC TACTAATGCG TATGACGAAC GCAGTGACGA CCACAAAAGA ATTCCCTCTA	540
TATAAGAAGG CATTCAATTCC CATTGAGG ATCATCAGAT ACTAACCAAT ATTTCTC	597

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 1982 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 62..1426

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAGCCCGCGT TCTCTCCGGC GCTCCGCCCG GAGAGCCGTG GATAGATTAA GGAAGACGCC 60  
C ATG TCG CAC GGT GCA AGC AGC CGG CCC GCA ACC GCC CGC AAA TCC 106  
Met Ser His Gly Ala Ser Ser Arg Pro Ala Thr Ala Arg Lys Ser  
1 5 10 15  
TCT GGC CTT TCC GGA ACC GTC CGC ATT CCC GGC GAC AAG TCG ATC TCC 154  
Ser Gly Leu Ser Gly Thr Val Arg Ile Pro Gly Asp Lys Ser Ile Ser  
20 25 30  
CAC CGG TCC TTC ATG TTC GGC GGT CTC GCG AGC GGT GAA ACG CGC ATC 202  
His Arg Ser Phe Met Phe Gly Gly Leu Ala Ser Gly Glu Thr Arg Ile  
35 40 45  
ACC GGC CTT CTG GAA GGC GAG GAC GTC ATC AAT ACG GGC AAG GCC ATG 250  
Thr Gly Leu Leu Glu Gly Glu Asp Val Ile Asn Thr Gly Lys Ala Met  
50 55 60  
CAG GCC ATG GGC GCC AGG ATC CGT AAG GAA GGC GAC ACC TGG ATC ATC 298  
Gln Ala Met Gly Ala Arg Ile Arg Lys Glu Gly Asp Thr Trp Ile Ile  
65 70 75  
GAT GGC GTC GGC AAT GGC GGC CTC CTG GCG CCT GAG GCG CCG CTC GAT 346  
Asp Gly Val Gly Asn Gly Gly Leu Leu Ala Pro Glu Ala Pro Leu Asp  
80 85 90 95  
TTC GGC AAT GCC GCC ACG GGC TGC CGC CTG ACC ATG GGC CTC GTC GGG 394  
Phe Gly Asn Ala Ala Thr Gly Cys Arg Leu Thr Met Gly Leu Val Gly  
100 105 110  
GTC TAC GAT TTC GAC AGC ACC TTC ATC GGC GAC GCC TCG CTC ACA AAG 442  
Val Tyr Asp Phe Asp Ser Thr Phe Ile Gly Asp Ala Ser Leu Thr Lys  
115 120 125  
CGC CCG ATG GGC CGC GTG TTG AAC CCG CTG CGC GAA ATG GGC GTG CAG 490  
Arg Pro Met Gly Arg Val Leu Asn Pro Leu Arg Glu Met Gly Val Gln  
130 135 140

GTG AAA TCG GAA GAC GGT GAC CGT CTT CCC GTT ACC TTG CGC GGG CCG 538  
Val Lys Ser Glu Asp Gly Asp Arg Leu Pro Val Thr Leu Arg Gly Pro  
145 150 155

AAG ACG CCG ACG CCG ATC ACC TAC CGC GTG CCG ATG GCC TCC GCA CAG 586  
Lys Thr Pro Thr Pro Ile Thr Tyr Arg Val Pro Met Ala Ser Ala Gln  
160 165 170 175

GTG AAG TCC GCC GTG CTC GCC GGC CTC AAC ACG CCC GGC ATC ACG 634  
Val Lys Ser Ala Val Leu Leu Ala Gly Leu Asn Thr Pro Gly Ile Thr  
180 185 190

ACG GTC ATC GAG CCG ATC ATG ACG CGC GAT CAT ACG GAA AAG ATG CTG 682  
Thr Val Ile Glu Pro Ile Met Thr Arg Asp His Thr Glu Lys Met Leu  
195 200 205

CAG GGC TTT GGC GCC AAC CTT ACC GTC GAG ACG GAT GCG GAC GGC GTG 730  
Gln Gly Phe Gly Ala Asn Leu Thr Val Glu Thr Asp Ala Asp Gly Val  
210 215 220

CGC ACC ATC CGC CTG GAA GGC CGC GGC AAG CTC ACC GGC CAA GTC ATC 778  
Arg Thr Ile Arg Leu Glu Gly Arg Gly Lys Leu Thr Gly Gln Val Ile  
225 230 235

GAC GTG CCG GGC GAC CCG TCC TCG ACG GCC TTC CCG CTG GTT GCG GCC 826  
Asp Val Pro Gly Asp Pro Ser Ser Thr Ala Phe Pro Leu Val Ala Ala  
240 245 250 255

CTG CTT GTT CCG GGC TCC GAC GTC ACC ATC CTC AAC GTG CTG ATG AAC 874  
Leu Leu Val Pro Gly Ser Asp Val Thr Ile Leu Asn Val Leu Met Asn  
260 265 270

CCC ACC CGC ACC GGC CTC ATC CTG ACG CTG CAG GAA ATG GGC GCC GAC 922  
Pro Thr Arg Thr Gly Leu Ile Leu Thr Leu Gln Glu Met Gly Ala Asp  
275 280 285

ATC GAA GTC ATC AAC CCG CGC CTT GCC GGC GGC GAA GAC GTG GCG GAC 970  
Ile Glu Val Ile Asn Pro Arg Leu Ala Gly Gly Glu Asp Val Ala Asp  
290 295 300

CTG CGC GTT CGC TCC TCC ACG CTG AAG GGC GTC ACG GTG CCG GAA GAC 1018  
Leu Arg Val Arg Ser Ser Thr Leu Lys Gly Val Thr Val Pro Glu Asp  
305 310 315

CGC GCG CCT TCG ATG ATC GAC GAA TAT CCG ATT CTC GCT GTC GCC GCC 1066  
Arg Ala Pro Ser Met Ile Asp Glu Tyr Pro Ile Leu Ala Val Ala Ala  
320 325 330 335

GCC TTC GCG GAA GGG GCG ACC GTG ATG AAC GGT CTG GAA GAA CTC CGC 1114  
Ala Phe Ala Glu Gly Ala Thr Val Met Asn Gly Leu Glu Leu Arg  
340 345 350

GTC AAG GAA AGC GAC CGC CTC TCG GCC GTC GCC AAT GGC CTC AAG CTC 1162  
Val Lys Glu Ser Asp Arg Leu Ser Ala Val Ala Asn Gly Leu Lys Leu  
355 360 365

AAT GGC GTG GAT TGC GAT GAG GGC GAG ACG TCG CTC GTC GTG CGC GGC 1210  
Asn Gly Val Asp Cys Asp Glu Gly Glu Thr Ser Leu Val Val Arg Gly  
370 375 380

CGC CCT GAC GGC AAG GGG CTC GGC AAC GCC TCG GGC GCC GCC GTC GCC 1258  
Arg Pro Asp Gly Lys Gly Leu Gly Asn Ala Ser Gly Ala Ala Val Ala  
385 390 395

ACC CAT CTC GAT CAC CGC ATC GCC ATG AGC TTC CTC GTC ATG GGC CTC 1306  
Thr His Leu Asp His Arg Ile Ala Met Ser Phe Leu Val Met Gly Leu  
400 405 410 415

GTG TCG GAA AAC CCT GTC ACG GTG GAC GAT GCC ACG ATG ATC GCC ACG 1354  
Val Ser Glu Asn Pro Val Thr Val Asp Asp Ala Thr Met Ile Ala Thr  
420 425 430

AGC TTC CCG GAG TTC ATG GAC CTG ATG GCC GGG CTG GGC GCG AAG ATC 1402  
Ser Phe Pro Glu Phe Met Asp Leu Met Ala Gly Leu Gly Ala Lys Ile  
435 440 445

GAA CTC TCC GAT ACG AAG GCT GCC TGATGACCTT CACAATCGCC ATCGATGGTC 1456  
Glu Leu Ser Asp Thr Lys Ala Ala  
450 455

CCGCTGCGGC CGGCAAGGGG ACGCTCTCGC GCCGTATCGC GGAGGTCTAT GGCTTTCATC 1516

ATCTCGATAC GGGCCTGACC TATCGCGCCA CGGCCAAAGC GCTGCTCGAT CGGGCCCTGT 1576

CGCTTGATGA CGAGGCCGTT GCGGCCGATG TCGCCCGCAA TCTCGATCTT GCCGGGCTCG 1636

ACCGGTCGGT CCTGTGGCC CATGCCATCG GCGAGGGGGC TTCAAGATC GCGGTATGC 1696

CCTCGGTGCG CGGGGCGCTG GTCGAGGCCG AGCGCAGCTT TGCGGCGCGT GAGCCGGGCA 1756

CGGTGCTGGA TCGACCGCATCGG ATCGGCACGG TGGTCTGCCG GGATGCGCCG GTGAAGCTCT 1816

ATGTCACCGC GTCACCGGAA GTGCGCGCGA AACGCCGCTA TGACGAAATC CTCGGCAATG 1876

GCGGGTTGGC CGATTACGGG ACGATCCTCG AGGATATCCG CCGCCGCGAC GAGCGGGACA 1936

TGGGTCGGGC GGACAGTCCT TTGAAGCCCG CCGACGATGC GCACCTT

1982

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 455 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ser His Gly Ala Ser Ser Arg Pro Ala Thr Ala Arg Lys Ser Ser  
1 5 10 15

Gly Leu Ser Gly Thr Val Arg Ile Pro Gly Asp Lys Ser Ile Ser His  
20 25 30

Arg Ser Phe Met Phe Gly Gly Leu Ala Ser Gly Glu Thr Arg Ile Thr  
35 40 45

Gly Leu Leu Glu Gly Glu Asp Val Ile Asn Thr Gly Lys Ala Met Gln  
50 55 60

Ala Met Gly Ala Arg Ile Arg Lys Glu Gly Asp Thr Trp Ile Ile Asp  
65 70 75 80

Gly Val Gly Asn Gly Gly Leu Leu Ala Pro Glu Ala Pro Leu Asp Phe  
85 90 95

Gly Asn Ala Ala Thr Gly Cys Arg Leu Thr Met Gly Leu Val Gly Val  
100 105 110

Tyr Asp Phe Asp Ser Thr Phe Ile Gly Asp Ala Ser Leu Thr Lys Arg  
115 120 125

Pro Met Gly Arg Val Leu Asn Pro Leu Arg Glu Met Gly Val Gln Val  
130 135 140

Lys Ser Glu Asp Gly Asp Arg Leu Pro Val Thr Leu Arg Gly Pro Lys  
145 150 155 160

Thr Pro Thr Pro Ile Thr Tyr Arg Val Pro Met Ala Ser Ala Gln Val  
165 170 175

Lys Ser Ala Val Leu Leu Ala Gly Leu Asn Thr Pro Gly Ile Thr Thr  
180 185 190

Val Ile Glu Pro Ile Met Thr Arg Asp His Thr Glu Lys Met Leu Gln  
195 200 205

Gly Phe Gly Ala Asn Leu Thr Val Glu Thr Asp Ala Asp Gly Val Arg  
210 215 220

Thr Ile Arg Leu Glu Gly Arg Gly Lys Leu Thr Gly Gln Val Ile Asp  
225 230 235 240

Val Pro Gly Asp Pro Ser Ser Thr Ala Phe Pro Leu Val Ala Ala Leu  
245 250 255

Leu Val Pro Gly Ser Asp Val Thr Ile Leu Asn Val Leu Met Asn Pro  
260 265 270

Thr Arg Thr Gly Leu Ile Leu Thr Leu Gln Glu Met Gly Ala Asp Ile  
275 280 285

Glu Val Ile Asn Pro Arg Leu Ala Gly Gly Glu Asp Val Ala Asp Leu  
290 295 300

Arg Val Arg Ser Ser Thr Leu Lys Gly Val Thr Val Pro Glu Asp Arg  
305 310 315 320

Ala Pro Ser Met Ile Asp Glu Tyr Pro Ile Leu Ala Val Ala Ala Ala  
325 330 335

Phe Ala Glu Gly Ala Thr Val Met Asn Gly Leu Glu Glu Leu Arg Val  
340 345 350

Lys Glu Ser Asp Arg Leu Ser Ala Val Ala Asn Gly Leu Lys Leu Asn  
355 360 365

Gly Val Asp Cys Asp Glu Gly Glu Thr Ser Leu Val Val Arg Gly Arg  
370 375 380

Pro Asp Gly Lys Gly Leu Gly Asn Ala Ser Gly Ala Ala Val Ala Thr  
385 390 395 400

His Leu Asp His Arg Ile Ala Met Ser Phe Leu Val Met Gly Leu Val  
405 410 415

Ser Glu Asn Pro Val Thr Val Asp Asp Ala Thr Met Ile Ala Thr Ser  
420 425 430

Phe Pro Glu Phe Met Asp Leu Met Ala Gly Leu Gly Ala Lys Ile Glu  
435 440 445

Leu Ser Asp Thr Lys Ala Ala  
450 455

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1673 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 86..1432

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTAGGCCACAC ATAATTACTA TAGCTAGGAA GCCCCCTATC TCTCAATCCC GCGTGATCGC 60

GCCAAAATGT GACTGTGAAA AATCC ATG TCC CAT TCT GCA TCC CCG AAA CCA 112  
Met Ser His Ser Ala Ser Pro Lys Pro  
1 5

GCA ACC GCC CGC CGC TCG GAG GCA CTC ACG GGC GAA ATC CGC ATT CCG 150  
Ala Thr Ala Arg Arg Ser Glu Ala Leu Thr Gly Glu Ile Arg Ile Pro  
10 15 20 25

GGC GAC AAG TCC ATC TCG CAT CGC TCC TTC ATG TTT GGC GGT CTC GCA 208  
Gly Asp Lys Ser Ile Ser His Arg Ser Phe Met Phe Gly Gly Leu Ala  
30 35 40

TCG GGC GAA ACC CGC ATC ACC GGC CTT CTG GAA GGC GAG GAC GTC ATC 256  
Ser Gly Thr Arg Ile Thr Gly Leu Leu Glu Gly Glu Asp Val Ile  
45 50 55

AAT ACA GGC CGC GCC ATG CAG GCC ATG GGC GCG AAA ATC CGT AAA GAG  
394 Asn Thr Gly Arg Ala Met Gln Ala Met Gly Ala Lys Ile Arg Lys Glu  
60 65 70

GGC GAT GTC TGG ATC ATC AAC GGC GTC GGC AAT GGC TGC CTG TTG CAG 352  
Gly Asp Val Trp Ile Ile Asn Gly Val Gly Asn Gly Cys Leu Leu Gln

	75	80	85	
CCC GAA GCT GCG CTC GAT TTC GGC AAT GCC GGA ACC GGC GCG CGC CTC				400
Pro Glu Ala Ala Leu Asp Phe Gly Asn Ala Gly Thr Gly Ala Arg Leu				
90	95		100	105
ACC ATG GGC CTT GTC GGC ACC TAT GAC ATG AAG ACC TCC TTT ATC GGC				448
Thr Met Gly Leu Val Gly Thr Tyr Asp Met Lys Thr Ser Phe Ile Gly				
110		115		120
GAC GCC TCG CTG TCG AAG CGC CCG ATG GGC CGC GTG CTG AAC CCG TTG				496
Asp Ala Ser Leu Ser Lys Arg Pro Met Gly Arg Val Leu Asn Pro Leu				
125		130		135
CGC GAA ATG GGC GTT CAG GTG GAA GCA GCC GAT GGC GAC CGC ATG CCG				544
Arg Glu Met Gly Val Gln Val Glu Ala Ala Asp Gly Asp Arg Met Pro				
140		145		150
CTG ACG CTG ATC GGC CCG AAG ACG GCC AAT CCG ATC ACC TAT CGC GTG				592
Leu Thr Leu Ile Gly Pro Lys Thr Ala Asn Pro Ile Thr Tyr Arg Val				
155		160		165
CCG ATG GCC TCC GCG CAG GTA AAA TCC GCC GTG CTG CTC GCC GGT CTC				640
Pro Met Ala Ser Ala Gln Val Lys Ser Ala Val Leu Leu Ala Gly Leu				
170		175		180
AAC ACG CCG GGC GTC ACC ACC GTC ATC GAG CCG GTC ATG ACC CGC GAC				688
Asn Thr Pro Gly Val Thr Val Ile Glu Pro Val Met Thr Arg Asp				
190			195	200
CAC ACC GAA AAG ATG CTG CAG GGC TTT GGC GCC GAC CTC ACG GTC GAG				736
His Thr Glu Lys Met Leu Gln Gly Phe Gly Ala Asp Leu Thr Val Glu				
205		210		215
ACC GAC AAG GAT GGC GTG CGC CAT ATC CGC ATC ACC GGC CAG GGC AAG				784
Thr Asp Lys Asp Gly Val Arg His Ile Arg Ile Thr Gly Gln Gly Lys				
220		225		230
CTT GTC GGC CAG ACC ATC GAC GTG CCG GGC GAT CCG TCA TCG ACC GCC				832
Leu Val Gly Gln Thr Ile Asp Val Pro Gly Asp Pro Ser Ser Thr Ala				
235		240		245
TTC CCG CTC GTT GCC CTT CTG GTG GAA GGT TCC GAC GTC ACC ATC				880
Phe Pro Leu Val Ala Ala Leu Val Glu Gly Ser Asp Val Thr Ile				
250		255		260
CGC AAC GTG CTG ATG AAC CCG ACC CGT ACC GGC CTC ATC CTC ACC TTG				928
Arg Asn Val Leu Met Asn Pro Thr Arg Thr Gly Leu Ile Leu Thr Leu				

	270	275	280	
CAG GAA ATG GGC GCC GAT ATC GAA GTG CTC AAT GCC CGT CTT GCA GGC Gln Glu Met Gly Ala Asp Ile Glu Val Leu Asn Ala Arg Leu Ala Gly	285	290	295	976
GGC GAA GAC GTC GCC GAT CTG CGC GTC AGG GCT TCG AAG CTC AAG GGC Gly Glu Asp Val Ala Asp Leu Arg Val Arg Ala Ser Lys Leu Lys Gly	300	305	310	1024
⋮				
GTC GTC GTT CCG CCG GAA CGT GCG CCG TCG ATG ATC GAC GAA TAT CCG Val Val Val Pro Pro Glu Arg Ala Pro Ser Met Ile Asp Glu Tyr Pro	315	320	325	1072
GTC CTG GCG ATT GCC GCC TCC TTC GCG GAA GGC GAA ACC GTG ATG GAC Val Leu Ala Ile Ala Ala Ser Phe Ala Glu Gly Glu Thr Val Met Asp	330	335	340	1120
345				
GGG CTC GAC GAA CTG CGC GTC AAG GAA TCG GAT CGT CTG GCA GCG GTC Gly Leu Asp Glu Leu Arg Val Lys Glu Ser Asp Arg Leu Ala Ala Val	350	355	360	1168
GCA CGC GGC CTT GAA GCC AAC GGC GTC GAT TGC ACC GAA GGC GAG ATG Ala Arg Gly Leu Glu Ala Asn Gly Val Asp Cys Thr Glu Gly Glu Met	365	370	375	1216
380	385	390		1264
TCG CTG ACG GTT CGC GGC CGC CCC GAC GGC AAG GGA CTG GGC GGC GGC Ser Leu Thr Val Arg Gly Arg Pro Asp Gly Lys Gly Leu Gly Gly				
395	400	405		1312
ACG GTT GCA ACC CAT CTC GAT CAT CGT ATC GCG ATG AGC TTC CTC GTG Thr Val Ala Thr His Leu Asp His Arg Ile Ala Met Ser Phe Leu Val				
410	415	420	425	1360
ATG GGC CTT CGG GCG GAA AAG CCG GTG ACG GTT GAC GAC AGT AAC ATG Met Gly Leu Ala Ala Glu Lys Pro Val Thr Val Asp Asp Ser Asn Met				
430	435	440		1408
ATC GCC ACG TCC TTC CCC GAA TTC ATG GAC ATG ATG CCG GGA TTG GGC Ile Ala Thr Ser Phe Pro Glu Phe Met Asp Met Met Pro Gly Leu Gly				
445				
GCA AAG ATC GAG TTG AGC ATA CTC TAGTCACTCG ACAGCGAAAA TATTATTTGC Ala Lys Ile Glu Leu Ser Ile Leu				1462
GAGATTGGGC ATTATTACCG GTTGGTCTCA GCGGGGGTTT AATGTCCAAT CTTCCATACG				1522

TAACAGCATC AGGAAATATC AAAAAAGCTT TAGAAGGAAT TGCTAGAGCA GCGACGCCGC	1582
CTAAGCTTTC TCAAGACTTC GTTAAACTG TACTGAAATC CCGGGGGGTC CGGGGATCAA	1642
ATGACTTCAT TTCTGAGAAA TTGGCCTCGC A	1673

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 449 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Ser His Ser Ala Ser Pro Lys Pro Ala Thr Ala Arg Arg Ser Glu			
1	5	10	15
Ala Leu Thr Gly Glu Ile Arg Ile Pro Gly Asp Lys Ser Ile Ser His			
20	25	30	
Arg Ser Phe Met Phe Gly Gly Leu Ala Ser Gly Glu Thr Arg Ile Thr			
35	40	45	
Gly Leu Leu Glu Gly Glu Asp Val Ile Asn Thr Gly Arg Ala Met Gln			
50	55	60	
Ala Met Gly Ala Lys Ile Arg Lys Glu Gly Asp Val Trp Ile Ile Asn			
65	70	75	80
Gly Val Gly Asn Gly Cys Leu Leu Gln Pro Glu Ala Ala Leu Asp Phe			
85	90	95	
Gly Asn Ala Gly Thr Gly Ala Arg Leu Thr Met Gly Leu Val Gly Thr			
100	105	110	
Tyr Asp Met Lys Thr Ser Phe Ile Gly Asp Ala Ser Leu Ser Lys Arg			
115	120	125	
Pro Met Gly Arg Val Leu Asn Pro Leu Arg Glu Met Gly Val Gln Val			
130	135	140	

Glu Ala Ala Asp Gly Asp Arg Met Pro Leu Thr Leu Ile Gly Pro Lys  
145 150 155 160

Thr Ala Asn Pro Ile Thr Tyr Arg Val Pro Met Ala Ser Ala Gln Val  
165 170 175

Lys Ser Ala Val Leu Leu Ala Gly Leu Asn Thr Pro Gly Val Thr Thr  
180 185 190

Val Ile Glu Pro Val Met Thr Arg Asp His Thr Glu Lys Met Leu Gln  
195 200 205

Gly Phe Gly Ala Asp Leu Thr Val Glu Thr Asp Lys Asp Gly Val Arg  
210 215 220

His Ile Arg Ile Thr Gly Gln Gly Lys Leu Val Gly Gln Thr Ile Asp  
225 230 235 240

Val Pro Gly Asp Pro Ser Ser Thr Ala Phe Pro Leu Val Ala Ala Leu  
245 250 255

Leu Val Glu Gly Ser Asp Val Thr Ile Arg Asn Val Leu Met Asn Pro  
260 265 270

Thr Arg Thr Gly Leu Ile Leu Thr Leu Gln Glu Met Gly Ala Asp Ile  
275 280 285

Glu Val Leu Asn Ala Arg Leu Ala Gly Gly Glu Asp Val Ala Asp Leu  
290 295 300

Arg Val Arg Ala Ser Lys Leu Lys Gly Val Val Pro Pro Glu Arg  
305 310 315 320

Ala Pro Ser Met Ile Asp Glu Tyr Pro Val Leu Ala Ile Ala Ala Ser  
325 330 335

Phe Ala Glu Gly Glu Thr Val Met Asp Gly Leu Asp Glu Leu Arg Val  
340 345 350

Lys Glu Ser Asp Arg Leu Ala Ala Val Ala Arg Gly Leu Glu Ala Asn  
355 360 365

Gly Val Asp Cys Thr Glu Gly Glu Met Ser Leu Thr Val Arg Gly Arg  
370 375 380

Pro Asp Gly Lys Gly Leu Gly Gly Thr Val Ala Thr His Leu Asp  
385 390 395 400

His Arg Ile Ala Met Ser Phe Leu Val Met Gly Leu Ala Ala Glu Lys  
405 410 415

Pro Val Thr Val Asp Asp Ser Asn Met Ile Ala Thr Ser Phe Pro Glu  
420 425 430

Phe Met Asp Met Met Pro Gly Leu Gly Ala Lys Ile Glu Leu Ser Ile  
435 440 445

Leu :

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1500 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 34..1380

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTGATCGCGC CAAAATGTGA CTGTGAAAAA TCC ATG TCC CAT TCT GCA TCC CCG 54  
Met Ser His Ser Ala Ser Pro  
1 5

AAA CCA GCA ACC GCC CGC TCG GAG GCA CTC ACG GGC GAA ATC CGC 102  
Lys Pro Ala Thr Ala Arg Arg Ser Glu Ala Leu Thr Gly Glu Ile Arg  
10 15 20

ATT CCG GGC GAC AAG TCC ATC TCG CAT CGC TCC TTC ATG TTT GGC GGT 150  
Ile Pro Gly Asp Lys Ser Ile Ser His Arg Ser Phe Met Phe Gly Gly  
25 30 35

CTC GCA TCG GGC GAA ACC CGC ATC ACC GGC CTT CTG GAA GGC GAG GAC 198  
Leu Ala Ser Gly Glu Thr Arg Ile Thr Gly Leu Leu Glu Gly Glu Asp  
40 45 50 55

GTC ATC AAT ACA GCA CGC GCC ATG CAG GCC ATG GGC GCG AAA ATC CGT 246  
Val Ile Asn Thr Gly Arg Ala Met Gln Ala Met Gly Ala Lys Ile Arg  
60 65 70

AAA GAG GGC GAT GTC TGG ATC ATC AAC GGC GTC GGC AAT GGC TGC CTG 294  
Lys Glu Gly Asp Val Trp Ile Ile Asn Gly Val Gly Asn Gly Cys Leu  
75 80 85

TTG CAG CCC GAA GCT GCG CTC GAT TTC GGC AAT GCC GGA ACC GGC GCG 342  
Leu Gln Pro Glu Ala Ala Leu Asp Phe Gly Asn Ala Gly Thr Gly Ala  
90 95 100

CGC CTC ACC ATG GGC CTT GTC GGC ACC TAT GAC ATG AAG ACC TCC TTT 390  
Arg Leu Thr Met Gly Leu Val Gly Thr Tyr Asp Met Lys Thr Ser Phe  
105 110 115

ATC GGC GAC GCC TCG CTG TCG AAG CGC CCG ATG GGC CGC GTG CTG AAC 438  
Ile Gly Asp Ala Ser Leu Ser Lys Arg Pro Met Gly Arg Val Leu Asn  
120 125 130 135

CCG TTG CGC GAA ATG GGC GTT CAG GTG GAA GCA GGC GAT GGC GAC CGC 486  
Pro Leu Arg Glu Met Gly Val Gln Val Glu Ala Ala Asp Gly Asp Arg  
140 145 150

ATG CCG CTG ACG CTG ATC GGC CCG AAG ACG GGC AAT CCG ATC ACC TAT 534  
Met Pro Leu Thr Leu Ile Gly Pro Lys Thr Ala Asn Pro Ile Thr Tyr  
155 160 165

CGC GTG CCG ATG GCC TCC GCG CAG GTA AAA TCC GCC GTG CTG CTC GCC 582  
Arg Val Pro Met Ala Ser Ala Gln Val Lys Ser Ala Val Leu Leu Ala  
170 175 180

GGT CTC AAC ACG CCG GGC GTC ACC ACC GTC ATC GAG CCG GTC ATG ACC 630  
Gly Leu Asn Thr Pro Gly Val Thr Thr Val Ile Glu Pro Val Met Thr  
185 190 195

CGC GAC CAC ACC GAA AAG ATG CTG CAG GGC TTT GGC GCC GAC CTC ACG 678  
Arg Asp His Thr Glu Lys Met Leu Gln Gly Phe Gly Ala Asp Leu Thr  
200 205 210 215

GTC GAG ACC GAC AAG GAT GGC GTG CGC CAT ATC CGC ATC ACC GGC CAG 726  
Val Glu Thr Asp Lys Asp Gly Val Arg His Ile Arg Ile Thr Gly Gln  
220 225 230

GGC AAG CTT GTC GGC CAG ACC ATC GAC GTG CCG GGC GAT CCG TCA TCG 774  
Gly Lys Leu Val Gly Gln Thr Ile Asp Val Pro Gly Asp Pro Ser Ser  
235 240 245

ACC GCC TTC CCG CTC GTT GCC CTT CTG GTG GAA GGT TCC GAC GTC 822  
Thr Ala Phe Pro Leu Val Ala Ala Leu Leu Val Glu Gly Ser Asp Val  
250 255 260

ACC ATC CGC AAC GTG CTG ATG AAC CCG ACC CGT ACC GGC CTC ATC CTC 870  
Thr Ile Arg Asn Val Leu Met Asn Pro Thr Arg Thr Gly Leu Ile Leu  
265 270 275

ACC TTG CAG GAA ATG GGC GCC GAT ATC GAA GTG CTC AAT GCC CGT CTT 918  
Thr Leu Gln Glu Met Gly Ala Asp Ile Glu Val Leu Asn Ala Arg Leu  
280 285 290 295

GCA GGC GGC GAA GAC GTC GCC GAT CTG CGC GTC AGG GCT TCG AAG CTC 966  
Ala Gly Gly Glu Asp Val Ala Asp Leu Arg Val Arg Ala Ser Lys Leu  
300 305 310

AAG GGC GTC GTC GTT CCG CCG GAA CGT GCG CCG TCG ATG ATC GAC GAA 1014  
Lys Gly Val Val Val Pro Pro Glu Arg Ala Pro Ser Met Ile Asp Glu  
315 320 325

TAT CCG GTC CTG GCG ATT GCC GCC TCC TTC GCG GAA GGC GAA ACC GTG 1062  
Tyr Pro Val Leu Ala Ile Ala Ala Ser Phe Ala Glu Gly Glu Thr Val  
330 335 340

ATG GAC GGG CTC GAC GAA CTG CGC GTC AAG GAA TCG GAT CGT CTG GCA 1110  
Met Asp Gly Leu Asp Glu Leu Arg Val Lys Glu Ser Asp Arg Leu Ala  
345 350 355

GCG GTC GCA CGC GGC CTT GAA GCC AAC GGC GTC GAT TGC ACC GAA GGC 1158  
Ala Val Ala Arg Gly Leu Glu Ala Asn Gly Val Asp Cys Thr Glu Gly  
360 365 370 375

GAG ATG TCG CTG ACG GTT CGC GGC CGC CCC GAC GGC AAG GGA CTG GGC 1206  
Glu Met Ser Leu Thr Val Arg Gly Arg Pro Asp Gly Lys Gly Leu Gly  
380 385 390

GGC GGC ACG GTT GCA ACC CAT CTC GAT CAT CGT ATC GCG ATG AGC TTC 1254  
Gly Thr Val Ala Thr His Leu Asp His Arg Ile Ala Met Ser Phe  
395 400 405

CTC GTG ATG GGC CTT GCG GCG GAA AAG CCG GTG ACG GTT GAC GAC AGT 1302  
Leu Val Met Gly Leu Ala Ala Glu Lys Pro Val Thr Val Asp Asp Ser  
410 415 420

AAC ATG ATC GCC ACG TCC TTC CCC GAA TTC ATG GAC ATG ATG CCG GGA 1350  
Asn Met Ile Ala Thr Ser Phe Pro Glu Phe Met Asp Met Met Pro Gly  
425 430 435

TTG GGC GCA AAG ATC GAG TTG AGC ATA CTC TAGTCACTCG ACAGCGAAAAA 1400  
Leu Gly Ala Lys Ile Glu Leu Ser Ile Leu  
440 445

TATTATTTGC GAGATTGGGC ATTATTACCG GTTGGTCTCA GCGGGGTTT AATGTCCAAT 1460  
CTTCCATACG TAACAGCATC AGGAAATATC AAAAAAGCTT 1500

•

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 449 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser His Ser Ala Ser Pro Lys Pro Ala Thr Ala Arg Arg Ser Glu  
1 5 10 15

Ala Leu Thr Gly Glu Ile Arg Ile Pro Gly Asp Lys Ser Ile Ser His  
20 25 30

Arg Ser Phe Met Phe Gly Gly Leu Ala Ser Gly Glu Thr Arg Ile Thr  
35 40 45

Gly Leu Leu Glu Gly Glu Asp Val Ile Asn Thr Gly Arg Ala Met Gln  
50 55 60

Ala Met Gly Ala Lys Ile Arg Lys Glu Gly Asp Val Trp Ile Ile Asn  
65 70 75 80

Gly Val Gly Asn Gly Cys Leu Leu Gln Pro Glu Ala Ala Leu Asp Phe  
85 90 95

Gly Asn Ala Gly Thr Gly Ala Arg Leu Thr Met Gly Leu Val Gly Thr  
100 105 110

Tyr Asp Met Lys Thr Ser Phe Ile Gly Asp Ala Ser Leu Ser Lys Arg  
115 120 125

Pro Met Gly Arg Val Leu Asn Pro Leu Arg Glu Met Gly Val Gln Val  
130 135 140

Glu Ala Ala Asp Gly Asp Arg Met Pro Leu Thr Leu Ile Gly Pro Lys  
145 150 155 160

Thr Ala Asn Pro Ile Thr Tyr Arg Val Pro Met Ala Ser Ala Gln Val  
165 170 175

Lys Ser Ala Val Leu Leu Ala Gly Leu Asn Thr Pro Gly Val Thr Thr  
180 185 190

Val Ile Glu Pro Val Met Thr Arg Asp His Thr Glu Lys Met Leu Gln  
195 200 205

Gly Phe Gly Ala Asp Leu Thr Val Glu Thr Asp Lys Asp Gly Val Arg  
210 215 220

His Ile Arg Ile Thr Gly Gln Gly Lys Leu Val Gly Gln Thr Ile Asp  
225 230 235 240

Val Pro Gly Asp Pro Ser Ser Thr Ala Phe Pro Leu Val Ala Ala Leu  
245 250 255

Leu Val Glu Gly Ser Asp Val Thr Ile Arg Asn Val Leu Met Asn Pro  
260 265 270

Thr Arg Thr Gly Leu Ile Leu Thr Leu Gln Glu Met Gly Ala Asp Ile  
275 280 285

Glu Val Leu Asn Ala Arg Leu Ala Gly Gly Glu Asp Val Ala Asp Leu  
290 295 300

Arg Val Arg Ala Ser Lys Leu Lys Gly Val Val Val Pro Pro Glu Arg  
305 310 315 320

Ala Pro Ser Met Ile Asp Glu Tyr Pro Val Leu Ala Ile Ala Ala Ser  
325 330 335

Phe Ala Glu Gly Glu Thr Val Met Asp Gly Leu Asp Glu Leu Arg Val  
340 345 350

Lys Glu Ser Asp Arg Leu Ala Ala Val Ala Arg Gly Leu Glu Ala Asn  
355 360 365

Gly Val Asp Cys Thr Glu Gly Glu Met Ser Leu Thr Val Arg Gly Arg  
370 375 380

Pro Asp Gly Lys Gly Leu Gly Gly Thr Val Ala Thr His Leu Asp  
385 390 395 400

His Arg Ile Ala Met Ser Phe Leu Val Met Gly Leu Ala Ala Glu Lys  
405 410 415

Pro Val Thr Val Asp Asp Ser Asn Met Ile Ala Thr Ser Phe Pro Glu  
420 425 430

Phe Met Asp Met Met Pro Gly Leu Gly Ala Lys Ile Glu Leu Ser Ile  
435 440 445

Leu

.

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 423 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ser Leu Thr Leu Gln Pro Ile Ala Arg Val Asp Gly Thr Ile Asn Leu  
1 5 10 15

Pro Gly Ser Lys Thr Val Ser Asn Arg Ala Leu Leu Ala Ala Leu  
20 25 30

Ala His Gly Lys Thr Val Leu Thr Asn Leu Leu Asp Ser Asp Asp Val  
35 40 45

Arg His Met Leu Asn Ala Leu Thr Ala Leu Gly Val Ser Tyr Thr Leu  
50 55 60

Ser Ala Asp Arg Thr Arg Cys Glu Ile Ile Gly Asn Gly Gly Pro Leu  
65 70 75 80

His Ala Glu Gly Ala Leu Glu Leu Phe Leu Gly Asn Ala Gly Thr Ala  
85 90 95

Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Ser Asn Asp Ile Val  
100 105 110

Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly His Leu Val  
115 120 125

Asp Ala Leu Arg Leu Gly Gly Ala Lys Ile Thr Tyr Leu Glu Gln Glu  
130 135 140

Asn Tyr Pro Pro Leu Arg Leu Gln Gly Phe Thr Gly Gly Asn Val  
145 150 155 160

Asp Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu Leu Met  
165 170 175

Thr Ala Pro Leu Ala Pro Glu Asp Thr Val Ile Arg Ile Lys Gly Asp  
180 185 190

Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu Asn Leu Met Lys Thr  
195 200 205

Phe Gly Val Glu Ile Glu Asn Gln His Tyr Gln Gln Phe Val Val Lys  
210 215 220

Gly Gly Gln Ser Tyr Gln Ser Pro Gly Thr Tyr Leu Val Glu Gly Asp  
225 230 235 240

Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Ala Ala Ile Lys Gly Gly  
245 250 255

Thr Val Lys Val Thr Gly Ile Gly Arg Asn Ser Met Gln Gly Asp Ile  
260 265 270

Arg Phe Ala Asp Val Leu Glu Lys Met Gly Ala Thr Ile Cys Trp Gly  
275 280 285

Asp Asp Tyr Ile Ser Cys Thr Arg Gly Glu Leu Asn Ala Ile Asp Met  
290 295 300

Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr Ala Ala  
305 310 315 320

Leu Phe Ala Lys Gly Thr Thr Arg Leu Arg Asn Ile Tyr Asn Trp Arg  
325 330 335

Val Lys Glu Thr Asp Arg Leu Phe Ala Met Ala Thr Glu Leu Arg Lys  
340 345 350

Val Gly Ala Glu Val Glu Glu Gly His Asp Tyr Ile Arg Ile Thr Pro  
355 360 365

```

Pro Glu Lys Leu Asn Phe Ala Glu Ile Ala Thr Tyr Asn Asp His Arg
370           375           380

Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro Val Thr
385           390           395           400

Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr Phe Glu
* 405           410           415

Gln Leu Ala Arg Ile Ser Gln
420

```

(2) INFORMATION FOR SEQ ID NO:9:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1377 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

CCATGGCTCA CGGTGCAAGC AGCCGTCCAG CAACTGCTCG TAAGTCCTCT GGTCTTCTG 60
GAACCGTCCG TATTCCAGGT GACAAGTCTA TCTCCACAG GTCCTTCATG TTTGGAGGTC 120
TCGCTAGCGG TGAAACTCGT ATCACCGGTC TTTTGGAAAGG TGAAGATGTT ATCAACACTG 180
GTAAGGCTAT GCAAGCTATG GGTGCCAGAA TCCGTAAGGA AGGTGATACT TGGATCATTG. 240
ATGGTGTGGA TAACGGTGGG CTCCTTGCTC CTGAGGCTCC TCTCGATTTC GGTAACGCTG 300
CAACTGGTTG CCGTTTGACT ATGGGTCTTG TTGGTGTTA CGATTTCGAT AGCACTTTCA 360
TTGGTGACGC TTCTCTCACT AAGCGTCCAA TGGGTCGTGT GTTGAACCCA CTTCGCGAAA 420
TGGGTGTGCA GGTGAAGTCT GAAGACGGTG ATCGTCTTCC AGTTACCTTG CGTGGACCAA 480
AGACTCCAAC GCCAATCACC TACAGGGTAC CTATGGCTTC CGCTCAAGTG AAGTCCGCTG 540
TTCTGCTTGC TGGTCTCAAC ACCCCAGGTA TCACCACTGT TATCGAGCCA ATCATGACTC 600
GTGACCAACAC TGAAAAGATG CTTCAAGGTT TTGGTGCTAA CCTTACCGTT GAGACTGATG 660

```

CTGACGGTGT GCGTACCATC CGTCTTGAAG GTCGTGGTAA GCTCACCGGT CAAAGTGATTG 720  
ATGTTCCAGG TGATCCATCC TCTACTGCTT TCCCATTGGT TGCTGCCTTG CTTGTTCCAG 780  
GTTCCGACGT CACCATCCTT AACGTTTGA TGAACCCAAC CCGTACTGGT CTCATCTTGA 840  
CTCTGCAGGA AATGGGTGCC GACATCGAAG TGATCAACCC ACGTCTTGCT GGTGGAGAAG 900  
ACGTGGCTGA CTTGGCTGTT CGTTCTTCTA CTTTGAAGGG TGTTACTGTT CCAGAAGACC 960  
GTGCTCCTTC TATGATCGAC GAGTATCCAA TTCTCGCTGT TGCAGCTGCA TTGCTGAAG 1020  
GTGCTACCGT TATGAACGGT TTGGAAGAAC TCCGTGTTAA GGAAAGCGAC CGTCTTCTG 1080  
CTGTCGAAA CGGTCTCAAG CTCAACGGTG TTGATTGCGA TGAAGGTGAG ACTTCTCTCG 1140  
TCGTGCGTGG TCGTCCTGAC GGTAAGGGTC TCGGTAACGC TTCTGGAGCA GCTGTCGCTA 1200  
CCCACCTCGA TCACCGTATC GCTATGAGCT TCCTCGTTAT GGGTCTCGTT TCTGAAAACC 1260  
CTGTTACTGT TGATGATGCT ACTATGATCG CTACTAGCTT CCCAGAGTTC ATGGATTTGA 1320  
TGGCTGGTCT TGGAGCTAAG ATCGAACTCT CCGACACTAA GGCTGCTTGA TGAGCTC 1377

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 318 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 87..317

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGATCTATCG ATAAGCTGAA TGTAAATTGGA GGAAGATCAA AATTTCAAT CCCCATTCTT 60  
CGATTGCTTC AATTGAAGTT TCTCCG ATG GCG CAA GTT AGC AGA ATC TGC AAT 113  
Met Ala Gln Val Ser Arg Ile Cys Asn  
1 5

GGT GTG CAG AAC CCA TCT CTT ATC TCC AAT CTC TCG AAA TCC AGT CAA	161
Gly Val Gln Asn Pro Ser Leu Ile Ser Asn Leu Ser Lys Ser Ser Gln	
10 15 20 25	
CGC AAA TCT CCC TTA TCG GTT TCT CTG AAG ACG CAG CAG CAT CCA CGA	209
Arg Lys Ser Pro Leu Ser Val Leu Lys Thr Gln Gln His Pro Arg	
30 35 40	
GCT TAT CCG ATT TCG TCG TGG GGA TTG AAG AAG AGT GGG ATG ACG	257
Ala Tyr Pro Ile Ser Ser Trp Gly Leu Lys Lys Ser Gly Met Thr	
45 50 55	
TTA ATT GGC TCT GAG CTT CGT CCT CTT AAG GTC ATG TCT TCT GTT TCC	305
Leu Ile Gly Ser Glu Leu Arg Pro Leu Lys Val Met Ser Ser Val Ser	
60 65 70	
ACG GCG TGC ATG C	318
Thr Ala Cys Met	
75	

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu	
1 5 10 15	
Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val	
20 25 30	
Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser	
35 40 45	
Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg	
50 55 60	
Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Cys Met	
65 70 75	

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 402 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)  
:
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 87..401

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGATCTATCG ATAAGCTTGA TGTAATTGGA GGAAGATCAA AATTTCAAT CCCCCATTCTT	60
CGATTGCTTC AATTGAAGTT TCTCCG ATG GCG CAA GTT AGC AGA ATC TGC AAT	113
Met Ala Gln Val Ser Arg Ile Cys Asn	
1 5	
GGT GTG CAG AAC CCA TCT CTT ATC TCC AAT CTC TCG AAA TCC AGT CAA	161
Gly Val Gln Asn Pro Ser Leu Ile Ser Asn Leu Ser Lys Ser Ser Gln	
10 15 20 25	
CGC AAA TCT CCC TTA TCG GTT TCT CTG AAG ACG CAG CAG CAT CCA CGA	209
Arg Lys Ser Pro Leu Ser Val Ser Leu Lys Thr Gln Gln His Pro Arg	
30 35 40	
GCT TAT CCG ATT TCG TCG TCG TGG GGA TTG AAG AAG AGT GGG ATG ACG	257
Ala Tyr Pro Ile Ser Ser Ser Trp Gly Leu Lys Lys Ser Gly Met Thr	
45 50 55	
TTA ATT GGC TCT GAG CTT CGT CCT CTT AAG GTC ATG TCT TCT GTT TCC	305
Leu Ile Gly Ser Glu Leu Arg Pro Leu Lys Val Met Ser Ser Val Ser	
60 65 70	
ACG GCG GAG AAA GCG TCG GAG ATT GTA CTT CAA CCC ATT AGA GAA ATC	353
Thr Ala Glu Lys Ala Ser Glu Ile Val Leu Gln Pro Ile Arg Glu Ile	
75 80 85	
TCC GGT CTT ATT AAG TTG CCT GGC TCC AAG TCT CTA TCA AAT AGA ATT	401
Ser Gly Leu Ile Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile	
90 95 100 105	

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu  
1 5 10 15

Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val  
20 25 30

Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser  
35 40 45

Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg  
50 55 60

Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Glu Lys Ala Ser Glu  
65 70 75 80

Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro  
85 90 95

Gly Ser Lys Ser Leu Ser Asn Arg Ile  
100 105

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 14..232

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGATCTTCA AGA ATG GCA CAA ATT AAC AAC ATG GCT CAA GGG ATA CAA	49
Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln	
1 5 10	
ACC CTT AAT CCC AAT TCC AAT TTC CAT AAA CCC CAA GTT CCT AAA TCT	97
Thr Leu Asn Pro Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser	
15 20 25	
TCA AGT TTT CTT GTT TTT GGA TCT AAA AAA CTG AAA AAT TCA GCA AAT	145
Ser Ser Phe Leu Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn	
30 35 40	
TCT ATG TTG GTT TTG AAA AAA GAT TCA ATT TTT ATG CAA AAG TTT TGT	193
Ser Met Leu Val Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys	
45 50 55 60	
TCC TTT AGG ATT TCA GCA TCA GTG GCT ACA GCC TGC ATG C	233
Ser Phe Arg Ile Ser Ala Ser Val Ala Thr Ala Cys Met	
65 70	

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro	
1 5 10 15	
Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu	
20 25 30	
Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val	
35 40 45	
Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile	
50 55 60	

Ser Ala Ser Val Ala Thr Ala Cys Met  
65 70

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 352 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 49..351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

AGATCTGCTA GAAATAATT TGTTAACCT TAAGAAGGAG ATATATCC ATG GCA CAA Met Ala Gln 1	57
ATT AAC AAC ATG GCT CAA GGG ATA CAA ACC CTT AAT CCC AAT TCC AAT Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro Asn Ser Asn 5 10 15	105
TTC CAT AAA CCC CAA GTT CCT AAA TCT TCA AGT TTT CTT GTT TTT GGA Phe His Lys Pro Gln Val Pro Lys Ser Ser Phe Leu Val Phe Gly 20 25 30 35	153
TCT AAA AAA CTG AAA AAT TCA GCA AAT TCT ATG TTG GTT TTG AAA AAA Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val Leu Lys Lys 40 45 50	201
GAT TCA ATT TTT ATG CAA AAG TTT TGT TCC TTT AGG ATT TCA GCA TCA Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile Ser Ala Ser 55 60 65	249
GTG GCT ACA GCA CAG AAG CCT TCT GAG ATA GTG TTG CAA CCC ATT AAA Val Ala Thr Ala Gln Lys Pro Ser Glu Ile Val Leu Gln Pro Ile Lys 70 75 80	297
GAG ATT TCA GGC ACT GTT AAA TTG CCT GGC TCT AAA TCA TTA TCT AAT Glu Ile Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn 85 90 95	345

AGA ATT C 352  
Arg Ile  
100

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 101 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro  
1 5 10 15

Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu  
20 25 30

Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val  
35 40 45

Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile  
50 55 60

Ser Ala Ser Val Ala Thr Ala Gln Lys Pro Ser Glu Ile Val Leu Gln  
65 70 75 80

Pro Ile Lys Glu Ile Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser  
85 90 95

Leu Ser Asn Arg Ile  
100

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Xaa His Gly Ala Ser Ser Arg Pro Ala Thr Ala Arg Lys Ser Ser Gly  
1 5 10 15  
Leu Xaa Gly Thr Val Arg Ile Pro Gly Asp Lys Met  
20 25

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Pro Ser Met Ile Asp Glu Tyr Pro Ile Leu Ala Val  
1 5 10

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ile Thr Gly Leu Leu Glu Gly Glu Asp Val Ile Asn Thr Gly Lys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGATHGAYG ARTAYCC

17

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GARGAYGTNA THAACAC

17

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GARGAYGTNA THAATAC

17

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CGTGGATAGA TCTAGGAAGA CAACCATGGC TCACGGTC

38

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGATAGATTA AGGAAGACGC GCATGCTTCA CGGTGCAAGC AGCC

44

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GGCTGCCTGA TGAGCTCCAC AATGCCCATC GATGG

35

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CGTCGCTCGT CGTGCCTGGC CGCCCTGACG GC

32

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGGGCAAGGC CATGCAGGCT ATGGGCGCC

29

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CGGGCTGCCG CCTGACTATG GGCCTCGTCG G

31

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Xaa	His	Ser	Ala	Ser	Pro	Lys	Pro	Ala	Thr	Ala	Arg	Arg	Ser	Glu
1					5					10				15

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GCGGTBGCSC GYTTSGG

17

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Pro Gly Asp Lys Ser Ile Ser His Arg Ser Phe Met Phe Gly Gly Leu  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Leu Asp Phe Gly Asn Ala Ala Thr Gly Cys Arg Leu Thr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CGGCAATGCC GCCACCGGCG CGCGCC

26

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GGACGGCTGC TTGCACCGTG AAGCATGCTT AAGCTTGGCG TAATCATGG

49

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GGAAGACGCC CAGAATTCAC GGTGCAAGCA GCCGG

35

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: note= "Xaa at position 2 is Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, or Glu"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: note= "Xaa at position 4 is Ser or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Arg Xaa His Xaa Glu  
1 5

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "Xaa at position 4 is Ser or Thr"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Gly Asp Lys Xaa  
1

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: note= "Xaa at position 4 is Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Ser Ala Gln Xaa Lys  
1 5

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "Xaa at position 2 is Ala Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Asn Xaa Thr Arg  
1

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1287 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1287

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

ATG AAA CGA GAT AAG GTG CAG ACC TTA CAT GGA GAA ATA CAT ATT CCC	48
Met Lys Arg Asp Lys Val Gln Thr Leu His Gly Glu Ile His Ile Pro	
1 5 10 15	
GGT GAT AAA TCC ATT TCT CAC CGC TCT GTT ATG TTT GGC GCG CTA GCG	96
Gly Asp Lys Ser Ile Ser His Arg Ser Val Met Phe Gly Ala Leu Ala	
20 25 30	
·	
GCA GGC ACA ACA ACA GTT AAA AAC TTT CTG CCG GGA GCA GAT TGT CTG	144
Ala Gly Thr Thr Thr Val Lys Asn Phe Leu Pro Gly Ala Asp Cys Leu	
35 40 45	
AGC ACG ATC GAT TGC TTT AGA AAA ATG GGT GTT CAC ATT GAG CAA AGC	192
Ser Thr Ile Asp Cys Phe Arg Lys Met Gly Val His Ile Glu Gln Ser	
50 55 60	
AGC AGC GAT GTC GTG ATT CAC GGA AAA GGA ATC GAT GCC CTG AAA GAG	240
Ser Ser Asp Val Val Ile His Gly Lys Gly Ile Asp Ala Leu Lys Glu	
65 70 75 80	
CCA GAA AGC CTT TTA GAT GTC GGA AAT TCA GGT ACA ACG ATT CGC CTG	288
Pro Glu Ser Leu Leu Asp Val Gly Asn Ser Gly Thr Thr Ile Arg Leu	
85 90 95	
ATG CTC GGA ATA TTG GCG GGC CGT CCT TTT TAC AGC GCG GTA GCC GGA	336
Met Leu Gly Ile Leu Ala Gly Arg Pro Phe Tyr Ser Ala Val Ala Gly	
100 105 110	
GAT GAG AGC ATT GCG AAA CGC CCA ATG AAG CGT GTG ACT GAG CCT TTG	384
Asp Glu Ser Ile Ala Lys Arg Pro Met Lys Arg Val Thr Glu Pro Leu	
115 120 125	
AAA AAA ATG GGG GCT AAA ATC GAC GGC AGA GCC GGC GGA GAG TTT ACA	432
Lys Lys Met Gly Ala Lys Ile Asp Gly Arg Ala Gly Gly Glu Phe Thr	
130 135 140	
CCG CTG TCA GTG AGC GGC GCT TCA TTA AAA GGA ATT GAT TAT GTA TCA	480
Pro Leu Ser Val Ser Gly Ala Ser Leu Lys Gly Ile Asp Tyr Val Ser	
145 150 155 160	
CCT GTT GCA AGC GCG CAA ATT AAA TCT GCT GTT TTG CTG GCC GGA TTA	528
Pro Val Ala Ser Ala Gln Ile Lys Ser Ala Val Leu Leu Ala Gly Leu	
165 170 175	

CAG GCT GAG GGC ACA ACA ACT GTA ACA GAG CCC CAT AAA TCT CGG GAC Gln Ala Glu Gly Thr Thr Thr Val Thr Glu Pro His Lys Ser Arg Asp 180 185 190	576
CAC ACT GAG CGG ATG CTT TCT GCT TTT GGC GTT AAG CTT TCT GAA GAT His Thr Glu Arg Met Leu Ser Ala Phe Gly Val Lys Leu Ser Glu Asp 195 200 205	624
CAA ACG AGT GTT TGC ATT GCT GGT GGC CAG AAA CTG ACA GCT GCT GAT Gln Thr Ser Val Ser Ile Ala Gly Gly Gln Lys Leu Thr Ala Ala Asp 210 215 220	672
ATT TTT GTT CCT GGA GAC ATT TCT TCA GCC GCG TTT TTC CTT GCT GCT Ile Phe Val Pro Gly Asp Ile Ser Ser Ala Ala Phe Phe Leu Ala Ala 225 230 235 240	720
GGC GCG ATG GTT CCA AAC AGC AGA ATT GTC TTG AAA AAC GTC GGT TTA Gly Ala Met Val Pro Asn Ser Arg Ile Val Leu Lys Asn Val Gly Leu 245 250 255	768
AAT CCG ACT CGG ACA GGT ATT ATT GAT GTC CTT CAA AAC ATG GGG GCA Asn Pro Thr Arg Thr Gly Ile Ile Asp Val Leu Gln Asn Met Gly Ala 260 265 270	816
AAA CTT GAA ATC AAA CCA TCT GCT GAT AGC GGT GCA GAG CCT TAT GGA Lys Leu Glu Ile Lys Pro Ser Ala Asp Ser Gly Ala Glu Pro Tyr Gly 275 280 285	864
GAT TTG ATT ATA GAA ACG TCA TCT CTA AAG GCA GTT GAA ATC GGA GGA Asp Leu Ile Ile Glu Thr Ser Ser Leu Lys Ala Val Glu Ile Gly Gly 290 295 300	912
GAT ATC ATT CCG CGT TTA ATT GAT GAG ATC CCT ATC ATC GCG CTT CTT Asp Ile Ile Pro Arg Leu Ile Asp Glu Ile Pro Ile Ile Ala Leu Leu 305 310 315 320	960
GCG ACT CAG GCG GAA GGA ACC ACC GTT ATT AAG GAC GCG GCA GAG CTA Ala Thr Gln Ala Glu Gly Thr Thr Val Ile Lys Asp Ala Ala Glu Leu 325 330 335	1008
AAA GTG AAA GAA ACA AAC CGT ATT GAT ACT GTT GTT TCT GAG CTT CGC Lys Val Lys Glu Thr Asn Arg Ile Asp Thr Val Val Ser Glu Leu Arg 340 345 350	1056
AAG CTG GGT GCT GAA ATT GAA CCG ACA GCA GAT GGA ATG AAG GTT TAT Lys Leu Gly Ala Glu Ile Glu Pro Thr Ala Asp Gly Met Lys Val Tyr 355 360 365	1104

GGC AAA CAA ACG TTG AAA GGC GGC GCT GCA GTG TCC AGC CAC GGA GAT Gly Lys Gln Thr Leu Lys Gly Gly Ala Ala Val Ser Ser His Gly Asp 370 375 380	1152
CAT CGA ATC GGA ATG ATG CTT GGT ATT GCT TCC TGT ATA ACG GAG GAG His Arg Ile Gly Met Met Leu Gly Ile Ala Ser Cys Ile Thr Glu Glu 385 390 395 400	1200
CCG ATT GAA ATC GAG CAC ACG GAT GCC ATT CAC GTT TCT TAT CCA ACC Pro Ile Glu Ile Glu His Thr Asp Ala Ile His Val Ser Tyr Pro Thr 405 410 415	1248
TTC TTC GAG CAT TTA AAT AAG CTT TCG AAA AAA TCC TGA Phe Phe Glu His Leu Asn Lys Leu Ser Lys Lys Ser 420 425	1287

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 428 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Met Lys Arg Asp Lys Val Gln Thr Leu His Gly Glu Ile His Ile Pro 1 5 10 15
Gly Asp Lys Ser Ile Ser His Arg Ser Val Met Phe Gly Ala Leu Ala 20 25 30
Ala Gly Thr Thr Val Lys Asn Phe Leu Pro Gly Ala Asp Cys Leu 35 40 45
Ser Thr Ile Asp Cys Phe Arg Lys Met Gly Val His Ile Glu Gln Ser 50 55 60
Ser Ser Asp Val Val Ile His Gly Lys Gly Ile Asp Ala Leu Lys Glu 65 70 75 80
Pro Glu Ser Leu Leu Asp Val Gly Asn Ser Gly Thr Thr Ile Arg Leu 85 90 95
Met Leu Gly Ile Leu Ala Gly Arg Pro Phe Tyr Ser Ala Val Ala Gly

100	105	110
Asp Glu Ser Ile Ala Lys Arg Pro Met Lys Arg Val Thr Glu Pro Leu		
115	120	125
Lys Lys Met Gly Ala Lys Ile Asp Gly Arg Ala Gly Gly Glu Phe Thr		
130	135	140
Pro Leu Ser Val Ser Gly Ala Ser Leu Lys Gly Ile Asp Tyr Val Ser		
145	150	155
160		
Pro Val Ala Ser Ala Gln Ile Lys Ser Ala Val Leu Leu Ala Gly Leu		
165	170	175
Gln Ala Glu Gly Thr Thr Val Thr Glu Pro His Lys Ser Arg Asp		
180	185	190
His Thr Glu Arg Met Leu Ser Ala Phe Gly Val Lys Leu Ser Glu Asp		
195	200	205
Gln Thr Ser Val Ser Ile Ala Gly Gly Gln Lys Leu Thr Ala Ala Asp		
210	215	220
Ile Phe Val Pro Gly Asp Ile Ser Ser Ala Ala Phe Phe Leu Ala Ala		
225	230	235
240		
Gly Ala Met Val Pro Asn Ser Arg Ile Val Leu Lys Asn Val Gly Leu		
245	250	255
Asn Pro Thr Arg Thr Gly Ile Ile Asp Val Leu Gln Asn Met Gly Ala		
260	265	270
Lys Leu Glu Ile Lys Pro Ser Ala Asp Ser Gly Ala Glu Pro Tyr Gly		
275	280	285
Asp Leu Ile Ile Glu Thr Ser Ser Leu Lys Ala Val Glu Ile Gly Gly		
290	295	300
Asp Ile Ile Pro Arg Leu Ile Asp Glu Ile Pro Ile Ile Ala Leu Leu		
305	310	315
320		
Ala Thr Gln Ala Glu Gly Thr Thr Val Ile Lys Asp Ala Ala Glu Leu		
325	330	335
Lys Val Lys Glu Thr Asn Arg Ile Asp Thr Val Val Ser Glu Leu Arg		
340	345	350

Lys Leu Gly Ala Glu Ile Glu Pro Thr Ala Asp Gly Met Lys Val Tyr  
355 360 365

Gly Lys Gln Thr Leu Lys Gly Gly Ala Ala Val Ser Ser His Gly Asp  
370 375 380

His Arg Ile Gly Met Met Leu Gly Ile Ala Ser Cys Ile Thr Glu Glu  
385 390 395 400

Pro Ile Glu Ile Glu His Thr Asp Ala Ile His Val Ser Tyr Pro Thr  
405 410 415

Phe Phe Glu His Leu Asn Lys Leu Ser Lys Lys Ser  
420 425

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1293 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1293

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

ATG GTA AAT GAA CAA ATC ATT GAT ATT TCA GGT CCG TTA AAG GGC GAA 48  
Met Val Asn Glu Gln Ile Ile Asp Ile Ser Gly Pro Leu Lys Gly Glu  
1 5 10 15

ATA GAA GTG CCG GGC GAT AAG TCA ATG ACA CAC CGT GCA ATC ATG TTG 96  
Ile Glu Val Pro Gly Asp Lys Ser Met Thr His Arg Ala Ile Met Leu  
20 25 30

GCG TCG CTA GCT GAA GGT GTA TCT ACT ATA TAT AAG CCA CTA CTT GGC 144  
Ala Ser Leu Ala Glu Gly Val Ser Thr Ile Tyr Lys Pro Leu Leu Gly  
35 40 45

GAA GAT TGT CGT CGT ACG ATG GAC ATT TTC CGA CAC TTA GGT GTA GAA 192  
Glu Asp Cys Arg Arg Thr Met Asp Ile Phe Arg His Leu Gly Val Glu  
50 55 60

ATC AAA GAA GAT GAT GAA AAA TTA GTT GTG ACT TCC CCA GGA TAT CAA 240  
Ile Lys Glu Asp Asp Glu Lys Leu Val Val Thr Ser Pro Gly Tyr Gln  
65 70 75 80

GTT AAC ACG CCA CAT CAA GTA TTG TAT ACA GGT AAT TCT GGT ACG ACA 288  
Val Asn Thr Pro His Gln Val Leu Tyr Thr Gly Asn Ser Gly Thr Thr  
85 90 95

ACA CGA TTA TTG GCA GGT TTG TTA AGT GGT TTA GGT AAT GAA AGT GTT 336  
Thr Arg Leu Leu Ala Gly Leu Leu Ser Gly Leu Gly Asn Glu Ser Val  
100 105 110

TTG TCT GGC GAT GTT TCA ATT GGT AAA AGG CCA ATG GAT CGT GTC TTG 384  
Leu Ser Gly Asp Val Ser Ile Gly Lys Arg Pro Met Asp Arg Val Leu  
115 120 125

AGA CCA TTG AAA CTT ATG GAT GCG AAT ATT GAA GGT ATT GAA GAT AAT 432  
Arg Pro Leu Lys Leu Met Asp Ala Asn Ile Glu Gly Ile Glu Asp Asn  
130 135 140

TAT ACA CCA TTA ATT ATT AAG CCA TCT GTC ATA AAA GGT ATA AAT TAT 480  
Tyr Thr Pro Leu Ile Ile Lys Pro Ser Val Ile Lys Gly Ile Asn Tyr  
145 150 155 160

CAA ATG GAA GTT GCA AGT GCA CAA GTA AAA AGT GCC ATT TTA TTT GCA 528  
Gln Met Glu Val Ala Ser Ala Gln Val Lys Ser Ala Ile Leu Phe Ala  
165 170 175

AGT TTG TTT TCT AAG GAA CCG ACC ATC ATT AAA GAA TTA GAT GTA AGT 576  
Ser Leu Phe Ser Lys Glu Pro Thr Ile Ile Lys Glu Leu Asp Val Ser  
180 185 190

CGA AAT CAT ACT GAG ACG ATG TTC AAA CAT TTT AAT ATT CCA ATT GAA 624  
Arg Asn His Thr Glu Thr Met Phe Lys His Phe Asn Ile Pro Ile Glu  
195 200 205

GCA GAA GGG TTA TCA ATT AAT ACA ACC CCT GAA GCA ATT CGA TAC ATT 672  
Ala Glu Gly Leu Ser Ile Asn Thr Thr Pro Glu Ala Ile Arg Tyr Ile  
210 215 220

AAA CCT GCA GAT TTT CAT GTT CCT GGC GAT ATT TCA TCT GCA GCG TTC 720  
Lys Pro Ala Asp Phe His Val Pro Gly Asp Ile Ser Ser Ala Ala Phe  
225 230 235 240

TTT ATT GTT GCA GCA CTT ATC ACA CCA GGA AGT GAT GTA ACA ATT CAT 768  
Phe Ile Val Ala Ala Leu Ile Thr Pro Gly Ser Asp Val Thr Ile His  
245 250 255

AAT GTT GGA ATC AAT CAA ACA CGT TCA GGT ATT ATT GAT ATT GTT GAA 816  
Asn Val Gly Ile Asn Gln Thr Arg Ser Gly Ile Ile Asp Ile Val Glu  
260 265 270

AAA ATG GGC GGT AAT ATC CAA CTT TTC AAT CAA ACA ACT GGT GCT GAA 864  
Lys Met Gly Gly Asn Ile Gln Leu Phe Asn Gln Thr Thr Gly Ala Glu  
275 280 285

CCT ACT GCT TCT ATT CGT ATT CAA TAC ACA CCA ATG CTT CAA CCA ATA 912  
Pro Thr Ala Ser Ile Arg Ile Gln Tyr Thr Pro Met Leu Gln Pro Ile  
290 295 300

ACA ATC GAA GGA GAA TTA GTT CCA AAA GCA ATT GAT GAA CTG CCT GTA 960  
Thr Ile Glu Gly Glu Leu Val Pro Lys Ala Ile Asp Glu Leu Pro Val  
305 310 315 320

ATA GCA TTA CTT TGT ACA CAA GCA GTT GGC ACG AGT ACA ATT AAA GAT 1008  
Ile Ala Leu Leu Cys Thr Gln Ala Val Gly Thr Ser Thr Ile Lys Asp  
325 330 335

GCC GAG GAA TTA AAA GTA AAA GAA ACA AAT AGA ATT GAT ACA ACG GCT 1056  
Ala Glu Glu Leu Lys Val Lys Glu Thr Asn Arg Ile Asp Thr Thr Ala  
340 345 350

GAT ATG TTA AAC TTG TTA GGG TTT GAA TTA CAA CCA ACT AAT GAT GGA 1104  
Asp Met Leu Asn Leu Leu Gly Phe Glu Leu Gln Pro Thr Asn Asp Gly  
355 360 365

TTG ATT ATT CAT CCG TCA GAA TTT AAA ACA AAT GCA ACA GAT ATT TTA 1152  
Leu Ile Ile His Pro Ser Glu Phe Lys Thr Asn Ala Thr Asp Ile Leu  
370 375 380

ACT GAT CAT CGA ATA GGA ATG ATG CTT GCA GTT GCT TGT GTA CTT TCA 1200  
Thr Asp His Arg Ile Gly Met Met Leu Ala Val Ala Cys Val Leu Ser  
385 390 395 400

AGC GAG CCT GTC AAA ATC AAA CAA TTT GAT GCT GTA AAT GTA TCA TTT 1248  
Ser Glu Pro Val Lys Ile Lys Gln Phe Asp Ala Val Asn Val Ser Phe  
405 410 415

CCA GGA TTT TTA CCA AAA CTA AAG CTT TTA CAA AAT GAG GGA TAA 1293  
Pro Gly Phe Leu Pro Lys Leu Lys Leu Leu Gln Asn Glu Gly  
420 425 430

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 430 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Met Val Asn Glu Gln Ile Ile Asp Ile Ser Gly Pro Leu Lys Gly Glu  
1 5 10 15

Ile Glu Val Pro Gly Asp Lys Ser Met Thr His Arg Ala Ile Met Leu  
20 25 30

Ala Ser Leu Ala Glu Gly Val Ser Thr Ile Tyr Lys Pro Leu Leu Gly  
35 40 45

Glu Asp Cys Arg Arg Thr Met Asp Ile Phe Arg His Leu Gly Val Glu  
50 55 60

Ile Lys Glu Asp Asp Glu Lys Leu Val Val Thr Ser Pro Gly Tyr Gln  
65 70 75 80

Val Asn Thr Pro His Gln Val Leu Tyr Thr Gly Asn Ser Gly Thr Thr  
85 90 95

Thr Arg Leu Leu Ala Gly Leu Leu Ser Gly Leu Gly Asn Glu Ser Val  
100 105 110

Leu Ser Gly Asp Val Ser Ile Gly Lys Arg Pro Met Asp Arg Val Leu  
115 120 125

Arg Pro Leu Lys Leu Met Asp Ala Asn Ile Glu Gly Ile Glu Asp Asn  
130 135 140

Tyr Thr Pro Leu Ile Ile Lys Pro Ser Val Ile Lys Gly Ile Asn Tyr  
145 150 155 160

Gln Met Glu Val Ala Ser Ala Gln Val Lys Ser Ala Ile Leu Phe Ala  
165 170 175

Ser Leu Phe Ser Lys Glu Pro Thr Ile Ile Lys Glu Leu Asp Val Ser  
180 185 190

Arg Asn His Thr Glu Thr Met Phe Lys His Phe Asn Ile Pro Ile Glu  
195 200 205

Ala Glu Gly Leu Ser Ile Asn Thr Thr Pro Glu Ala Ile Arg Tyr Ile  
210 215 220

Lys Pro Ala Asp Phe His Val Pro Gly Asp Ile Ser Ser Ala Ala Phe  
225 230 235 240

Phe Ile Val Ala Ala Leu Ile Thr Pro Gly Ser Asp Val Thr Ile His  
245 250 255

Asn Val Gly Ile Asn Gln Thr Arg Ser Gly Ile Ile Asp Ile Val Glu  
260 265 270

Lys Met Gly Gly Asn Ile Gln Leu Phe Asn Gln Thr Thr Gly Ala Glu  
275 280 285

Pro Thr Ala Ser Ile Arg Ile Gln Tyr Thr Pro Met Leu Gln Pro Ile  
290 295 300

Thr Ile Glu Gly Glu Leu Val Pro Lys Ala Ile Asp Glu Leu Pro Val  
305 310 315 320

Ile Ala Leu Leu Cys Thr Gln Ala Val Gly Thr Ser Thr Ile Lys Asp  
325 330 335

Ala Glu Glu Leu Lys Val Lys Glu Thr Asn Arg Ile Asp Thr Thr Ala  
340 345 350

Asp Met Leu Asn Leu Leu Gly Phe Glu Leu Gln Pro Thr Asn Asp Gly  
355 360 365

Leu Ile Ile His Pro Ser Glu Phe Lys Thr Asn Ala Thr Asp Ile Leu  
370 375 380

Thr Asp His Arg Ile Gly Met Met Leu Ala Val Ala Cys Val Leu Ser  
385 390 395 400

Ser Glu Pro Val Lys Ile Lys Gln Phe Asp Ala Val Asn Val Ser Phe  
405 410 415

Pro Gly Phe Leu Pro Lys Leu Lys Leu Leu Gln Asn Glu Gly  
420 425 430

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GGAACATATG AAACGAGATA AGGTGCAG

28

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GGAATTCAAA CTTCAGGATC TTGAGATAGA AAATG

35

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GGGGCCATGG TAAATGAACA AATCATTG

28

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

.

(ii) MOLECULE TYPE: Other nucleic acid

- (A) DESCRIPTION: Synthetic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GGGGGAGCTC ATTATCCCTC ATTTTGTAAA AGC

33

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 480 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Leu Thr Asp Glu Thr Leu Val Tyr Pro Phe Lys Asp Ile Pro Ala Asp  
1 5 10 15

Gln Gln Lys Val Val Ile Pro Pro Gly Ser Lys Ser Ile Ser Asn Arg  
20 25 30

Ala Leu Ile Leu Ala Ala Leu Gly Glu Gly Gln Cys Lys Ile Lys Asn  
35 40 45

Leu Leu His Ser Asp Asp Thr Lys His Met Leu Thr Ala Val His Glu  
50 55 60

Leu Lys Gly Ala Thr Ile Ser Trp Glu Asp Asn Gly Glu Thr Val Val  
65 70 75 80

Val Glu Gly His Gly Gly Ser Thr Leu Ser Ala Cys Ala Asp Pro Leu  
85 90 95

Tyr Leu Gly Asn Ala Gly Thr Ala Ser Arg Phe Leu Thr Ser Leu Ala  
100 105 110

Ala Leu Val Asn Ser Thr Ser Ser Gln Lys Tyr Ile Val Leu Thr Gly  
115 120 125

Asn Ala Arg Met Gln Gln Arg Pro Ile Ala Pro Leu Val Asp Ser Leu  
130 135 140

Arg Ala Asn Gly Thr Lys Ile Glu Tyr Leu Asn Asn Glu Gly Ser Leu  
145 150 155 160

Pro Ile Lys Val Tyr Thr Asp Ser Val Phe Lys Gly Gly Arg Ile Glu  
165 170 175

Leu Ala Ala Thr Val Ser Ser Gln Tyr Val Ser Ser Ile Leu Met Cys  
180 185 190

Ala Pro Tyr Ala Glu Glu Pro Val Thr Leu Ala Leu Val Gly Gly Lys  
195 200 205

Pro Ile Ser Lys Leu Tyr Val Asp Met Thr Ile Lys Met Met Glu Lys  
210 215 220

Phe Gly Ile Asn Val Glu Thr Ser Thr Thr Glu Pro Tyr Thr Tyr Tyr  
225 230 235 240

Ile Pro Lys Gly His Tyr Ile Asn Pro Ser Glu Tyr Val Ile Glu Ser  
245 250 255

Asp Ala Ser Ser Ala Thr Tyr Pro Leu Ala Phe Ala Ala Met Thr Gly  
260 265 270

Thr Thr Val Thr Val Pro Asn Ile Gly Phe Glu Ser Leu Gln Gly Asp  
275 280 285

Ala Arg Phe Ala Arg Asp Val Leu Lys Pro Met Gly Cys Lys Ile Thr  
290 295 300

Gln Thr Ala Thr Ser Thr Thr Val Ser Gly Pro Pro Val Gly Thr Leu  
305 310 315 320

Lys Pro Leu Lys His Val Asp Met Glu Pro Met Thr Asp Ala Phe Leu  
325 330 335

Thr Ala Cys Val Val Ala Ala Ile Ser His Asp Ser Asp Pro Asn Ser  
340 345 350

Ala Asn Thr Thr Thr Ile Glu Gly Ile Ala Asn Gln Arg Val Lys Glu  
355 360 365

Cys Asn Arg Ile Leu Ala Met Ala Thr Glu Leu Ala Lys Phe Gly Val  
370 375 380

Lys Thr Thr Glu Leu Pro Asp Gly Ile Gln Val His Gly Leu Asn Ser  
385 390 395 400

Ile Lys Asp Leu Lys Val Pro Ser Asp Ser Ser Gly Pro Val Gly Val  
• 405 410 415

Cys Thr Tyr Asp Asp His Arg Val Ala Met Ser Phe Ser Leu Leu Ala  
420 425 430

Gly Met Val Asn Ser Gln Asn Glu Arg Asp Glu Val Ala Asn Pro Val  
435 440 445

Arg Ile Leu Glu Arg His Cys Thr Gly Lys Thr Trp Pro Gly Trp Trp  
450 455 460

Asp Val Leu His Ser Glu Leu Gly Ala Lys Leu Asp Gly Ala Glu Pro  
465 470 475 480

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 460 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Leu Ala Pro Ser Ile Glu Val His Pro Gly Val Ala His Ser Ser Asn  
1 5 10 15

Val Ile Cys Ala Pro Pro Gly Ser Lys Ser Ile Ser Asn Arg Ala Leu  
20 25 30

Val Leu Ala Ala Leu Gly Ser Gly Thr Cys Arg Ile Lys Asn Leu Leu  
35 40 45

His Ser Asp Asp Thr Glu Val Met Leu Asn Ala Leu Glu Arg Leu Gly  
50 55 60

Ala Ala Thr Phe Ser Trp Glu Glu Gly Glu Val Leu Val Val Asn  
65 70 75 80

Gly Lys Gly Gly Asn Leu Gln Ala Ser Ser Ser Pro Leu Tyr Leu Gly  
85 90 95

Asn Ala Gly Thr Ala Ser Arg Phe Leu Thr Thr Val Ala Thr Leu Ala  
100 105 110

Asn Ser Ser Thr Val Asp Ser Ser Val Leu Thr Gly Asn Asn Arg Met  
115 120 125

Lys Gln Arg Pro Ile Gly Asp Leu Val Asp Ala Leu Thr Ala Asn Val  
130 135 140

Leu Pro Leu Asn Thr Ser Lys Gly Arg Ala Ser Leu Pro Leu Lys Ile  
145 150 155 160

Ala Ala Ser Gly Gly Phe Ala Gly Gly Asn Ile Asn Leu Ala Ala Lys  
165 170 175

Val Ser Ser Gln Tyr Val Ser Ser Leu Leu Met Cys Ala Pro Tyr Ala  
180 185 190

Lys Glu Pro Val Thr Leu Arg Leu Val Gly Gly Lys Pro Ile Ser Gln  
195 200 205

Pro Tyr Ile Asp Met Thr Thr Ala Met Met Arg Ser Phe Gly Ile Asp  
210 215 220

Val Gln Lys Ser Thr Thr Glu Glu His Thr Tyr His Ile Pro Gln Gly  
225 230 235 240

Arg Tyr Val Asn Pro Ala Glu Tyr Val Ile Glu Ser Asp Ala Ser Cys  
245 250 255

Ala Thr Tyr Pro Leu Ala Val Ala Val Thr Gly Thr Thr Cys Thr  
260 265 270

Val Pro Asn Ile Gly Ser Ala Ser Leu Gln Gly Asp Ala Arg Phe Ala  
275 280 285

Val Glu Val Leu Arg Pro Met Gly Cys Thr Val Glu Gln Thr Glu Thr  
290 295 300

Ser Thr Thr Val Thr Gly Pro Ser Asp Gly Ile Leu Arg Ala Thr Ser  
305 310 315 320

Lys Arg Gly Tyr Gly Thr Asn Asp Arg Cys Val Pro Arg Cys Phe Arg  
325 330 335

Thr Gly Ser His Arg Pro Met Glu Lys Ser Gln Thr Thr Pro Pro Val  
340 345 350

Ser Ser Gly Ile Ala Asn Gln Arg Val Lys Glu Cys Asn Arg Ile Lys  
355 360 365

Ala Met Lys Asp Glu Leu Ala Lys Phe Gly Val Ile Cys Arg Glu His  
370 375 380

Asp Asp Gly Leu Glu Ile Asp Gly Ile Asp Arg Ser Asn Leu Arg Gln  
385 390 395 400

Pro Val Gly Gly Val Phe Cys Tyr Asp Asp His Arg Val Ala Phe Ser  
405 410 415

Phe Ser Val Leu Ser Leu Val Thr Pro Gln Pro Thr Leu Ile Leu Glu  
420 425 430

Lys Glu Cys Val Gly Lys Thr Trp Pro Gly Trp Trp Asp Thr Leu Arg  
435 440 445

Gln Leu Phe Lys Val Lys Leu Glu Gly Lys Glu Leu  
450 455 460

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Lys Ala Ser Glu Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu  
1 5 10 15

Ile Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu  
20 25 30

Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser  
35 40 45

Asp Asp Ile Asn Tyr Met Leu Asp Ala Leu Lys Lys Leu Gly Leu Asn  
50 55 60

Val Glu Arg Asp Ser Val Asn Asn Arg Ala Val Val Glu Gly Cys Gly  
65 70 75 80

Gly Ile Phe Pro Ala Ser Leu Asp Ser Lys Ser Asp Ile Glu Leu Tyr  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Ala Ala Gly Gly Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Asp Val Glu Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val  
145 150 155 160

Asn Ala Asn Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Val Pro  
195 200 205

Tyr Val Glu Met Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Ala  
210 215 220

Glu His Ser Asp Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val  
260 265 270

Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Lys Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val  
290 295 300

Thr Val Thr Gly Pro Ser Arg Asp Ala Phe Gly Met Arg His Leu Arg  
305 310 315 320

Ala Val Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr  
355 360 365

Glu Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys  
370 375 380

Val Ile Thr Pro Pro Ala Lys Val Lys Pro Ala Glu Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp  
405 410 415

Val Pro Val Thr Ile Lys Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asp Tyr Phe Gln Val Leu Glu Ser Ile Thr Lys His  
435 440

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 444 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Lys Ala Ser Glu Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu  
1 5 10 15

Ile Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu  
20 25 30  
.

Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser  
35 40 45

Asp Asp Ile Asn Tyr Met Leu Asp Ala Leu Lys Arg Leu Gly Leu Asn  
50 55 60

Val Glu Thr Asp Ser Glu Asn Asn Arg Ala Val Val Glu Gly Cys Gly  
65 70 75 80

Gly Ile Phe Pro Ala Ser Ile Asp Ser Lys Ser Asp Ile Glu Leu Tyr  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Ala Ala Gly Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Asp Val Glu Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val  
145 150 155 160

Asn Ala Asn Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Val Asp Lys Leu Ile Ser Val Pro  
195 200 205

Tyr Val Glu Met Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Val  
210 215 220

Glu His Ser Asp Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Cys Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val  
260 265 270

Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Lys Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val  
290 295 300

Thr Val Thr Gly Pro Pro Arg Asp Ala Phe Gly Met Arg His Leu Arg  
305 310 315 320

Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr  
355 360 365

Glu Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys  
370 375 380

Val Ile Thr Pro Pro Lys Lys Val Lys Thr Ala Glu Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp  
405 410 415

Val Pro Ile Thr Ile Asn Asp Ser Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asp Tyr Phe Gln Val Leu Glu Arg Ile Thr Lys His  
435 440

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Lys Pro Asn Glu Ile Val Leu Gln Pro Ile Lys Asp Ile Ser Gly Thr  
1 5 10 15

Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu  
20 25 30

Ala Ala Leu Ser Lys Gly Arg Thr Val Val Asp Asn Leu Leu Ser Ser  
35 40 45

Asp Asp Ile His Tyr Met Leu Gly Ala Leu Lys Thr Leu Gly Leu His  
50 55 60

Val Glu Asp Asp Asn Glu Asn Gln Arg Ala Ile Val Glu Gly Cys Gly  
65 70 75 80

Gly Gln Phe Pro Val Gly Lys Ser Glu Glu Glu Ile Gln Leu Phe  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Val Ala Gly Gly His Ser Arg Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Asp Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Glu Val Asp Cys Phe Leu Gly Thr Asn Cys Pro Pro Val Arg Ile  
145 150 155 160

Val Ser Lys Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Val Pro  
195 200 205

Tyr Val Glu Met Thr Leu Lys Leu Met Cys Arg Phe Gly Val Ser Val  
210 215 220

Glu His Thr Ser Ser Trp Asp Lys Phe Leu Val Arg Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Gly Lys Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Val Thr Gly Gly Thr Val Thr Val  
260 265 270

Glu Gly Cys Gly Thr Ser Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Lys Met Gly Ala Glu Val Thr Trp Thr Glu Asn Ser Val  
290 295 300

Thr Val Lys Gly Pro Pro Arg Asn Ser Ser Gly Met Lys His Leu Arg  
305 310 315 320

Ala Val Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr  
355 360 365

Glu Leu Arg Lys Leu Gly Ala Thr Val Val Glu Gly Ser Asp Tyr Cys  
370 375 380

Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Glu Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp  
405 410 415

Val Pro Val Thr Ile Lys Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asn Tyr Phe Asp Val Leu Gln Gln Tyr Ser Lys His  
435 440

(2) INFORMATION FOR SEQ ID NO:54:

- 1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 444 amino acids
  - (B) TYPE: amino acid
  - (C) TOPOLOGY: linear
- 2) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Lys Pro His Glu Ile Val Leu Xaa Pro Ile Lys Asp Ile Ser Gly Thr  
1 5 10 15

Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu  
20 25 30

Ala Ala Leu Ser Glu Gly Arg Thr Val Val Asp Asn Leu Leu Ser Ser  
35 40 45

Asp Asp Ile His Tyr Met Leu Gly Ala Leu Lys Thr Leu Gly Leu His  
50 55 60

Val Glu Asp Asp Asn Glu Asn Gln Arg Ala Ile Val Glu Gly Cys Gly  
65 70 75 80

Gly Gln Phe Pro Val Gly Lys Lys Ser Glu Glu Glu Ile Gln Leu Phe  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Val Ala Gly Gly His Ser Arg Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Asp Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Glu Val Asp Cys Ser Leu Gly Thr Asn Cys Pro Pro Val Arg Ile  
145 150 155 160

Val Ser Lys Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Val Pro  
195 200 205

Tyr Val Glu Met Thr Leu Lys Leu Met Glu Arg Phe Gly Val Phe Val  
210 215 220

Glu His Ser Ser Gly Trp Asp Arg Phe Leu Val Lys Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Gly Lys Ala Phe Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Val Thr Gly Gly Thr Val Thr Val  
260 265 270

Glu Gly Cys Gly Thr Ser Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Lys Met Gly Ala Glu Val Thr Trp Thr Glu Asn Ser Val  
290 295 300

Thr Val Lys Gly Pro Pro Arg Asn Ser Ser Gly Met Lys His Leu Arg  
305 310 315 320

Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr  
355 360 365

Glu Leu Arg Lys Leu Gly Ala Thr Val Val Glu Gly Ser Asp Tyr Cys  
370 375 380

Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Glu Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp  
405 410 415

Val Pro Val Thr Ile Lys Asn Pro Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asp Tyr Phe Glu Val Leu Gln Lys Tyr Ser Lys His  
435 440

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Lys Pro Ser Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly Thr  
1 5 10 15

Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu  
20 25 30

Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Ser Ser  
35 40 45

Asp Asp Ile His Tyr Met Leu Gly Ala Leu Lys Thr Leu Gly Leu His  
50 55 60

Val Glu Glu Asp Ser Ala Asn Gln Arg Ala Val Val Glu Gly Cys Gly  
65 70 75 80

Gly Leu Phe Pro Val Gly Lys Glu Ser Lys Glu Glu Ile Gln Leu Phe  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Val Ala Gly Gly Asn Ser Arg Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Ser Asp Leu Val Asp Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Glu Val Asp Cys Phe Leu Gly Thr Lys Cys Pro Pro Val Arg Ile  
145 150 155 160

Val Ser Lys Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Thr Ala Leu Leu Met Ala Ala Pro Leu Ala  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Asp Lys Leu Ile Ser Val Pro  
195 200 205

Tyr Val Glu Met Thr Leu Lys Leu Met Glu Arg Phe Gly Ile Ser Val  
210 215 220

Glu His Ser Ser Ser Trp Asp Arg Phe Phe Val Arg Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Gly Lys Ala Phe Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Val Thr Gly Gly Thr Ile Thr Val  
260 265 270

Glu Gly Cys Gly Thr Asn Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Lys Met Gly Ala Glu Val Thr Trp Thr Glu Asn Ser Val  
290 295 300

Thr Val Lys Gly Pro Pro Arg Ser Ser Ser Gly Arg Lys His Leu Arg  
305 310 315 320

Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Tyr Ala Asp Gly Pro Thr Ala Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr  
355 360 365

Glu Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Pro Asp Tyr Cys  
370 375 380

Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Asp Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp  
405 410 415

Val Pro Val Thr Ile Asn Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asn Tyr Phe Asp Val Leu Gln Gln Tyr Ser Lys His  
435 440

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly  
1 5 10 15

Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu  
20 25 30

Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn  
35 40 45

Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu  
50 55 60

Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly Cys  
65 70 75 80

Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe  
85 90 95

Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr  
100 105 110

Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met  
115 120 125

Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly  
130 135 140

Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val  
145 150 155 160

Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser  
165 170 175

Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu Pro  
180 185 190

Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Ile Pro  
195 \* 200 205

Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala  
210 215 220

Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys  
225 230 235 240

Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala  
245 250 255

Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val  
260 265 270

Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu  
275 280 285

Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val  
290 295 300

Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys  
305 310 315 320

Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu  
325 330 335

Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val  
340 345 350

Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr  
355 360 365

Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys  
370 375 380

Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr  
385 390 395 400

Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu  
405 410 415

Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro  
420 425 430

Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn  
435 440

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 427 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Met Glu Ser Leu Thr Leu Gln Pro Ile Ala Arg Val Asp Gly Ala Ile  
1 5 10 15

Asn Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Leu Ala  
20 25 30

Ala Leu Ala Cys Gly Lys Thr Val Leu Thr Asn Leu Leu Asp Ser Asp  
35 40 45

Asp Val Arg His Met Leu Asn Ala Leu Ser Ala Leu Gly Ile Asn Tyr  
50 55 60

Thr Leu Ser Ala Asp Arg Thr Arg Cys Asp Ile Thr Gly Asn Gly Gly  
65 70 75 80

Pro Leu Arg Ala Pro Gly Ala Leu Glu Leu Phe Leu Gly Asn Ala Gly  
85 90 95

Thr Ala Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Gln Asn Glu  
100 105 110

Ile Val Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly His  
115 120 125

Leu Val Asp Ser Leu Arg Gln Gly Gly Ala Asn Ile Asp Tyr Leu Glu  
130 135 140

Gln Glu Asn Tyr Pro Pro Leu Arg Leu Arg Gly Gly Phe Ile Gly Gly  
145 150 155 160

Asp Ile Glu Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu  
165 170 175

Leu Met Thr Ala Pro Leu Ala Pro Lys Asp Thr Ile Ile Arg Val Lys  
180 185 190

Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu Asn Leu Met  
195 200 205

Lys Thr Phe Gly Val Glu Ile Ala Asn His His Tyr Gln Gln Phe Val  
210 215 220

Val Lys Gly Gly Gln Gln Tyr His Ser Pro Gly Arg Tyr Leu Val Glu  
225 230 235 240

Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Gly Ala Ile Lys  
245 250 255

Gly Gly Thr Val Lys Val Thr Gly Ile Gly Arg Lys Ser Met Gln Gly  
260 265 270

Asp Ile Arg Phe Ala Asp Val Leu Glu Lys Met Gly Ala Thr Ile Thr  
275 280 285

Trp Gly Asp Asp Phe Ile Ala Cys Thr Arg Gly Glu Leu His Ala Ile  
290 295 300

Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr  
305 310 315 320

Thr Ala Leu Phe Ala Lys Gly Thr Thr Leu Arg Asn Ile Tyr Asn  
325 330 335

Trp Arg Val Lys Glu Thr Asp Arg Leu Phe Ala Met Ala Thr Glu Leu  
340 345 350

Arg Lys Val Gly Ala Glu Val Glu Glu Gly His Asp Tyr Ile Arg Ile  
355 360 365

Thr Pro Pro Ala Lys Leu Gln His Ala Asp Ile Gly Thr Tyr Asn Asp  
370 375 380

His Arg Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro  
385 390 395 400

Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr  
405 410 415

Phe Glu Gln Leu Ala Arg Met Ser Thr Pro Ala  
420 425

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 427 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Met Glu Ser Leu Thr Leu Gln Pro Ile Ala Arg Val Asp Gly Ala Ile  
1 5 10 15

Asn Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Ala  
20 25 30

Ala Leu Ala Cys Gly Lys Thr Val Leu Thr Asn Leu Leu Asp Ser Asp  
35 40 45

Asp Val Arg His Met Leu Asn Ala Leu Ser Ala Leu Gly Ile Asn Tyr  
50 55 60

Thr Leu Ser Ala Asp Arg Thr Arg Cys Asp Ile Thr Gly Asn Gly Gly  
65 70 75 80

Pro Leu Arg Ala Ser Gly Thr Leu Glu Leu Phe Leu Gly Asn Ala Gly  
85 90 95

Thr Ala Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Gln Asn Glu  
100 105 110

Ile Val Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly His  
115 120 125

Leu Val Asp Ser Leu Arg Gln Gly Gly Ala Asn Ile Asp Tyr Leu Glu  
130 135 140

Gln Glu Asn Tyr Pro Pro Leu Arg Leu Arg Gly Gly Phe Ile Gly Gly  
145 150 155 160

Asp Ile Glu Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu  
165 170 175

Leu Met Thr Ala Pro Leu Ala Pro Glu Asp Thr Ile Ile Arg Val Lys  
180 185 190

Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu Asn Leu Met  
195 200 205

Lys Thr Phe Gly Val Glu Ile Ala Asn His His Tyr Gln Gln Phe Val  
210 215 220

Val Lys Gly Gly Gln Gln Tyr His Ser Pro Gly Arg Tyr Leu Val Glu  
225 230 235 240

Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Gly Gly Ile Lys  
245 250 255

Gly Gly Thr Val Lys Val Thr Gly Ile Gly Gly Lys Ser Met Gln Gly  
260 265 270

Asp Ile Arg Phe Ala Asp Val Leu His Lys Met Gly Ala Thr Ile Thr  
275 280 285

Trp Gly Asp Asp Phe Ile Ala Cys Thr Arg Gly Glu Leu His Ala Ile  
290 295 300

Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr  
305 310 315 320

Thr Ala Leu Phe Ala Lys Gly Thr Thr Leu Arg Asn Ile Tyr Asn  
325 330 335

Trp Arg Val Lys Glu Thr Asp Arg Leu Phe Ala Met Ala Thr Glu Leu  
340 345 350

Arg Lys Val Gly Ala Glu Val Glu Glu Gly His Asp Tyr Ile Arg Ile  
355 360 365

Thr Pro Pro Ala Lys Leu Gln His Ala Asp Ile Gly Thr Tyr Asn Asp  
370 375 380

His Arg Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro  
385 390 395 400

Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr  
405 410 415

Phe Glu Gln Leu Ala Arg Met Ser Thr Pro Ala  
420 425

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 427 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Met Glu Ser Leu Thr Leu Gln Pro Ile Ala Arg Val Asp Gly Thr Val  
1 5 10 15

Asn Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Ala  
20 25 30

Ala Leu Ala Arg Gly Thr Thr Val Leu Thr Asn Leu Leu Asp Ser Asp  
35 40 45

Asp Val Arg His Met Leu Asn Ala Leu Ser Ala Leu Gly Val His Tyr  
50 55 60

Val Leu Ser Ser Asp Arg Thr Arg Cys Glu Val Thr Gly Thr Gly Gly  
65 70 75 80

Pro Leu Gin Ala Gly Ser Ala Leu Glu Leu Phe Leu Gly Asn Ala Gly  
85 90 95

Thr Ala Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Ser Asn Asp  
100 105 110

Ile Val Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly His  
115 120 125

Leu Val Asp Ala Leu Arg Gln Gly Gly Ala Gln Ile Asp Tyr Leu Glu  
130 135 140

Gln Glu Asn Tyr Pro Pro Leu Arg Leu Arg Gly Gly Phe Thr Gly Gly  
145 150 155 160

Asp Val Glu Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu  
165 170 175

Leu Met Ala Ser Pro Leu Ala Pro Gln Asp Thr Val Ile Ala Ile Lys  
180 185 190

Gly Glu Leu Val Ser Arg Pro Tyr Ile Asp Ile Thr Leu His Leu Met  
195 200 205

Lys Thr Phe Gly Val Glu Val Glu Asn Gln Ala Tyr Gln Arg Phe Ile  
210 215 220

Val Arg Gly Asn Gln Gln Tyr Gln Ser Pro Gly Asp Tyr Leu Val Glu  
225 230 235 240

Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Gly Ala Ile Lys  
245 250 255

Gly Gly Thr Val Lys Val Thr Gly Ile Gly Arg Asn Ser Val Gln Gly  
260 265 270

Asp Ile Arg Phe Ala Asp Val Leu Glu Lys Met Gly Ala Thr Val Thr  
275 280 285

Trp Gly Glu Asp Tyr Ile Ala Cys Thr Arg Gly Glu Leu Asn Ala Ile  
290 295 300

Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr  
305 310 315 320

Ala Ala Leu Phe Ala Arg Gly Thr Thr Leu Arg Asn Ile Tyr Asn  
325 330 335

Trp Arg Val Lys Glu Thr Asp Arg Leu Phe Ala Met Ala Thr Glu Leu  
340 345 350

Arg Lys Val Gly Ala Glu Val Glu Gly Glu Asp Tyr Ile Arg Ile  
355 360 365

Thr Pro Pro Leu Thr Leu Gln Phe Ala Glu Ile Gly Thr Tyr Asn Asp  
370 375 380

His Arg Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro  
385 390 395 400

Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr  
405 410 415

Phe Gly Gln Leu Ala Arg Ile Ser Thr Leu Ala  
420 425

(2) INFORMATION FOR SEQ ID NO:60:

:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 427 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Met Leu Glu Ser Leu Thr Leu His Pro Ile Ala Leu Ile Asn Gly Thr  
1 5 10 15

Val Asn Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Leu  
20 25 30

Ala Ala Leu Ala Glu Gly Thr Thr Gln Leu Asn Asn Leu Leu Asp Ser  
35 40 45

Asp Asp Ile Arg His Met Leu Asn Ala Leu Gln Ala Leu Gly Val Lys  
50 55 60

Tyr Arg Leu Ser Ala Asp Arg Thr Arg Cys Glu Val Asp Gly Leu Gly  
65 70 75 80

Gly Lys Leu Val Ala Glu Gln Pro Leu Glu Leu Phe Leu Gly Asn Ala  
85 90 95

Gly Thr Ala Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Lys Asn  
100 105 110

Asp Ile Val Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly  
115 120 125

His Leu Val Asp Ala Leu Arg Gln Gly Gly Ala Gln Ile Asp Tyr Leu  
130 135 140

Glu Gln Glu Asn Tyr Arg Arg Cys Ile Ala Gly Gly Phe Arg Gly Gly  
145 150 155 160

Lys Leu Thr Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu  
165 170 175

Leu Met Thr Ala Pro Leu Ala Glu Gln Asp Thr Glu Ile Gln Ile Gln  
180 185 190

Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu His Leu Met  
195 200 205

Lys Ala Phe Gly Val Asp Val Val His Glu Asn Tyr Gln Ile Phe His  
210 215 220

Ile Lys Gly Gly Gln Thr Tyr Arg Ser Pro Gly Ile Tyr Leu Val Glu  
225 230 235 240

Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Ala Ala Ile Lys  
245 250 255

Gly Gly Thr Val Arg Val Thr Gly Ile Gly Lys Gln Ser Val Gln Gly  
260 265 270

Asp Thr Lys Phe Ala Asp Val Leu Glu Lys Met Gly Ala Lys Ile Ser  
275 280 285

Trp Gly Asp Asp Tyr Ile Glu Cys Ser Arg Gly Glu Leu Gln Gly Ile  
290 295 300

Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr  
305 310 315 320

Thr Ala Leu Phe Ala Asp Gly Pro Thr Val Ile Arg Asn Ile Tyr Asn  
325 330 335

Trp Arg Val Lys Glu Thr Asp Arg Leu Ser Ala Met Ala Thr Glu Leu  
340 345 350

Arg Lys Val Gly Ala Glu Val Glu Glu Gly Gln Asp Tyr Ile Arg Val  
355 360 365

Val Pro Pro Ala Gln Leu Ile Ala Ala Glu Ile Gly Thr Tyr Asn Asp  
370 375 380

His Arg Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro  
385 390 395 400

Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr  
405 410 415

Phe Glu Gln Leu Ala Arg Leu Ser Gln Ile Ala  
420 425

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 432 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Met Glu Lys Ile Thr Leu Ala Pro Ile Ser Ala Val Glu Gly Thr Ile  
1 5 10 15

Asn Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ala Leu Leu Leu Ala  
20 25 30

Ala Leu Ala Lys Gly Thr Thr Lys Val Thr Asn Leu Leu Asp Ser Asp  
35 40 45

Asp Ile Arg His Met Leu Asn Ala Leu Lys Ala Leu Gly Val Arg Tyr  
50 55 60

Gln Leu Ser Asp Asp Lys Thr Ile Cys Glu Ile Glu Gly Leu Gly Gly  
65 70 75 80

Ala Phe Asn Ile Gln Asp Asn Leu Ser Leu Phe Leu Gly Asn Ala Gly  
85 90 95

Thr Ala Met Arg Pro Leu Thr Ala Ala Leu Cys Leu Lys Gly Asn His  
100 105 110

Glu Val Glu Ile Ile Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro  
115 120 125

Ile Leu His Leu Val Asp Ala Leu Arg Gln Ala Gly Ala Asp Ile Arg  
130 135 140

Tyr Leu Glu Asn Glu Gly Tyr Pro Pro Leu Ala Ile Arg Asn Lys Gly  
145 150 155 160

Ile Lys Gly Gly Lys Val Lys Ile Asp Gly Ser Ile Ser Ser Gln Phe  
165 170 175

Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala Glu Asn Asp Thr Glu  
180 185 190

Ile Glu Ile Ile Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr  
195 200 205

Leu Ala Met Met Arg Asp Phe Gly Val Lys Val Glu Asn His His Tyr  
210 215 220

Gln Lys Phe Gln Val Lys Gly Asn Gln Ser Tyr Ile Ser Pro Asn Lys  
225 230 235 240

Tyr Leu Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala  
245 250 255

Gly Ala Ile Lys Gly Lys Val Lys Val Thr Gly Ile Gly Lys Asn Ser  
260 265 270

Ile Gln Gly Asp Arg Leu Phe Ala Asp Val Leu Glu Lys Met Gly Ala  
275 280 285

Lys Ile Thr Trp Gly Glu Asp Phe Ile Gln Ala Glu His Ala Glu Leu  
290 295 300

Asn Gly Ile Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr  
305 310 315 320

Ile Ala Thr Thr Ala Leu Phe Ser Asn Gly Glu Thr Val Ile Arg Asn  
325 330 335

Ile Tyr Asn Trp Arg Val Lys Glu Thr Asp Arg Leu Thr Ala Met Ala  
340 345 350

Thr Glu Leu Arg Lys Val Gly Ala Glu Val Glu Glu Gly Glu Asp Phe  
355 360 365

Ile Arg Ile Gln Pro Leu Ala Leu Asn Gln Phe Lys His Ala Asn Ile  
370 375 380

Glu Thr Tyr Asn Asp His Arg Met Ala Met Cys Phe Ser Leu Ile Ala  
385 390 395 400

Leu Ser Asn Thr Pro Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys  
405 410 415

Thr Phe Pro Thr Phe Phe Asn Glu Phe Glu Lys Ile Cys Leu Lys Asn  
420 425 430

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 441 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Val Ile Lys Asp Ala Thr Ala Ile Thr Leu Asn Pro Ile Ser Tyr Ile  
1 5 10 15

Glu Gly Glu Val Arg Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ala  
20 25 30

Leu Leu Leu Ser Ala Leu Ala Lys Gly Lys Thr Thr Leu Thr Asn Leu  
35 40 45

Leu Asp Ser Asp Asp Val Arg His Met Leu Asn Ala Leu Lys Glu Leu  
50 55 60

Gly Val Thr Tyr Gln Leu Ser Glu Asp Lys Ser Val Cys Glu Ile Glu  
65 70 75 80

Gly Leu Gly Arg Ala Phe Glu Trp Gln Ser Gly Leu Ala Leu Phe Leu  
85 90 95

Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Leu Cys Leu  
100 105 110

Ser Thr Pro Asn Arg Glu Gly Lys Asn Glu Ile Val Leu Thr Gly Glu  
115 120 125

Pro Arg Met Lys Glu Arg Pro Ile Gln His Leu Val Asp Ala Leu Cys  
130 135 140

Gln Ala Gly Ala Glu Ile Gln Tyr Leu Glu Gln Glu Gly Tyr Pro Pro  
145 150 155 160

Ile Ala Ile Arg Asn Thr Gly Leu Lys Gly Gly Arg Ile Gln Ile Asp  
165 170 175

Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu Leu Met Ala Ala Pro  
180 185 190  
↓  
Met Ala Glu Ala Asp Thr Glu Ile Glu Ile Gly Glu Leu Val Ser  
195 200 205

Lys Pro Tyr Ile Asp Ile Thr Leu Lys Met Met Gln Thr Phe Gly Val  
210 215 220

Glu Val Glu Asn Gln Ala Tyr Gln Arg Phe Leu Val Lys Gly His Gln  
225 230 235 240

Gln Tyr Gln Ser Pro His Arg Phe Leu Val Glu Gly Asp Ala Ser Ser  
245 250 255

Ala Ser Tyr Phe Leu Ala Ala Ala Ile Lys Gly Lys Val Lys Val  
260 265 270

Thr Gly Val Gly Lys Asn Ser Ile Gln Gly Asp Arg Leu Phe Ala Asp  
275 280 285

Val Leu Glu Lys Met Gly Ala His Ile Thr Trp Gly Asp Asp Phe Ile  
290 295 300

Gln Val Glu Lys Gly Asn Leu Lys Gly Ile Asp Met Asp Met Asn His  
305 310 315 320

Ile Pro Asp Ala Ala Met Thr Ile Ala Thr Thr Ala Leu Phe Ala Glu  
325 330 335

Gly Glu Thr Val Ile Arg Asn Ile Tyr Asn Trp Arg Val Lys Glu Thr  
340 345 350

Asp Arg Leu Thr Ala Met Ala Thr Glu Leu Arg Lys Val Gly Ala Glu  
355 360 365

Val Glu Glu Gly Glu Asp Phe Ile Arg Ile Gln Pro Leu Asn Leu Ala  
370 375 380

Gln Phe Gln His Ala Glu Leu Asn Ile His Asp His Arg Met Ala Met  
385 390 395 400

Cys Phe Ala Leu Ile Ala Leu Ser Lys Thr Ser Val Thr Ile Leu Asp  
405 410 415

Pro Ser Cys Thr Ala Lys Thr Phe Pro Thr Phe Leu Ile Leu Phe Thr  
420 425 430

Leu Asn Thr Arg Glu Val Ala Tyr Arg  
435 440

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 426 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Asn Ser Leu Arg Leu Glu Pro Ile Ser Arg Val Ala Gly Glu Val Asn  
1 5 10 15

Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Ala Ala  
20 25 30

Leu Ala Arg Gly Thr Thr Arg Leu Thr Asn Leu Leu Asp Ser Asp Asp  
35 40 45

Ile Arg His Met Leu Ala Ala Leu Thr Gln Leu Gly Val Lys Tyr Lys  
50 55 60

Leu Ser Ala Asp Lys Thr Glu Cys Thr Val His Gly Leu Gly Arg Ser  
65 70 75 80

Phe Ala Val Ser Ala Pro Val Asn Leu Phe Leu Gly Asn Ala Gly Thr  
85 90 95

Ala Met Arg Pro Leu Cys Ala Ala Leu Cys Leu Gly Ser Gly Glu Tyr  
100 105 110

Met Leu Gly Gly Glu Pro Arg Met Glu Glu Arg Pro Ile Gly His Leu  
115 120 125

Val Asp Cys Leu Ala Leu Lys Gly Ala His Ile Gln Tyr Leu Lys Lys  
130 135 140

Asp Gly Tyr Pro Pro Leu Val Val Asp Ala Lys Gly Leu Trp Gly Gly  
145 150 155 160

Asp Val His Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Phe  
165 170 175

Leu Met Ala Ala Pro Ala Met Ala Pro Val Ile Pro Arg Ile His Ile  
180 185 190

Lys Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu His Ile  
195 200 205 \*

Met Asn Ser Ser Gly Val Val Ile Glu His Asp Asn Tyr Lys Leu Phe  
210 215 220

Tyr Ile Lys Gly Asn Gln Ser Ile Val Ser Pro Gly Asp Phe Leu Val  
225 230 235 240

Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Gly Ala Ile  
245 250 255

Lys Gly Lys Val Arg Val Thr Gly Ile Gly Lys His Ser Ile Gly Asp  
260 265 270

Ile His Phe Ala Asp Val Leu Glu Arg Met Gly Ala Arg Ile Thr Trp  
275 280 285

Gly Asp Asp Phe Ile Glu Ala Glu Gln Gly Pro Leu His Gly Val Asp  
290 295 300

Met Asp Met Asn His Ile Pro Asp Val Gly His Asp His Ser Gly Gln  
305 310 315 320

Ser His Cys Leu Pro Arg Val Pro Pro His Ser Gln His Leu Gln Leu  
325 330 335

Ala Val Arg Asp Asp Arg Cys Thr Pro Cys Thr His Gly His Arg Arg  
340 345 350

Ala Gln Ala Gly Val Ser Glu Glu Gly Thr Thr Phe Ile Thr Arg Asp  
355 360 365

Ala Ala Asp Pro Ala Gln Ala Arg Arg Asp Arg His Leu Gln Arg Ser  
370 375 380

Arg Ile Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Ile Ala Val  
385 390 395 400

Thr Ile Asn Asp Pro Gly Cys Thr Ser Lys Thr Phe Pro Asp Tyr Phe  
405 410 415

Asp Lys Leu Ala Ser Val Ser Gln Ala Val  
420 425

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 442 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Met Ser Gly Leu Ala Tyr Leu Asp Leu Pro Ala Ala Arg Leu Ala Arg  
1 5 10 15

Gly Glu Val Ala Leu Pro Gly Ser Lys Ser Ile Ser Asn Arg Val Leu  
20 25 30

Leu Leu Ala Ala Leu Ala Glu Gly Ser Thr Glu Ile Thr Gly Leu Leu  
35 40 45

Asp Ser Asp Asp Thr Arg Val Met Leu Ala Ala Leu Arg Gln Leu Gly  
50 55 60

Val Ser Val Gly Glu Val Ala Asp Gly Cys Val Thr Ile Glu Gly Val  
65 70 75 80

Ala Arg Phe Pro Thr Glu Gln Ala Glu Leu Phe Leu Gly Asn Ala Gly  
85 90 95

Thr Ala Phe Arg Pro Leu Thr Ala Ala Leu Ala Leu Met Gly Gly Asp  
100 105 110

Tyr Arg Leu Ser Gly Val Pro Arg Met His Glu Arg Pro Ile Gly Asp  
115 120 125

Leu Val Asp Ala Leu Arg Gln Phe Gly Ala Gly Ile Glu Tyr Leu Gly  
130 135 140

Gln Ala Gly Tyr Pro Pro Leu Arg Ile Gly Gly Ser Ile Arg Val  
145 150 155 160

Asp Gly Pro Val Arg Val Glu Gly Ser Val Ser Ser Gln Phe Leu Thr  
165 170 175

Ala Leu Leu Met Ala Ala Pro Val Leu Ala Arg Arg Ser Gly Gln Asp  
180 185 190

Ile Thr Ile Glu Val Val Gly Glu Leu Ile Ser Lys Pro Tyr Ile Glu  
195 200 205 \*

Ile Thr Leu Asn Leu Met Ala Arg Phe Gly Val Ser Val Arg Arg Asp  
210 215 220

Gly Trp Arg Ala Phe Thr Ile Ala Arg Asp Ala Val Tyr Arg Gly Pro  
225 230 235 240

Gly Arg Met Ala Ile Glu Gly Asp Ala Ser Thr Ala Ser Tyr Phe Leu  
245 250 255

Ala Leu Gly Ala Ile Gly Gly Pro Val Arg Val Thr Gly Val Gly  
260 265 270

Glu Asp Ser Ile Gln Gly Asp Val Ala Phe Ala Ala Thr Leu Ala Ala  
275 280 285

Met Gly Ala Asp Val Arg Tyr Gly Pro Gly Trp Ile Glu Thr Arg Gly  
290 295 300

Val Arg Val Ala Glu Gly Arg Leu Lys Ala Phe Asp Ala Asp Phe  
305 310 315 320

Asn Leu Ile Pro Asp Ala Ala Met Thr Ala Ala Thr Leu Ala Leu Tyr  
325 330 335

Ala Asp Gly Pro Cys Arg Leu Arg Asn Ile Gly Ser Trp Arg Val Lys  
340 345 350

Glu Thr Asp Arg Ile His Ala Met His Thr Glu Leu Glu Lys Leu Gly  
355 360 365

Ala Gly Val Gln Ser Gly Ala Asp Trp Leu Glu Val Ala Pro Pro Glu  
370 375 380

Pro Gly Gly Trp Arg Asp Ala His Ile Gly Thr Trp Asp Asp His Arg  
385 390 395 400

Met Ala Met Cys Phe Leu Leu Ala Ala Phe Gly Pro Ala Ala Val Arg  
405 410 415  
Ile Leu Asp Pro Gly Cys Val Ser Lys Thr Phe Pro Asp Tyr Phe Asp  
420 425 430  
Val Tyr Ala Gly Leu Leu Ala Ala Arg Asp  
435 440

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 427 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Met Glu Ser Leu Thr Leu Gln Pro Ile Ala Arg Val Asp Gly Ala Ile  
1 5 10 15  
Asn Leu Pro Gly Ser Lys Ser Val Ser Asn Arg Ala Leu Leu Leu Ala  
20 25 30  
Ala Leu Ala Cys Gly Lys Thr Val Leu Thr Asn Leu Leu Asp Ser Asp  
35 40 45  
Asp Val Arg His Met Leu Asn Ala Leu Ser Ala Leu Gly Ile Asn Tyr  
50 55 60  
Thr Leu Ser Ala Asp Arg Thr Arg Cys Asp Ile Thr Gly Asn Gly Gly  
65 70 75 80  
Pro Leu Arg Ala Ser Gly Thr Leu Glu Leu Phe Leu Gly Asn Ala Gly  
85 90 95  
Thr Ala Met Arg Pro Leu Ala Ala Leu Cys Leu Gly Gln Asn Glu  
100 105 110  
Ile Val Leu Thr Gly Glu Pro Arg Met Lys Glu Arg Pro Ile Gly His  
115 120 125

Leu Val Asp Ser Leu Arg Gln Gly Gly Ala Asn Ile Asp Tyr Leu Glu  
130 135 140

Gln Glu Asn Tyr Pro Pro Leu Arg Leu Arg Gly Gly Phe Ile Gly Gly  
145 150 155 160

Asp Ile Glu Val Asp Gly Ser Val Ser Ser Gln Phe Leu Thr Ala Leu  
165 170 175

Leu Met Thr Ala Pro Leu Ala Pro Glu Asp Thr Ile Ile Arg Val Lys  
180 185 190

Gly Glu Leu Val Ser Lys Pro Tyr Ile Asp Ile Thr Leu Asn Leu Met  
195 200 205

Lys Thr Phe Gly Val Glu Ile Ala Asn His His Tyr Gln Gln Phe Val  
210 215 220

Val Lys Gly Gly Gln Gln Tyr His Ser Pro Gly Arg Tyr Leu Val Glu  
225 230 235 240

Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Ala Gly Gly Ile Lys  
245 250 255

Gly Gly Thr Val Lys Val Thr Gly Ile Gly Gly Lys Ser Met Gln Gly  
260 265 270

Asp Ile Arg Phe Ala Asp Val Leu His Lys Met Gly Ala Thr Ile Thr  
275 280 285

Trp Gly Asp Asp Phe Ile Ala Cys Thr Arg Gly Glu Leu His Ala Ile  
290 295 300

Asp Met Asp Met Asn His Ile Pro Asp Ala Ala Met Thr Ile Ala Thr  
305 310 315 320

Thr Ala Leu Phe Ala Lys Gly Thr Thr Thr Leu Arg Asn Ile Tyr Asn  
325 330 335

Trp Arg Val Lys Glu Thr Asp Arg Leu Phe Ala Met Ala Thr Glu Leu  
340 345 350

Arg Lys Val Gly Ala Glu Val Glu Glu Gly His Asp Tyr Ile Arg Ile  
355 360 365

Thr Pro Pro Ala Lys Leu Gln His Ala Asp Ile Gly Thr Tyr Asn Asp  
370 375 380

His Arg Met Ala Met Cys Phe Ser Leu Val Ala Leu Ser Asp Thr Pro  
385 390 395 400

Val Thr Ile Leu Asp Pro Lys Cys Thr Ala Lys Thr Phe Pro Asp Tyr  
405 410 415

Phe Glu Gln Leu Ala Arg Met Ser Thr Pro Ala  
420 425

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1894 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 275..1618

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

ACGGGCTGTA ACGGTAGTAG GGGTCCCGAG CACAAAAGCG GTGCCGGCAA GCAGAACTAA	60
TTTCCATGGG GAATAATGGT ATTTCATTTGG TTTGGCCTCT GGTCTGGCAA TGGTTGCTAG	120
GCGATCGCCT GTTGAAATTA ACAAACTGTC GCCCTTCCAC TGACCATGGT AACGATGTTT	180
TTTACTTCCT TGACTAACCG AGGAAAATTT GGCGGGGGC AGAAATGCCA ATACAATTAA	240
GCTTGGTCTT CCCTGCCCCCT AATTTGTCCC CTCC ATG GCC TTG CTT TCC CTC Met Ala Leu Leu Ser Leu	292
1 5	
AAC AAT CAT CAA TCC CAT CAA CGC TTA ACT GTT AAT CCC CCT GCC CAA	340
Asn Asn His Gln Ser His Gln Arg Leu Thr Val Asn Pro Pro Ala Gln	
10 15 20	
GGG GTC GCT TTG ACT GGC CGC CTA AGG GTG CCG GGG GAT AAA TCC ATT	388
Gly Val Ala Leu Thr Gly Arg Leu Arg Val Pro Gly Asp Lys Ser Ile	
25 30 35	

TCC CAT CGG GCC TTG ATG TTG GGG GCG ATC GCC ACC GGG GAA ACC ATT Ser His Arg Ala Leu Met Leu Gly Ala Ile Ala Thr Gly Glu Thr Ile 40 45 50	436
ATC GAA GGG CTA CTG TTG GGG GAA GAT CCC CGT AGT ACG GCC CAT TGC Ile Glu Gly Leu Leu Leu Gly Glu Asp Pro Arg Ser Thr Ala His Cys 55 60 65 70	484
TTT CGG GCC ATG GGA GCA GAA ATC AGC GAA CTA AAT TCA GAA AAA ATC Phe Arg Ala Met Gly Ala Glu Ile Ser Glu Leu Asn Ser Glu Lys Ile 75 80 85	532
ATC GTT CAG GGT CGG GGT CTG GGA CAG TTG CAG GAA CCC AGT ACC GTT Ile Val Gln Gly Arg Gly Leu Gly Gln Leu Gln Glu Pro Ser Thr Val 90 95 100	580
TTG GAT GCG GGG AAC TCT GGC ACC ACC ATG CGC TTA ATG TTG GGC TTG Leu Asp Ala Gly Asn Ser Gly Thr Thr Met Arg Leu Met Leu Gly Leu 105 110 115	628
CTA GCC GGG CAA AAA GAT TGT TTA TTC ACC GTC ACC GGC GAT GAT TCC Leu Ala Gly Gln Lys Asp Cys Leu Phe Thr Val Thr Gly Asp Asp Ser 120 125 130	676
CTC CGT CAC CGC CCC ATG TCC CGG GTA ATT CAA CCC TTG CAA CAA ATG Leu Arg His Arg Pro Met Ser Arg Val Ile Gln Pro Leu Gln Gln Met 135 140 145 150	724
GGG GCA AAA ATT TGG GCC CGG AGT AAC GGC AAG TTT GCG CCG CTG GCA Gly Ala Lys Ile Trp Ala Arg Ser Asn Gly Lys Phe Ala Pro Leu Ala 155 160 165	772
GTC CAG GGT AGC CAA TTA AAA CCG ATC CAT TAC CAT TCC CCC ATT GCT Val Gln Gly Ser Gln Leu Lys Pro Ile His Tyr His Ser Pro Ile Ala 170 175 180	820
TCA GCC CAG GTA AAG TCC TGC TTG CTA GCG GGG TTA ACC ACC ACC GAG Ser Ala Gln Val Lys Ser Cys Leu Leu Leu Ala Gly Leu Thr Thr Glu 185 190 195	868
GGG GAC ACC ACG GTT ACA GAA CCA GCT CTA TCC CGG GAT CAT AGC GAA Gly Asp Thr Thr Val Thr Glu Pro Ala Leu Ser Arg Asp His Ser Glu 200 205 210	916
CGC ATG TTG CAG GCC TTT GGA GCC AAA TTA ACC ATT GAT CCA GTA ACC Arg Met Leu Gln Ala Phe Gly Ala Lys Leu Thr Ile Asp Pro Val Thr 215 220 225 230	964

CAT AGC GTC ACT GTC CAT GGC CCG GCC CAT TTA ACG GGG CAA CGG GTG 1012  
His Ser Val Thr Val His Gly Pro Ala His Leu Thr Gly Gln Arg Val  
235 240 245

GTG GTG CCA GGG GAC ATC AGC TCG GCG GCC TTT TGG TTA GTG GCG GCA 1060  
Val Val Pro Gly Asp Ile Ser Ser Ala Ala Phe Trp Leu Val Ala Ala  
250 255 260

TCC ATT TTG CCT GGA TCA GAA TTG TTG GTG GAA AAT GTA GGC ATT AAC 1108  
Ser Ile Leu Pro Gly Ser Glu Leu Leu Val Glu Asn Val Gly Ile Asn  
265 270 275

CCC ACC AGG ACA GGG GTG TTG GAA GTG TTG GCC CAG ATG GGG GCG GAC 1156  
Pro Thr Arg Thr Gly Val Leu Glu Val Leu Ala Gln Met Gly Ala Asp  
280 285 290

ATT ACC CCG GAG AAT GAA CGA TTG GTA ACG GGG GAA CCG GTA GCA GAT 1204  
Ile Thr Pro Glu Asn Glu Arg Leu Val Thr Gly Glu Pro Val Ala Asp  
295 300 305 310

CTG CGG GTT AGG GCA AGC CAT CTC CAG GGT TGC ACC TTC GGC GGC GAA 1252  
Leu Arg Val Arg Ala Ser His Leu Gln Gly Cys Thr Phe Gly Gly Glu  
315 320 325

ATT ATT CCC CGA CTG ATT GAT GAA ATT CCC ATT TTG GCA GTG GCG GCG 1300  
Ile Ile Pro Arg Leu Ile Asp Glu Ile Pro Ile Leu Ala Val Ala Ala  
330 335 340

GCC TTT GCA GAG GGC ACT ACC CGC ATT GAA GAT GCC GCA GAA CTG AGG 1348  
Ala Phe Ala Glu Gly Thr Thr Arg Ile Glu Asp Ala Ala Glu Leu Arg  
345 350 355

GTT AAA GAA AGC GAT CGC CTG GCG GCC ATT GCT TCG GAG TTG GGC AAA 1396  
Val Lys Glu Ser Asp Arg Leu Ala Ala Ile Ala Ser Glu Leu Gly Lys  
360 365 370

ATG GGG GCC AAA GTC ACC GAA TTT GAT GAT GGC CTG GAA ATT CAA GGG 1444  
Met Gly Ala Lys Val Thr Glu Phe Asp Asp Gly Leu Glu Ile Gln Gly  
375 380 385 390

GGA AGC CCG TTA CAA GGG GCC GAG GTG GAT AGC TTG ACG GAT CAT CGC 1492  
Gly Ser Pro Leu Gln Gly Ala Glu Val Asp Ser Leu Thr Asp His Arg  
395 400 405

ATT GCC ATG GCG TTG GCG ATC GCT TTA CGT AGT GGG GGG CAA ACA 1540  
Ile Ala Met Ala Leu Ala Ile Ala Ala Leu Gly Ser Gly Gly Gln Thr  
410 415 420

ATT ATT AAC CGG GCG GAA GCG GCG GCC ATT TCC TAT CCA GAA TTT TTT Ile Ile Asn Arg Ala Glu Ala Ala Ala Ile Ser Tyr Pro Glu Phe Phe	1588
425 430 435	
GGC ACG CTA GGG CAA GTT GCC CAA GGA TAAAGTTAGA AAAACTCCTG Gly Thr Leu Gly Gln Val Ala Gln Gly	1635
440 445	
GGCGGTTTGT AAATGTTTA CCAAGGTAGT TTGGGGTAAA GGCCCCAGCA AGTGCTGCCA	1695
GGGTAATTAA TCCGCAATTG ACCAATCGGC ATGGACCGTA TCGTTCAAAC TGGGTAATTG	1755
TCCCTTTAAT TCCTTAAAG CTCGCTTAAA ACTGCCAAC GTATCTCCGT AATGGCGAGT	1815
GAGTAGAAGT AATGGGGCCA AACGGCGATC GCCACGGAA ATTAAAGCCT GCATCACTGA	1875
CCACTTATAA CTTTCGGGA	1894

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 447 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Met Ala Leu Leu Ser Leu Asn Asn His Gln Ser His Gln Arg Leu Thr	
1 5 10 15	
Val Asn Pro Pro Ala Gln Gly Val Ala Leu Thr Gly Arg Leu Arg Val	
20 25 30	
Pro Gly Asp Lys Ser Ile Ser His Arg Ala Leu Met Leu Gly Ala Ile	
35 40 45	
Ala Thr Gly Glu Thr Ile Ile Glu Gly Leu Leu Gly Glu Asp Pro	
50 55 60	
Arg Ser Thr Ala His Cys Phe Arg Ala Met Gly Ala Glu Ile Ser Glu	
65 70 75 80	
Leu Asn Ser Glu Lys Ile Ile Val Gln Gly Arg Gly Leu Gly Gln Leu	
85 90 95	

Gln Glu Pro Ser Thr Val Leu Asp Ala Gly Asn Ser Gly Thr Thr Met  
100 105 110

Arg Leu Met Leu Gly Leu Leu Ala Gly Gln Lys Asp Cys Leu Phe Thr  
115 120 125

Val Thr Gly Asp Asp Ser Leu Arg His Arg Pro Met Ser Arg Val Ile  
130 135 140

Gln Pro Leu Gln Gln Met Gly Ala Lys Ile Trp Ala Arg Ser Asn Gly  
145 150 155 160

Lys Phe Ala Pro Leu Ala Val Gln Gly Ser Gln Leu Lys Pro Ile His  
165 170 175

Tyr His Ser Pro Ile Ala Ser Ala Gln Val Lys Ser Cys Leu Leu Leu  
180 185 190

Ala Gly Leu Thr Thr Glu Gly Asp Thr Thr Val Thr Glu Pro Ala Leu  
195 200 205

Ser Arg Asp His Ser Glu Arg Met Leu Gln Ala Phe Gly Ala Lys Leu  
210 215 220

Thr Ile Asp Pro Val Thr His Ser Val Thr Val His Gly Pro Ala His  
225 230 235 240

Leu Thr Gly Gln Arg Val Val Val Pro Gly Asp Ile Ser Ser Ala Ala  
245 250 255

Phe Trp Leu Val Ala Ala Ser Ile Leu Pro Gly Ser Glu Leu Leu Val  
260 265 270

Glu Asn Val Gly Ile Asn Pro Thr Arg Thr Gly Val Leu Glu Val Leu  
275 280 285

Ala Gln Met Gly Ala Asp Ile Thr Pro Glu Asn Glu Arg Leu Val Thr  
290 295 300

Gly Glu Pro Val Ala Asp Leu Arg Val Arg Ala Ser His Leu Gln Gly  
305 310 315 320

Cys Thr Phe Gly Gly Glu Ile Ile Pro Arg Leu Ile Asp Glu Ile Pro  
325 330 335

Ile Leu Ala Val Ala Ala Ala Phe Ala Glu Gly Thr Thr Arg Ile Glu  
340 345 350

Asp Ala Ala Glu Leu Arg Val Lys Glu Ser Asp Arg Leu Ala Ala Ile  
355 360 365

Ala Ser Glu Leu Gly Lys Met Gly Ala Lys Val Thr Glu Phe Asp Asp  
370 375 380

Gly Leu Glu Ile Gln Gly Gly Ser Pro Leu Gln Gly Ala Glu Val Asp  
385 390 395 400

Ser Leu Thr Asp His Arg Ile Ala Met Ala Leu Ala Ile Ala Ala Leu  
405 410 415

Gly Ser Gly Gly Gln Thr Ile Ile Asn Arg Ala Glu Ala Ala Ile  
420 425 430

Ser Tyr Pro Glu Phe Phe Gly Thr Leu Gly Gln Val Ala Gln Gly  
435 440 445

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1479 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 107..1438

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

TTTAAAAAACA ATGAGTTAAA AAATTATTTT TCTGGCACAC GCGCTTTTT TGCACTTTTT 60  
CTCCCCATTTT TCGGGCACAA TAACGTTGGT TTTATAAAAG GAAATG ATG ATG ACG 115  
Met Met Thr  
AAT ATA TGG CAC ACC GCG CCC GTC TCT GCG CTT TCC GGC GAA ATA ACG 163  
Asn Ile Trp His Thr Ala Pro Val Ser Ala Leu Ser Gly Glu Ile Thr  
5 10 15

COMPUTER GENERATED REPORT

ATA TGC GGC GAT AAA TCA ATG TCG CAT CGC GCC TTA TTA TTA GCA GCG 211  
Ile Cys Gly Asp Lys Ser Met Ser His Arg Ala Leu Leu Leu Ala Ala  
20 25 30 35

TTA GCA GAA GGA CAA ACG GAA ATC CGC GGC TTT TTA GCG TGC GCG GAT 259  
Leu Ala Glu Gly Gln Thr Glu Ile Arg Gly Phe Leu Ala Cys Ala Asp  
40 45 50

TGT TTG GCG ACG CGG CAA GCA TTG CGC GCA TTA GGC GTT GAT ATT CAA 307  
Cys Leu Ala Thr Arg Gln Ala Leu Arg Ala Leu Gly Val Asp Ile Gln  
55 60 65 \*

AGA GAA AAA GAA ATA GTG ACG ATT CGC GGT GTG GGA TTT CTG GGT TTG 355  
Arg Glu Lys Glu Ile Val Thr Ile Arg Gly Val Gly Phe Leu Gly Leu  
70 75 80

CAG CCG CCG AAA GCA CCG TTA AAT ATG CAA AAC AGT GGC ACT AGC ATG 403  
Gln Pro Pro Lys Ala Pro Leu Asn Met Gln Asn Ser Gly Thr Ser Met  
85 90 95

CGT TTA TTG GCA GGA ATT TTG GCA GCG CAG CGC TTT GAG AGC GTG TTA 451  
Arg Leu Leu Ala Gly Ile Leu Ala Ala Gln Arg Phe Glu Ser Val Leu  
100 105 110 115

TGC GGC GAT GAA TCA TTA GAA AAA CGT CCG ATG CAG CGC ATT ATT ACG 499  
Cys Gly Asp Glu Ser Leu Glu Lys Arg Pro Met Gln Arg Ile Ile Thr  
120 125 130

CCG CTT GTG CAA ATG GGG GCA AAA ATT GTC AGT CAC AGC AAT TTT ACG 547  
Pro Leu Val Gln Met Gly Ala Lys Ile Val Ser His Ser Asn Phe Thr  
135 140 145

GCG CCG TTA CAT ATT TCA GGA CGC CCG CTG ACC GGC ATT GAT TAC GCG 595  
Ala Pro Leu His Ile Ser Gly Arg Pro Leu Thr Gly Ile Asp Tyr Ala  
150 155 160

TTA CCG CTT CCC AGC GCG CAA TTA AAA AGT TGC CTT ATT TTG GCA GGA 643  
Leu Pro Leu Pro Ser Ala Gln Leu Lys Ser Cys Leu Ile Leu Ala Gly  
165 170 175

TTA TTG GCT GAC GGT ACC ACG CGG CTG CAT ACT TGC GGC ATC AGT CGC 691  
Leu Leu Ala Asp Gly Thr Thr Arg Leu His Thr Cys Gly Ile Ser Arg  
180 185 190 195

GAC CAC ACG GAA CGC ATG TTG CCG CTT TTT CGT GGC GCA CTT GAG ATC 739  
Asp His Thr Ile Arg Met Leu Pro Leu Phe Gly Gly Ala Leu Glu Ile  
200 205 210

AAG AAA GAG CAA ATA ATC GTC ACC GGT GGA CAA AAA TTG CAC GGT TGC Lys Lys Glu Gln Ile Ile Val Thr Gly Gly Gln Lys Leu His Gly Cys 215 220 225	787
GTG CTT GAT ATT GTC GGC GAT TTG TCG GCG GCG GCG TTT TTT ATG GTT Val Leu Asp Ile Val Gly Asp Leu Ser Ala Ala Ala Phe Phe Met Val 230 235 240	835
GCG GCT TTG ATT GCG CCG CGC GCG GAA GTC GTT ATT CGT AAT GTC GGC Ala Ala Leu Ile Ala Pro Arg Ala Glu Val Val Ile Arg Asn Val Gly 245 250 255	883
ATT AAT CCG ACG CGG GCG GCA ATC ATT ACT TTG TTG CAA AAA ATG GGC Ile Asn Pro Thr Arg Ala Ala Ile Ile Thr Leu Leu Gln Lys Met Gly 260 265 270 275	931
GGA CGG ATT GAA TTG CAT CAT CAG CGC TTT TGG GGC GCC GAA CCG GTG Gly Arg Ile Glu Leu His His Gln Arg Phe Trp Gly Ala Glu Pro Val 280 285 290	979
GCA GAT ATT GTT GTT TAT CAT TCA AAA TTG CGC GGC ATT ACG GTG GCG Ala Asp Ile Val Val Tyr His Ser Lys Leu Arg Gly Ile Thr Val Ala 295 300 305	1027
CCG GAA TGG ATT GCC AAC GCG ATT GAT GAA TTG CCG ATT TTT TTT ATT Pro Glu Trp Ile Ala Asn Ala Ile Asp Glu Leu Pro Ile Phe Phe Ile 310 315 320	1075
GCG GCA GCT TGC GCG GAA GGG ACG ACT TTT GTG GGC AAT TTG TCA GAA Ala Ala Ala Cys Ala Glu Gly Thr Thr Phe Val Gly Asn Leu Ser Glu 325 330 335	1123
TTG CGT CTG AAA GAA TCG GAT CGT TTA GCG GCG ATG GCG CAA AAT TTA Leu Arg Val Lys Glu Ser Asp Arg Leu Ala Ala Met Ala Gln Asn Leu 340 345 350 355	1171
CAA ACT TTG GGC GTG GCG TGC GAC GTT GGC GCC GAT TTT ATT CAT ATA Gln Thr Leu Gly Val Ala Cys Asp Val Gly Ala Asp Phe Ile His Ile 360 365 370	1219
TAT GGA AGA AGC GAT CGG CAA TTT TTA CCG GCG CGG GTG AAC AGT TTT Tyr Gly Arg Ser Asp Arg Gln Phe Leu Pro Ala Arg Val Asn Ser Phe 375 380 385	1267
GCG GAT CAT CGG ATT CGG ATG AGT TTG GCG GTG GCA GGT GTG CGC GCG Gly Asp His Arg Ile Ala Met Ser Leu Ala Val Ala Gly Val Arg Ala 390 395 400	1315

GCA GGT GAA TTA TTG ATT GAT GAC GGC GCG GTG GCG GCG GTT TCT ATG Ala Gly Glu Leu Leu Ile Asp Asp Gly Ala Val Ala Ala Val Ser Met 405 410 415	1363
CCG CAA TTT CGC GAT TTT GCC GCC GCA ATT GGT ATG AAT GTA GGA GAA Pro Gln Phe Arg Asp Phe Ala Ala Ala Ile Gly Met Asn Val Gly Glu 420 425 430 435	1411
AAA GAT GCG AAA AAT TGT CAC GAT TGATGGTCCT AGCGGTGTTG GAAAAGGCAC Lys Asp Ala Lys Asn Cys His Asp 440	1465
GGTGGCGCAA GCTT	1479

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 443 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Met Met Thr Asn Ile Trp His Thr Ala Pro Val Ser Ala Leu Ser Gly  
1 5 10 15

Glu Ile Thr Ile Cys Gly Asp Lys Ser Met Ser His Arg Ala Leu Leu  
20 25 30

Leu Ala Ala Leu Ala Glu Gly Gln Thr Glu Ile Arg Gly Phe Leu Ala  
35 40 45

Cys Ala Asp Cys Leu Ala Thr Arg Gln Ala Leu Arg Ala Leu Gly Val  
50 55 60

Asp Ile Gln Arg Glu Lys Glu Ile Val Thr Ile Arg Gly Val Gly Phe  
65 70 75 80

Leu Gly Leu Gln Pro Pro Lys Ala Pro Leu Asn Met Gln Asn Ser Gly  
85 90 95

Thr Ser Met Arg Leu Leu Ala Gly Ile Leu Ala Ala Gln Arg Phe Glu  
100 105 110

Ser Val Leu Cys Gly Asp Glu Ser Leu Glu Lys Arg Pro Met Gln Arg  
115 120 125

Ile Ile Thr Pro Leu Val Gln Met Gly Ala Lys Ile Val Ser His Ser  
130 135 140

Asn Phe Thr Ala Pro Leu His Ile Ser Gly Arg Pro Leu Thr Gly Ile  
145 150 155 160

Asp Tyr Ala Leu Pro Leu Pro Ser Ala Gln Leu Lys Ser Cys Leu Ile  
165 170 175

Leu Ala Gly Leu Leu Ala Asp Gly Thr Thr Arg Leu His Thr Cys Gly  
180 185 190

Ile Ser Arg Asp His Thr Glu Arg Met Leu Pro Leu Phe Gly Gly Ala  
195 200 205

Leu Glu Ile Lys Lys Glu Gln Ile Ile Val Thr Gly Gly Gln Lys Leu  
210 215 220

His Gly Cys Val Leu Asp Ile Val Gly Asp Leu Ser Ala Ala Ala Phe  
225 230 235 240

Phe Met Val Ala Ala Leu Ile Ala Pro Arg Ala Glu Val Val Ile Arg  
245 250 255

Asn Val Gly Ile Asn Pro Thr Arg Ala Ala Ile Ile Thr Leu Leu Gln  
260 265 270

Lys Met Gly Gly Arg Ile Glu Leu His His Gln Arg Phe Trp Gly Ala  
275 280 285

Glu Pro Val Ala Asp Ile Val Val Tyr His Ser Lys Leu Arg Gly Ile  
290 295 300

Thr Val Ala Pro Glu Trp Ile Ala Asn Ala Ile Asp Glu Leu Pro Ile  
305 310 315 320

Phe Phe Ile Ala Ala Ala Cys Ala Glu Gly Thr Thr Phe Val Gly Asn  
325 330 335

Leu Ser Glu Leu Arg Val Lys Glu Ser Asp Arg Leu Ala Ala Met Ala  
340 345 350

Gln Asn Leu Gln Thr Leu Gly Val Ala Cys Asp Val Gly Ala Asp Phe  
355 360 365

Ile His Ile Tyr Gly Arg Ser Asp Arg Gln Phe Leu Pro Ala Arg Val  
370 375 380

Asn Ser Phe Gly Asp His Arg Ile Ala Met Ser Leu Ala Val Ala Gly  
385 390 395 400

Val Arg Ala Ala Gly Glu Leu Leu Ile Asp Asp Gly Ala Val Ala Ala  
405 410 415

Val Ser Met Pro Gln Phe Arg Asp Phe Ala Ala Ala Ile Gly Met Asn  
420 425 430

Val Gly Glu Lys Asp Ala Lys Asn Cys His Asp  
435 440